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The Impact of Medicare Part D Coverage on Medication Adherence 
and Health Outcomes in End-stage Renal Disease (ESRD) Patients 
 
Haesuk Park, PhD 
The University of Texas at Austin, 2013 
Supervisor: Karen L. Rascati  
The purpose of this study was to investigate the impact of Medicare Part D 
coverage on medication adherence and health outcomes in dialysis patients.  A 
retrospective analysis (2006-2010) using the United States Renal Data System was 
conducted for Medicare-eligible dialysis patients.  Cardiovascular disease morbidity, 
healthcare utilization and expenditures, medication adherence, and mortality rates were 
compared, categorized based on patients’ Part D coverage in 2007 for those who: 1) did 
not reach the coverage gap (cohort 1); 2) reached the coverage gap but not catastrophic 
coverage (cohort 2); 3) reached catastrophic coverage (cohort 3); and 4) did not reach the 
coverage gap but received a low-income subsidy (cohort 4).  Cox proportional hazards 
models, Kaplan-Meier methods, logistic regressions, generalized linear models, and 
generalized estimating equations were used.   
A total of 11,732 patients were included as meeting inclusion criteria: 1) cohort 1: 
3,678 patients had out-of-pocket drug costs <$799; 2) cohort 2: 4,349 patients had out-of-
pocket drug costs between $799 and $3,850; 3) cohort 3: 1,310 patients had out-of-pocket 
vii 
drug costs > $3,850; and 4) cohort 4: the remaining 2,395 patients had out-of-pocket drug 
costs <$799 but received a low-income subsidy.  After adjusting for demographic and 
clinical factors, patients in cohort 2 and cohort 3 had 42 percent and 36 percent increased 
risk of cardiovascular disease (odds ratio (OR)=1.42, 95% confidence interval (CI):1.20-
1.67; OR=1.38, 95% CI:1.10-1.72); and had 36 percent and 37 percent higher death rates 
compared to those in cohort 4, respectively (hazard ratio (HR)=1.36, 95% CI:1.27-1.44; 
HR=1.37, 95% CI:1.27-1.48).  Patients in cohort 2 were more likely to be nonadherent 
to medications for diabetes (OR=1.72, 95% CI:1.48-1.99), hypertension (OR=1.69, 95% 
CI:1.54-1.85), hyperlipidemia (OR=2.01, 95% CI:1.76-2.29), hyperphosphatemia 
(OR=1.74, 95% CI:1.55-1.95), and hyperparathyroidism (OR=2.08, 95% CI:1.66-2.60) 
after reaching the coverage gap.  These patients had total health care costs that were 
$2,644 higher due to increased rates of hospitalization and outpatient visits, despite 
$2,419 lower pharmacy costs compared to patients in cohort 4 after controlling for 
covariates (p<0.0001).    
Reaching the Part D coverage gap was associated with decreased medication 
adherence and unfavorable clinical and economic outcomes in dialysis patients. 
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Chapter 1: Literature Review 
 
1.1 Literature Review 
 
This chapter is a review of the literature relevant to this dissertation.  The following 
broad areas will be covered in the literature review: 
 Epidemiology of end-stage renal disease (ESRD) in the United States; 
 Cardiovascular disease in ESRD patients; 
 Prescription medication and pill burden in ESRD patients; 
 An overview of the Medicare Part D prescription drug benefit in ESRD patients;  
 Discussion about the impact of cost sharing policies on health outcomes; 
 Discussion about the impact of Part D on health outcomes; and 
 Discussion about the impact of Part D on dialysis patients. 
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1.2 Section 1: End-stage Renal Disease (ESRD) 
1.2.1 ESRD in the United States 
End-stage renal disease (ESRD) patients are those who require renal replacement therapy, 
including hemodialysis, peritoneal dialysis or kidney transplantation as lifesaving 
measures. (National Kidney Foundation 2002)   
Chronic Kidney Disease (CKD) is the standard term to describe the chronic renal 
dysfunction that occurs prior to ESRD.  CKD is defined as the presence of either kidney 
damage or decreased kidney function as evidenced by a glomerulo-filtration rate (GFR) < 
60mL/min/1.73 m2 for 3 or more months. (National Kidney Foundation 2002)  Kidney 
damage is defined as pathologic abnormalities or markers of damage, including 
abnormalities in blood or urine tests or imaging studies.  The CKD trajectory has five 
stages, based on the calculated GFR (Table 1.1).  
 
Table 1.1   Definition and Stages of Chronic Kidney Disease (NKF, 2002) 
Stage Description GFR (mL/min/1.73 m2) 
1 Kidney damage with normal or ↑ GFR ≥ 90 
2 Kidney damage with mild ↓ GFR 60-89 
3 Moderate ↓ GFR 30-59 
4 Severe ↓ GFR 15-29 
5 Kidney failure < 15 (or dialysis) 
Source: The National Kidney Foundation (NKF) Kidney Disease Outcomes Quality Initiative 
(KDOQI) clinical practice guidelines for chronic kidney disease: evaluation, classification and 
stratification 
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This CKD staging system was adapted by the National Kidney Foundation (NKF) Kidney 
Disease Outcomes Quality Initiative (KDOQI).  Stage 5 CKD is described as kidney 
failure.  Kidney failure is not synonymous with ESRD, which is an administrative term 
in the United States (U.S.) based on eligibility for coverage by Medicare, specifically 
patients with kidney failure who require renal replacement therapy. (National Kidney 
Foundation 2002)  Approximately 98 percent of patients with kidney failure in the U.S. 
are also ESRD patients.   
 
1.2.1.1 Prevalence and Incidence 
The number of U.S. patients with ESRD exceeded 570,000 in 2010. (US Renal Data 
System 2011)  As of December 31, 2009, the prevalent population included 370,274 
patients on hemodialysis and 27,522 on peritoneal dialysis, as well as 172,553 with a 
functioning kidney transplant (Figure 1.1). (US Renal Data System 2011)  The rate of 
prevalent ESRD cases reached 1,738 per million.  The prevalent dialysis population has 
grown to 397,796 patients, from 48,855 in 1980 and 110,656 in 1988.  The transplant 
population has increased to 172,553 patients through 2009, from 10,138 in 1980 and 
41,194 in 1988 (Figure 1.1).  The prevalent population and the transplant population 
have doubled every 10 years. (Collins, Foley et al. 2009)   
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Figure 1.1  Prevalent Patient by Modality, 2009 
 
                
                     Year  
Source: The United States Renal Data System (USRDS) 2011 Annual Report  
The incident population growth has slowed significantly over the last 10 years, rising or 
decreasing one to two percent per year (Figure 1.2). (Collins, Foley et al. 2009)  In 
2009, 104,252 new patients began ESRD therapy on hemodialysis, 6,966 were placed on 
peritoneal dialysis, and 2,500 received a preemptive transplant.  
Figure 1.2  Adjusted Incident Rates of ESRD & Annual Percent Change 
 
 
Year 
 
                              Year 
Source: The United States Renal Data System (USRDS) 2011 Annual Report 
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1.2.1.2 Patient Characteristics and Treatment  
According to United States Renal Data System (USRDS) Annual Reports, the adjusted 
rate of prevalent ESRD for patients age 65-75 has increased 28 percent (6,066 per million 
population) since 2000, while the rate among those age 75 and older has grown 37 
percent (5,545 per million population). (US Renal Data System 2011)  Among those 
ages 20-44 and 45-64, growth has been 13 and 20 percent, respectively.  Although the 
rate of growth is relatively small, the total number of patients in the ESRD program 
appears to be driven by the group aged 45 to 64 years, accounting for 40 percent of the 
prevalent population (250,878 patients). (US Renal Data System 2011)  
By race, rates of prevalent ESRD were higher in the African American and Native 
American populations, at 5,284 and 2,735 per million population in 2009, respectively, 
compared to 1,279 and 2,101 among whites and Asians, respectively.  Hispanics 
reached 2,538 per million population in 2009, 1.5 times greater than the prevalence in the 
non-Hispanic population. (US Renal Data System 2011)  In 2009, among 113,636 
incident patients, the mean age was 62.6 years and 65.7 percent were white.  Twenty-
eight percent of patients were African American and the primary diagnosis of incident 
dialysis was diabetes (44.6%), which was followed by hypertension (28.9%), 
glomerulonephritis (9.5%), and cystic kidney disease (2.5%). (US Renal Data System 
2011)   
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Diabetes remained the dominant primary cause of incident ESRD, with reported rates of 
148.8 cases per million in 2009.  Among younger adults (30-39 years), rates have 
declined in white individuals since the 1990s and remained constant in Asian and 
Hispanic populations, whereas rates have continued to rise among African American and 
Native American groups.  Among older adults (60-69 years), rates seem to have 
stabilized in the past five years in all racial and ethnic groups, although disparities remain 
marked. (Foley and Collins 2007; Collins, Foley et al. 2009)  For hypertension, the 
second most common cause of ESRD, incident rates remained considerably higher in 
African American individuals in all age groups.  
 
The two major renal replacement therapies for ESRD are dialysis and kidney 
transplantation.  Hemodialysis was the first widely available renal replacement therapy 
and is still the most common.  Among US patients with ESRD, 66 percent receive 
hemodialysis.  A hemodialysis regimen is based on two pillars: restriction of certain 
nutrients and removal of waste metabolites from the blood by regular dialysis. 
(Denhaerynck, Manhaeve et al. 2007)  Successful hemodialysis depends on four factors: 
(1) fluid restrictions, (2) dietary guidelines, (3) prescription medications, and (4) 
attendance at hemodialysis sessions. (Denhaerynck, Manhaeve et al. 2007)  Fluid 
restrictions can be as severe as a maximum of 500 mL of fluid intake daily, depending on 
the residual diuresis.  Prescribed dietary restrictions limit sodium, potassium, and 
protein intake.  The goals of the medication regimen are to treat or prevent 
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cardiovascular comorbid conditions and keep a stable mineral blood balance.  
Attendance at dialysis sessions implies both regular attendance (no skipping of sessions) 
and full completion of the sessions (no shortening of a session). (Denhaerynck, 
Manhaeve et al. 2007)     
 
1.2.1.3 Mortality 
Survival rates have improved steadily in the US ESRD population since the late 1980s, 
which is remarkable considering the ever-expanding burden of comorbidity in incident 
patients. (Foley and Collins 2007)  However, although dialysis effectively contributes to 
long-term survival, morbidity and mortality of dialysis patients remains high, especially 
due to high cardiovascular morbidity and mortality.  Every year, 10 to 20 percent of all 
patients on dialysis die.  The average expected remaining lifetime for patients on 
dialysis is 5.9 years, compared with 16.4 years for kidney transplant recipients and 25.2 
years for the general population. (US Renal Data System 2010)  Approximately 20 
percent of dialysis patients die within the first year of diagnosis. (US Renal Data System 
2010)  Only 33 percent of patients on hemodialysis survive to the fifth year of treatment, 
whereas 70 percent of patients who have kidney transplants are alive after 5 years. (US 
Renal Data System 2011)   
In 2009, the adjusted rate of all-cause mortality was seven times greater for dialysis 
patients than for individuals in the general Medicare population (Figure 1.3).  Rates rise 
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by age, reaching 274 per 1,000 patient-years at risk for ESRD patient age 65 and older, 
and 313 per 1,000 patient-years at risk for dialysis patients of the same age.   
Figure 1.3  Adjusted All-cause Mortality in the ESRD & General Populations, by 
Age, 2009 
 
Source: The United States Renal Data System (USRDS) 2011 Annual Report 
 
Cardiovascular disease (CVD) is the leading cause of mortality in ESRD, accounting for 
about 45 percent of all deaths. (Wright and Hutchison 2009)  Cardiovascular mortality is 
10 to 30 times higher in patients treated by dialysis than in the general population, despite 
stratification by sex, race, and the presence of diabetes. (Meyer and Levey 1998)  After 
adjustment for age, CVD mortality remains 5-folder higher in dialysis patients than in the 
general population.  The high mortality rate is likely due to both a high case fatality rate 
and a high prevalence of CVD. (Levey, Beto et al. 1998; Sarnak, Levey et al. 2003)   
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1.2.2 Cardiovascular Events in Patients with ESRD 
1.2.2.1 Cardiovascular Disease (CVD) 
The incidence of CVD was estimated to be 11-16 percent in the dialysis population (Park, 
Rascati et al. 2011), which is five- to 15-fold higher than that seen in the general 
population. (Longenecker, Coresh et al. 2002)  CVD accounted for approximately half 
of the deaths in ESRD and contributed to the extraordinarily high total annual mortality - 
23 percent - observed in such patients. (US Renal Data System 2009)    
 
In addition to an increased risk of death, CVD is associated with high rates of resource 
utilization.  On average, dialysis patients are hospitalized between 1.8 and 2.4 times 
annually, with a mean length of stay of 13.7 days per patient per year. (US Renal Data 
System 2008)  Approximately 19 to 33 percent of these hospitalizations are attributable 
to CVD.  Once patients reach ESRD and enter dialysis programs, they have an 
alarmingly high rate of cardiovascular death - with those in the youngest age group of < 
25 years having equivalent cardiovascular mortality rates compared to 75- to 85- year-
olds in the general population. (Foley, Parfrey et al. 1998)  
 
1.2.2.2 Risk Factors for CVD in Patients with ESRD 
The Framingham Heart Study identified a set of individual biomarkers, behaviors, and 
demographic characteristics that are routinely used to predict the risk of CVD. (Wilson, 
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D'Agostino et al. 1998)  These risk factors - which include age, gender, history of 
diabetes, total cholesterol, systolic blood pressure, and smoking status -  have been 
extensively validated in multiple populations. (Grundy 2005)  
 
However, the Framingham instrument has demonstrated poor overall accuracy in 
predicting cardiac events in individuals with CKD. (Weiner, Tighiouart et al. 2007)  
Patients with ESRD have higher rates of cardiovascular morbidity and mortality than 
would be predicted by Framingham models of cardiovascular risk. (McClellan and 
Chertow 2005)  There are many reasons for this, including the confounding additional 
cardiovascular risk arising from malnutrition which occurs because kidney dysfunction 
leads to a catabolic state.  This then promotes inflammation, a key trigger in the 
development of cardiovascular disease. (Bergstrom and Lindholm 1998)  
 
The traditional risk factors for CVD such as hypertension, dyslipidemia, diabetes, and 
obesity are highly prevalent in ESRD populations.  There are many other cardiovascular 
risk factors that are uremia-specific or much more common in patients with ESRD than in 
the general population. (Wright and Hutchison 2009)  These factors include anemia, 
hyperparathyroidism, carnitine deficiency, hyperhomocysteinemia, low vitamin C, high 
lipoprotein levels and small apolipoprotein size. (Wright and Hutchison 2009)  The 
presence of these risk factors in dialysis patients clearly enhances the incidence and 
severity of CVD and associated mortality.  Therefore, the strategy to lower CVD 
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incidence and mortality should be a combined effort targeting potential risk factors 
including traditional (i.e., diabetes mellitus, hypertension, and hyperlipidemia) and 
dialysis-specific factors (i.e., phosphorous level and parathyroid level). (Cheigh and Kim 
1999)  
 
Understanding the literature on risk factors of CVD and current recommended guidelines 
to prevent CVD for ESRD are crucial.  Although studies have shown the beneficial 
effects of several medication classes in decreasing CVD morbidity and mortality in the 
general population, information is limited for dialysis patients.  In an effort to improve 
clinical outcomes among patients with ESRD, the National Kidney Foundation (NKF) 
launched the Kidney Disease Outcomes Quality Initiative (KDOQI) clinical practice 
guidelines in 1995.  The KDOQI guidelines cover many aspects of care for 
hemodialysis patients including dialysis, anemia, diabetes mellitus (National Kidney 
Foundation 2007), cardiovascular disease (National Kidney Foundation 2005), 
dyslipidemia (National Kidney Foundation 2003), and bone and mineral metabolism. 
(Kidney Disease: Improving Global Outcomes (KDIGO) 2009)   
 
1.2.2.3 Diabetes Mellitus and ESRD 
Diabetes mellitus and CKD are potent independent risk factors for cardiovascular events 
and progression to ESRD. (Go, Chertow et al. 2004)  Patients with both conditions are, 
therefore, at exceedingly high risk of CVD.  Diabetic nephropathy is the most common 
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cause of ESRD in North America, accounting for approximately 44.6 percent of patients 
undergoing incident dialysis. (US Renal Data System 2011)  Diabetes deteriorates 
kidney function through microvascular complications caused by chronic hyperglycemia.   
 
The NKF and the American Heart Association (AHA) have recently issued guidelines 
and scientific statements recommending that people with both CKD and diabetes be 
considered in the highest risk category for CVD.  Having CKD with diabetes mellitus is 
far worse than for either condition alone because the combination is one the most 
powerful predictors of major adverse cardiovascular events and death. (National Kidney 
Foundation 2007)  Indeed, while current NKF KDOQI guidelines suggest a target 
HbA1c level of seven percent for all diabetic patients with or without chronic kidney 
disease, very little evidence supports this recommendation.  Patients with chronic 
kidney disease and ESRD have not been included routinely in most studies, and the 
relation between markers of glycemic control and mortality is poorly defined in this 
population. (Shurraw, Majumdar et al. 2010)  
There have been very few published studies that have examined the association between 
HbA1c and clinical outcomes in dialysis patients.  A population-based cohort study was 
conducted in Canada to determine whether HbA1c levels were independently associated 
with important clinical outcomes, such as all-cause mortality, cardiovascular events, 
hospitalizations, and kidney failure, in patients with diabetes mellitus and stage 3 to 4 
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CKD. (Shurraw, Hemmelgarn et al. 2011)  This study found that regardless of baseline 
GFR, a higher HbA1c level was strongly and independently associated with excess risk 
of all outcomes (P<.001 for all comparison).  However, the association with mortality 
was U-shaped, which had increases in the risk of mortality apparent at HbA1c levels 
lower than 6.5 percent and higher than 8.0 percent. (Shurraw, Hemmelgarn et al. 2011)   
 
Two retrospective cohort studies in patients undergoing hemodialysis reported little or no 
association between HbA1c level and all-cause mortality. (Shurraw, Majumdar et al. 
2010; Williams, Lacson et al. 2010)  Shurraw’s population-based retrospective cohort 
study of all maintenance hemodialysis patients in the Northern Alberta Renal Program 
(Alberta, Canada) found that high HbA1c levels were not associated with mortality. 
(Shurraw, Majumdar et al. 2010)  Another retrospective analysis used a time-dependent 
Cox model for patients treated in a large dialysis center, the Fresenius Medical Care-
North America facilities, and reported that HbA1c categories <6.5% and >11% were 
associated with increased mortality risk. (Williams, Lacson et al. 2010)  
These findings contrast with the largest observational study, which found that higher 
levels of HbA1c were incrementally associated with higher death risk in 23,618 patients 
undergoing hemodialysis in Davita outpatient clinics. (Kalantar-Zadeh, Kopple et al. 
2007)  Unadjusted survival analyses indicated paradoxically lower morality risk with 
higher HbA1c as previous studies reported.  However, after controlling for potential 
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confounders including demographics, dialysis vintage, dose, comorbidity, anemia, 
malnutrition and inflammation compared with HbA1c in the 5-6% range, the adjusted all-
cause and cardiovascular mortality risks for HbA1c ≥ 10% were 41 and 73 percent 
greater, respectively (P<0.05). (Kalantar-Zadeh, Kopple et al. 2007)   
 
1.2.2.3.1 Treatment of Diabetes Mellitus in Dialysis Patients 
In patients with ESRD, second-generation sulfonylureas, (such as glipizide) are 
recommended because metabolites are not active and there is less potential for the 
development of hypoglycemia compared to first-generation medications. (National 
Kidney Foundation 2007)  Insulin and thiazolidinediones are suitable for patients with 
ESRD.  Metformin is contraindicated in male patients with serum creatinine > 1.5mg/dL 
and in female patients with serum creatinine >1.4 mg/dL because it is cleared by the 
kidney and may build up with even modest impairment of kidney function, putting 
patients at risk of lactic acidosis (Table 1.2). (National Kidney Foundation 2007) 
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Table 1.2   Dosing Adjustments for Drugs Used to Treat Hyperglycemia in ESRD 
Patients 
Class Drug Dosing recommendation for 
dialysis patients 
First-generation 
sulfonylureas 
Acetohexamide, 
Chlorpropamide, 
Tolazamide, Tolbutamide 
Avoid 
Second-generation 
sulfonylureas 
Glipizide Preferred sulfonylurea 
No dose adjustment necessary 
Gliclazide Preferred sulfonylurea 
No dose adjustment necessary 
Not available in US 
Glyburide, Glimepiride Avoid 
Alpha-glucosidase 
inhibitors 
Acarbose Avoid 
Miglib Avoid 
Biguanides Metformin Avoid 
Meglitinides Repaglinide No dose adjustment necessary 
Nateglinide Avoid 
Thiazolidinediones Pioglitazone No dose adjustment necessary 
Rosiglitazone No dose adjustment necessary 
Incretin minetic Exenatide No dose adjustment necessary 
Amylin analog Praminide No data available 
DPP-4 inhibitor Sitagliptin Reduce dose by 75% 
(25mg/day) 
Source: The National Kidney Foundation KDOQI clinical practice guidelines and 
clinical practice recommendations for diabetes and chronic kidney disease 
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1.2.2.4 Hypertension and ESRD 
Hypertension is very prevalent among dialysis patients (50-60%) when hypertension is 
defined as blood pressure > 150/90 mm Hg for hemodialysis patients and contributes to 
increased cardiovascular morbidity in patients. (National Kidney Foundation 2005)  
While blood pressure control may improve cardiovascular outcomes in hemodialysis 
patients, the management of blood pressure in this population is challenging.  
Nonpharmacologic interventions to improve blood pressure include educating patients 
about limiting sodium intake, ensuring adequate sodium removal during hemodialysis, 
and achieving target dry weight. (Inrig 2010)  However, most patients require 
antihypertensive medications to achieve an appropriate blood pressure.   
 
It has long been believed that hypertension is a major cause of morbidity and mortality in 
dialysis patients, as is the case in the general population. (Charra, Calemard et al. 1996; 
Foley, Parfrey et al. 1996)  Foley et al. conducted a prospective study with a cohort of 
432 dialysis patients followed for an average of 41 months.  After adjusting for age, 
diabetes, heart disease, and hemoglobin levels, each 10mmHg rise in mean arterial blood 
pressure was independently associated with the development of cardiac failure and 
ischemic heart disease. (Foley, Parfrey et al. 1996)   
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Several observational studies, however, have not shown a consistent association between 
blood pressure and mortality.  Many of them have shown a U-shaped relationship with 
both low and high blood pressure being associated with an increased relative risk of 
death. (Zager, Nikolic et al. 1998; Foley, Herzog et al. 2002; Stidley, Hunt et al. 2006; 
Myers, Adams et al. 2010)  Zagar et al. reported a U-shaped relationship to the pre-
dialysis systolic blood pressure with the lowest mortality observed in the group being 
associated with blood pressure between 160 and 179 mmHg. (Zager, Nikolic et al. 1998).  
These observations were subsequently supported by other investigators.  The USRDS 
Dialysis Morbidity and Mortality Waves 3 and 4 Study, a randomized generated sample 
of 11,142 subjects receiving hemodialysis was examined. (Foley, Herzog et al. 2002)  In 
a comorbidity-adjusted model, low pre-dialysis diastolic, low post-dialysis diastolic, and 
high post-dialysis systolic blood pressure value were associated with higher mortality.  
Nonetheless, antihypertensive therapy, especially using beta-blockers, was statistically 
significantly associated with longer survival. (Foley, Herzog et al. 2002) 
 
Recent studies explored further the relationship between blood pressure and mortality 
using stratification by time, age, race, and diabetes status. (Stidley, Hunt et al. 2006; 
Myers, Adams et al. 2010)  Stidley et al. conducted a retrospective study to determine 
the relationship between blood pressure and mortality in 16,959 dialysis patients. 
(Stidley, Hunt et al. 2006)  The results demonstrated that the relationship between 
baseline blood pressure and mortality changed over time; low systolic blood pressure 
18 
(<120 mmHg) was associated with increased mortality in year 1-2. (Stidley, Hunt et al. 
2006)  High systolic blood pressure (≥150 mmHg) was associated with increased 
mortality among patients who survived ≥3 years. (Stidley, Hunt et al. 2006)  In addition, 
Myers et al. reported that low systolic blood pressure was associated with increased 
mortality, and the association was more pronounced among older patients and those with 
diabetes.  However, higher systolic blood pressure was associated with increased 
mortality among younger patients, regardless of race or diabetes status. (Myers, Adams et 
al. 2010) 
 
1.2.2.4.1 Treatment of Hypertension in Dialysis Patients 
Blood pressure is usually raised in patients receiving dialysis, possibly because the role of 
the kidneys in blood pressure homoeostasis is impaired; chronic volume overload and a 
range of other factors might also contribute to high blood pressure. (Heerspink, Ninomiya 
et al. 2009) 
 
The NKF KDOQI has recently recommend pre-dialysis (<140/90 mmHg) and post-
dialysis (<130/80 mmHg) blood pressure goals. (National Kidney Foundation 2005)  
The supporting evidence was graded as weak because it was extrapolated from the 
general population.  The KDOQI Clinical practice guidelines for CVD in dialysis 
patients recommends drugs that inhibit the renin-angiotensin system, such as angiotensin-
converting-enzyme (ACE) inhibitors or angiotensin II-receptor blockers.  These are 
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preferred because they cause greater regression of left ventricular hypertrophy, reduce 
sympathetic nerve activity, reduce pulse wave velocity, may improve endothelial 
function, and may reduce oxidative stress. (National Kidney Foundation 2005) 
 
There was an important worldwide hemodialysis study, representing approximately 70 
percent of the world’s hemodialysis patient population, coordinated by the Arbor 
Research Collaborative for Health. (Health 2012)  The Dialysis Outcomes and Practice 
Patterns Study (DOPPS) was an international, prospective, observational study of 
practice patterns and associated outcomes involving maintenance hemodialysis facilities 
and patients. (Pisoni, Gillespie et al. 2004)  The DOPPS comprise three phases (DOPPS 
I-III).  In DOPPS I (1996-2001), 17,034 patients were sampled from 308 dialysis 
facilities in France, Germany, Italy, Spain, the United Kingdom, Japan and the U.S.  In 
DOPPS II (2002-2004), 12,839 patients were sampled from 322 facilities in 12 countries 
(the original 7 countries, with Australia, Belgium, Canada, New Zealand, and Sweden).  
In DOPPS III (2005-2007), more than 9,000 patients were sampled from 12 countries.  
Nationally representative samples of dialysis facilities were recruited in each country.  
Within each participating facility, study patients were randomly selected. 
  
The efficacy and safety of lowering blood pressure in dialysis patients are unknown as 
showned previously, however, but the benefits of antihypertensive agents have been 
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reported. (Lopes, Bragg-Gresham et al. 2009)  Data from DOPPS I and DOPPS II were 
used to assess which classes of antihypertensive agents were associated with a lower risk 
of all-cause and cardiovascular-related mortalities.  Despite large variations across 
countries in antihypertensive agents used for hemodialysis patients, significant 
associations with a reduction in cardiovascular mortality rates were observed for 
angiotensin receptor blockers and beta blockers. (Lopes, Bragg-Gresham et al. 2009)   
 
Furthermore, two recent meta-analyses of randomized controlled trials revealed control 
of blood pressure in hemodialysis patients contributes to regression of left ventricular 
hypertrophy and improved cardiovascular morbidity and mortality rates. (Agarwal and 
Sinha 2009; Heerspink, Ninomiya et al. 2009)  Agarwal et al. found that patients on 
antihypertensive therapy compared with the control group had a 38 percent reduced risk 
for cardiovascular events (p<0.05).  In the eight evaluated studies by Heerspink et al., 
antihypertensive therapy was associated with a 29 percent lower relative risk of 
cardiovascular events (p<0.05), a 20 percent lower relative risk of all-cause mortality 
(p<0.05), and a 29 percent lower relative risk of cardiovascular mortality (p<0.05), even 
though the absolute reductions in blood pressure were small. (Heerspink, Ninomiya et al. 
2009)  
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1.2.2.5 Hyperlipidemia and ESRD   
Dyslipidemia is common in people with diabetes and CKD.  Hypercholesterolemia has 
been established as one of the primary risk factors associated with CVD outcomes in the 
general population.  However, the association between quantitative lipid abnormalities 
and outcomes in ESRD are inconsistent and counterintuitive. (Foley and Parfrey 1998)  
Surprisingly, higher cholesterol levels have been associated with lower mortality in 
dialysis patients (Lowrie and Lew 1990), which stands in marked contrast to prospective 
studies and clinical trial findings in the general population.  Lowrie et al. revealed that 
overall mortality in 12,000 ESRD patients increased exponentially when the serum total 
cholesterol decreased from a range of 200-250 to less than 100mg/dL. (Lowrie and Lew 
1990)  This prospective study in dialysis patients also found that hypocholesterolemia 
was an independent predictor of death in dialysis patients.  A recent study has replicated 
this reverse epidemiology for lipid variables.  Data revealed that lower levels of low-
density lipoprotein (LDL) and total cholesterol were predictors of an increased mortality 
rate. (Bowden, La Bounty et al. 2011) 
   
It has been suggested, but remains unproven, that this paradoxical U-shaped relationship 
between mortality and total cholesterol in ESRD may be explained partly by reverse 
causation, in which advanced CVD leads to inflammation and/or malnutrition and lower 
cholesterol levels, or a confounding effect of inflammation and/or lower cholesterol 
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levels and higher mortality rates. (Coresh, Longenecker et al. 1998; National Kidney 
Foundation 2003; Liu, Coresh et al. 2004)  A prospective study revealed that there was a 
strong and positive association of serum cholesterol levels with overall and CVD 
mortality in the absence of inflammation/malnutrition, whereas an inverse association of 
cholesterol levels with all-cause mortality and a U-shaped relationship with CVD 
mortality in presence of inflammation/malnutrition was found. (Liu, Coresh et al. 2004)  
Other studies have suggested these same findings in dialysis patients who had 
inflammation and were malnourished. (Nurmohamed and Nube 2005; Diepeveen, 
Wetzels et al. 2008)  
 
1.2.2.5.1 Treatment of Dyslipidemia in ESRD 
Although the published data have yet to confirm the target of treatment for dyslipidemia 
in dialysis patients, the NKF KDOQI clinical practice guidelines for managing 
dyslipidemia were published in 2003. (National Kidney Foundation 2003)   
4.1. For adults with stage 5 CKD and fasting triglycerides ≥ 500mg/dL (≥ 
5.65mmol/L) that cannot be corrected by removing an underlying cause, 
treatment with therapeutic lifestyle changes and a triglyceride-lowering agent 
should be considered. 
4.2 For adults with stage 5 CKD and LDL ≥ 100mg/dL (≥ 2.59mmol/L), treatment 
should be considered to reduce LDL to <100mg/dL (< 2.59mmol/L). 
4.3 For adults with stage 5 CKD and LDL <100mg/dL (<2.59mmol/L), fasting 
triglycerides ≥ 200 mg/dL (≥ 2.26mmol/L), and non-high-density lipoprotein 
(HDL) cholesterol (total cholesterol minus HDL) ≥ 130 mg/dL (≥ 3.36mmol/L), 
treatment should be considered to reduce non-HDL cholesterol to < 130 md/dL 
(<3.36 mmol/L). 
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Results from several randomized controlled trials (RCTs) in hemodialysis patients did not 
indicate significant improvements in reduction in CVD with the use of statins. (Wanner, 
Krane et al. 2005; Holdaas, Holme et al. 2011)  The 4D trial (Die Detsche Diabetes 
Dialysis Studie) had a total of 1,200 type II diabetics undergoing hemodialysis who were 
randomized to atorvastatin 20mg/day or placebo for four years.  This study found that 
atorvastatin had a non-significant eight percent relative risk reduction in cardiovascular 
events. (Wanner, Krane et al. 2005)  Another randomized controlled trial, the AURORA 
(A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: an 
Assessment of Survival and Cardiovascular Events), compared rosuvastatin 10mg/day 
with placebo in 2,700 hemodialysis patients. (Holdaas, Holme et al. 2011)  Assignment 
to rosuvastatin was associated with a non-significant 16.2 percent reduction in risk for 
CVD and mortality with mean follow-up of 3.2 years. (Holdaas, Holme et al. 2011)  
In contrast, a recent randomized clinical trial demonstrated favorable results of using 
statins on occurrence of a first major vascular event in patients with CKD.  The SHARP 
(Study of Heart and Renal Protection) trial included 9,270 patients, who were randomly 
assigned to simvastatin 20mg plus ezetimibe 10mg versus matching placebo. (Baigent, 
Landray et al. 2011)  During five years, allocation to simvastatin plus ezetimibe reduced 
LDL cholesterol by an average of 0.85 mmol/L, yielding a reduction of 17 percent in 
major atherosclerotic events but no benefit on survival. (Baigent, Landray et al. 2011)   
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There were observational studies suggesting a benefit from treating dyslipidemia in 
patients on hemodialysis.  In the USRDS Dialysis Morbidity and Mortality Study, 3,700 
patients on hemodialysis were followed for two years.  Statin users had a 32 percent 
relative risk reduction in total mortality, whereas fibrate users had no reduction in 
cardiovascular or total mortality. (Seliger, Weiss et al. 2002)  In the Dialysis Outcomes 
Practice Patterns Study (DOPPS), 9,800 hemodialysis patients were followed for five 
years, and statin users had a 31 percent relative risk reduction in total mortality compared 
with nonusers. (Andreucci, Fissell et al. 2004)  
 
1.2.2.6 Mineral and Bone Disorder (MBD) and ESRD  
Recently, the Kidney Disease Improving Global Outcomes (KDIGO) published clinical 
practice guidelines on the management of chronic kidney disease-mineral and bone 
disorder (CKD-MBD). (Kidney Disease: Improving Global Outcomes (KDIGO) 2009)  
CKD-MBD was defined as the broader clinical syndrome encompassing mineral, bone, 
and calcific cardiovascular abnormalities that develop as a complication of CKD. (Moe 
SM 2009)  Disturbed mineral and bone metabolism is common in CKD patients, 
especially abnormalities in serum calcium, phosphorous, and parathyroid hormone levels.  
It is an important cause of morbidity and decreased health-related quality of life in CKD 
patients. (Moe, Drueke et al. 2006)  Importantly, these disorders in mineral and bone 
metabolism have been associated with increased cardiovascular calcification, morbidity, 
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and mortality (Covic, Kothawala et al. 2009) and result in a high burden of economic 
costs. (Komaba, Moriwaki et al. 2009)   
Specifically, high phosphorous levels have been associated with a greater risk for all-
cause and cardiovascular mortality, as well as hospitalizations due to both cardiovascular 
events and fractures. (Block, Hulbert-Shearon et al. 1998; Block, Klassen et al. 2004; 
Kestenbaum, Sampson et al. 2005; Tentori, Blayney et al. 2008)  Consequently, 
phosphate control has become an important therapeutic target in CKD, primarily to 
reduce the risk of vascular calcification and cardiovascular mortality. (Hutchison 2009)  
In addition to high phosphorous levels, secondary hyperparathyroidism (sHPT) is 
common in patients with ESRD, affecting most of those who are receiving hemodialysis. 
This disorder is characterized by persistently elevated levels of parathyroid hormone and 
complicated by important disturbances in mineral metabolism. (Block, Martin et al. 2004) 
Bone disease is the most widely recognized consequence of sHPT.  Several reports 
indicated, however, that alterations in calcium and phosphorus metabolism, partially as a 
result of sHPT contribute to soft-tissue and vascular calcification, cardiovascular disease, 
and risk of death. (Block and Port 2000) 
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1.2.2.6.1 Hyperphosphatemia 
Treatment guidelines issued by the NKF KDOQI recommend that serum phosphorous 
levels should be maintained between 3.5 and 5.5 mg/dl for patients with ESRD. (Eknoyan 
2003)  
About 90 percent of dialysis patients continue to require oral phosphate binders 
(Mohammed and Hutchison 2008) due to limited effectiveness of dietary phosphate 
restriction (Uribarri 2007) and insufficiency of hemodialysis to maintain phosphate levels 
within recommended targets. (Hutchison 2009)  The most commonly used phosphate 
binders are calcium salts.  Calcium-based binders (calcium carbonate and calcium 
acetate) have been the standard of care in phosphate-binding therapy for almost 20 years 
and are relatively inexpensive. (Sprague 2007)  However, calcium salts have been 
associated with an increased risk of hypercalcemia and vascular calcification, especially 
with long-term or high-dose use. (Chertow, Raggi et al. 2004)  In addition, the KDOQI 
panel recommends that the daily calcium intake from phosphate binders should not 
exceed 1,500mg, which could limit the use of calcium-based binders. (Eknoyan 2003)  
Thus, there is significant interest in the optimal use of non-calcium binders to achieve 
and maintain KDOQI targets. (Barton Pai, Conner et al. 2009)  Lanthanum carbonate, 
sevelamer hydrochloride, and sevelamer carbonate are non-calcium, non-aluminum 
binders available in the U.S. (Mohammed and Hutchison 2008)   
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Isakova noted longer survival for hemodialysis patients prescribed versus not prescribed 
phosphate binders even for patients with serum phosphorous levels within the 
recommended range (3.5-5.5 mg/dL). (Isakova, Gutierrez et al. 2009)  Further evidence 
of association between prescribed phosphate binders and mortality was provided by the 
DOPPS, a prospective cohort study of 23,898 maintenance hemodialysis patients at 923 
facilities in 12 countries. (Lopes A.A. 2012)  This study found that patients prescribed 
phosphate binders had a 25 percent lower mortality rate (hazard ratio, 0.75; 95% CI, 
0.68-0.83) when adjusted for serum phosphorus level and other covariates; further 
adjustment for nutritional indicators attenuated this association (hazard ratio, 0.88; 95% 
CI, 0.80-0.97).  The improved patient survival in facilities with a higher percentage of 
patients prescribed phosphate binders was explained in part by the better nutritional status 
and more liberal dietary intake with phosphate binders. (Isakova, Gutierrez et al. 2009) 
 
1.2.2.6.2 Secondary Hyperparathyroidism 
Treatment guidelines issued by the NKF KDOQI recommend that patients be treated to 
achieve parathyroid hormone levels between 150 and 300 pg/ml. (Eknoyan 2003) 
Cinacalcet (Senipar®) is a first-in-class calciminetic used with other therapies such as 
phosphate binders and vitamin D sterols, for sHPT in patients on dialysis.  Calciminetic 
acts directly on calcium-sensing receptors expressed in parathyroid glands, and reduces 
parathyroid hormone secretion by rendering parathyroid cells more sensitive to inhibitory 
actions of extracellular calcium. (Goodman, Hladik et al. 2002)  Since cinacalcet 
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became commercially available in 2004, there were few studies that examined health 
outcomes associated with use of cinacalcet.   
 
In a combined analysis of four randomized, double-blind, placebo-controlled clinical 
trials, Cunningham et al. found that randomization to cinacalcet led to significant 
reductions in the risk of parathyroidectomy, fracture, and cardiovascular hospitalization. 
(Cunningham, Danese et al. 2005)  
  
Recently, an observational study examined the impact of cinacalcet treatment on all-
cause and cardiovascular-related survival in hemodialysis patients. (Block, Zaun et al. 
2010)  This study found that the adjusted all-cause mortality rate for patients with 
cinacalcet prescriptions was 26 percent lower than for non-cinacalcet patients (hazard 
ratio, 0.74; 95% CI, 0.68-0.78). (Block, Zaun et al. 2010)  In addition, the adjusted 
cardiovascular mortality rate was 24 percent lower in patients with cinacalcet compared 
to control patients (hazard ratio, 0.76; 95% CI, 0.66-0.86).   
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1.2.3 Prescription Medications, Pill Burden, and Adherence in ESRD Patients   
Chronic dialysis patients face many health problems including chronic inflammatory 
state, malnutrition, increase risk for cardiovascular morbidity and mortality, phosphate 
retention, secondary hyperparathyroidism, diabetes and dyslipidemia as a result of 
incomplete replacement of kidney function. (Katzir, Boaz et al. 2010)  Most patients 
therefore require polypharmacy which often includes phosphate binders, vitamin D or 
calcimimetic preparations, statin agents, erythropoietin, and iron supplements as well as 
medications for comorbidities. 
  
Estimates of medication use among ESRD patients range from 10 to 14 medications per 
day in the U.S. (Manley, Bailie et al. 2000; Manley, Garvin et al. 2004)  Manley et al. 
noted that patients were prescribed, on average, 12.3 ± 5.0 (median 12) different 
medications (2.6 ± 1.4 clinic medications and 10.0±4.5 home medications) in ambulatory 
hemodialysis patients within the Dialysis Clinic database. (Manley, Garvin et al. 2004)  
Upon further examination of home medications, researchers found that cardiac 
medications (any agent used for hypertension, congestive heart failure, coronary artery 
disease, arrhythmia, or hyperlipidemia), gastrointestinal medications, and phosphate 
binding agents accounted for 55 percent of medication expenditures. (Manley and 
Cannella 2005)  Diabetes mellitus patients were prescribed more medications than non-
diabetes mellitus patients (11.1±4.6 versus 9.6±4.8; p<0.001).  Medication costs for 
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hemodialysis patients were estimated to be $16,000 per patient per year. (Manley and 
Cannella 2005)  
Much of the more recent empirical literature on prescription drug adherence in dialysis 
has focused on phosphate binders and cinacalcet. (Chiu, Teitelbaum et al. 2009; Lee, 
Song et al. 2011)  Recently, Chiu et al. assessed total pill burden, adherence to 
phosphate binders, and serum phosphorous levels in 253 prevalent chronic dialysis 
patients. (Chiu, Teitelbaum et al. 2009)  The results showed that the median daily pill 
burden was 19; in addition, 25 percent of patients took more than 25 pills per day.  
Phosphate binders accounted for 50 percent of the daily pill burden; and only 38 percent 
of the patients were adherent to their phosphate binder therapy (≥ 80% pill consumption). 
(Chiu, Teitelbaum et al. 2009)  Although there was no significant relationship between 
adherence and serum phosphorus levels, a significant inverse relationship between 
adherence to phosphate binders and pill burden from phosphate binders was observed 
(p<0.05). (Chiu, Teitelbaum et al. 2009)   
 
Lee et al. conducted a retrospective cohort study of dialysis patients with an initial 
cinacalcet prescription to assess the relationship between cinacalcet adherence and 
healthcare costs. (Lee, Song et al. 2011)  Medication possession ratio (MPR) was used 
to measure adherence.  Patients were dichotomized as adherent (<180 days refill gap) or 
non-adherent (≥180 day refill gap).  Researchers found that 30 percent of patients 
discontinued cinacalcet by the 6th month, and 46 percent by the 12th month post-index 
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date, respectively. (Lee, Song et al. 2011)  Adherent patients at 12 months were further 
dichotomized as low adherent (<0.8 MPR) and high adherent (≥0.8 MPR).  During 12 
months, 27 percent were low adherent (i.e., without a 180-day gap but < 0.8 MPR), and 
28 percent were high adherent (i.e., without a 180-day gap and ≥ 0.8 MPR).  High 
cinacalcet adherence was associated with significantly lower inpatient costs with cost-
savings of greater magnitude ($8,899) than the increased medication costs ($5,858).  In 
another study of the assessment of adherence to cinacalcet in dialysis patients in a 
Missouri state-funded pharmacy program, Gincherman et al. found similar adherence 
rates, where 29 percent patients were highly adherent (≥ 0.8 MPR). (Gincherman, 
Moloney et al. 2010) 
 
A recent systematic literature review of the Medline and Pubmed database (1971-2008) 
was conducted to quantify non-adherence in hemodialysis patients to certain oral 
medications and to raise awareness of factors that may cause problems in a patient’s 
adherence to this treatment. (Schmid, Hartmann et al. 2009)  A total of 19 studies were 
identified as reporting total rates of non-adherence to oral medication among adult 
hemodialysis patients:  (1) 18/19 studies for phosphate binders, (2) 11/19 studies for 
antihypertensive drugs, and (3) 8/19 studies for oral calcium supplementation.  Self-
reports or structured interviews (patients self-reports, 16/19 studies) were the most 
frequently used tools to assess adherence rates.   
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Two studies by Curtin et al. used medication event monitoring devices (MEMS) to 
monitor adherence to antihypertensives and phosphate binders. (Curtin, Svarstad et al. 
1997; Curtin, Svarstad et al. 1999).  The first study found that almost 30 percent of older 
patients (> 65) and more than 32 percent of younger patients (≤ 65) missed their 
antihypertensives completely on 20 percent or more of the prescribed days.  In addition, 
18 percent of the older patients, but 33 percent of younger patients, missed their 
phosphate binders on 20 percent or more of prescribed days. (Curtin, Svarstad et al. 
1997)  Another study described the prevalence, severity, and patterns of non-compliance 
with prescribed medications among hemodialysis patients. (Curtin, Svarstad et al. 1999)  
The results demonstrated that 52 percent of patients monitored for antihypertensive use 
were repeatedly noncompliant according to the MEMS, whereas 42 percent were 
noncompliant based on the pill count over a six-weeks monitored period.  For phosphate 
binders, 70 percent of patients were estimated to be repeatedly noncompliant both by 
MEMS measurement and pill count.   
 
1.2.4 Summary of Section 
The prevalence of ESRD is continuously increasing in the U.S.  However, morbidity 
and mortality of maintenance of dialysis patients remain high and only about one-third of 
the US hemodialysis patients are alive after five years.  CVD is the leading cause of 
mortality in ESRD.  Notably, patients with ESRD have a very high prevalence of CVD 
risk factors such as diabetes, hyperlipidemia and hypertension, but they are also exposed 
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to other non-traditional, uremia-related cardiovascular disease factors (i.e., calcium and 
phosphate metabolism).  Most dialysis patients therefore require many medications and 
have a high pill burden.  Unfortunately, poor adherence with prescribed medication is a 
widely recognized problem in dialysis patients due to the complexity of the regimen and 
lifelong duration of therapy.  
Most dialysis patients are eligible for Medicare benefits.  The next chapter will review 
the Medicare Part D prescription drug benefit in ESRD patients.  In addition, the next 
chapter will discuss the impact of cost-sharing policies on health outcomes, and the 
impact of Part D on health outcomes in general populations and dialysis patients. 
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1.3 Section 2: Medicare Part D  
1.3.1 Medicare Overview 
Established in 1965 under Title XVIII of the Social Security Act, Medicare was initially 
established to provide health insurance to individuals age 65 and older, regardless of 
income or medical history. (The Henry J. Kaiser Family Foundation 2010)  The 
program was expanded in 1972 to include individuals under age 65 with permanent 
disabilities and people suffering from ESRD.  In 2001, Medicare eligibility expanded 
further to cover people with amyotrophic lateral sclerosis (ALS, or Lou Gehring’s 
disease).  Individuals age 65 and over qualify for Medicare if they are U.S. citizens or 
permanent legal residents. (The Henry J. Kaiser Family Foundation 2010)  Individuals 
qualify without regard to their medical history or preexisting conditions, and do not need 
to meet an income or asset test.  Adults under age 65 with permanent disabilities are 
eligible for Medicare after receiving Social Security Disability Income (SSDI) payments 
for 24 months, even if they have not made payroll tax contributions for 40 quarters. (The 
Henry J. Kaiser Family Foundation 2010)  People with ESRD or Lou Gehrig’s disease 
are eligible for Medicare benefits as soon as they begin receiving SSDI payments, 
without having to wait 24 months. (The Henry J. Kaiser Family Foundation 2010)  
In 2010, approximately 47 million Americans had Medicare coverage, including 39 
million people aged 65 and older and another eight million younger adults with 
permanent disabilities. (The Henry J. Kaiser Family Foundation 2010)  Medicare 
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spending was estimated to be $519 billion in 2010, nearly 25 percent of all spending on 
health in the U.S. (The Henry J. Kaiser Family Foundation 2010) 
Medicare consists of four parts, each covering different benefits: Part A, Part B, Part C, 
and Part D. (The Henry J. Kaiser Family Foundation 2011)  
Part A is known as the Hospital Insurance program which covers inpatient hospital 
services, skilled nursing facilities, home health, and hospice care.  Individuals who are 
entitled to Part A do not pay premiums for covered services.  Individuals aged 65 and 
over who are not entitled to Part A, such as those who did not pay enough Medicare taxes 
during their working years, can pay a monthly premium to receive Part A benefits. (The 
Henry J. Kaiser Family Foundation 2010)  Part A benefits are subject to a deductible 
($1,156 in 2012) and coinsurance. (Klees 2009)  In 2011, Part A accounted for 
approximately 31 percent of Medicare benefit spending.   
 
Part B is the Supplementary Medical Insurance program, and helps pay for physician, 
outpatient, home health, and preventive services.  Part B is voluntary, but about 95 
percent of beneficiaries with Part A are also enrolled in Part B. (The Henry J. Kaiser 
Family Foundation 2010)  For most individuals who become entitled to Part A, 
enrollment in Part B is automatic unless the individual declines enrollment.  Individuals 
who do not sign up for Part B when they are first eligible typically pay a penalty for late 
enrollment, in addition to the regular monthly premium ($110.50 in 2010) with the 
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exception of individuals if they receive employment-based coverage. (The Henry J. 
Kaiser Family Foundation 2010)  Part B benefits are subject to an annual deductible 
($155 in 2010), and 20 percent coinsurance generally applies for most Part B benefits. 
(Klees 2009)  Part B accounted for 18 percent of benefit spending in 2011. 
 
Medicare Parts A and B constitute the original fee-for-service Medicare program. 
Medicare Part C is an alternative to traditional Medicare.  While all Medicare 
beneficiaries can receive their benefits through the traditional fee-for-service program, 
most beneficiaries enrolled in both Part A and Part B can choose to participate in a Part C 
program instead. (Klees 2009) 
 
Part C refers to the Medicare Advantage program, which allows beneficiaries to enroll in 
a private plan, such as a health maintenance organization (HMO), preferred provider 
organization (PPO), or private fee-for-service (PFFS) plan.  Beneficiaries may generally 
elect to enroll in a Medicare Advantage plan on an annual basis between October 15 and 
December 7 of each year during the annual election period.  Nearly 12 million 
beneficiaries were enrolled in a Medicare Advantage Plan in 2011 (25% of all 
beneficiaries). (The Henry J. Kaiser Family Foundation 2011)  Medicare Advantage 
accounted for 21 percent of benefit spending in 2011. 
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Part D is the voluntary, subsidized outpatient prescription drug benefit, with additional 
subsidies for beneficiaries with low incomes and modest assets.  The Part D benefit is 
offered through private plans - either stand-alone prescription drug plans (PDPs) or 
Medicare Advantage prescription drug plans (MAPDs) - that contract with Medicare. 
(The Henry J. Kaiser Family Foundation 2009)  Plans are required to provide a standard 
benefit or one that is actuarially equivalent, and may offer more generous benefits.  Part 
D enrollees pay a monthly premium, along with cost-sharing amounts for each 
prescription.  Part D is funded by general revenues, beneficiary premiums, and state 
payments, and it accounted for 12 percent of benefit spending in 2011. (The Henry J. 
Kaiser Family Foundation 2011)  More than 29 million beneficiaries were enrolled in a 
Medicare Part D plan in 2011. (The Henry J. Kaiser Family Foundation 2011) 
 
1.3.2 Medicare Part D 
In 2006, the U.S. government expanded its Medicare health insurance program to offer a 
prescription drug insurance benefit, Medicare Part D, to improve affordability of essential 
medications for the beneficiaries. (Centers for Medicare and Medicaid Services 2005)  
Medicare beneficiaries have access to an outpatient prescription drug benefit (Part D) 
offered through private health plans: either stand-alone PDPs or MAPDs, as described 
above.  In 2010, 1,576 PDPs were available nationwide, up from 1,429 in 2006.  
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Beneficiaries in most states could choose from at least 45 stand-alone PDPs and multiple 
MAPDs. (The Henry J. Kaiser Family Foundation 2010) 
To obtain Part D benefits, beneficiaries must enroll in a PDP or MAPD.  The annual 
election period for Part D benefits runs from November 15 to December 31 of each year, 
until 2011, when the election period was changed to October 15 to December 7.  
Individuals who delay enrollment in Part D and are without creditable drug coverage, at 
least comparable to the Part D standard benefit, pay a permanent premium penalty for 
late enrollment. (The Henry J. Kaiser Family Foundation 2010)  In 2010, the national 
average monthly Part D premium including PDPs and MAPDs was $31.94.  Monthly 
Part D premiums and cost-sharing amounts are not uniform nationwide, but vary across 
plans and regions, ranging from a low of $8.80 in Oregon and Washington to a high of 
$120.20 in Delaware, Maryland, and Washington, D.C. (Foundation 2010) 
Part D coverage includes most FDA-approved prescription drugs and biological products.  
However, plans may set up formularies for their prescription drug coverage, subject to 
certain statutory standards.  Medicare excludes some drugs for anorexia, weight loss, 
weight gain, infertility, cosmetic purposes (e.g., hair growth), cold and cough medicines, 
nonprescription or over-the-counter products, barbiturates, benzodiazepines, and vitamins 
and minerals, except for active vitamin D analog. (Levinson 2006)  
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The Part D program differs significantly from the traditional Medicare program in that it 
relies on numerous private companies that offer plans with varying cost sharing structures 
and provisions to provide benefits. (Howell, Powers et al. 2012)  The standard Part D 
benefit design includes a novel cost containment feature, the “coverage gap.” (Neuman, 
Strollo et al. 2007)  In 2007, patients with total Part D drug costs up to $2,400 fell into 
the initial coverage phase, while those with costs over that amount entered the coverage 
gap (also called the “donut hole”), in which they were responsible for 100 percent of drug 
costs. (US Renal Data System 2011)  At the end of the gap, patients whose out-of-
pocket costs reached $3,850 ($265 deductible + $600 out-of-pocket (25% of $2400) + 
$2985) then entered the catastrophic coverage phase, in which they paid only a fraction 
of overall drug costs (Figure 1.4). (US Renal Data System 2011)  The Part D coverage 
gap involves substantial periods of uncovered drug use and may increase out-of-pocket 
spending for beneficiaries because they pay the full price of drugs filled during these 
periods. (Fung, Mangione et al. 2010)   
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Figure 1.4  Standard Medicare Prescription Drug Benefit, 2007 
 
Source: The Henry J. Kaiser Family Foundation Medicare Fact Sheet 
 
The Part D program offers a low-income subsidy (LIS) benefit to enrollees with limited 
assets ($12,510/individual; $25,010/couple in 2010) and income at or below 150 percent 
of the federal poverty level ($16,245 for an individual; $21,855 for a couple in 2010), 
including those who are dually-enrolled. (The Henry J. Kaiser Family Foundation 2011)  
The LIS provides full or partial waivers for many out-of-pocket cost sharing 
requirements, including premiums, deductibles, and copayments, and provides full or 
partial coverage during the coverage gap. (The Henry J. Kaiser Family Foundation 2011; 
US Renal Data System 2011)  The Centers for Medicare & Medicaid (CMS) estimates 
41 
that 12.5 million beneficiaries were potentially eligible for the LIS as of February 2009. 
(Centers for Medicare & Medicaid Service 2012)   
 
Among Part D enrollees who filled one or more prescriptions but did not receive the LIS 
in 2007, 26 percent had spending high enough to reach the coverage gap. (Hoadley J 
2008)  Fifteen percent of these Part D enrollees who reached the coverage gap 
ultimately had spending high enough to reach catastrophic coverage. (Hoadley J 2008)  
Applying this estimate to the entire population of Part D enrollees, the analysis suggested 
that about 3.4 million beneficiaries (14 percent of all Part D enrollees) reached the 
coverage gap and faced the full cost of their prescriptions. (The Henry J. Kaiser Family 
Foundation 2010)  
  
1.3.3 Prescription Drug Cost Sharing  
Prescription drug expenditures are one of the fastest growing components of national 
health expenditures.  Over the past decade, the cost of prescription drugs has been rising 
at about 10 percent per year. (Smith, Cowan et al. 2005; Goldman 2009)  In an attempt 
to control prescription drug costs, health plans and employers have increased prescription 
drug cost sharing amounts for patients.  Cost sharing represents the price of the 
prescription drug to the insured patient, while insurance covers the remainder of the cost. 
(Gibson, Ozminkowski et al. 2005)  The typical features are copayments, coinsurance, 
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deductibles, and upper limits on coverage. (Phelps 2010)  An increase in the level of 
cost sharing specified in insurance policies may be implemented by raising copayments, 
adding a flat fee assessed per prescription (e.g., $10), or increasing the coinsurance ratio - 
a fixed fraction of each dollar of cost (e.g., 20%). (Phelps 2010) 
     
Insurers call the change in behavior that occurs when a person becomes insured “moral 
hazard.”  Moral hazard occurs when an insured person makes extra purchases that he or 
she would not otherwise have purchased. (Nyman 2004)  In theory, increasing the share 
of costs paid by patients creates an incentive for more efficient use of care. (Phelps 2010)  
Cost sharing can be advantageous when physician and patients collaborate on 
appropriate, cost-effective drug therapy decisions. (Hsu, Price et al. 2006)  Conversely, 
the burden of cost sharing can create barriers to care, especially for patients requiring 
long-term drug therapy. (Piette, Heisler et al. 2006; Goldman, Joyce et al. 2004)  It is 
widely accepted, based on considerable evidence accumulated over decades of study, that 
higher cost sharing will lead to reduced healthcare expenditures. (Chernew and 
Newhouse 2008)  However, the impact of cost sharing on health status has been much 
more controversial. 
 
1.3.3.1 The RAND Health Insurance Experiment 
To date, the most comprehensive, ‘gold standard’ study to examine the impact of cost 
sharing on health utilization and outcomes has been the RAND Health Insurance 
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Experiment (HIE). (Brook, Ware et al. 1983; Manning, Newhouse et al. 1987)  The 
RAND HIE was a randomized, controlled trial conducted by the federal government in 
the 1970s in which almost 6,000 enrollees were randomized to various insurance plans. 
(Phelps 2010)  
The insurance plans differed by coinsurance rate and maximum out-of-pocket costs.  
The coinsurance rates were 0, 25, 50, or 95 percent.  Each plan had maximum annual 
out-of-pocket expenses of 5, 10, 15 percent of family income, up to a maximum of 
$1,000. (Manning, Newhouse et al. 1987)  Beyond the maximum out-of-pocket 
expenses, the insurance plan reimbursed all covered expenses in full. (Manning, 
Newhouse et al. 1987)  
   
The RAND HIE revealed several important findings, one of which was that coinsurance 
rates influenced medical utilization and expenditures. (Manning, Newhouse et al. 1987)  
Coinsurance rates were inversely associated with the probability of receiving any medical 
care.  The probability of receiving medical care in the free care cohort was significantly 
greater compared with the 95 percent coinsurance cohort (86.8% vs 67.7%; p<0.001). 
(Manning, Newhouse et al. 1987)  Another analysis of the RAND data found that the 
cost sharing cohorts were nearly one-third less likely to see a physician when they had 
minor symptoms (e.g., cough, sneezing, allergies, or stomach flu) than the free care 
cohort (6.3% vs 9%; p<0.04). (Shapiro, Ware et al. 1986)  The cost sharing cohorts and 
the free care cohort did not differ significantly in seeking care for serious symptoms (e.g., 
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chest pain, bleeding, loss of consciousness, or shortness of breath) (17.9% vs 22.3%; 
p=0.095). (Shapiro, Ware et al. 1986)  In addition, negative relationships were found 
between the coinsurance rate and total medical costs, although there was no difference in 
inpatient costs.  Mean total cost for the free care cohort was significantly higher ($749) 
than the cost for the 95 percent insurance cohort ($518) (p<0.001).  
Overall, an important finding was that although increased cost sharing was associated 
with decreased health care expenses, decreased health expenditures were not found to be 
associated with negative health consequences. (RAND Health 2006; Saverno K.R. 2011)  
Although the cost sharing cohorts used fewer services, their health outcomes did not 
differ from the free care cohort.  Availability of the free care plan did not affect self-
assessed health status, smoking habits, weight, or cholesterol. (Brook, Ware et al. 1983; 
Keeler, Sloss et al. 1987)  
 
However, there were exceptions to this overall finding; especially among people who 
were less healthy and of lower socioeconomic status at the start of the experiment.  They 
had better outcomes under the free care plan for four of the 30 conditions measured (e.g., 
hypertension, vision, dental care, and serious symptoms). (RAND Health 2006)  For 
example, the free care cohort had greater reductions in blood pressure and better 
functional far vision than cost sharing cohorts. (Keeler, Sloss et al. 1987)  In addition, 
for individuals with low socioeconomic status who began the study in poor health, the 
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prevalence of serious symptoms was higher in the cost sharing cohorts than the free care 
cohort (29.1% vs 23.8%; p<0.004). (Shapiro, Ware et al. 1986) 
    
Upon further examination, among people under the age of 65 who were at risk for 
adverse health outcomes (a group defined as the least healthy 25 percent of those studied 
with respect to self-reported physiologic measures and health related habits), the free care 
cohort had a reduction in the estimated risk of death by 10 percent, as compared with the 
cost sharing cohorts. (Brook, Ware et al. 1983)  Much of the more recent empirical 
literature on the impact of cost sharing on prescription utilization has come from 
observational research.   
 
1.3.3.2 Observational Studies: Prescription Cost Sharing 
Unlike RAND HIE where cost sharing changes occurred across nearly all health services, 
the post-RAND HIE literature on cost sharing has focused on prescription drug cost 
sharing. (Goldman, Joyce et al. 2004; Goldman, Joyce et al. 2007)  
 
A retrospective study from 1997 to 2000 found that doubling co-payments was associated 
with a reduction in use by 25 to 45 percent across eight common drug classes. (Goldman, 
Joyce et al. 2004)  The largest decreases occurred for nonsteroidal anti-inflammatory 
drugs (NSAIDs) (45%) and antihistamines (44%).  Reductions in overall days supplied 
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of antihyperlipidemics (34%), antiulcerants (33%), antiasthmatics (32%), 
antihypertensives (26%), antidepressants (26%), and antidiabetics (25%) were also 
observed. (Goldman, Joyce et al. 2004) 
  
Goodman et al. reviewed and summarized the 1985-2006 prescription drug cost sharing 
literature. (Goldman, Joyce et al. 2007)  Researchers found that increased cost sharing 
was associated with lower rates of drug treatment, lower rates of adherence, and more 
frequent discontinuation of therapy. (Goldman, Joyce et al. 2007)  On average, a 10 
percent increase in drug cost sharing resulted in prescription drug spending decreases of 
two percent to six percent, depending on class of drug and condition of the patient. 
(Goldman, Joyce et al. 2007) 
   
Out-of-pocket costs borne by patients usually are a major salient determinant of 
therapeutic adherence and, therefore, of the effectiveness of prescribed medications. 
(Hirth, Greer et al. 2008)  Even small increases in these costs can lead to potentially 
important reductions in medication adherence, which, in turn, can have serious 
consequences for patients’ health. (Goldman, Joyce et al. 2004) 
 
Several studies have documented that higher out-of-pocket medication costs, lower 
patient incomes, and less generous prescription benefits are each associated with lower 
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rates of prescription drug use. (Federman, Adams et al. 2001; Goldman, Joyce et al. 
2004; Piette, Heisler et al. 2004; Safran, Neuman et al. 2005)  Safran et al. documented 
variations in prescription use and out-of-pocket spending by drug coverage, poverty, and 
disease burden.  They examined cost-related nonadherence from 2003 national survey 
data in noninstitutionalized Medicare beneficiaries. (Safran, Neuman et al. 2005)  The 
researchers found that three attributes including: no coverage, low income, and high 
disease burden, were significantly associated with higher cost-related non-adherence 
(p<0.001). (Safran, Neuman et al. 2005)  Seniors without coverage reported 
significantly more cost-related non-adherence than those with coverage (p<0.001).  
More than 20 percent of seniors with congestive heart failure, diabetes, or multiple 
chronic conditions who lacked coverage reported that they did not fill at least one of their 
chronic disease medications in the past year because of costs. (Safran, Neuman et al. 
2005) 
  
A national survey examining the cost-related underuse of medications among chronically 
ill adults found that 18 percent of respondents cut back on medication use due to cost in 
the previous year.  Although rates of underuse varied substantially across treatments, 
prescription coverage and out-of-pocket costs were determinants of underuse across 
medication types. (Piette, Heisler et al. 2004)   
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Federman et al. conducted a cross-sectional retrospective study using 1997 Medicare 
Current Beneficiary Survey (MCBS), a nationally representative survey of randomly 
sampled Medicare beneficiaries conducted by CMS. (Federman, Adams et al. 2001)  
The findings indicated that statin use ranged from four percent in Medicare patients 
without drug coverage to 27 percent in patients with employer-sponsored drug coverage 
(P<0.001).  Another cross-sectional study reported that seniors in high-risk groups with 
no coverage had three to 15 times higher odds of medication restriction than others with 
partial or full coverage (p<0.001). (Steinman, Sands et al. 2001) 
The negative unintended consequences of drug cost sharing - including increased 
emergency department visits and nursing home admission, as well as decreased health 
status - have been observed. (Soumerai, Ross-Degnan et al. 1991; Tamblyn, Laprise et al. 
2001)  A time-series analysis of New Hampshire Medicaid’s implementation of a three 
prescription per month cap compared the rate of admission to nursing homes and 
hospitals for elderly patients in New Hampshire with a comparison cohort in a state 
without the cap (New Jersey). (Soumerai, Ross-Degnan et al. 1991)  In New Hampshire, 
the 35 percent decline in the use of study drugs after the cap was applied was associated 
with an increase in rates of admission to nursing homes, whereas no changes were 
observed in the comparison cohort. (Soumerai, Ross-Degnan et al. 1991)  When the cap 
was discontinued after 11 months, the use of medications returned nearly to baseline 
levels, and the excess risk of admission to nursing home vanished. (Soumerai, Ross-
Degnan et al. 1991)  Tamblyn et al. also demonstrated that increased cost sharing for 
49 
prescription drugs in elderly persons was followed by reductions in use of essential drugs 
and a higher rate of serious adverse events (i.e., the first occurrence of acute care 
hospitalization, long-term care admission, or death) or emergency department visits in 
Canada. (Tamblyn, Laprise et al. 2001)  
 
1.3.4 Impact of Medicare Part D coverage on Health Outcomes: Evidence to Date 
As mentioned earlier, a unique feature of the Medicare Part D drug benefit is the 
coverage gap, or so-called “doughnut hole,” where Part D enrollees are required to pay 
100 percent of total drug costs after their spending exceeds the initial coverage limit and 
before reaching the catastrophic coverage limit. (The Henry J. Kaiser Family Foundation 
2010)   
To date, researchers have observed reduced drug utilization among beneficiaries enrolled 
in Medicare Part D who reach the coverage gap spending threshold and have no financial 
assistance to pay for drugs. (Pedan, Lu et al. 2009; Schneeweiss, Patrick et al. 2009; 
Zhang, Donohue et al. 2009) 
 
Zhang et al. examined how MAPD beneficiaries with hypertension and diabetes respond 
to the increase in out-of-pocket drug spending after reaching the doughnut hole. (Zhang, 
Donohue et al. 2009)  Results indicated a 14 percent reduction in monthly prescriptions 
among beneficiaries who entered the coverage gap.  A study of senior Medicare 
50 
beneficiaries found that patients reaching the coverage gap experienced a 10 percent 
decrease in obtaining essential medications. (Pedan, Lu et al. 2009)  Nair et al. revealed 
that among patients with congestive heart failure, diabetes, dyslipidemia, or hypertension, 
27 percent of patients reached the coverage gap in 2006, of which four percent passed 
through the gap (to catastrophic coverage). (Nair, Frech-Tamas et al. 2011)  Patients < 
65 years were more likely to reach the gap sooner as compared to older beneficiaries and 
those without diabetes.  Beneficiaries took an average of 8.1 months to reach the gap 
and faced a 60 percent increase in out-of-pocket expenditures in the gap phase. (Nair, 
Frech-Tamas et al. 2011)  
 
In a survey of Kaiser Permanente-Northern California patients in 2006, approximately 36 
percent of Medicare Part D beneficiaries reported at least one of their responses to drug 
costs: cost-coping behavior (26%), reduced adherence (15%), or experiencing financial 
burden (7%). (Hsu, Fung et al. 2008)  Beneficiaries with lower household income (< $ 
40,000/year) more frequently reported cost responses. (Hsu, Fung et al. 2008)  Further 
evidence of predictors of the increased risk of using cost-lowering strategies when 
beneficiaries reached the coverage gap was provided by an evaluation of Kaiser 
Permanente Colorado patients. (Cronk, Humphries et al. 2008)  Results indicated that 
Medicare beneficiaries with a drug benefit threshold were three times more likely to 
adopt cost-lowering strategies (i.e., using less of a medication, discontinuing a 
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medication, or not filling a prescription) than beneficiaries who did not have a drug 
benefit threshold when entering the coverage gap.  
  
Several other studies have demonstrated decreases in medication adherence and 
unintended health outcomes in Medicare Part D beneficiaries who entered the coverage 
gap phase. (Hsu, Price et al. 2006; Raebel, Delate et al. 2008; Fung, Mangione et al. 
2010; Hales and George 2010; Polinski, Shrank et al. 2011)  An analysis of stand-alone 
PDP beneficiaries - who were randomly selected, and who utilized at least one 
cardiovascular medication - reported that 17 percent delayed medication, 12 percent 
switched medication, 10 percent both delayed and stopped medication, and 10 percent 
stopped at least one medication within the coverage gap. (Hales and George 2010)  In 
addition, Polinski et al. employed propensity-score matching to control for covariates in 
Medicare beneficiaries in 2006 and/or 2007. (Polinski, Shrank et al. 2011)  After 
matching, coverage gap-exposed beneficiaries were twice as likely to discontinue but less 
likely to switch a drug after reaching their coverage gap (all P<0.05). (Polinski, Shrank et 
al. 2011)  They were slightly more likely to have reduced adherence, defined as the 
proportion of days covered (PDC) ≥ 80%.  More specifically, Fung et al. focused on the 
impact of the coverage gap among MAPD beneficiaries with diabetes. (Fung, Mangione 
et al. 2010)  Researchers noted that out-of-pocket expenditures were 189 percent higher 
and adherence to three chronic medications - including oral diabetes, hypertension, and 
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lipid drugs - was significantly lower among beneficiaries with a coverage gap versus no 
gap. (Fung, Mangione et al. 2010)  
Kaiser Permanente Colorado expanded upon previous adherence studies by investigating 
medical service utilization for Part D beneficiaries who reached the coverage gap. 
(Raebel, Delate et al. 2008)  This analysis revealed that beneficiaries who reached the 
coverage gap were older, had greater comorbidity, received more medications, and had 
more medical visits than beneficiaries who did not reach the gap. (Raebel, Delate et al. 
2008)  After adjustment, those who reached the coverage gap had an 85 percent and a 
60 percent greater incidence of inpatient and emergency department use, respectively, 
compared to the group with no threshold (p<0.05).  Adherence to chronic medications 
declined over time in both groups, but the decline was greater for beneficiaries who reach 
the coverage gap. 
 
A prospective cohort study examining medical service utilization, mortality rates and 
medical costs in 2003 was conducted by Kaiser Permanente-Northern California.  
Although the study was conducted before Part D was implemented, this study compared 
the clinical and economic outcomes between Medicare+Choice (now Medicare 
Advantage) beneficiaries whose annual drug benefits were capped at $1,000 and 
beneficiaries whose drug benefits were unlimited. (Hsu, Price et al. 2006)  Hue et al. 
found that individuals whose benefits were capped had a 13 percent, nine percent, and 22 
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percent greater incidence of inpatient use, emergency department use, and death, 
respectively (p<0.05). (Hsu, Price et al. 2006)  Those whose benefits were capped were 
30 percent, 27 percent, and 33 percent more likely to be non-adherent to long-term drug 
therapy for hypertension, hyperlipidemia, and diabetes, respectively. (Hsu, Price et al. 
2006)  Furthermore, this study revealed that the physiological outcomes (e.g., blood 
pressure, cholesterol, and glycated hemoglobin level) were significantly worse for 
individuals whose benefits were capped than those whose benefits were not capped 
(p<0.05). (Hsu, Price et al. 2006)  Authors highlighted the cap on drug benefits ($1,000) 
was associated with lower drug consumption and unfavorable clinical outcomes.  
  
1.3.5 Medicare Part D in ESRD Patients 
1.3.5.1 Medicare in ESRD Patients 
Since 1972, ESRD patients (dialysis and transplant) have been entitled to Medicare 
coverage through amendments to the Social Security Act.  There are some unique 
features of Medicare for ESRD patients.  Most dialysis and transplant patients are 
enrolled in the original fee-for-service Medicare (Part A and Part B).  Under current 
Medicare legislation, new dialysis patients cannot enroll in a Medicare Advantage plan 
(Part C). (St Peter 2008)  The only exception to this ban is that dialysis patients can 
enroll in a Medicare Advantage Special Needs Plan approved by CMS that accepts ESRD 
patients. (Centers for Medicare & Medicaid Service 2012)  Patients who were already 
enrolled in a Medical Advantage plan when diagnosed with CKD can remain in their 
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plan.  New kidney transplant patients can enroll in Medicare Advantage plans as long as 
they do not need dialysis and meet Medicare eligibility criteria. (St Peter 2007)   
 
Regardless of age or disability, most patients are eligible for Medicare benefits beginning 
in the fourth month after diagnosis. (St Peter 2007)  The exception is patients who 
undergo home (peritoneal) dialysis; patients who begin training for peritoneal dialysis 
can enroll in Medicare in the first month after ESRD diagnosis. (St Peter 2007)  If 
individuals are eligible for Medicare only due to permanent kidney failure, their 
eligibility does not start until the fourth month of dialysis.  When individuals have 
employer group health plans, that plan is the only payer for the first three months of 
dialysis. (Centers for Medicare & Medicaid Service 2012)  Once individuals become 
eligible for Medicare at the fourth month of dialysis, there is another period of time, 
called a coordination period, when employer group health plans continue to pay health 
care bills. (Centers for Medicare & Medicaid Service 2012)  However, the plans do not 
pay 100 percent of bills, as Medicare pays some of the remaining costs under Medicare 
‘secondary payer’ rules.  At the end of the 30-month coordination period, Medicare pays 
first for all Medicare-covered services.  Employer group health plans can pay for 
services not covered by Medicare. (Centers for Medicare & Medicaid Service 2012) 
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The economic burden of ESRD on dialysis is substantial.  The recent USRDS estimated 
that healthcare payers spend approximately $23 billion to treat ESRD annually. (US 
Renal Data System 2011)  Dialysis patients, less than one percent of all Medicare 
beneficiaries, consumed 6.4 percent of the US Medicare budget in 2006. (US Renal Data 
System 2011)  Nine in ten prevalent hemodialysis patients had some type of Medicare 
coverage in 2009, with 40 percent covered solely by Medicare, 32 percent under 
Medicare/Medicaid, 12 percent by Medicare HMO, six percent under Medicare as a 
secondary payer (Figure 1.5).  
Figure 1.5  Incident Patient Distribution, by First Modality & Payer 
 
Source: The United States Renal Data System (USRDS) 2011 Annual Report 
 
1.3.5.2 Prescription Drug Coverage in ESRD Patients: Medicare Part D 
Before 2006, Medicare enrolled patients accessed prescription drugs via other insurance 
plans with drug coverage, state Medicaid programs, pharmaceutical-assistance programs, 
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samples from physician, or out-of-pocket payment.  Now, however, any patient enrolled 
in either Medicare Part A or Part B can enroll in a Part D plan. (St Peter 2007)  Patients 
with both Medicare and Medicaid (dually eligible), who before 2006 received 
prescription benefits under state Medicaid programs, now obtain Part D covered drugs 
under Medicare Part D. (St Peter 2008) 
In most cases, dialysis patients are allowed to join a stand-alone PDP, but not a MAPD.  
Exceptions can be made when patients enroll in a Medicare Advantage Special Needs 
Plan approved by CMS.  In addition, patients who are already enrolled in an MAPD 
when diagnosed with CKD can remain in their plan. (St Peter 2008) 
Dialysis patients dually-enrolled in Medicaid and Medicare qualify for low income 
subsidy (LIS), and, if they do not choose a plan, are automatically enrolled in a Medicare 
Part D plan.  Sixty-five percent of hemodialysis patients with Part D coverage are 
dually-eligible LIS beneficiaries. (US Renal Data System 2011)  
 
Medicare Part D covers most medications taken by ESRD patients at home, while 
Medicare Part B covers those administered during dialysis (e.g., erythropoiesis 
stimulating agents, IV vitamin D) as well as immunosuppressive medications for patients 
with Medicare-covered transplants. (US Renal Data System 2011)  The USRDS 
estimated the per person per year (PPPY) total cost of medications covered by Medicare 
Part D to be $5,536 for dialysis patients and $6,183 for transplant patients; which is 2.3- 
2.5 times higher, respectively, than in the general Medicare population. (US Renal Data 
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System 2011)  In 2008, Medicare Part D costs for ESRD patients reached $1.54 billion, 
while Medicare Part B costs were $1.87 billion. (US Renal Data System 2011)  Total 
net Part D payment for patients with identified kidney disease (hemodialysis, peritoneal 
dialysis, and transplant patients, and CKD patients on dialysis) was $5 billion in 2008, 
which accounted for 10 percent of total Part D prescription drug costs. (US Renal Data 
System 2011)   
In 2008, 42-48 percent of hemodialysis, peritoneal dialysis, and transplant patients 
reached the coverage gap, and 8-13 percent reached catastrophic coverage, compared to 
23 percent and three percent, respectively, in the general Medicare program (Figure 1.6). 
(US Renal Data System 2011)  
Figure 1.6  Cumulative Percent of Part D Non-LIS Enrollees who Reach the 
Coverage Gap, 2008 
 
 
 
 
 
 
Source: The United States Renal Data System (USRDS) 2011 Annual Report 
Not surprisingly, among those who reached the gap but did not reach catastrophic 
coverage, the number of prescription fills declined once the gap was reached (Table 1.3).  
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For example, hemodialysis patients who reached the coverage gap, but not catastrophic 
coverage, had 4.74 prescription fills per month during the initial coverage period but 
reduced their prescription fills to 4.42 during the coverage gap period.  The authors 
attributed this to a reduction in medication adherence or to a decision to obtain 
medications outside the Part D plan.  Interestingly, the reduction in prescription fills was 
not seen in patients who reached catastrophic coverage.  
 
Table 1.3   Part-D Covered Prescription Fills per Person per Month in Part D 
Non-LIS Enrollees, by Modality, 2008 
 
Source: The United States Renal Data System (USRDS) 2011 Annual Report 
 
1.3.5.3 Impact of Medicare Part D on Patients with ESRD: Evidence to Date 
Patients with ESRD may benefit significantly from the Part D drug benefit, given their 
need for greater numbers of prescription drugs. (Patel and Davis 2006)  This population, 
however, appears to be at a higher risk of falling into the coverage gap than other 
Medicare beneficiaries with Part D.  Despite a rich body of literature on the negative 
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association between prescription drug cost sharing and medical/drug utilization and 
health outcomes in general populations, there is a paucity of empirical data focusing on 
these relationship among dialysis patients.   
To date, several published studies, mainly survey data, reported higher cost-related non-
adherence and higher out-of-pocket costs in patients with ESRD compared to patients 
without ESRD. (Hirth, Greer et al. 2008; Frankenfield, Howell et al. 2011; Smith, Witten 
et al. 2011)  Hirth et al. examined out-of-pocket spending and cost-related non-
adherence using samples of hemodialysis patients from 12 countries. (Hirth, Greer et al. 
2008)  Data were gathered from 2002 to 2004 as part of the Dialysis Outcomes and 
Practice Patterns Study (DOPPS), an observational study of hemodialysis practices and 
outcomes in 12 countries.  Patient questionnaires were administered to a prevalent 
cross-section of patients (N=7,766).  The proportion of patients reporting that they 
sometimes did not purchase medications because of cost varied widely across countries, 
ranging from three percent in Japan to 29 percent in the United States.  However, the 
correlation between cost pressures and underuse was not consistent, which indicated that 
country-specific factors, other than health policies that determine out-of-pocket burdens, 
need to be considered. (Hirth, Greer et al. 2008) 
 
Smith et al. conducted a study to investigate barriers with Medicare Part D medication 
access and changes in medication-taking behaviors observed while in the coverage gap 
among dialysis patients. (Smith, Witten et al. 2011)  The survey was administered to 
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183 nephrology social workers in a variety of settings (e.g., dialysis organization, 
hospital-based dialysis units, and independent dialysis units).  Results indicated that the 
most common problems seen for dialysis patients with their Medicare Part D plans were 
issues related to the coverage gap (donut hole).  Fifty-five percent of respondents 
reported that over 80 percent of their patients experienced difficulties with the coverage 
gap.  The most common patient behaviors included decreasing dosing frequency, 
spending less money on other basic needs, using other sources for their prescriptions, and 
using store discounts on generic medications once reaching the coverage gap. (Smith, 
Witten et al. 2011)  Reflecting on the results of this survey, researchers noted that 
dialysis patients exhibited harmful medication-taking behavior during their coverage gap 
which led to a reduced use of medication, which may result in health care complications 
and increased use of medical services. (Smith, Witten et al. 2011)    
 
Another recent survey assessed self-reported cost-related non-adherence (defined as 
delaying or not filling a prescription due to cost concerns) among Medicare Part D 
beneficiaries with ESRD. (Frankenfield, Howell et al. 2011)  The 2007 Medicare 
Consumer Assessment of Health Provider and Systems (CAHPS) survey was 
administered by the CMS.  Frankenfield et al. found that ESRD patients were 
significantly more likely than those without ESRD to report cost-related non-adherence. 
(Frankenfield, Howell et al. 2011)  After controlling for potential confounding factors 
(e.g., age, gender, and chronic conditions), ESRD patients remained 23 percent more 
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likely than respondents without ESRD to report cost-related non-adherence. 
(Frankenfield, Howell et al. 2011) 
      
A retrospective cohort study examining the potential impact of Medicare Part D on total 
and out-of-pocket expenditures also revealed substantial financial burden on ESRD 
beneficiaries compared with other Medicare beneficiaries. (Patel and Davis 2006)  Patel 
et al. used the Medicare Current Beneficiary Survey (MCBS) Cost and Use data (1997-
2001) to estimate the impact of the standard Part D benefit on drug expenditures.  Total 
annual costs and out-of-pocket costs in 2006 were estimated to be more than two-fold 
higher for Medicare beneficiaries with ESRD compared with those without (total costs: 
$6,488 versus $2,705; out-of-pocket: $2,329 versus $1,311). (Patel and Davis 2006) 
 
1.3.6 Summary of Section 
Most dialysis patients are eligible for Medicare benefits; nine in 10 prevalent 
hemodialysis patients have some type of Medicare coverage.  A unique feature of the 
Medicare Part D drug benefit is the coverage gap, where Part D enrollees are required to 
pay 100 percent of total drug costs.  Several studies have demonstrated decreases in 
medication adherence and unintended health outcomes in Medicare Part D beneficiaries 
who entered the coverage gap phase in general populations.  Beneficiaries with ESRD 
may be especially sensitive to coverage gap issues, given the large number of 
medications required to manage multiple comorbid conditions. 
62 
1.4 Section 3: Study Purpose, Objectives and Hypotheses 
1.4.1 Statement of Problem 
Patients with ESRD cope with a very complex and costly disease - often with multiple 
comorbidities: diabetes, hypertension, anemia, bone and mineral metabolism disorders, 
and cardiovascular disorders. (St Peter 2007)  Notably, patients with ESRD have a very 
high prevalence of cardiovascular disease risk factors such as diabetes, hyperlipidemia, 
and hypertension, but they are also exposed to other non-traditional, uremia-related 
cardiovascular disease factors (e.g., calcium and phosphate metabolism). (Parfrey and 
Foley 1999; Covic, Kothawala et al. 2009)  The management of ESRD requires 
adherence to dialysis treatments, dietary restrictions, and a drug regimen requiring 
patients to take multiple medications throughout the day. (Frankenfield, Howell et al. 
2011)  Estimates of medication use among ESRD patients range from 10 to 14 
medications per day in the U.S. (Manley, Bailie et al. 2000; Manley, Garvin et al. 2004)  
A recent systematic literature review found that more than half of the included studies 
reported non-adherence rates of ≥ 50 percent in the ESRD population. (Schmid, 
Hartmann et al. 2009)   
 
Most dialysis patients are eligible for Medicare benefits beginning in the fourth month 
after diagnosis.  Nine in 10 prevalent hemodialysis patients had some type of Medicare 
coverage in 2009.  Patients with ESRD may benefit significantly from the Part D drug 
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benefit, given their need for greater numbers of prescription drugs. (Patel and Davis 
2006)  This population, however, appears to be at a higher risk of falling into the 
coverage gap than other Medicare beneficiaries with Part D because of their need for 
chronic drug therapy and multiple drugs to treat comorbid conditions. (St Peter 2007)  
In 2008, 47 percent of dialysis patients reached the coverage gap, and 13 percent reached 
the catastrophic coverage phase, compared to 23 percent and three percent, respectively, 
in the general Medicare program. (US Renal Data System 2011)  In 2007, patients with 
total Part D drug costs up to $2,400 fell into the initial coverage phase, while those with 
costs over that amount entered the coverage gap (“donut hole”), in which they were 
responsible for 100 percent of drug costs. (The Henry J. Kaiser Family Foundation 2010)  
The Part D coverage gap involves substantial periods of uncovered drug use and may 
increase out-of-pocket spending for beneficiaries because they pay the full price of 
medications filled during these periods.   
 
Previous studies indicated that increasing out-of-pocket costs as patients entered the 
coverage gap resulted in adverse consequences. (Hsu, Price et al. 2006; Pedan, Lu et al. 
2009; Zhang, Donohue et al. 2009; Nair, Frech-Tamas et al. 2011)  Many studies have 
shown Medicare beneficiaries with a drug benefit threshold were significantly more 
likely to adopt cost-lowering strategies (e.g., using less of a medication, discontinuing a 
medication, or not filling a prescription) than beneficiaries who did not have a drug 
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benefit threshold when entering the coverage gap. (Cronk, Humphries et al. 2008; Pedan, 
Lu et al. 2009)  Several studies have demonstrated the consequences of cost-related 
medication underuse, including increased emergency department visits, psychiatric 
admissions, and nursing home admissions, as well as decreased health status. (Soumerai, 
Ross-Degnan et al. 1991; Tamblyn, Laprise et al. 2001)  Despite a rich body of literature 
on the association between Medicare Part D coverage and medical/drug utilization and 
health outcomes in general populations, (Hsu, Price et al. 2006; Raebel, Delate et al. 
2008; Fung, Mangione et al. 2010; Hales and George 2010; Polinski, Shrank et al. 2011) 
there is a need for empirical data focusing on these relationships among dialysis patients.  
Information regarding how and to what extent this Part D coverage gap has affected 
prescription drug utilization and outcomes in dialysis patients is lacking.  The impact of 
Part D coverage on health outcomes in dialysis patients warrants empirical evaluation. 
 
1.4.2 Purpose of Study 
This study aims to examine the consequences of Medicare Part D coverage in dialysis 
patients.  The purpose of this study was to evaluate and compare A) medication 
adherence and costs, B) medical service utilization/costs, and C) mortality among 
Medicare beneficiaries with dialysis, categorized into four cohorts based on their Part D 
coverage. 
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The first objective was to compare characteristics among the four cohorts based on Part D 
coverage.  Objective 2 was to examine medication-taking behaviors, defined in terms of 
medication adherence and persistence among Medicare beneficiaries with dialysis who 
received drug therapy for hypertension, hyperlipidemia, diabetes mellitus, 
hyperphosphatemia, and/or hyperparathyroidism.  Objective 3 was to assess pharmacy 
utilization and costs.  Objective 4 was to measure cardiovascular morbidity rates.  
Objective 5 was to assess the patterns of cardiovascular-related and all-cause medical 
service utilization and associated costs (e.g., hospitalization, outpatient, and skilled 
nursing home services).  Objective 6 was to measure cardiovascular-related and all-
cause mortality rates in Medicare beneficiaries with dialysis.  
 
Specifically, the purpose was to compare the four cohorts of patients, categorized based 
on their Part D coverage in 2007:   
1) cohort 1: patients who did not reach the coverage gap (out-of-pocket costs < 
$799; total drug costs < $2,400)  
2) cohort 2: patients who reached the coverage gap but did not reach the point of 
receiving catastrophic coverage ($799 ≤ out-of-pocket costs < $3,850; $2,400 ≤ 
total drug costs <$5,451) 
3) cohort 3: patients who reached catastrophic coverage ($3,850 ≤ out-of-pocket 
costs; $5451 ≤ total drug costs) 
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4) cohort 4: patients who did not reach the coverage gap and received the low-
income subsidy - LIS (out-of-pocket costs < $799) 
 
It is anticipated that findings from this study will add significant contributions to the 
empirical literature concerning the impact of Medicare Part D coverage on health 
outcomes in Medicare beneficiaries with dialysis.  Below is a description of the study 
objectives and hypotheses.  
 
1.4.3 Objectives and Hypotheses  
1.4.3.1 Objective 1: Patient Characteristics 
 To compare patient characteristics (age, gender, race, region of residence, 
primary disease causing ESRD, ESRD duration, and comorbidities) for 
Medicare beneficiaries with dialysis, by four Part D cohort categories.   
 
H0 (1a): Mean age will not differ significantly when categorized by Part D 
coverage.  
H0 (1b): The proportion of patients in each gender category will not differ 
significantly when categorized by Part D coverage.  
H0 (1c): The proportion of patients in each race category will not differ 
significantly when categorized by Part D coverage.  
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H0 (1d): The proportion of patients in each region category will not differ 
significantly when categorized by Part D coverage. 
H0 (1e): The proportion of patients in each primary disease causing ESRD will not 
differ significantly when categorized by Part D coverage. 
H0 (1f): Mean ESRD duration will not differ significantly when categorized by Part 
D coverage. 
H0 (1g): Mean comorbidity score (Charlson Comorbidity Index (CCI) score) will 
not differ significantly when categorized by Part D coverage. 
H0 (1h-1m): The proportion of patients in the presence of cardiovascular disease 
[H0(1h)], diabetes mellitus [H0(1i)], hypertension [H0(1j)], dyslipidemia 
[H0(1k)], cancer [H0(1l)], chronic lung disease [H0(1m)]) will not differ 
significantly when categorized by Part D coverage.  
 
1.4.3.2 Objective 2: Medication Utilization and Costs  
 To determine whether the proportion and number of prescription 
medications and pharmacy costs (i.e., antihyperglycemics, 
antihypertensives, lipid-lowering drugs, phosphate binders, or cinacalcet) 
differ, by four Part D cohort categories.   
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H0 (2a-e): The proportion of patients using antihyperglycemics [H0(2a)], 
antihypertensives [H0(2b)], lipid-lowering drugs [H0(2c)], phosphate binders 
[H0(2d)], or cinacalcet [H0(2e)]) will not differ significantly when 
categorized by Part D coverage. 
H0 (2f-j): The mean number of antihyperglycemics [H0(2f)], antihypertensives 
[H0(2g)], lipid-lowering drugs [H0(2h)], phosphate binders [H0(2i)], or 
cinacalcet [H0(2j)]) will not differ significantly when categorized by Part D 
coverage. 
H0 (2k-p): Mean pharmacy costs (i.e., antihyperglycemics [H0(2k)], antihypertensives 
[H0(2l)], lipid-lowering drugs [H0(2m)], phosphate binders [H0(2n)], cinacalcet 
[H0(2o)] or all prescription H0(2p)] ) will not differ significantly when 
categorized by Part D coverage.   
 
1.4.3.3 Objective 3: Medication Adherence and Persistence 
 To determine whether medication adherence and persistence among 
patients receiving drug therapy for diabetes, hypertension, hyperlipidemia, 
hyperphosphatemia, or secondary parathyroid differ significantly, by four 
Part D cohort categories, while controlling for the following covariates: 
age, gender, race, region of residence, primary disease causing ESRD, 
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ESRD duration, CCI score, presence of chronic disease including diabetes 
mellitus, hypertension, dyslipidemia, cancer, chronic lung disease.      
 
H0 (3a-e): Medication adherence (i.e., antihyperglycemics [H0(3a)], antihypertensives 
[H0(3b)], lipid-lowering drugs [H0(3c)], phosphate binders [H0(3d)], or 
cinacalcet [H0(3e)]) will not differ significantly when categorized by Part D 
coverage while controlling for covariates.   
H0 (3f-j): The proportion of patients who are adherent (MPR ≥ 80%) to 
antihyperglycemics [H0(3f)], antihypertensives [H0(3g)], lipid-lowering drugs 
[H0(3h)], phosphate binders [H0(3i)], or cinacalcet [H0(3j)]) will not differ 
significantly when categorized by Part D coverage while controlling for 
covariates. 
 
 To determine whether medication adherence differs before and after the 
coverage gap was exceeded among patients reaching the coverage gap, but 
not catastrophic coverage (cohort 2), while controlling for the following 
covariates: age, gender, race, region of residence, primary disease causing 
ESRD, ESRD duration, CCI score, presence of chronic disease including 
diabetes mellitus, hypertension, dyslipidemia, cancer, chronic lung disease 
and CVD. 
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H0(3k-o):Medication adherence with antihyperglycemics [H0(3k)], 
antihypertensives [H0(3l)], lipid-lowering drugs [H0(3m)], phosphate binders 
[H0(3n)], or cinacalcet [H0(3o)]) will not differ significantly before and after 
reaching the gap while controlling for covariates. 
H0(3p-t):The proportion of patients who are adherent (MPR ≥ 80%) to 
antihyperglycemics [H0(3p)], antihypertensives [H0(3q)], lipid-lowering 
drugs [H0(3r)], phosphate binders [H0(3s)], or cinacalcet [H0(3t)]) will not 
differ significantly before and after reaching the gap while controlling for 
covariates. 
H0(3u-y):Medication persistence with antihyperglycemics [H0(3u)], 
antihypertensives [H0(3v)], lipid-lowering drugs [H0(3w)], phosphate 
binders [H0(3x)], or cinacalcet [H0(3y)]) will not differ significantly when 
categorized by Part D coverage while controlling for covariates.   
H0(3z-zd): The proportion of patients who are persistent (until a 30-day gap) to 
antihyperglycemics [H0(3z)], antihypertensives [H0(3za)], lipid-lowering 
drugs [H0(3zb)], phosphate binders [H0(3zc)], or cinacalcet [H0(3zd)]) will not 
differ significantly when categorized by Part D coverage while 
controlling for covariates.   
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1.4.3.4 Objective 4: Cardiovascular Disease Morbidity   
 To determine whether cardiovascular morbidity rates among Medicare 
beneficiaries with dialysis differ, by the four Part D cohort categories 
while controlling for the following covariates: age, gender, race, region of 
residence, primary disease causing ESRD, ESRD duration, CCI score, 
presence of chronic disease including diabetes mellitus, hypertension, 
dyslipidemia, cancer, chronic lung disease. 
 
H0 (4): The incidence of cardiovascular disease will not differ significantly when 
categorized by Part D coverage, while controlling for covariates.  
 
1.4.3.5 Objective 5: Cardiovascular-related and All-cause Medical Service 
Utilization/Costs 
 To determine whether cardiovascular-related and all-cause medical service 
utilization (i.e., hospitalization, outpatient and other visits) and costs 
among Medicare beneficiaries with dialysis differ, by four Part D cohort 
categories, while controlling for the following covariates: age, gender, 
race, region of residence, primary disease causing ESRD, ESRD duration, 
CCI score, presence of chronic disease including diabetes mellitus, 
hypertension, dyslipidemia, cancer, chronic lung disease and CVD. 
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H0 (5a-c): The proportion of patients who use any medical services including 
inpatient [H0(5a)], outpatient [H0(5b)], and other visits [H0(5c)] will not differ 
significantly when categorized by Part D coverage, while controlling for 
covariates.  
H0 (5d-f): The mean number of medical service visits (i.e., inpatient [H0(5d)], 
outpatient [H0(5e)], and other visits [H0(5f)]) will not differ significantly 
when categorized by Part D coverage, while controlling for covariates. 
H0 (5g-i): The proportion of patients who use medical services related to 
cardiovascular disease including inpatient [H0(5g)], outpatient [H0(5h)], and 
other visits [H0(5i)], will not differ significantly when categorized by Part 
D coverage, while controlling for covariates. 
H0 (5j-l): The mean number of medical service visits (i.e., inpatient [H0(5j)], 
outpatient [H0(5k)], and other visits [H0(5l)]) will not differ significantly 
when categorized by Part D coverage. 
H0 (5m-t): Mean all-cause medical care costs including inpatient [H0(5m)], outpatient 
[H0(5n)], physician/supplier [H0(5o)], other visits [H0(5p)], dialysis [H0(5q)], 
total medical care costs [H0(5r)], pharmacy costs [H0(5s)], and all-cause total 
health care costs [H0(5t)] will not differ significantly when categorized by 
Part D coverage, while controlling for covariates. 
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H0 (5u-y): Mean cardiovascular disease-related medical care costs including 
inpatient [H0(5u)], outpatient [H0(5v)], and physician/supplier [H0(5w)], and 
other visits [H0(5x)], and total costs [H0(5y)], will not differ significantly 
when categorized by Part D coverage, while controlling for covariates. 
 
1.4.3.6 Objective 6: All-cause and Cardiovascular-related Mortality 
 To determine whether cardiovascular-related and all-cause mortality rates 
among Medicare beneficiaries with dialysis differ, by four Part D cohort 
categories, while controlling for the following covariates: age, gender, 
race, region of residence, primary disease causing ESRD, ESRD duration, 
CCI score, presence of chronic disease including diabetes mellitus, 
hypertension, dyslipidemia, cancer, chronic lung disease, and CVD. 
H0 (6a): All-cause mortality rates will not differ when categorized by Part D 
coverage while controlling for covariates. 
H0 (6b): Cardiovascular-related mortality rates will not differ when categorized by 
Part D coverage while controlling for covariates.  
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Chapter 2: Methodology 
 
2.1: Chapter Overview 
This chapter provides a detailed description of the methodology used to evaluate the 
association between Part D coverage and various outcomes.  The outcomes include 
medication-taking behaviors, patterns of cardiovascular-related and all-cause medical 
care utilization and associated costs, and cardiovascular-related and all-cause mortality 
rates in Medicare beneficiaries with dialysis.  The data source and study design are 
described including study design structure, study population, inclusion, and exclusion 
criteria.  Detailed descriptions of the study phases I-IV, study variables, and statistical 
analysis are also presented.  
 
2.2: Data Source 
The data for this analysis were provided by the United States Renal Data System 
(USRDS).  The USRDS is a national data system that collects, analyzes, and distributes 
information about end-stage renal disease (ESRD) in the United States.  The data for 
this study were obtained from the 2006-2010 USRDS.   
 
The USRDS is funded directly by the National Institutes of Health, National Institute of 
Diabetes and Digestive and Kidney Diseases (NIDDK). (United States Renal Data 
System)  The data used by the USRDS originate from the Centers for Medicare & 
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Medicaid Services (CMS), the United Network for Organ Sharing (UNOS), the ESRD 
Networks, and the USRDS special studies section.  These data have been collected from 
all patients in the United States who have received Medicare-reimbursed maintenance 
renal replacement therapy since 1977.  This database is estimated to include 
approximately 95 percent of the patients who receive renal replacement therapy in the 
United States.  To be included in the database, patients must be receiving long-term 
dialysis therapy or have undergone renal transplantation.  Patients are excluded if they 
received dialysis for acute renal failure only, died of renal failure before receiving 
dialysis or renal transplantation, or did not accept renal replacement therapy.   
   
Data for input into the database that was utilized for this analysis was derived from the 
following sources that are summarized in the USRDS Researcher’s Guide (2011). (US 
Renal Data System 2011)  A quoted summary description of each from the guide 
follows: 
 
PMMIS/REBUS/REMIS Database System 
The major source of ESRD patient information for the USRDS is the CMS Renal 
Beneficiary and Utilization System (REBUS), which was adopted in 1995 as the 
On-Line Transaction Processing system from its predecessor, the previous 
Program Management and Medical Information System (PMMIS) database.  The 
PMMIS/REBUS database contains demographic, diagnosis, and treatment history 
information for all Medicare beneficiaries with ESRD.  The database has been 
expanded to include non-Medicare patients. 
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CMS regularly updates the PMMIS/REBUS database, using the Medicare 
Enrollment Database (EDB), Medicare inpatient and outpatient claims, the UNOS 
transplant database, the ESRD Medical Evidence Report (form CMS-2728) 
provided by the ESRD Networks, the ESRD Death Notification (form CMS-
2746) obtained from renal providers, and the ESRD Networks’ Standard 
Information Management System database.  
 
CMS Medical Evidence Report (Form CMS-2728)  
The CMS Medical Evidence Report is completed by the renal provider for each 
new ESRD patient, and is sent to CMS through the ESRD Networks.  It 
establishes Medicare eligibility for individuals who previously were not Medicare 
beneficiaries, reclassifies previously eligible Medicare beneficiaries as ESRD 
patients, and provides demographic and diagnostic information for all new ESRD 
patients regardless of Medicare entitlement.  Since 1995, providers were 
required to file the Medical Evidence Report for all new ESRD patients regardless 
of Medicare eligibility status.  The form includes comorbid conditions, 
employment status, expanded race categories, ethnicity, and biochemical data at 
ESRD onset.  
The revision of the Medical Evidence Report was introduced in May 2005.  It 
allows users to specify whether the Medicare registration is initial (new ESRD 
patient), re-entitlement (reinstating Medicare entitlement after a lapse due to no 
claims being filed for 12 or more months or a functioning graft for 36 or more 
months), or supplemental (updating missing or incorrect information).  Data 
fields for nephrologist care, dietitian care, and access type were also added, with 
their respective time intervals relative to ESRD onset.  Data on the laboratory 
values hematocrit, creatinine clearance, BUN, and urea clearance are no longer 
collected.  Added laboratory values are HbA1c and lipid profiles (TC, LDL, and 
HDL cholesterol, and TG).  
 
CMS ESRD Death Notification (Form CMS-2746)  
Like the Medical Evidence Report, the Death Notification form is data rich, and 
CMS requires renal providers to complete it.  Providers usually have 45 days to 
report ESRD death events to their respective ESRD Networks, including 
information about place, time, and cause of death.   
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CMS Medicare Enrollment Database (EDB) 
The CMS Enrollment Database is the designated repository of all Medicare 
beneficiary enrollment and entitlement data, including current and historical 
information on beneficiary residence, Medicare as Secondary Payer (MSP) status, 
and Health Insurance Claim/ Beneficiary Identification Code cross-referencing.  
 
CMS Paid Claims Records 
Inpatient transplant and outpatient dialysis claims records are sometimes used to 
identify new ESRD patients for whom no Medical Evidence Report has been 
filed.  These patients are most likely to be non-Medicare patients or beneficiaries 
already receiving Medicare because of age or disability.  For patients without 
Medicare Evidence reports, these claims are the only reliable information from 
which to determine first ESRD service dates.  Bills for some Medicare-eligible 
patients may not be submitted to or paid by Medicare.  These patients are MSP 
patients covered by private insurance, HMOs, Medicaid, or the Department of 
Veterans Affairs.  
 
CMS ESRD Standard Analytical Files (SAFs)  
The CMS SAFs contain data from final action claims, submitted by Medicare 
beneficiaries, in which all adjustments have been resolved.  For Part A 
institutional claims, the USRDS uses the following SAF claims: 
 Inpatient 
 Outpatient 
 Skilled nursing facility  
 Home health agency  
 Hospice 
 
For Part B physician/supplier SAF claims: 
 Physician/supplier 
 Durable medical equipment  
 
CMS SAFs are updated each quarter through June of the next year, when the 
annual files are finalized.  Datasets for the current year are created six months 
into the year and updated quarterly until finalized at 18 months, after which files 
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are frozen and will not include late arriving claims.  Annual files are, thus, 
approximately 98 percent complete.   
Medicare medical claims are of two types: (1) institutional claims primarily for 
Part A, and (2) physician/supplier claims for all of Medicare Part B.  Some Part 
B claims, however, are institutional claims, notably those for outpatients.  The 
institutional claims files contain data from final action claims submitted by 
Medicare beneficiaries 
 
Medicare Prescription Drug Files 
Effective January 1, 2006, Part D is an optional prescription drug benefit for 
individuals who are entitled to Medicare benefits under Part A or enrolled in 
Medicare benefits under Part B.  Part D data are obtained from CMS annually 
with USRDS-provided Finder Files.  Part D data are divided into two separate 
files: an annual enrollment file containing monthly indicators of enrollment in 
Part D, and a prescription drug event file (PDE) containing details of prescriptions 
filled by Part D beneficiaries.  
Since the Part D benefit is voluntary, not all Medicare beneficiaries are enrolled in 
Part D.  The annual enrollment file contains 12 monthly indicators that detail 
whether the beneficiary is enrolled in Part D, and if so, the type of plan.  There 
are also monthly indicators for retiree drug subsidy and low income subsidy 
(LIS).  
The structure of the USRDS data base is shown in Figure 2.1.  
Figure 2.1  Structure of the USRDS Database  
 
Reference: USRDS Researcher’s Guide (2011) 
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Protection of Human Subjects 
This study is a secondary data analysis of the USRDS database.  Prior to obtaining any 
data from USRDS, approval from The University of Texas at Austin Institutional Review 
Board (IRB) was obtained. 
 
2.3: Study Design 
A cross-sectional retrospective design was employed for this study.  This is a 
retrospective analysis using demographic data, Part D prescription claims, Part A & Part 
B medical claims, CMS medical evidence report, and mortality data for patients who 
were undergoing dialysis between January 1, 2006 and December 31, 2007.  Outcomes 
were compared among the four cohorts: 1) patients who did not reach the coverage gap; 
2) patients who reached the coverage gap but not catastrophic coverage; 3) patients who 
reached catastrophic coverage; and 4) patients who received LIS and do not reach the 
coverage gap.  
 
The study observation period consisted of a total of five years and the study outcomes 
were composed of four phases.  The first period (phase I), January to December 2006, 
constituted the baseline covariate assessment period.  In Phase I, the study sample was 
described with regard to demographic and clinical characteristics.  January through 
December 2007 (phase II) is the one-year post-index Part D coverage exposure period.  
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In Phase II, medication utilization, costs, and medication adherence were measured for 
five therapeutic classes of outpatient prescription drugs including antihyperglycemic 
medications, antihypertensive medications, lipid-lowering medications, phosphate 
binders, and calcimimetic medications.  The third period (phase III), January through 
December 2007, is a 1-year medical service follow-up period.  In Phase III, the 
incidence of cardiovascular disease (CVD), medical resource utilization (i.e., inpatient 
and outpatient) and related costs were calculated for cardiovascular-related and all-cause 
medical services with adjustments for covariates.  The fourth period (phase IV), January 
2008 to December 2010 is a 3-year mortality rate follow-up period.  In Phase IV, the 
time to occurrence of cardiovascular-related and all-cause death were examined.  In 
order to be eligible for the study, patients were required to have been alive and enrolled 
in Part D throughout 2007. Thus, mortality was measured between January 2008 and 
December 2010.     
2.3.1 Study Design Structure  
The study design structure is depicted in Figure 2.2 below. 
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Figure 2.2  Study Design Structure 
 
OOP : out of pocket ; LIS : low income subsidy; CVD : cardiovascular disease
Phase I
Phase II
Phase III
Phase IV
01/01/200901/01/2007 01/01/2008
Exposure 1-year (2007)
Outcomes assessmentBaseline covariate 
assessment; 1-year
01/01/2006
• Objective 1 : 
Demographics 
Clinical factors
12/31/2010
 Objective 2 : Medication use and costs 
 Objective 3 : Medication adherence and persistence  
[1-year follow-up]
 Objective 4 : Incidence of CVD
and costs
 Objective 5 : Medical service util ization   
(1) All-cause 
(2) CVD-related 
[1-year follow-up]
 Objective 6 :              
Mortality
[3-year follow-up]
(1)  OOP costs < $799
(2)  $799 =< OOP costs < $3850
(3)  $3850 =< OOP costs
(4)  OOP costs < $799 with LIS
Study Cohorts 
(based on 2007 Part D 
coverage)
Dialysis patients with Part D 
plan enrollment  in 2007  
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2.3.2 Study Population 
Four cohorts were created based on patients’ Medicare Part D coverage in 2007.  Before 
reaching the Part D coverage gap, the beneficiary usually pays a deductible and/or 
coinsurance up to the coverage gap.  Once the threshold is reached, the beneficiary pays 
100 percent of his or her drug costs out-of-pocket until a second threshold, the 
catastrophic coverage level, is reached.  In 2007, the coverage gap and catastrophic 
coverage levels were reached when the beneficiary had spent $779 and $3850 out-of-
pocket costs, respectively. 
The first cohort was composed of patients who did not reach the coverage gap in 2007, 
paying out-of-pocket costs < $799.  The second cohort was composed of patients who 
reached the coverage gap in 2007, paying $799 ≤ out-of-pocket costs < $3850.  The 
third cohort was composed of patients who reached catastrophic coverage in 2007, 
paying $3850 ≤ out-of-pocket costs.  The fourth cohort consisted of patients who 
received the LIS and paid out-of-pocket costs < $799.  Medicare Part D prescription 
data, Part A and Part B medical service data, treatment modality history file, pay history 
file, medical evidence file, and demographic data were extracted for these patients from 
the appropriate databases and merged by patient USRDS ID.  Individual entry and exit 
into the Medicare Part D coverage gap were determined by using 2007 Part D 
prescription claims data.      
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2.3.2.1 Inclusion Criteria 
The current research is a cross-sectional retrospective study of all patients who 
experienced ESRD and received dialysis.  The patients were identified using data 
acquired from the SAFs of USRDS.  Patients were included in the study if they (1) were 
designated by CMS as having ESRD, (2) underwent dialysis from January 1, 2006 to 
December 31, 2007, (3) were at least 18 years old on January 1, 2006 and alive on 
December 31, 2007, (4) were continuously enrolled in a Medicare Part D plan in 2007, in 
order for complete 12 months of pharmacy data to be captured and (5) were enrolled in 
both Medicare Part A and Part B coverage from January 1, 2006 to December 31, 2007.   
 
2.3.2.2 Exclusion Criteria 
Patients were excluded if they (1) were Medicare/Medicaid dual-eligible beneficiaries for 
Part A and/or Part B or Part D plans, (2) received a kidney transplant between January 1, 
2006 and December 31, 2007, or (3) were in an employer-sponsored health benefit plans.  
Because the inclusion criteria for the study required that individuals remain in Medicare 
plans throughout both years, beneficiaries who died in 2006 or 2007 were excluded. 
The index date for patients in this study was defined as January 1, 2007.  This study 
required patients to enroll in a Medicare Part D plan throughout 2007 to ensure that all 
patients had Part D during the exposure period.   
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2.4: Study Outcomes and Variables 
As mentioned earlier, the study was composed of four phases.  The following section 
describes the phases of the study in detail.   
2.4.1 Phase I: Demographic and Clinical Characteristics (January to December 
2006) 
In Phase I, the study population was described and compared among Part D cohorts in 
terms of demographic characteristics (age, gender, race, and region of residence), primary 
disease causing ESRD, ESRD duration, CCI scores, and presence of chronic diseases 
(CVD, diabetes mellitus, hypertension, dyslipidemia, cancer, and chronic lung disease).  
Baseline covariates were assessed during the 1-year period prior to 2007. 
 
2.4.2 Phase II: Medication Adherence and Costs (January to December 2007) 
In Phase II, prescription drug utilization included five therapeutic classes of outpatient 
prescription drugs: (1) antihyperglycemic prescriptions, (2) antihypertensive 
prescriptions, (3) lipid-lowering prescriptions, (4) phosphate binder prescriptions, and (5) 
calcimimetic prescriptions.  Medication use was identified from Part D prescription 
claims data.  For each Medicare prescription claim, Medicare Part D data contains a de-
identified beneficiary USRDS identification number, prescription characteristics (i.e., 
prescription service date, quantity dispensed, days of supply, national drug code (NDC), 
brand name, generic name), and coverage characteristics (patient pay amount, gross drug 
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cost).  Pharmacy claims were identified by generic names.  Section 2.5.2.4 describes 
generic names for outpatient prescription drugs in detail.  
2.4.2.1 Medication Use and Costs 
Medication use was defined as one or more prescription fills in any of the therapeutic 
classes for the period of January 1, 2007 through December 31, 2007.  Medication use 
was measured by the percentage of patients who had any use of five therapeutic classes 
of outpatient prescription drugs and the mean numbers of medications.  Medication 
costs were defined as total drug costs and out-of-pocket costs for each therapeutic class 
and all medications.  Out-of-pocket costs for each prescription are equal to the amount 
paid directly by the patient.  Total drug costs for each prescription are defined payments 
including the amount Medicare paid plus patient out-of-pocket costs.   
2.4.2.2 Medication Adherence and Persistence 
Medication adherence, treatment patterns, and persistence were calculated for each class 
of outpatient prescription drug separately.  For this analysis, patients were included if 
they received at least two prescriptions in each therapeutics class of drugs.  
Medication adherence 
Before calculating medication adherence, medication treatment patterns were assessed 
(i.e., mono, dual, triple, or quad therapy).  Monotherapy was defined as treatment with 
only one medication class within each therapeutic class (e.g., sulfonylureas, biguanides, 
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or thiazolidinediones in antihyperglycemic prescriptions).  Dual therapy refers to a 
coadministration of 2 separate medication classes with at least 2 overlapping periods of 
30 days or 1 overlapping period of 60 days (e.g., sulfonylureas and biguanides, or 
sulfonylureas and thiazolidinediones, etc.).  Triple therapy was defined as a 
coadministration of 3 separate medication classes at least 2 overlapping periods of 30 
days or 1 overlapping period of 60 days (e.g., sulfonylureas and biguanides and 
thiazolidinediones).  Quad therapy refers to a coadministration of 4 separate medication 
classes with at least 2 overlapping periods of 30 days or 1 overlapping period of 60 days.   
  
Medication adherence was defined using the medication possession ratio (MPR), which is 
the sum of total days’ supply for all fills divided by the number of days during the study 
period. MPR for dual, triple, and quad therapies were determined by calculating the 
average of the MPRs of the individual medications that constituted the dual, triple, and 
quad therapies.   
 
Formula for calculating MPR is shown below; 
MPR (monotherapy) = 
𝑆𝑢𝑚 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑑𝑎𝑦𝑠 𝑠𝑢𝑝𝑝𝑙𝑦 𝑓𝑜𝑟 𝑎𝑙𝑙 𝑓𝑖𝑙𝑙𝑠
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑎𝑦𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑡𝑢𝑑𝑦 𝑝𝑒𝑟𝑖𝑜𝑑
 
MPR (dual therapy) = 
𝑆𝑢𝑚 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑑𝑎𝑦𝑠 𝑠𝑢𝑝𝑝𝑙𝑦 𝑓𝑜𝑟 𝑎𝑙𝑙 𝑓𝑖𝑙𝑙𝑠/2
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑎𝑦𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑡𝑢𝑑𝑦 𝑝𝑒𝑟𝑖𝑜𝑑
 
MPR (triple therapy) = 
 𝑆𝑢𝑚 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑑𝑎𝑦𝑠 𝑠𝑢𝑝𝑝𝑙𝑦 𝑓𝑜𝑟 𝑎𝑙𝑙 𝑓𝑖𝑙𝑙𝑠/3
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑎𝑦𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑡𝑢𝑑𝑦 𝑝𝑒𝑟𝑖𝑜𝑑
 
87 
MPR (quad therapy) = 
 𝑆𝑢𝑚 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑑𝑎𝑦𝑠 𝑠𝑢𝑝𝑝𝑙𝑦 𝑓𝑜𝑟 𝑎𝑙𝑙 𝑓𝑖𝑙𝑙𝑠/4
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑎𝑦𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑡𝑢𝑑𝑦 𝑝𝑒𝑟𝑖𝑜𝑑
 
 
In addition MPR calculations were dichotomized, with adherence defined as MPR ≥ 80% 
and non-adherence defined as MPR < 80%.  MPR values > 100% were truncated at 
100% for the purpose of analyses.  The number of days in the study period for 
mediation therapy was defined as the longest period among; 1) the number of days 
between first and last fills plus days supply of the last fill, 2) the number of days between 
first fill and Dec 31, 2007.  
To increase our understanding of the temporal dynamics of drug adherence among the 
primary cohort (cohort 2) who reached the coverage gap but not catastrophic coverage, 
separate analyses were performed.  Adherence before and after reaching the coverage 
gap were examined using generalized-estimating-equation (GEE) methods.  This model 
allows each comparison group to have its own profile over time.   
To examine drug adherence before and after the coverage gap was exceeded, the date in 
which a patient exceeds the $799 out-of-pocket costs was identified; and adherence 
before and after that date was examined. (Hsu, Price et al. 2006)  If claims included the 
date which the patient exceeded the $799 out-of-pocket costs, the claim was separated 
into two claims; one before and one after that date.  The first and second claims were 
included in calculating adherence before and after, respectively.  Patients were included 
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if they received at least two prescriptions and at least one prescription before the 
coverage gap date in each of the therapeutic class of drugs.  
The analysis was limited to prescriptions filled during 2007.  Section 2.6.2.1 describes 
the GEE model in detail.   
 
Medication persistence 
Medication persistence is frequently computed alongside medication adherence to 
indicate how long patients remain on prescribed medications.  Medication persistence 
was defined as the duration of therapy from the first fill date until discontinuation. 
(Cramer, Roy et al. 2008; McHorney, Victor Spain et al. 2009)  Mean persistence to the 
index medication was calculated by summing the number of days from the filling of the 
first medication to the end date of the last medication claim (fill date plus days supply) 
prior to a 30-day gap (note: a 60-day gap was also used for a sensitivity analysis).  
Kaplan-Meier survival curves were used to depict the percentage of patients who 
remained persistent in the study period.  Cox regression analyses by therapeutic class 
were used to measure the difference among the study cohorts while controlling for 
covariates.  Section 2.6.6.1 describes the Kaplan-Meier method and the Cox 
proportional hazards regression model in detail.  
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2.4.3 Phase III: Medical Services and Costs (January to December 2007) 
In Phase III, the incidence of CVD, medical service utilization, and related costs were 
examined.  The data were obtained from Part A institutional claims and Part B 
physician/supplier claims.  Each institutional medical claim (Part A) contains a de-
identified beneficiary USRDS identification number, diagnostic and procedural codes, 
medical service characteristics (beginning and ending date of service), and coverage 
characteristics (total charges, Medicare payments).  Each physician/supplier claim (Part 
B) includes a de-identified beneficiary USRDS identification number, diagnostic and 
healthcare common procedure coding system (HCPCS) codes, service characteristics 
(beginning and ending date of service) and coverage characteristics (submitted charges, 
allowed charges, claim payment amount).  
 
2.4.3.1 Incidence of Cardiovascular Disease  
The incidence of CVD was defined as the number of patients who were newly diagnosed 
with CVD during a 1-year follow-up between January 1, 2007 and December 31, 2007.  
CVD was defined as medical services (International Classification of Disease, Ninth 
Revision (ICD-9-CM) codes) for acute myocardial infarction (AMI), atrial fibrillation 
(AF), cerebrovascular accident/transient ischemic attack (CVA/TIA), congestive heart 
failure (CHF), and peripheral arterial disease (PAD).(US Renal Data System 2011)  
CVD-related treatments were identified by current procedural terminology (CPT) codes 
including percutaneous coronary interventions (PCI), coronary artery bypass graft 
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surgery (CABG), and use of an implantable cardioverter defibrillator (ICD) or cardiac 
resynchronization therapy with defibrillator (CRT-D) (Appendix B). (US Renal Data 
System 2011)  Each of the eight events was defined on the date of the first appearance 
of a diagnosis or procedure code in the 2007 claims.  The 2006 claims were used to 
ensure that no CVD events occurred in 2006.   
 
2.4.3.2 Medical Service Utilization  
Two medical utilization categories were assessed in the analysis: cardiovascular-related 
and all-cause medical service utilization.  Cardiovascular-related resource use was 
defined as at least one medical service claim with a relevant ICD-9-CM code or CPT 
code.  All-cause medical services were defined by medical service claims for any 
reason.  Medical services consisted of inpatient, outpatient, and other (i.e., home health 
agency, skilled nursing facility, or hospice).  Medical service utilization was measured 
by the percentage of patients who used these medical services for a 1-year follow-up 
period.  The mean number of visits for medical services was also calculated.   
 
2.4.3.3 Medical Service Costs 
Medical costs per person per year were calculated for cardiovascular-related medical 
services and all-cause medical services.  Medical costs were estimated from the 
Medicare perspective for a 1-year period between January 1, 2007 and December 31, 
2007.  Adjusted mean medical costs were estimated from two-part models which are 
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computed by multiplying the adjusted probability obtained from the logistic regression 
model (part 1) with predicted costs from the general linear model (part 2), as described in 
Section 2.5.5.2.1.   
Costs were defined as payments made by Medicare for cardiovascular-related and all-
cause medical service costs including inpatient, outpatient and other visits.  Medical 
service costs per year per person were calculated for a 1-year follow-up period of January 
1, 2007 through December 31, 2007.   
 
2.4.4 Phase IV: Mortality Rates (January 2008 to December 2010) 
To assess the effect of the coverage gap on mortality rates - including cardiovascular-
related mortality and all-cause mortality - survival analysis was used.  Cardiovascular 
causes of death were defined as those attributed to CVD.  All-cause mortality included 
death from cardiovascular causes and non-cardiovascular causes.  Because the inclusion 
criteria for the study required that individuals remain in Medicare plans throughout 2007, 
mortality in 2008-2010 was assessed.  Survival analysis examined whether the 3-year 
survival rate was associated with Part D coverage groupings.  Cox proportional hazards 
regression models estimated the hazard ratios of the association between Part D coverage 
cohorts and mortality; controlling for age, gender, race, region of residence, primary 
disease causing ESRD, ESRD duration, CCI score, presence of chronic disease including 
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cardiovascular disease, diabetes mellitus, hypertension, dyslipidemia, cancer, chronic 
lung disease. 
Sensitivity analysis was also conducted for all of the covariates in the base case above as 
well as laboratory surrogates including GFR, BMI, serum creatinine, serum hematocrit, 
hemoglobin value (g/dl), serum albumin (g/dl), BUN, and ethnicity (Hispanic vs Non-
Hispanic) and the receipt of transplant.  Note: These laboratory data were obtained from 
the CMS End-Stage Renal Disease Medical Evidence Report (CMS-2728), which is used 
to register patients at the onset of ESRD.  Thus, these laboratory data were recorded not 
during the same period of time but when patients began dialysis.  Section 2.6.6.1 
describes the Kaplan-Meier method and the Cox proportional hazards regression model 
in detail.  
 
2.4.5 Independent Variables 
2.4.5.1 Part D Coverage Variable  
In this study, the four cohorts of Part D beneficiaries were categorized based on their Part 
D coverage in 2007.  The first cohort consisted of patients who did not reach the 
coverage gap (cohort 1; out-of-pocket costs < $799).  The second cohort was comprised 
of patients who reached the coverage gap but did not reach the point of receiving 
catastrophic coverage (cohort 2; $799 ≤ out-of-pocket costs < $3,850).  The third cohort 
included patients who reached catastrophic coverage (cohort 3; $3,850 ≤ out-of-pocket 
costs).  The fourth cohort was comprised of patients who did not reach the coverage gap 
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and receive the LIS (cohort 4; out-of-pocket costs < $799).  Patients who received the 
LIS for their premium and copayment were included in cohort 4 because of their unique 
benefit structure.   
 
2.4.5.2 Demographic and Clinical Variables 
The following demographic and clinical variables were identified: age, gender, race, 
region of residence, primary disease causing ESRD, and ESRD duration (Table 2.1). 
Table 2.1   Definitions of Demographic Variables  
Name Level Definition 
Age Continuous Age on January 1, 2007  
Gender Categorical 0: Female 
1: Male 
Race Categorical 1: Black 
2: White 
3: Other – Native American, Asian, 
and other 
Region of residence Categorical 1: Midwest 
2: Northeast 
3: South 
4: West 
Primary disease causing 
ESRD 
 
Categorical 1: Diabetes 
2: Hypertension 
3: Glomerulonephritis 
4: Cystic kidney 
5. Other 
ESRD duration Continuous Disease duration on January 1, 2007 
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2.4.5.3 Comorbidity Variables 
The CCI scores were used to calculate comorbidity severity scores.  The presence of 
chronic diseases (CVD, diabetes mellitus, hypertension, and dyslipidemia) was also 
assessed (Table 2.2 and Table 2.3).   
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Table 2.2   Charlson Comorbidity Index (CCI)  
Diagnoses ICD-9 codes Weight 
Myocardial infarction 410.xx, 412 1 
Congestive heart failure 428.x 1 
Peripheral vascular disease 441.x, 443.9, 785.4, V43.4, 38.48(P) 1 
Cerebrovascular disease 430-437.x, 438 1 
Dementia 290.x 1 
Chronic pulmonary disease 490-496, 500-505, 506.4 1 
Ulcer disease 531.4x-531.7x, 532.4x-532.7x, 533.4x-
533.7x, 534.4x-534.7x, 531.0x-531.3x, 
532.0x-532.3x, 533.0x-533.0x, 534.0x-
534.3x, 531.9, 532.9, 533.9, 534.9 
1 
Various cirrhosis 571.2, 571.4, 571.5, 571.6 1 
Diabetes 250.0x-250.3x, 250.7x 1 
Connective tissue disease 710.x, 714.x, 725.x 1 
Hemiplegia 342.x, 344.1 2 
Moderate or severe renal 
disease 
582.x, 583.0-583.7, 585, 586, 588.x 2 
Diabetes with 
complications 
250.4x-250.6x 2 
Various cancers 140.x-172.x, 174.x-195.x, 200.x-208.x 2 
Moderate or severe liver 
disease 
572.2-572.8 3 
Metastatic cancers 196.x-199.9 6 
HIV/AIDS 042.x-044.9 6 
 Updated Charlson Codes (2008)  
Depression 296.2x-296.3 1 
Use of warfarin Used drug data 1 
Hypertension 401.x-401.9 1 
Skin ulcers/cellulitis 682.x-682.9, 707.x-707.9 2 
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Table 2.3   Presence of Chronic Disease 
Name Level Definition 
Cardiovascular disease Categorical 0: No 
1: Yes 
Diabetes mellitus Categorical 0: No 
1: Yes 
Hypertension Categorical 0: No 
1: Yes 
Dyslipidemia 
 
Categorical 0: No 
1: Yes 
Cancer Categorical 0: No 
1: Yes 
Chronic lung disease Categorical 0: No 
1: Yes 
 
2.4.5.4 Medication Variables 
Use of antihyperglycemic drugs, antihypertensive drugs, lipid-lowering drugs, phosphate 
binders, and calcimimetic drugs were included (Tables 2.4 - 2.8).   
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Table 2.4   Antihyperglycemic Drugs 
Drug Class Generic Name 
Sulfonylureas Glipizide, Acetohexamide, Chlorpropamide, 
Tolazamide, Tolbutamide, Glyburide, Glimepiride, 
Glipizide/Metformin, Glyburide/Metformin   
Alpha-glucosidase inhibitors Acarbose, Miglib 
Biguanides Metformin HCl 
Meglitinides Repaglinide, Nateglinide 
Thiazolidinediones Pioglitazone, Pioglitazone/glimepiride, 
Pioglitazone/Metformin, Rosiglitazone, 
Rosiglitazone/Glimepiride, Rosiglitazone/Metformin 
DPP-4 inhibitors Sitagliptin, Sitagliptin/Metformin, Saxagliptin 
GLP agonist Exenatide, Pramlintide acetate 
Insulin Hum Insulin/Reg Insulin Hm, Insulin Aspart, Insulin 
Detemir, Insulin Glargine, Insulin Glulisine, Insulin 
Isophane, Insulin Lispro, Insulin Npl/Insulin Lispro, 
Insulin Regular, Human, Insulin Regular, 
Human&Rel.Unt, Insulin Zinc Extend Human Rec, 
Insulin Zinc Human Rec,Insuln Asp Prt/Insulin Aspart, 
Human Insulin Isophane, Reg Insulin 
Hm/Rlse/Chbr/Ihlr 
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Table 2.5   Antihypertensive Drugs 
Drug Class Generic Name 
ACE Inhibitors 
 
Benazepril, Benazepril/Hydrochlorothiazide, Captopril, 
Captopril/Hydrochlorothiazide, Enalapril Maleate, 
Enalapril Maleate/Felodipine, 
Enalapril/Hydrochlorothiazide, Enalaprilat Dihydrate, 
Fosinopril Sodium, Fosinopril/Hydrochlorothiazide, 
Lisinopril, Lisinopril/Hydrochlorothiazide, Moexipril 
HCl, Moexipril/Hydrochlorothiazide, Perindopril 
Erbumine, Quinapril HCl,  
Quinapril/Hydrochlorothiazide, Ramipril, Trandolapril, 
Trandolapril/Verapamil HCl 
ARBs 
 
Candesartan Cilexetil, 
Candesartan/Hydrochlorothiazide, Eprosartan 
Mesylate, Eprosartan/Hydrochlorothiazide, Irbesartan, 
Irbesartan/Hydrochlorothiazide, Losartan Potassium, 
Losartan/Hydrochlorothiazide, Olmesartan Medoxomil, 
Olmesartan/Hydrochlorothiazide, Telmisartan, 
Telmisartan/Hydrochlorothiazide,             
Valsartan, Valsartan/Hydrochlorothiazide 
Calcium-channel Blockers 
 
 
Amlodipine Besylate/Olmesartan, Amlodipine 
Besylate, Amlodipine Besylate/Benazepril, 
Amlodipine/Atorvast, Amlodipine/Valsartan, 
Diltiazem HCl, Felodipine, Isradipine, Nicardipine 
HCl, Nifedipine, Nimodipine, Nisoldipine, Verapamil 
HCl 
Beta-blocker 
 
Acebutolol HCl, Atenolol, Atenolol/Chlorthalidone, 
Betaxolol HCl, Bisoprolol Fumarate, Bisoprolol 
Fumarate/ Hydrochlorothiazide, Carteolol HCl, 
Carvedilol, Carvedilol Phosphate, Labetalol Hcl, 
Metoprolol Succinate, Metoprolol Tartrate, 
Metoprolol/Hydrochlorothiazide, Nadolol, Pindolol, 
Propranolol HCl, Propranolol/Hydrochlorothiazide, 
Timolol, Timolol Maleate 
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Table 2.5 (continued) 
Alpha-Agonists 
 
Clonidine HCl, Clonidine HCl/Chlorthalidone, 
Guanabenz Acetate, Guanfacine HCl, Methyldopa, 
Methyldopa/Hydrochlorothiazide 
Alpha-Blockers Doxazosin Mesylate, Prazosin HCl, Terazosin HCl 
Aldosteron blocker Eplerenone, Spironolact/Hydrochlorothiazid, 
Spironolactone, Spironolactone Micronized 
Direct Renin Inhibitor Aliskiren Hemifumarate 
Diuretic 
Indapamide, Hydrochlorothiazide, Torsemide, 
Chlorothiazide, Bumetanide, Hydrochlorothiazide, 
Furosemide, Chlorthalidone, Bumetanide, Amiloride 
Hcl, Triamterene, Triamterene/Hydrochlorothiazide 
Vasodilator 
Aspirin/Dipyridamole, Dipyridamole, Hydralazine 
HCl, Hydralazine/Hydrochlorothiazid, Isosorb 
Dinit/Hydralazine HCl, Isosorbide Dinitrate, Isosorbide 
Mononitrate, Minoxidil, 
Nitroglycerin,Nitroglycerin/D5W 
Other 
Reserpine 
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Table 2.6   Lipid-lowering Drugs 
Drug Class Generic Name 
Statins Atorvastatin, Fluvastatin, Lovastatin, Pravastatin, 
Simvastatin  
Fibrate Bezafibrate, Clofibrate, Ciprofibrate, Fenofibrate, 
Gemfibrozil       
Niacin Niacin 
Bile acid sequestrants Cholestyramine/Aspartame, Cholestyramine/Sucrose 
Ezetimibe Ezetimibe 
 
Table 2.7   Phosphate Binders 
Drug Class Generic Name 
Lanthanum  Lanthanum carbonate 
Sevelamer Sevelamer HCl, Sevelamer carbonate 
Calcium Calcium Acetate, Calcium Carbonate, Calcium 
Carbonate/Mag Carb/Fa, Calcium Carbonate/Vitamin 
D2, Calcium Carbonate/Vitamin D3 
 
 
Table 2.8   Calcimimetic Drugs  
Drug Class Generic Name 
Cinacalcet  Sensipar 
 
 
2.5 Statistical Analysis 
All data manipulation and statistical analyses were performed using SAS software 
(version 9.2; SAS Institute Inc., Cary, North Carolina) and Stata (version 11.1; Stata 
Corp, College Station, Texas).  All statistical analyses were two-tailed, with significance 
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level set a priori at α = 0.05.  Descriptive statistics were conducted to compare the 
demographic and clinical variables.  Categorical variables (e.g., gender, race, ethnicity 
and presence of chronic diseases) were examined using Pearson Chi-square tests.  
Continuous variables (e.g., age, CCI, and ESRD duration) were compared using one-way 
ANOVAs and the Kruskal-Wallis test, a nonparametric alternative to ANOVA.  
Normally distributed data were analyzed using ANOVA, whereas non-normally 
distributed data were analyzed using Kruskal-Wallis tests.  
Adjusted regression models were built using GEE models, logistic regressions, GLMs, 
zero-inflated Poisson regression models, two-part models, and Cox proportional hazards 
regression models.  Medication adherence and persistence were measured using logistic 
regression and Cox proportional hazards regression models, respectively.  To examine 
differences in drug adherence before and after the coverage gap was exceeded, GEE 
models were used.  Medical service utilization was estimated using zero-inflated 
Poisson regression models.  Annual medical service costs for the cohorts were 
calculated using two-part models consisting of logistic regression of the probability of 
any costs and linear regression of costs for patients with costs.  Logistic regression 
examined whether the 1-year incidence of CVD was associated with the level of Part D 
coverage.  Survival analyses including Kaplan-Meier and Cox proportional hazards 
regressions examined whether the 3-year survival rates were associated with the Part D 
coverage gap.  
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All models to assess association between Part D coverage levels and outcomes were 
adjusted for age, gender, race, region of residence, primary disease causing ESRD, ESRD 
duration, CCI score, presence of chronic disease including cardiovascular disease, 
diabetes mellitus, hypertension, dyslipidemia, cancer, chronic lung disease.  Cohort 4 
served as the reference cohort, controlling for covariates.   
 
2.5.1 Objective 1: Demographic Characteristics  
For objective 1, Pearson Chi-square tests were conducted to compare the distribution of 
gender, race, presence of chronic diseases, and primary disease causing ESRD, 
categorized by Part D coverage levels.  Mean age, the CCI score, and ESRD duration 
were compared using ANOVAs. 
 
2.5.2 Objective 2: Medication Utilization and Costs 
For objective 2, bivariate analyses (Pearson Chi-square and ANOVA or Kruskal-Wallis) 
were performed to compare the proportion and number of oral prescription drugs (i.e., 
antihyperglycemics, antihypertensives, lipid-lowering drugs, phosphate binders, or 
cinacalcet), categorized by the Part D coverage.  
Pharmacy costs for each of the five therapeutic classes of outpatient prescription and all 
prescription drugs were compared across Part D coverage categories using one-way 
ANOVAs and Kruskal-Wallis tests.   
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2.5.3 Objective 3: Medication Adherence and Persistence 
For objective 3, ANOVAs and Kruskal-Wallis tests were performed to compare mean 
MPR and persistence until the first 30-day gap (or 60-day gap for sensitivity analysis) in 
five therapeutic classes of outpatient prescription drugs, including antihyperglycemics, 
antihypertensives, lipid-lowering drugs, phosphate binders, or cinacalcet, categorized by 
Part D coverage.  Medication adherence was dichotomized, with adherence defined as 
MPR ≥ 80 percent; and nonadherence defined as MPR < 80 percent.  Pearson Chi-
square tests were used to compare the proportions of patients who were adherent.  
Logistic regression was used to measure the proportion of patients who were adherent 
(MPR ≥ 80 %), controlling for of age, gender, race, region of residence, primary disease 
causing ESRD, ESRD duration, CCI score, presence of chronic disease including CVD, 
diabetes mellitus, hypertension, dyslipidemia, cancer, chronic lung disease.  Kaplan-
Meier survival curves were used to depict the percentage of patients who remained 
persistent among the cohorts.  Cox proportional hazards regression was used to measure 
the difference in persistence among the cohorts with the same covariates used in the 
logistic regression.  Adherence before and after the date in which patients who reached 
the coverage gap but did not reach the point of receiving catastrophic coverage (cohort 2: 
$799 ≤ out-of-pocket costs < $3,850) were compared using generalized estimating 
equations (GEE), controlling for the same covariates with logistic and Cox proportional 
hazards regressions.   
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2.5.3.1 Generalized Estimating Equations (GEE) 
The GEE method, an extension of the quasi-likelihood approach, was used to analyze 
longitudinal and other correlated data. (Hanley, Negassa et al. 2003)  While applications 
of generalized linear models are abundant, there are many situations in which repeated 
response measurements are made on the same unit, and, thus, this information forms a 
cluster of correlated observations. (Myers 2012)  The advantage of GEE models is their 
control for correlation by incorporating the correlation structure into the regression model 
as a covariate.  
The basic structure of the GEE model with within-subject correlation is shown below 
(Twisk 2003):  
𝑌𝑖𝑡  =  𝐵𝑜  + ∑ 𝐵𝑖𝑗 𝑋𝑖𝑡𝑗 + 𝐵2𝑡 + ⋯ + 𝐶𝑂𝑅𝑅𝑖𝑡 + ε𝑖𝑡 
𝑗
𝑗=1
 
Where 𝑌𝑖𝑡  == observations for subject i at time t; 
 𝐵𝑜 = intercept; 
𝑋𝑖𝑡𝑗 = independent variable j for subject i at time t; 
𝐵𝑖𝑗  = regression coefficient for independent variable j;  
J = number of independent variables; 
t = time; 
β2 = regression coefficient for time; 
𝐶𝑂𝑅𝑅𝑖𝑡 = working correlation structure; and 
ε𝑖𝑡 = error for subject i at time t. 
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2.5.4 Objective 4: Cardiovascular Disease Morbidity 
For objective 4, the incidence of CVD was compared among the study cohorts, 
categorized by Part D coverage.  Logistic regression was used to examine whether the 
1-year cardiovascular incidence rates were associated with Part D coverage. The 
following variables were controlled for in the Cox regression: age, gender, race, region of 
residence, primary disease causing ESRD, ESRD duration, CCI score, presence of 
chronic disease including cardiovascular disease, diabetes mellitus, hypertension, 
dyslipidemia, cancer, and chronic lung disease. 
 
2.5.5 Objective 5: Cardiovascular-related and All-cause Medical Service Utilization 
and Costs 
2.5.5.1 Medical Service Utilization 
For objective 5, cardiovascular-related and all-cause medical service utilization rates 
were defined by inpatient, outpatient or other claims having an ICD-9-CM code or CPT 
code of interest.  Medical service utilization was measured by the percentage of patients 
who had medical services (i.e., inpatient, outpatient or other visits) for the 1-year follow-
up period.  The mean numbers of visits for medical services were also estimated.  The 
inferential analysis estimated unadjusted differences in the percentage of patients and the 
mean number of cardiovascular-related medical services among the study cohorts, with 
statistical significance determined using chi-square, ANOVA, or the Kruskal-Wallis tests.  
Zero-inflated Poisson regression was used to calculate the adjusted mean utilization rates, 
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adjusting for age, gender, race, region of residence, primary disease causing ESRD, 
ESRD duration, CCI score, presence of chronic disease including cardiovascular disease, 
diabetes mellitus, hypertension, dyslipidemia, cancer, chronic lung disease.  
 
2.5.5.1.1 Zero-inflated Poisson Regression 
In many cases of medical service utilization, the data exhibit an excessively large 
proportion of zeros that is significantly larger than that expected in the Poisson 
distribution.  To accommodate zero inflation, Mullahy proposed a zero-inflated Poisson 
model that assumes a two-state process. (Mullahy 1986)  The zero-inflated Poisson 
regression has two equations, one is a logit specification that separates the excess of zeros 
from the rest, (i.e., those patients that have no medical service utilization from the 
others), and the other equation is a Poisson specification that counts the number of 
medical services. (Sole-Auro, Guillen et al. 2012)  The Vuong test was used to test 
whether the zero-inflated Poisson regression was a better fit than the standard Poisson 
regression.  
The basic structure of the zero-inflated Poisson regression model is shown below 
(Mullahy 1998; Lee, Wang et al. 2006): 
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Where 0 < Ø < 1 so that it incorporates more zeros than those permitted under the 
Poisson assumption (Ø=0).  It was assumed that a discrete count response variable Y 
follows a zero-inflated Poisson distribution.   
 
2.5.5.2 Medical Service Costs 
Medical service costs per year per person were calculated for cardiovascular-related and 
all-cause medical services, defined by medical claims.  Cost differences among the 
study cohorts were calculated using both descriptive analysis and multivariate regression.  
The inferential analysis estimated the unadjusted differences in the mean annual medical 
service costs among the study cohorts, with statistical significance determined using one-
way ANOVA and Kruskal-Wallis tests.  The adjusted mean costs for medical services 
were estimated from two-part models, which are computed by multiplying the adjusted 
probability obtained from the logistic regression model (part 1) with predicted costs from 
the general linear model (part 2).   
 
2.5.5.2.1 Two-part Models 
Annual medical service costs for the four cohorts were calculated using a two-part model. 
(Mullahy 1998)  Two-part models are often used to model cost data that include many 
zero observations. (Buntin and Zaslavsky 2004)  In the first part, logistic regression was 
used to predict the likelihood of having cost greater than zero.  A generalized linear 
model (GLM) with log link function was used in the second part to estimate the mean 
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annual healthcare costs for patients with positive health care costs.  The adjusted mean 
costs estimated from two-part models were computed by multiplying the adjusted 
probability obtained from the logistic regression model (part 1) with the predicted cost 
from the GLM model (part 2).   
Cohort 4 (out-of-pocket < $799 with LIS) served as the reference cohort, controlling for 
baseline covariates.  A bootstrap resampling method was used to estimate the 95% 
confidence intervals of the healthcare cost differences among the study cohorts.   
The basic structure of the two-part model is shown below (Mullahy 1998): 
E (Y | X) = P (Y > 0 | X) E (Y | Y > 0, X) 
 Part 1:  P (Y > 0 | X) 
The first part of the model predicts the probability of any use, specified as a 
probit.  
 Part 2: E (Y | Y > 0, X) 
 
The second part of the model predicts costs conditional on nonzero costs.  To 
obtain unconditional predicted costs, the probabilities of use from the first part are 
multiplied by expected levels from the second part of the model.   
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2.5.6 Objective 6: All-cause and Cardiovascular-related Mortality  
For objective 6, the associations between Part D coverage levels and 3-year mortality 
rates were assessed using survival analyses.  Survival curves were calculated using the 
Kaplan-Meier method.  Cox proportional hazards regression models estimated the 
hazard ratios of the association between Part D coverage levels and mortality.  
Cardiovascular causes of death were defined as those attributed to CVD.  All-cause 
mortality included death from cardiovascular causes and non-cardiovascular causes.   
 
2.5.6.1 Survival Analysis 
Survival analysis is a technique used to make comparisons of the time to occurrence of 
events of interests in two or more treatment groups.  Survival analysis has become a 
popular tool in observational and experimental studies involving follow-up study 
participants over time.  The most commonly used survival analysis methods include the 
Kaplan-Meier survival function and the Cox proportional hazards function.  This study 
used the Kaplan-Meier survival function to plot survival curves and the Cox proportional 
hazards regression model to quantify the hazards ratios for Part D coverage levels and 
other covariates.   
2.5.6.1.1 Kaplan-Meier Method  
The Kaplan-Meier method is frequently used to estimate survival functions.  This 
method can depict the percentage of patients surviving at intervals and test the 
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differences between survival functions of two or more treatment groups.  Kaplan-Meier 
curves were generated for the 3-year overall and cardiovascular event-free survival 
among the study cohorts.  
The equation used to calculate the Kaplan-Meier function is (Allison PD 1995): 
 
S(t) = the survival function (proportion of patients surviving after time t or 
proportion of patients with survival time greater than t) at time t 
t j = the time at which one or more individuals experience the event of interest 
d j = the number of individuals who experience the event of interest at t j 
n j =the number of individuals at risk at time t j 
the quantity in the brackets is the conditional probability of surviving to time t j 
+1, given that one survived to time t j. (Allison PD 1995) 
However, the Kaplan-Meier method is limited to calculating the survival probability 
involving a single categorical predictor and cannot quantify the effect of individual 
variables on survival time while controlling for other covariates.  When multiple 
predictors are involved to explain an event, the Cox proportional hazards regression 
model is preferred.   
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2.5.6.1.2 The Cox Proportional Hazards Regression Model 
The Cox proportional hazard models belong to the family of survival analyses.  This 
model has become popular because it easily incorporates time-dependent covariates and 
is effective at controlling for multiple covariates, and can easily accommodate discrete 
and continuous measurement of event times. (Allison PD 1995) 
The basic structure of the Cox proportional hazard regression model is shown below 
(Cox 1972):  
 
 
hi (t): the hazard at time t 
h0 (t): the baseline hazard 
X: an independent variable in the model 
β: the regression coefficient for the corresponding independent variable.   
 
 Table 2.9 provides a summary of study hypotheses and statistical techniques.      
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Table 2.9   Summary of Objectives, Hypotheses Tested, Study Variable(s), and Statistical Tests  
Objective/Hypothesis 
Study 
Phase 
Dependent Variable 
Independent 
Variable 
Test 
Objective 1 
To compare patient characteristics for Medicare 
beneficiaries with dialysis, categorized into four 
cohorts based on their Part D coverage. 
Phase I    
H0 (1a): Mean age will not differ significantly when 
categorized by Part D coverage. 
 Age Part D coverage ANOVA, Kruskal-Wallis 
test 
H0 (1b): The proportion of patients in each gender 
category will not differ significantly when categorized 
by Part D coverage. 
 Gender Part D coverage Pearson Chi-square (x2) 
H0 (1c): The proportion of patients in each race category 
will not differ significantly when categorized by Part D 
coverage. 
 Race Part D coverage Pearson Chi-square (x2) 
H0 (1d): The proportion of patients in each region 
category will not differ significantly when categorized 
by Part D coverage. 
 Region of residence Part D coverage Pearson Chi-square (x2) 
H0 (1e): The proportion of patients in primary disease 
causing ESRD will not differ significantly when 
categorized by Part D coverage. 
 Primary disease 
causing ESRD 
Part D coverage Pearson Chi-square (x2) 
H0 (1f): Mean ESRD duration will not differ 
significantly when categorized by Part D coverage. 
 ESRD duration Part D coverage ANOVA, Kruskal-Wallis 
test 
H0 (1g): Mean comorbidity score will not differ 
significantly when categorized by Part D coverage. 
 Charlson 
Comorbidity Index 
(CCI) scores 
Part D coverage ANOVA, Kruskal-Wallis 
test 
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Table 2.9 (continued) 
H0 (1h- 1m): The proportion of patients in each presence 
of chronic diseases (cardiovascular disease [H0(1h)], 
diabetes mellitus [H0(1i)], hypertension [H0(1j)], 
dyslipidemia [H0(1k)], cancer [H0(1l)], chronic lung 
disease [H0(1m)]) will not differ significantly when 
categorized by Part D coverage. 
 Cardiovascular 
disease, diabetes 
mellitus, 
hypertension, 
dyslipidemia, cancer, 
chronic lung disease 
Part D coverage Pearson Chi-square (x2) 
Objective 2 
To determine whether the proportion and number of 
oral prescription medications and pharmacy costs differ 
when categorized by Part D coverage.   
Phase 
II 
   
H0 (2a-e): The proportion of patients using 
antihyperglycemics [H0(2a)], antihypertensives [H0(2b)], 
lipid-lowering drugs [H0(2c)], phosphate binders [H0(2d)], 
or cinacalcet [H0(2e)]) will not differ significantly when 
categorized by Part D coverage. 
 Proportion of patients 
using 
antihyperglycemics, 
antihypertensives, 
lipid-lowering drugs, 
phosphate binders, 
cinacalcet 
Part D coverage Pearson Chi-square (x2) 
H0 (2f-j): The mean number of antihyperglycemics 
[H0(2f)], antihypertensives [H0(2g)], lipid-lowering drugs 
[H0(2h)], phosphate binders [H0(2i)], or cinacalcet [H0(2j)]) 
will not differ significantly when categorized by Part D 
coverage. 
 Number of 
antihyperglycemics, 
antihypertensives, 
lipid-lowering drugs, 
phosphate binders, 
cinacalcet 
Part D coverage ANOVA 
Kruskal-Wallis test 
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Table 2.9 (continued) 
H0 (2k-p): Pharmacy costs (i.e., antihyperglycemics 
[H0(2k)], antihypertensives [H0(2l)], lipid-lowering drugs 
[H0(2m)], phosphate binders [H0(2n)], cinacalcet [H0(2o)] or 
all [H0(2p)] ) will not differ significantly when 
categorized by Part D coverage. 
 Total pharmacy costs, 
out-of-pocket costs 
Part D coverage ANOVA 
Kruskal-Wallis test 
Objective 3 
To determine whether medication adherence and 
persistence among patients receiving drug therapy for 
diabetes, hypertension, hyperlipidemia, 
hyperphosphatemia or secondary parathyroid differ 
when categorized by Part D coverage. 
Phase 
II 
   
H0 (3a-e):  Medication adherence (i.e., 
antihyperglycemics [H0(3a)], antihypertensives [H0(3b)], 
lipid-lowering drugs [H0(3c)], phosphate binders [H0(3d)], 
or cinacalcet [H0(3e)]) will not differ significantly when 
categorized by Part D coverage.   
 MPR 
 
Part D coverage ANOVA 
Kruskal-Wallis test 
 
 
H0 (3f-j): The proportion of patients who are adherent 
(MPR ≥ 80%) to antihyperglycemics [H0(3f)], 
antihypertensives [H0(3g)], lipid-lowering drugs [H0(3h)], 
phosphate binders [H0(3i)], or cinacalcet [H0(3j)] will not 
differ significantly when categorized by Part D 
coverage. 
 Proportion adherent 
 
Part D coverage Pearson Chi-square (x2) 
Logistic regression* 
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Table 2.9 (continued) 
To determine whether medication adherence differs 
before and after the coverage gap is exceed among 
patients receiving drug therapy in our primary cohort 
(cohort 2) who reach coverage gap but not catastrophic 
coverage. 
    
H0 (3k-o) : Medication adherence with 
antihyperglycemics [H0(3k)], antihypertensives [H0(3l)], 
lipid-lowering drugs [H0(3m)], phosphate binders [H0(3n)], 
or cinacalcet [H0(3o)] will not differ significantly before 
and after reaching the gap. 
 MPR Before and after 
reaching 
coverage gap 
(month 0) 
Paired t-test 
H0 (3p-t): The proportion of patients who are adherent 
(MPR ≥ 80%) to antihyperglycemics [H0(3p)], 
antihypertensives [H0(3q)], lipid-lowering drugs [H0(3r)], 
phosphate binders [H0(3s)], or cinacalcet [H0(3t)] will not 
differ significantly before and after reaching the gap. 
 Proportion adherent 
 
Part D coverage McNemar’s test 
Generalized estimating 
equation model (GEE)* 
H0 (3u-y): Medication persistence with 
antihyperglycemics [H0(3u)], antihypertensives [H0(3v)], 
lipid-lowering drugs [H0(3w)], phosphate binders [H0(3x)], 
or cinacalcet [H0(3y)] will not differ significantly when 
categorized by Part D coverage.   
 Persistence Part D coverage ANOVA 
Kruskal-Wallis test 
 
 
H0 (3z-zd): The proportion of patients who are persistent 
(until 30days gap) to antihyperglycemics [H0(3z)], 
antihypertensives [H0(3za)], lipid-lowering drugs [H0(3zb)], 
phosphate binders [H0(3zc)], or cinacalcet [H0(3zd)] will 
not differ significantly when categorized by Part D 
coverage.   
 Proportion persistent  Kaplan-Meier curves 
Cox proportional 
regression* 
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Table 2.9 (continued) 
Objective 4 
To determine whether cardiovascular morbidity rates 
differ when categorized by Part D coverage. 
Phase 
III 
   
H0 (4): Incidence of cardiovascular disease will not 
differ significantly when categorized by Part D 
coverage 
 Incidence of 
cardiovascular 
disease 
Part D coverage Logistic regression*  
Objective 5 
To determine whether all-cause and cardiovascular-
related medical service utilization (i.e, inpatient, 
outpatient, and other visits) and costs differ when 
categorized by Part D coverage. 
Phase 
III 
   
H0 (5a-c): The proportion of patients used all-cause 
medical services including inpatient [H0(5a)], outpatient 
[H0(5b)], and other visits [H0(5c)] will not differ 
significantly when categorized by Part D coverage.  
 Proportion of patients 
with all-cause 
inpatient, outpatient, 
other visits 
Part D coverage Pearson Chi-square (x2) 
H0 (5d-f): Mean numbers of medical service visits (i.e., 
inpatient [H0(5d)], outpatient [H0(5e)], and other visits 
[H0(5f)], ) will not differ significantly when categorized 
by Part D coverage. 
 Mean numbers of  
all-cause inpatient, 
outpatient, other 
visits 
Part D coverage Kruskal-Wallis test 
Poisson regression* 
Zero-inflated Poisson 
regression* 
H0 (5g-i): The proportion of patients used medical 
services related to cardiovascular disease including 
inpatient [H0(5g)], outpatient [H0(5h)], and other visits 
[H0(5i)], will not differ significantly when categorized 
by Part D coverage. 
 Proportion of patients 
with cardiovascular-
related 
inpatient, outpatient, 
other visits  
Part D coverage Pearson Chi-square (x2) 
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Table 2.9 (continued) 
H0 (5j-l): Mean numbers of cardiovascular-related 
medical service visits (i.e., inpatient [H0(5j)], outpatient 
[H0(5k)], and other visits [H0(5l)]) will not differ 
significantly when categorized by Part D coverage. 
 Mean numbers of 
cardiovascular-
related inpatient, 
outpatient, other 
visits 
Part D coverage Kruskal-Wallis test 
Poisson regression* 
Zero-inflated Poisson 
regression* 
H0 (5m-t): All-cause medical care costs including 
inpatient [H0(5m)], outpatient [H0(5n)], physician/supplier 
[H0(5o)], other visits [H0(5p)], dialysis [H0(5q)], and total 
medical costs [H0(5r)], pharmacy costs [H0(5s)] and total 
health care costs [H0(5t)] will not differ significantly 
when categorized by Part D coverage. 
 All-cause medical 
care costs 
Part D coverage Kruskal-Wallis test 
Generalized linear model 
(GLM)* 
Two-part model* 
H0 (5u-y): Cardiovascular disease-related medical care 
costs including inpatient [H0(5u)], outpatient [H0(5v)], 
physician/supplier [H0(5w)], other visits [H0(5x)], and total 
medical service costs [H0(5y)], will not differ 
significantly when categorized by Part D coverage. 
 Cardiovascular-
related medical care 
costs 
Part D coverage Kruskal-Wallis test 
Generalized linear model 
(GLM)* 
Two-part model* 
Objective 6 
To determine whether cardiovascular-related and all-
cause mortality rates differ when categorized by Part D 
coverage. 
Phase 
IV 
   
H0 (6a): All-cause mortality rates will not differ when 
categorized by Part D coverage. 
 All-cause mortality 
rates  
Part D coverage Kaplan-Meier curves 
Cox proportional 
regression*  
H0 (6b): Cardiovascular-related mortality rates will not 
differ when categorized by Part D coverage. 
 Cardiovascular-
related mortality rates 
Part D coverage Kaplan-Meier curves 
Cox proportional 
regression* 
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2.6 Sample Size Calculations 
This section discussed sample size calculations for the statistical analyses used for this 
study.  Sample size calculations conducted for statistical tests under objectives 2-6 
including multiple regression, logistic regression, and Cox proportional hazards 
regression.  Sample size calculations were performed using PASS (Power Analysis & 
Sample Size) software (version 12; NCSS Statistical Software, Kaysville, Utah).  Using 
the PASS 12 software and varying the parameter required for sample size calculations 
over a range of values, the largest sample size obtained was chosen as the required 
sample size for each regression.    
 
2.6.1 Multiple Regression Analysis  
Given 15 independent variables, an alpha of 0.05 and power equal to 0.8, the estimated 
total sample size of 205 patients were required for multiple regressions as shown in Table 
2.10. (Cohen 1988) 
 
2.6.2 Logistic Regression Analysis 
Table 2.11 presents the estimates of sample sizes required for the logistic regression 
analysis.  Based on the estimates of sample size obtained, an estimated total sample size 
of 7714 patients was required for the logistic regression (α = 0.05; power=0.8). (Hsieh, 
Bloch et al. 1998)   
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Table 2.10  Estimates of Sample Size for Multiple Regression Analysis 
N Alpha 
Ind. 
Variables 
Tested a 
R2 b 
Ind. 
Variables 
Controlled c  
R2 b 
186 0.05 20 0.1 15 0.1 
94 0.05 20 0.2 15 0.1 
66 0.05 20 0.3 15 0.1 
53 0.05 20 0.4 15 0.1 
47 0.05 20 0.5 15 0.1 
  
    
  
205 0.05 20 0.1 15 0.01 
103 0.05 20 0.2 15 0.01 
71 0.05 20 0.3 15 0.01 
57 0.05 20 0.4 15 0.01 
49 0.05 20 0.5 15 0.01 
  a Ind. Variables Tested are those variables whose regression coefficients are tested against zero. 
b R2 is the amount that is added to the overall R-Squared value by these variables. 
c Ind. Variables Controlled are those variables whose influence is removed from experimental 
error. 
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Table 2.11  Estimates of Sample Size for Logistic Regression Analysis 
N P0 a P1 b Odds Ratio c R-Squared d 
4571 0.3 0.320 1.1 0.1 
603 0.3 0.358 1.3 0.1 
252 0.3 0.391 1.5 0.1 
147 0.3 0.421 1.7 0.1 
100 0.3 0.449 1.9 0.1 
  
   
  
5877 0.3 0.320 1.1 0.3 
775 0.3 0.358 1.3 0.3 
324 0.3 0.391 1.5 0.3 
189 0.3 0.421 1.7 0.3 
129 0.3 0.449 1.9 0.3 
  
   
  
6000 0.2 0.216 1.1 0.1 
791 0.2 0.245 1.3 0.1 
331 0.2 0.273 1.5 0.1 
193 0.2 0.298 1.7 0.1 
132 0.2 0.322 1.9 0.1 
  
   
  
7714 0.2 0.216 1.1 0.3 
1018 0.2 0.245 1.3 0.3 
426 0.2 0.273 1.5 0.3 
248 0.2 0.298 1.7 0.3 
170 0.2 0.322 1.9 0.3 
 
a P0 is the response probability at the mean of X. 
b P1 is the response probability when X is increased to one standard deviation above the 
mean. 
c Odds Ratio is the odds ratio when P1 is on top. That is, it is [P1/(1-P1)]/[P0/(1-P0)]. 
d R-Squared is the R2 achieved when X is regressed on the other independent variables in 
the regression.  
121 
2.6.3 Cox Proportional Hazards Regression Analysis 
Table 2.12 presents the estimates of sample size required for the Cox proportional 
hazards regression analysis.  Based on the estimates of sample size obtained, an 
estimated total sample size of 599 patients was required for the Cox proportional hazards 
regression (α = 0.05; power=0.8). (Schoenfeld 1983; Hsieh and Lavori 2000)  
Table 2.12  Estimates of Sample Size for Cox Proportional Hazards Regression 
Analysis 
Sample 
Size (N) 
Reg. Coef. (B) a Event Rate (P) b 
R-Squared X1 vs 
Other X's (R2) c 
466 0.5 0.3 0.1 
117 1 0.3 0.1 
52 1.5 0.3 0.1 
30 2 0.3 0.1 
  
  
  
599 0.5 0.3 0.3 
150 1 0.3 0.3 
67 1.5 0.3 0.3 
38 2 0.3 0.3 
  
  
  
280 0.5 0.5 0.1 
70 1 0.5 0.1 
32 1.5 0.5 0.1 
18 2 0.5 0.1 
  
  
  
359 0.5 0.5 0.3 
90 1 0.5 0.3 
40 1.5 0.5 0.3 
23 2 0.5 0.3 
 
a B is the size of the regression coefficient to be detected 
b P is the event rate. 
c R2 is the R-squared achieved when X1 is regressed on the other covariates.   
122 
Chapter 3: Results 
 
3.1 Chapter Overview 
This chapter provides a detailed description of the results of the study.  
Study results presentation 
The results of the study are presented in order of the study objectives and corresponding 
hypotheses in accordance with the four study phases, i.e.: 
 Phase I: Demographic and Clinical Characteristics (Objective 1) 
 Phase II: Medication Adherence and Costs (Objectives 2-3) 
 Phase III: Medical Services and Costs (Objectives 4-5) 
 Phase IV: Mortality Rates (Objective 6) 
 
Sample Selection 
A total of 11732 patients were included as meeting inclusion criteria: 1) cohort 1: 3678 
patients (31.4%) had out-of-pocket drug costs <$799; 2) cohort 2: 4349 patients (37.1%) 
had out-of-pocket drug costs between $799 and $3850; 3) cohort 3: 1310 patients 
(11.2%) had out-of-pocket drug costs > $3850; and 4) cohort 4: the remaining 2395 
patients (20.4%) had out-of-pocket drug costs <$799 but received a low income subsidy.  
Fig 3.1 depicts the flow of sample selection process. 
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Figure 3.1  Diagram of the Selection of the Study Sample 
 
 
 
Enrollment data 
(Demographic file)
N= 2,260,986
RxHist60 (Treatment 
modality History and 
mortality file)
N= 2,255,534
Payhist (Pay history 
file)
N=2,255,534
2007 Prescription drug 
file (Part D)
N=569,193
2007 Institutional & 
Physician claims file
(Part A & B)
N=450,373
95 or 05 Evidence files 
(Sensitivity analysis)
N= 1,611,664↓ ↓ ↓ ↓ ↓
↓
Patients on dialysis 
(hemodialysis) during 
2006 Jan- 2007 Dec 
N=183,482
Patients with MPAB 
(Medicare Primary 
Part A & B) and no 
dual eligible during 2006 
Jan- 2007 Dec 
N=56,480
Patients with 1-year 
Part D full coverage 
without dual eligible 
months or retiree drug 
subsidy coverage 
N=110,959
Patients with at least 
one dialysis claim 
during 2007 
N=340,971
↓ ↓ ↓ ↓ ↓
↓ ↓ ↓ ↓ ↓
Cohort 1
Out-of-pocket costs < 
$799
n=3,678
Cohort 2
$799 ≤ Out-of-pocket 
costs < $3,850
n=4,349
Cohort 3
$3,850 ≤ Out-of-pocket 
costs
n=1,310
Cohort 4 (control) 
Patients who have LIS 
and Out-of-pocket 
costs  <$799
n=2,395
Hemodialysis patients continuously enrolled Parts A& B (2006-2007) and Part D (2007) 
Patients categorized based on their Part D coverage (out-of-pocket costs) in 2007,  N=11,732
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Patients’ out-of-pocket drug cost spending in 2007 was used to categorize patients into 
four cohorts.  To show the changes of out-of-pocket and total drug costs as patients 
reached coverage gap or catastrophic coverage phases, the number of pharmacy claims, 
total pharmacy costs and out-of-pocket costs by coverage phase (initial, coverage cap and 
catastrophic coverage phases) are listed in Table 3.1.   
 
Table 3.1   Number of Pharmacy Claims, Total Pharmacy Costs, Out-of-pocket 
Costs, and Ratio of Out-of-pocket Costs to Total Pharmacy Costs among Study 
Cohorts (N=11732)  
  
Cohort 1  
(n=3678) 
Cohort 2  
(n=4349) 
Cohort 3  
(n=1310) 
Cohort 4  
(n=2395) 
  Mean SD Mean SD Mean SD Mean SD 
Initial phase 
No. of pharmacy claims 32.4 20.0 36.7 16.0 25.1 11.9 53.5 32.3 
Total pharmacy costs $1,820 $1,618 $2,617 $1,599 $2,375 $542 $5,312 $4,869 
Out-of-pocket costs $423 $217 $736 $94 $677 $149 $192 $157 
Out-of-pocket/total costs 23.25%   28.12%   28.50%   3.62%   
Coverage gap phase 
No. of pharmacy claims     24.3 19.6 32.9 18.1     
Total pharmacy costs     $1,814 $1,811 $3,375 $1,075     
Out-of-pocket costs     $1,118 $843 $2,974 $288     
Out-of-pocket/total costs     61.64%   88.14%       
Catastrophic coverage phase 
No. of pharmacy claims         30.4 25.9     
Total pharmacy costs         $4,935 $7,218     
Out-of-pocket costs         $520 $952     
Out-of-pocket/total costs         10.53%       
Total  
No. of pharmacy claims 32.4 20.0 61.0 26.6 88.1 36.8 53.5 32.3 
Total pharmacy costs $1,820 $1,618 $4,431 $2,614 $10,659 $7,112 $5,312 $4,869 
Out-of-pocket costs $423 $217 $1,854 $827 $4,153 $780 $192 $157 
Out-of-pocket/total costs 23.25%   41.85%   38.96%   3.62%   
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3.2 Phase I: Demographic and Clinical Characteristics 
3.2.1 Objective 1: Demographic Characteristics  
Table 3.2 presents the demographic and clinical characteristics of the study sample. 
Age 
H0 (1a): Mean age will not differ significantly when categorized by Part D coverage.  
The mean ages of patients were 69.76 years (SD=12.67) in cohort 1, 72.54 years 
(SD=10.76) in cohort 2, 71.69 years (SD=10.88) in cohort 3, and 61.83 years (SD=13.84) 
in cohort 4, respectively.  A one-way ANOVA revealed that patient age differed 
significantly among cohorts (F=429.64; d.f.=3 ; p<.0001).  Patients in cohort 4 were 
more likely to be younger than other cohorts.  
H0 (1a): Rejected. 
 
Gender 
H0 (1b): The proportion of patients in each gender category will not differ significantly 
when categorized by Part D coverage. 
Sixty-two percent of patients (n=2272) in cohort 1, 55.3 percent of patients (n=2404) in 
cohort 2, 50 percent of patients (n=655) in cohort 3, and 52.5 percent of patients 
(n=1258) in cohort 4 were male, respectively.  A chi-square test showed that patient 
gender differed significantly among the cohorts (χ2=81.47; d.f.=3; p<.0001).  Patients in 
cohort 1 were more likely to be male compared to other cohorts. H0 (1b): Rejected. 
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Race 
H0 (1c): The proportion of patients in each race category will not differ significantly when 
categorized by Part D coverage.   
Sixty-two percent of patients in cohort 1, 76 percent of patients in cohort 2, and 80 
percent patients in cohort 3 were white compared to 46 percent of patients in cohort 4.  
A chi-square test showed that patient race differed significantly among the cohorts 
(χ2=776.14; d.f.=6; p<.0001).   
H0 (1c): Rejected. 
 
Region of residence 
H0 (1d): The proportion of patients in each region category will not differ significantly 
when categorized by Part D coverage. 
Thirty-nine percent of patients (n=1422) in cohort 1, 34.1 percent of patients (n=1484) in 
cohort 2, 32 of percent patients (n=421) in cohort 3, and 59.5 percent of patients 
(n=1425) in cohort 4 resided in the South, respectively.  A chi-square test showed that 
patient geographic region differed significantly among the cohorts (χ2=528.21; d.f.=3; 
p<.0001).  Patients in cohort 4 were more likely to live in the southern region compared 
to other cohorts. 
H0 (1d): Rejected. 
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Primary disease causing ESRD  
H0 (1e): The proportion of patients in primary disease causing ESRD will not differ 
significantly when categorized by Part D coverage. 
For patients in cohort 1, the proportion of ESRD due to diabetes and hypertension were 
39.8 percent and 32.7 percent, respectively.  For patients in cohorts 2 through 4, the 
proportion of ESRD caused by diabetes and hypertension ranged from 43.3 to 45.0 
percent and from 28.5 percent to 31.1 percent, respectively.  A chi-square test showed 
that the primary disease causing ESRD differed significantly among the cohorts 
(χ2=45.74; d.f.=12; p<.0001).   
H0 (1e): Rejected. 
 
ESRD duration 
H0 (1f): Mean ESRD duration will not differ significantly when categorized by Part D 
coverage. 
The mean ESRD durations of patients were 5.40 years (SD=4.30) in cohort 1, 4.77 years 
(SD=3.58) in cohort 2, 5.20 years (SD=4.06) in cohort 3, and 5.91 years (SD=4.48) in 
cohort 4.  A one-way ANOVA revealed that the mean ESRD duration differed 
significantly among the cohorts (χ2=147.82; d.f.=3 ; p<.0001).  Patients in cohort 2 were 
more likely to have shorter ESRD duration compared to other cohorts.  
H0 (1f): Rejected. 
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Charlson Comorbidity Index (CCI) scores 
H0 (1g): Mean comorbidity scores will not differ significantly when categorized by Part D 
coverage. 
The mean CCI scores of patients were 1.97 (SD=1.75) in cohort 1, 2.26 (SD=1.83) in 
cohort 2, 2.36 (SD=1.83) in cohort 3, and 1.93 (SD=1.72) in cohort 4.  A one-way 
ANOVA revealed that the mean CCI scores differed significantly among cohorts 
(F=103.70; d.f.=3; p<.0001).  Patients in cohort 1 or cohort 4 were more likely to have 
lower CCI scores than those in cohort 2 or cohort 3.  
H0 (1d): Rejected. 
 
Presence of chronic disease  
H0 (1h- 1m): The proportion of patients with chronic diseases (cardiovascular disease 
[H0(1h)], diabetes mellitus [H0(1i)], hypertension [H0(1j)], dyslipidemia [H0(1k)], cancer 
[H0(1l)], chronic lung disease [H0(1m)]) will not differ significantly when categorized by 
Part D coverage. 
Fifty-two percent of patients (n=1917) in cohort 1, 58.9 percent of patients (n=2562) in 
cohort 2, 60.8 percent of patients (n=797) in cohort 3, and 50.2 percent of patients 
(n=1202) in cohort 4 had a diagnosis of CVD, respectively.  A chi-square test showed 
that the proportion of patients with CVD differed significantly among the cohorts 
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(χ2=79.49; d.f.=3; p<.0001).  Patients in cohort 3 were more likely to have a diagnosis 
of CVD relative to the other 3 cohorts.   
H0 (1h): Rejected. 
 
Fifty percent of patients (n=1819) in cohort 1, 54.5 percent of patients (n=2372) in cohort 
2, 54.1 percent of patients (n=709) in cohort 3, and 53.2 percent of patients (n=1273) in 
cohort 4 had a diagnosis of diabetes mellitus, respectively.  A chi-square test showed 
that the proportion of patients with diabetes mellitus differed significantly among the 
cohorts (χ2=22.66; d.f.=3; p<.0001).  
H0 (1i): Rejected. 
 
Thirty-five percent of patients (n=1282) in cohort 1, 39.6 percent of patients (n=1722) in 
cohort 2, 41.1 percent of patients (n=538) in cohort 3, and 38.8 percent of patients 
(n=930) in cohort 4 had a diagnosis of hypertension, respectively.  A chi-square test 
showed that the proportion of patients with hypertension differed significantly among the 
cohorts (χ2=25.97; d.f.=3; p<.0001).  
H0 (1j): Rejected. 
 
Twelve percent of patients (n=431) in cohort 1, 14.4 percent of patients (n=628) in cohort 
2, 15.3 percent of patients (n=201) in cohort 3, and 10.5 percent of patients (n=251) in 
cohort 4 had a diagnosis of dyslipidemia, respectively.  A chi-square test showed that 
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the proportion of patients with dyslipidemia differed significantly among the cohorts 
(χ2=33.24; d.f.=3; p<.0001).  
H0 (1k): Rejected. 
 
Seven percent of patients (n=259) in cohort 1, 8.1 percent of patients (n=353) in cohort 2, 
9.4 percent of patients (n=123) in cohort 3, and 4.7 percent of patients (n=112) in cohort 
4 had a diagnosis of cancer, respectively.  A chi-square test showed that the proportion 
of patients with cancer differed significantly among the cohorts (χ2=37.73; d.f.=3; 
p<.0001).  
H0 (1l): Rejected. 
 
Nineteen percent of patients (n=684) in cohort 1, 22.4 percent of patients (n=974) in 
cohort 2, 24.5 percent of patients (n=321) in cohort 3, and 18.1 percent of patients 
(n=433) in cohort 4 had a diagnosis of chronic lung disease, respectively.  A chi-square 
test showed that the proportion of patients with chronic lung disease differed significantly 
among the cohorts (χ2=39.15; d.f.=3; p<.0001).  
H0 (1m): Rejected. 
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Table 3.2   Demographic and Clinical Characteristics in Study Cohorts (N= 11732) 
 
 
Cohort 1 
(n=3678) 
Cohort 2 
(n=4349) 
Cohort 3 
(n=1310) 
Cohort 4 
(n=2395) 
Test-
statistic 
p-value 
Age a Mean SD Mean SD Mean SD Mean SD     
  69.76 12.67 72.54 10.76 71.69 10.88 61.83 13.84 1018.55 <.0001 
Gender b N % N % N % N %     
Male 2272 61.77 2404 55.28 655 50.00 1258 52.53 81.47 <.0001 
Female 1406 38.23 1945 44.72 655 50.00 1137 47.47     
Race b N % N % N % N %     
Black 1233 33.52 912 20.97 220 16.79 1187 49.56 776.14 <.0001 
White 2302 62.59 3304 75.97 1055 80.53 1106 46.18     
Other  143 3.89 133 3.06 35 2.67 102 4.26     
Region of residence b N % N % N % N %     
Midwest 806 21.91 1169 26.88 320 24.43 300 12.53 528.21 <.0001 
Northeast 975 26.51 1162 26.72 386 29.47 521 21.75     
South 1422 38.66 1484 34.12 421 32.14 1425 59.50     
West 475 12.91 534 12.28 183 13.97 149 6.22     
Primary disease causing ESRD b N % N % N % N %     
Diabetes 1463 39.78 1958 45.02 567 43.28 1063 44.38 45.74 <.0001 
Hypertension 1202 32.68 1292 29.71 373 28.47 744 31.06     
Glomerulonephritis 415 11.28 433 9.96 118 9.01 253 10.56     
Cystic Kidney 108 2.94 128 2.94 47 3.59 54 2.25     
Other  490 13.32 538 12.37 205 15.65 281 11.73     
ESRD duration a Mean SD Mean SD Mean SD Mean SD     
  5.40 4.30 4.77 3.58 5.20 4.06 5.91 4.48 147.82 <.0001 
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Table 3.2 (continued) 
Comorbidity a Mean SD Mean SD Mean SD Mean SD     
Charlson Comorbidity Index (CCI) 1.97 1.75 2.26 1.83 2.36 1.83 1.93 1.72 103.70 <.0001 
Presence of chronic disease b N % N % N % N %     
Cardiovascular disease 1917 52.12 2562 58.91 797 60.84 1202 50.19 79.49 <.0001 
Diabetes mellitus 1819 49.46 2372 54.54 709 54.12 1273 53.15 22.66 <.0001 
Hypertension 1282 34.86 1722 39.60 538 41.07 930 38.83 25.97 <.0001 
Dyslipidemia 431 11.72 628 14.44 201 15.34 251 10.48 33.24 <.0001 
Cancer 259 7.04 353 8.12 123 9.39 112 4.68 37.73 <.0001 
Chronic lung disease 684 18.60 974 22.4 321 24.50 433 18.08 39.15 <.0001 
 
a ANOVA test 
b chi-square test
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3.3 Phase II: Medication Adherence and Costs 
3.3.1 Objective 2: Medication Utilization and Costs 
To determine whether the proportion and number of prescription medications and 
pharmacy costs differ when categorized by Part D coverage.   
 
3.3.1.1 Use of Oral Prescription Medications 
H0 (2a-e): The proportion of patients using antihyperglycemics [H0(2a)], antihypertensives 
[H0(2b)], lipid-lowering drugs [H0(2c)], phosphate binders [H0(2d)], or cinacalcet [H0(2e)]) 
will not differ significantly when categorized by Part D coverage. 
Table 3.3 shows the proportion of patients who had outpatient prescriptions for diabetes 
mellitus, hypertension, dyslipidemia, hyperphosphatemia, or hyperparathroidism.   
Twenty-eight percent of patients (n=1027) in cohort 1, 41.37 percent of patients (n=1799) 
in cohort 2, 42.44 percent of patients (n=556) in cohort 3, and 37.83 percent of patients 
(n=906) in cohort 4 had at least one claim for antihyperglycemic drugs, respectively.  A 
chi-square test showed that the proportion of patients with antihyperglycemic drugs 
differed significantly among the cohorts (χ2=182.83; d.f.=3; p<.0001).  
H0 (2a): Rejected. 
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Eight-one percent of patients (n=2975) in cohort 1, 91.42 percent of patients (n=3976) in 
cohort 2, 90.76 percent of patients (n=1189) in cohort 3, and 89.06 percent of patients 
(n=2133) in cohort 4 had at least one claim for antihypertensive drugs, respectively.  A 
chi-square test showed that the proportion of patients with antihypertensive drugs 
differed significantly among the cohorts (χ2=227.33; d.f.=3; p<.0001).  
H0 (2b): Rejected. 
 
Thirty-two percent of patients (n=1160) in cohort 1, 53.16 percent of patients (n=2312) in 
cohort 2, 60.53 percent of patients (n=793) in cohort 3, and 38.66 percent of patients 
(n=926) in cohort 4 had at least one claim for lipid-lowering drugs, respectively.  A chi-
square test showed that the proportion of patients with lipid-lowering drugs differed 
significantly among the cohorts (χ2=552.02; d.f.=3; p<.0001).  
H0 (2c): Rejected. 
 
Sixty percent of patients (n=2194) in cohort 1, 81.49 percent of patients (n=3544) in 
cohort 2, 91.60 percent of patients (n=1200) in cohort 3, and 80.33 percent of patients 
(n=1924) in cohort 4 had at least one claim for phosphate binders, respectively.  A chi-
square test showed that the proportion of patients with phosphate binders differed 
significantly among the cohorts (χ2=798.46; d.f.=3; p<.0001).  
H0 (2d): Rejected. 
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Twelve percent of patients (n=439) in cohort 1, 24.76 percent of patients (n=1077) in 
cohort 2, 49.39 percent of patients (n=647) in cohort 3, and 35.70 percent of patients 
(n=855) in cohort 4 had at least one claim for calcimimetics, respectively.  A chi-square 
test showed that the proportion of patients with calcimimetics differed significantly 
among the cohorts (χ2=876.76; d.f.=3; p<.0001).  
H0 (2e): Rejected. 
 
Note: Cinacalcet (Sensipar®) is the only available drug in calcimimetics in the United 
States so the generic name of cinacalcet will be used for calciminetics from this point 
forward.  
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Table 3.3   Proportion of Patients with Antihyperglycemics, Antihypertensives, Lipid-lowering Drugs, Phosphate 
Binders, or Cinacalcet among Cohorts (N=11732) 
 
  
Cohort 1 
(n=3678) 
Cohort 2 
(n=4349) 
Cohort 3 
(n=1310) 
Cohort 4 
(n=2395) 
    
  N % N % N % N % χ2 p-value 
Antihyperglycemic drugs 1027 27.92 1799 41.37 556 42.44 906 37.83 182.83 <.0001 
Antihypertensive drugs 2975 80.89 3976 91.42 1189 90.76 2133 89.06 227.33 <.0001 
Lipid-lowering drugs 1160 31.54 2312 53.16 793 60.53 926 38.66 552.02 <.0001 
Phosphate binders 2194 59.65 3544 81.49 1200 91.60 1924 80.33 798.46 <.0001 
Cinacalcet 439 11.94 1077 24.76 647 49.39 855 35.70 876.76 <.0001 
Note: Degrees of freedom equal 3 for all chi-square tests 
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H0 (2f-j): The mean number of antihyperglycemics [H0(2f)], antihypertensives [H0(2g)], 
lipid-lowering drugs [H0(2h)], phosphate binders [H0(2i)], or cinacalcet [H0(2j)]) will not 
differ significantly when categorized by Part D coverage. 
Table 3.4 showed the mean numbers of prescriptions by five therapeutic classes of 
outpatient prescription drugs among cohorts. 
A one-way ANOVA revealed that the mean number of antihyperglycemic drugs 
differed significantly when categorized by Part D coverage (F=92.95; d.f.=3; p<.0001).  
The mean number of antihypertensive drugs was 9.70 for patients in cohort 3 (SD=6.64), 
higher than the means for patients in cohort 2 (Mean= 7.21; SD=5.35) and cohort 4 
(Mean=7.20; SD=5.36), respectively.  Patients in cohort 1 (Mean= 5.16; SD= 3.90) had 
the least number of antihypertensive drugs compared to the other 3 cohorts.  A Kruskal-
Wallis test also showed a statistically significant difference among the cohorts 
(χ2=237.65; d.f.=3; p<.0001).   
H0 (2f): Rejected. 
 
A one-way ANOVA revealed that the mean number of antihypertensive drugs differed 
significantly when categorized by Part D coverage (F=255.54; d.f.=3; p<.0001).  The 
mean number of antihypertensive drugs was 23.08 (SD=15.78) for patients in cohort 3, 
which was higher than the means for patients in cohort 2 (Mean= 18.86; SD=12.98) and 
cohort 4 (Mean= 18.63; SD=13.64), respectively.  Patients in cohort 1 (Mean= 12.37; 
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SD= 10.30) had the least number of antihypertensive drugs compared to the other 3 
cohorts.  A Kruskal-Wallis test also showed a statistically significant difference among 
the cohorts (χ2=754.76; d.f.=3; p<.0001).   
H0 (2g): Rejected. 
 
A one-way ANOVA revealed that the mean number of lipid-lowering drugs differed 
significantly when categorized by Part D coverage (F=113.76; d.f.=3; p<.0001).  The 
mean number of lipid-lowering drugs was 8.70 (SD=4.74) for patients in cohort 3, higher 
than the means of 7.07 (SD=4.14) and 6.89 (SD=4.54) for patients in cohort 2 and cohort 
4, respectively.  Patients in cohort 1 (Mean= 5.09; SD= 3.71) had the least number of 
lipid-lowering drugs compared to other cohorts.  A Kruskal-Wallis test also showed a 
statistically significant difference among the cohorts (χ2=340.30; d.f.=3; p<.0001). 
H0 (2h): Rejected. 
 
A one-way ANOVA revealed that the mean number of phosphate binders differed 
significantly when categorized by Part D coverage (F=314.44; d.f.=3; p<.0001).  The 
mean number of phosphate binders was 8.20 for patients in cohort 3 (SD=4.65), higher 
than the means for patients in cohort 2 (Mean= 5.74; SD=3.88) and cohort 4 (Mean= 
5.65; SD=3.85), respectively.  Patients in cohort 1 (Mean= 4.03; SD= 2.99) had the least 
number of phosphate binders compared to the other 3 cohorts.  A Kruskal-Wallis test 
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also showed a statistically significant difference among the cohorts (χ2=869.73; d.f.=3; 
p<.0001). 
H0 (2i): Rejected. 
 
A one-way ANOVA revealed that the mean number of cinacalcet prescriptions differed 
significantly when categorized by Part D coverage (F=190.9; d.f.=3; p<.0001).  The 
mean number of cinacalcet prescriptions was 7.40 for patients in cohort 3 (SD=3.74), 
higher than the means for patients in cohort 2 (Mean= 4.42; SD=3.15) and cohort 4 
(Mean= 5.45; SD=3.67), respectively.  Patients in cohort 1 had the least number of 
cinacalcet prescriptions compared to other cohorts (Mean= 2.77; SD= 2.42).  A Kruskal-
Wallis test also showed a statistically significant difference among the cohorts 
(χ2=1856.81; d.f.=3; p<.0001).   
H0 (2j): Rejected. 
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Table 3.4   Number of Prescriptions by Five Therapeutic Classes of Outpatient Prescription Drugs among Cohorts 
(N=11732) 
 
  
Cohort 1 
(n=3678) 
Cohort 2 
(n=4349) 
Cohort 3 
(n=1310) 
Cohort 4 
(n=2395) 
    
  Mean SD Mean SD Mean SD Mean SD F-value p-value 
Antihyperglycemic drugs (n) 1027   1799   556   906       
No. of prescriptions  5.16 3.90 7.21 5.35 9.70 6.64 7.20 5.36 92.95 <.0001 
Antihypertensive drugs (n) 2975   3976   1189   2133     
No. of prescriptions  12.37 10.30 18.86 12.98 23.08 15.78 18.63 13.64 255.54 <.0001 
Lipid-lowering drugs (n) 1160   2312   793   926     
No. of prescriptions  5.09 3.71 7.07 4.41 8.70 4.74 6.89 4.54 113.76 <.0001 
Phosphate binders (n) 2194   3544   1200   1924     
No. of prescriptions 4.03 2.99 5.74 3.88 8.20 4.65 5.65 3.85 314.44 <.0001 
Cinacalcet (n) 439   1077   647   855     
No. of prescriptions  2.77 2.42 4.42 3.15 7.40 3.74 5.45 3.67 190.90 <.0001 
Note: Degree of freedom equal 3 for all one-way ANOVAs 
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3.3.1.2 Costs of Prescription Medications 
H0 (2k-p): Pharmacy costs (i.e., antihyperglycemics [H0(2k)], antihypertensives [H0(2l)], 
lipid-lowering drugs [H0(2m)], phosphate binders [H0(2n)], cinacalcet [H0(2o)], or all 
medication [H0(2p)] ) will not differ significantly when categorized by Part D coverage. 
Table 3.5 shows total pharmacy costs and out-of-pocket costs by five therapeutic classes 
of outpatient prescription drugs during 2007.  
 
One-way ANOVA revealed that mean total pharmacy costs including total and out-of-
pocket costs for antihyperglycemic drugs were significantly different among the cohorts 
(F=106.79; d.f.=3; p<.0001 and F=411.33; d.f.=3; p<.0001, respectively).  The mean 
total antihyperglycemic drug costs were $927 (SD=897) for patients in cohort 3, higher 
than the costs for patients in cohort 2 (Mean= $585; SD= 607) and cohort 4 (Mean=$608; 
SD=741); patients in cohort 1 had the lowest total cost compared to the other 3 cohorts 
(Mean=$327; SD=412).  The mean out-of pocket cost was $287 [SD=307] for patients 
in cohort 2, $141 lower than the cost for patients in cohort 3 (Mean=$428; SD=402), but 
$185 higher than the costs for cohort 1 (Mean=$102; SD=97) and cohort 4 (Mean=$32; 
SD=35).  A Kruskal-Wallis test also showed that pharmacy costs including total and 
out-of-pocket costs for antihyperglycemic drugs were significantly different among the 
cohorts (χ2=313.00; d.f.=3; p<.0001 and χ2=1540.16; d.f.=3; p<.0001, respectively).         
H0 (2k): Rejected. 
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One-way ANOVA revealed that pharmacy costs including total and out-of-pocket costs 
for antihypertensive drugs were significantly different among the cohorts (F=325.66; 
d.f.=3; p<.0001 and F=1173.42; d.f.=3; p<.0001, respectively).  The mean total 
antihypertensive drug costs were higher for patients in cohort 3 (Mean= $1056; SD=972) 
than the means for patients in cohort 2 (Mean= $758; SD= 640) and cohort 4 
(Mean=$785; SD=790); patients in cohort 1 (Mean=$405; SD=420) had the lowest mean 
total cost compared to the other 3 cohorts.  The mean out-of pocket cost was $365 
(SD=339) for patients in cohort 2, $153 lower than the cost for patients in cohort 3 
(Mean=$518; SD=496), but higher than the costs for those in cohort 1 (Mean=$120; 
SD=118) and cohort 4 (Mean=$51; SD=52).  A Kruskal-Wallis test also showed that 
pharmacy costs including total and out-of-pocket costs for antihypertensive drugs were 
significantly different among cohorts (χ2=903.43; d.f.=3; p<.0001 and χ2=3395.69; 
d.f.=3; p<.0001, respectively).         
H0 (2l): Rejected. 
 
One-way ANOVA revealed that pharmacy costs including total and out-of-pocket costs 
for lipid-lowering drugs were significantly different among cohorts (F=154.35; d.f.=3; 
p<.0001 and F=525.68; d.f.=3; p<.0001, respectively).  The mean total lipid-lowering 
drug cost was $733 for patients in cohort 3 (Mean= $733; SD=520), higher than the costs 
for patients in cohort 2 (Mean= $517; SD= 453) and cohort 4 (Mean=$525; SD=452); 
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mean total cost for patients in cohort 1 (Mean=$304; SD=314) was the lowest among the 
cohorts.  The mean out-of pocket costs were $240 (SD=242) for patients in cohort 2, 
$106 lower than the cost for patients in cohort 3 (Mean=$346; SD=274), but higher than 
the costs for cohort 1 (Mean=$82; SD=90) and cohort 4 (Mean=$29; SD=33).  A 
Kruskal-Wallis test also showed that pharmacy costs including total and out-of-pocket 
costs for lipid-lowering drugs were significantly different among cohorts (χ2=446.59; 
d.f.=3; p<.0001 and χ2=1747.61; d.f.=3; p<.0001, respectively).   
H0 (2m): Rejected. 
 
One-way ANOVA revealed that pharmacy costs including total and out-of-pocket costs 
for phosphate binders were significantly different among cohorts (F=502.82; d.f.=3; 
p<.0001 and F=1959.13; d.f.=3; p<.0001, respectively).  The mean total phosphate 
binder cost was $2,922 for patients in cohort 3 (SD=2301), higher than the costs for 
patients in cohort 2 (Mean= $1291; SD= 1288) and cohort 4 (Mean=$1877; SD=2151); 
patients in cohort 1 (Mean=$810; SD=898) had the lowest total cost among the cohorts.  
The mean out-of pocket costs were $454 [SD=455] for patients in cohort 2, $856 lower 
than the cost for patients in cohort 3 (Mean=$1130; SD=824), but higher than the costs 
for cohort 1 (Mean=$133; SD=109) and cohort 4 (Mean=$42; SD=59).  A Kruskal-
Wallis test also showed that pharmacy costs including total and out-of-pocket costs for 
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phosphate binders were significantly different among cohorts (χ2=1266.36; d.f.=3; 
p<.0001 and χ2=4816.94; d.f.=3; p<.0001, respectively).         
H0 (2n): Rejected. 
 
One-way ANOVA revealed that pharmacy costs including total and out-of-pocket costs 
for cinacalcet were significantly different among the cohorts (F=115.25; d.f.=3; p<.0001 
and F=663.31; d.f.=3; p<.0001, respectively).  The mean total cinacalcet cost for 
patients in cohort 3 (Mean= $3925; SD=3129) was higher than the costs for patients in 
cohort 2 (Mean= $2044; SD= 2076) and cohort 4 (Mean=$3109; SD=3012); for patients 
in cohort 1 had the lowest mean total costs (Mean=$1385; SD=1906) among the cohorts.  
The mean out-of pocket costs were$674 [SD=626] for patients in cohort 2, $807 lower 
than the cost for patients in cohort 3 (Mean=$1481; SD=1159), but higher than costs for 
cohort 1 (Mean=$152; SD=134) and cohort 4 (Mean=$44; SD=83).  A Kruskal-Wallis 
test also showed that total and out-of-pocket pharmacy costs for cinacalcet were 
significantly different among the cohorts (χ2=481.27; d.f.=3; p<.0001 and χ2=1856.81; 
d.f.=3; p<.0001, respectively). 
H0 (2o): Rejected. 
 
One-way ANOVA revealed that pharmacy costs including total and out-of-pocket costs 
for all prescription drugs were significantly different among the cohorts (F=6151.80; 
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d.f.=3; p<.0001 and F=9910.60; d.f.=3; p<.0001, respectively).  The mean total drug 
cost for patients in cohort 3 (Mean= $10659; SD=7112) was higher than the costs for 
patients in cohort 2 (Mean= $4431; SD= 2614) and cohort 4 (Mean=$5312; SD=4869); 
patients in cohort 1 had the lowest total drug cost (Mean=$1820; SD=1618) among the 
cohorts.  The mean out-of pocket costs were $1854 (SD=827) for patients in cohort 2, 
$2299 lower than the cost for patients in cohort 3 (Mean=$4153; SD=780), but higher 
than the costs for cohort 1 (Mean=$423; SD=217) and cohort 4 (Mean=$192; SD=157).  
A Kruskal-Wallis test also showed that total and out-of-pocket pharmacy costs for all 
prescription drugs were significantly different among cohort (χ2=6151.80; d.f.=3; 
p<.0001 and χ2=9910.60; d.f.=3; p<.0001, respectively). 
H0 (2p): Rejected. 
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Table 3.5   Total Pharmacy Costs and Out-of-pocket Costs by Five Therapeutic Classes of Outpatient Prescription 
Drugs and Total Prescription Drugs among Cohorts (N=11732) 
 
  
Cohort 1 
(n=3678) 
Cohort 2 
(n=4349) 
Cohort 3 
(n=1310) 
Cohort 4 
(n=2395) 
F-value 
  
  Mean SD Mean SD Mean SD Mean SD p-value 
Antidiabetic drugs (n=4288) 1027   1799   556   906   
 
  
Total costs $327 412 $585 607 $927 897 $608 741 106.79 <.0001 
Out-of-pocket costs  $102 97 $287 307 $428 402 $32 35 411.33 <.0001 
Antihypertensive drugs 
(n=10273) 2975   3976   1189   2133   
 
  
Total costs $405 420 $758 640 $1,056 972 $785 790 325.66 <.0001 
Out-of-pocket costs  $120 118 $365 339 $518 496 $51 52 1173.42 <.0001 
Lipid-lowering drugs (n=5191) 1160   2312   793   926   
 
  
Total costs $304 314 $517 453 $733 520 $525 452 154.35 <.0001 
Out-of-pocket costs $82 90 $240 242 $346 274 $29 33 525.68 <.0001 
Phosphate binders (n=8862) 2194   3544   1200   1924   
 
  
Total costs $810 898 $1,291 1,288 $2,922 2,301 $1,877 2,151 502.82 <.0001 
Out-of-pocket costs $133 109 $454 455 $1,130 824 $42 59 1959.13 <.0001 
Cinacalcet (n=3018) 439   1077   647   855   
 
  
Total costs $1,385 1,906 $2,044 2,076 $3,925 3,129 $3,109 3,012 115.25 <.0001 
Out-of-pocket costs $152 134 $674 626 $1,481 1,159 $44 83 663.31 <.0001 
All prescription drugs 
(N=11732) 3678   4349   1310   2395   
 
  
Total costs $1,820 1,618 $4,431 2,614 $10,659 7,112 $5,312 4,869 1871.87 <.0001 
Out-of-pocket costs $423 217 $1,854 827 $4,153 780 $192 157 17354.60 <.0001 
Note: Degrees of freedom equal 3 for all one-way ANOVAs 
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3.3.2 Objective 3: Medication Adherence and Persistence 
To determine whether medication adherence and persistence among patients receiving 
drug therapy for diabetes, hypertension, hyperlipidemia, hyperphosphatemia or secondary 
parathyroid differ when categorized by Part D coverage. 
Medication adherence and persistence were measured using both descriptive statistics and 
regression models.  One-way ANOVAs and Kruskal-Wallis tests were performed to 
compare mean MPR and persistence until the first 30-day gap.  Patients with an 
adherence (MPR) of less than 80 percent were assigned a value of 0 while 1 was assigned 
to those with MPR greater than or equal to 80 percent.  Pearson Chi-square tests was 
used to compare the proportions of patients who were adherent.  Logistic regression was 
employed to determine if adherence is associated with Part D coverage gap while 
controlling for age, gender, race, region of residence, primary disease causing ESRD, 
ESRD duration, CCI score, and presence of chronic disease including CVD, diabetes 
mellitus, hypertension, dyslipidemia, cancer, and chronic lung disease.  A generalized 
estimating equation model was used to determine if adherence was associated with pre- 
and post- Part D coverage gap while controlling for covariates.  Kaplan-Meier survival 
curves were used to depict the percentage of patients who remain persistent in the study 
period.  A Cox regression model was used to determine if persistence is associated with 
Part D coverage while controlling for covariates.  
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3.3.2.1 Mean Medication Possession Ratio (MPR) 
H0 (3a-e):  Medication adherence (i.e., antihyperglycemics [H0(3a)], antihypertensives 
[H0(3b)], lipid-lowering drugs [H0(3c)], phosphate binders [H0(3d)], or cinacalcet [H0(3e)]) 
will not differ significantly when categorized by Part D coverage.   
Table 3.6 shows the mean MPRs by five therapeutic classes of outpatient prescription 
drugs among cohorts.  One-way ANOVAs revealed that mean MPR differed 
significantly among cohorts across all five therapeutic classes of outpatient prescription 
medications.   
Regarding antihyperglycemic drug therapies, the mean MPR was 75.48 percent 
(SD=24.78) for patients in cohort 3, higher than the means for those in cohort 2 
(Mean=65.74%; SD=26.99) and cohort 4 (Mean=67.80%; SD=26.79).  The mean MPR 
was lowest for patients in cohort 1 (Mean=59.47%; SD=27.46) compared to the other 3 
cohorts.  A one-way ANOVA revealed that mean MPR differed significantly among 
cohorts (F=40.03; d.f.=3; p<.0001).  A Kruskal-Wallis test also showed a statistically 
significant difference among the cohorts (χ2=118.82; d.f.=3; p<.0001).  
H0 (3a): Rejected. 
 
Regarding antihypertensive drug therapies, the mean MPR for patients in cohort 3 was 
86.83 percent (SD=17.82), higher than the means for those in cohort 2 (Mean=82.38%; 
SD=19.85) and cohort 4 (Mean=79.08%; SD=22.27).  The mean MPR was lowest for 
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patients in cohort 1 (Mean=73.65%; SD=24.19).  A one-way ANOVA revealed that 
mean MPR differed significantly among the cohorts (F=137.03; d.f.=3; p<.0001).  A 
Kruskal-Wallis test also showed a statistically significant difference among the cohorts 
(χ2=362.69; d.f.=3; p<.0001).        
H0 (3b): Rejected. 
 
Regarding lipid-lowering drug therapies, the mean MPR for patients in cohort 3 was 
84.15 percent (SD=18.05), higher than the MPRs for those in cohort 2 (Mean=75.33%; 
SD=23.32) and cohort 4 (Mean=74.49%; SD=23.41).  The mean MPR was lowest for 
patients in cohort 1 (Mean=67.81%; SD=26.23) compared to the other 3 cohorts.  A 
one-way ANOVA revealed that mean MPR differed significantly among cohorts 
(F=68.44; d.f.=3; p<.0001).  A Kruskal-Wallis test also showed a statistically significant 
difference among the cohorts (χ2=172.34; d.f.=3; p<.0001).  
H0 (3c): Rejected. 
 
Regarding phosphate binder therapies, the mean MPR for patients in cohort 3 was 
70.84 percent (SD=22.64), higher than the means for those in cohort 2 (Mean=57.02%; 
SD=23.74) and cohort 4 (Mean=57.23%; SD=24.16).  The mean MPR was lowest for 
patients in cohort 1 (Mean=48.72%; SD=23.35) compared to the other 3 cohorts.  A 
one-way ANOVA revealed that mean MPR differed significantly among cohorts 
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(F=203.05; d.f.=3; p<.0001).  A Kruskal-Wallis test also showed a statistically 
significant difference among the cohorts (χ2=563.63; d.f.=3; p<.0001).  
H0 (3d): Rejected. 
 
Regarding cinacalcet therapies, the mean MPR for patients in cohort 3 was 77.22 
percent (SD=22.12), higher than the means for those in cohort 2 (Mean=56.81%; 
SD=25.79) and cohort 4 (Mean=65.05%; SD=25.74).  The mean MPR was the lowest 
for patients in cohort 1 (Mean=48.66%; SD=3.98) compared to the other 3 cohorts.  A 
one-way ANOVA revealed that mean MPR differed significantly among cohorts 
(F=112.62; d.f.=3; p<.0001).  A Kruskal-Wallis test also showed a statistically 
significant difference among the cohorts (χ2=295.50; d.f.=3; p<.0001).  
H0 (3e): Rejected. 
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Table 3.6   Mean MPR by Five Therapeutic Classes of Outpatient Prescription Drugs among Cohorts (N=11732) 
 
  
Cohort 1  
(n=3678) 
Cohort 2  
(n=4349) 
Cohort 3  
(n=1310) 
Cohort 4  
(n=2395) 
F-value 
  
  Mean SD Mean SD Mean SD Mean SD p-value 
Antihyperglycemic drugs 
(n=3819) 851   1630 42.68 523 13.69 815 21.34     
MPR (Mean, SD) 59.47 27.46 65.74 26.99 75.48 24.78 67.80 26.79 40.03 <.0001 
Antihypertensive drugs 
(n=9863) 2772   3863   1167   2061       
MPR (Mean, SD) 73.65 24.19 82.38 19.85 86.83 17.82 79.08 22.27 137.03 <.0001 
Lipid-lowering drugs 
(n=4607) 922   2119   746   820       
MPR (Mean, SD) 67.81 26.23 75.33 23.32 84.15 18.05 74.49 23.41 68.44 <.0001 
Phosphate binders (n=7753) 1729   3185   1151   1688       
MPR (Mean, SD) 48.72 23.35 57.02 23.74 70.84 22.64 57.23 24.16 203.05 <.0001 
Cinacalcet (n=2436) 261   854   606   718       
MPR (Mean, SD) 48.66 3.98 56.81 25.79 77.22 22.12 65.05 25.74 112.62 <.0001 
Note: Degrees of freedom equal 3 for all one-way ANOVAs 
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3.3.2.2 Proportion of Patients with MPR ≥ 80% 
H0 (3f-j): The proportion of patients who are adherent (MPR ≥ 80%) to 
antihyperglycemics [H0(3f)], antihypertensives [H0(3g)], lipid-lowering drugs [H0(3h)], 
phosphate binders [H0(3i)], or cinacalcet [H0(3j)]) will not differ significantly when 
categorized by Part D coverage. 
Table 3.7 shows the chi-square comparison of MPR≥80% by five therapeutic classes of 
outpatient prescription drugs.  A chi-square analysis of MPR revealed that the 
proportion of patients with MPR ≥ 80% differed significantly among the cohorts for all 
five therapeutic classes of outpatient prescription medications.   
Among patients on antihyperglycemic drugs (n=3918), 29.4 percent of patients in 
cohort 1, 38.2 percent patients in cohort 2, 52.6 percent patients in cohort 3, and 41.0 
percent patients were adherent (MPR≥ 80%) to antihyperglycemic drugs (χ2=75.58; 
d.f.=3; p<.0001).   
Among patients on antihypertensives (n=9863), 47.3 percent of patients in cohort 1, 
62.9 percent patients in cohort 2, 72.8 percent patients in cohort 3, and 57.0 percent 
patients were adherent (MPR≥ 80%) to antihypertensive drugs (χ2=274.12; d.f.=3; 
p<.0001).   
Among patients on lipid-lowering drugs (n=4607), 47.7 percent of patients in cohort 1, 
54.0 percent patients in cohort 2, 70.9 percent patients in cohort 3, and 51.5 percent 
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patients were adherent (MPR≥ 80%) to lipid-lowering drugs (χ2=135.14; d.f.=3; 
p<.0001).   
Among patients on phosphate binders (n=7753), 12.6 percent of patients in cohort 1, 
20.6 percent patients in cohort 2, 39.7 percent patients in cohort 3, and 21.0 percent 
patients were adherent (MPR≥ 80%) to phosphate binders (χ2=306.22; d.f.=3; p<.0001).   
Among patients on cinacalcet (n=2436), 17.2 percent of patients in cohort 1, 23.9 percent 
patients in cohort 2, 55.1 percent patients in cohort 3, and 37.1 percent patients were 
adherent (MPR≥ 80%) to cinacalcet (χ2=192.09; d.f.=3; p<.0001).   
Patients in cohort 3 were more likely to achieve adherence rates of ≥ 80 percent to 
antihyperglycemics, antihypertensives, lipid-lowering drugs, phosphate binders, and 
cinacalcet relative to those in cohort 2 or cohort 4, while patients in cohort 1 were less 
likely to be adherent to these drugs.  
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Table 3.7   Treatment Patterns and Proportion of Patients with MPR ≥ 80% in Patients by Five Therapeutic Classes 
of Outpatient Prescription Drugs among Cohorts (N=11732) 
  
Cohort 1 
(n=3678) 
Cohort 2 
(n=4349) 
Cohort 3 
(n=1310) 
Cohort 4 
(n=2395) 
 
χ2 
 
p-value 
  N % N % N % N % 
Antihyperglycemic drugs (n=3819) 851 22.28 1630 42.68 523 13.69 815 21.34     
Mono 835 98.12 1532 93.99 458 87.57 760 93.25     
Dual 15 1.76 96 5.89 63 12.05 54 6.63     
Triple 1 0.12 2 0.38 2 0.38 1 0.12     
MPR > 80% 250 29.38 622 38.16 275 52.58 334 40.98 75.58 <.0001 
Antihypertensive drugs (n=9863) 2772 28.11 3863 39.17 1167 11.83 2061 20.9     
Mono 1522 54.91 1359 35.18 361 30.93 746 36.2     
Dual 819 29.55 1289 33.37 369 31.62 695 33.72     
Triple 431 15.55 1190 30.81 433 37.1 612 29.69     
Quad 0 0 25 0.65 4 0.34 8 0.39     
MPR > 80% 1311 47.29 2431 62.93 849 72.75 1174 56.96 274.12 <.0001 
Lipid-lowering drugs (n=4607) 922 20.01 2119 46 746 16.19 820 17.8     
Mono 911 98.81 2011 94.9 680 91.15 790 96.34     
Dual 11 1.19 106 5 62 8.31 29 3.54     
Triple 0 0 2 0.09 4 0.54 1 0.12     
MPR > 80% 394 42.73 1144 53.99 529 70.91 422 51.46 135.14 <.0001 
Phosphate binders (n=7753) 1729 22.3 3185 41.08 1151 14.85 1688 21.77     
Mono 1709 98.84 3103 97.43 1087 94.44 1629 96.50     
Dual 20 1.16 80 2.51 62 5.39 59 3.5     
Triple 0 0 2 0.06 2 0.17 0 0     
MPR > 80% 218 12.61 655 20.57 457 39.7 355 21.03 306.22 <.0001 
Cinacalcet (n=2436) 261 7.1 854 19.64 606 46.26 718 29.98     
MPR > 80% 45 17.24 204 23.89 334 55.12 266 37.05 192.09 <.0001 
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Antihyperglycemics 
Table 3.8 shows the results of the logistic regression model comparing the proportion of 
patients with MPR≥ 80% in patients receiving antihyperglycemic drugs among cohorts, 
while controlling for covariates.  The overall statistics for the model testing the null 
hypothesis that all parameter estimates are equal to zero indicated that the null hypothesis 
was rejected (p<0.001).  In addition, the Hosmer-Lemeshow test indicated that the 
model was of good fit (χ2=6.78; d.f.=8; p=0.5602).   
This model indicated that patients in cohort 1 and cohort 2 were 47.7 percent and 23.8 
percent less likely to be adherent to antihyperglycemic drugs compared to patients in 
cohort 4, respectively (Odds Ratio (OR) =0.523; 95% CI= 0.422 – 0.647; OR=0.762; 
95% CI= 0.632 – 0.918).  However, patients in cohort 3 were 40.2 percent more likely 
to be adherent to antihyperglycemic drugs compared to those in cohort 4 after controlling 
for covariates (OR= 1.402; 95% CI= 1.109 – 1.771).  
Significant predictors of adherence to antihyperglycemic drugs were gender, race, ESRD 
duration, primary disease causing ESRD (hypertension), CCI score, and the presence of 
cancer.  Female gender was associated with a 12.8 percent decrease in the odds of 
adherence to antihyperglycemic drugs compared with male gender (OR = 0.872; 95% CI: 
0.761 – 0.998).  Being white and other were 51.9 percent and 50.6 percent more likely 
to be adherent to antihyperglycemic drugs compared with being black (OR= 1.519; 95% 
CI: 1.289 – 1.792; OR=1.506; 95% CI: 1.029 – 2.204).  Each year increase in ESRD 
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duration was associated with a 4.1 percent decrease in the odds of adherence to 
antihyperglycemic drugs (OR=0.959; 95% CI = 0.934-0.984).  Hypertension as the 
primary disease causing ESRD was associated with a 32.9 percent increase in the odds of 
being adherent to antihyperglycemic drugs compared with diabetes mellitus (OR=1.329; 
95% CI= 1.078 – 1.638).  Each unit increase in CCI score was associated with a 12.8 
percent decrease in the odds of being adherent to antihyperglycemic drugs (OR=0.872; 
95% CI = 0.808-0.941).  The presence of cancer was associated with a 44.7 percent 
increase in the odds of being adherent to antihyperglycemic drugs (OR=1.447; 95% CI= 
1.017 – 2.059).      
H0 (3f): Rejected. 
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Table 3.8   Logistic Regression Model Comparing the Proportion of Patients with 
MPR ≥ 80% in Patients Receiving Antihyperglycemic Drugs while Controlling for 
Covariates (N= 3918) 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
Wald 
Chi-
Square 
p-value Odds 
Ratio 
95% 
Confidence 
Interval 
Intercept -0.472 0.276 2.914 0.088     
Cohort a 
1 -0.649 0.109 35.239 <.0001 0.523 0.422 - 0.647 
2 -0.272 0.095 8.195 0.004 0.762 0.632 - 0.918 
3 0.338 0.119 8.010 0.005 1.402 1.109 - 1.771 
Age 0.005 0.003 2.176 0.140 1.005 0.998 - 1.012 
Gender b Female -0.137 0.069 3.928 0.048 0.872 0.761 - 0.998 
Race c 
White 0.418 0.084 24.817 <.0001 1.519 1.289 - 1.791 
Other 0.409 0.194 4.432 0.035 1.506 1.029 - 2.204 
Region of 
residence d 
Northeast  0.084 0.100 0.707 0.400 1.087 0.894 - 1.322 
South -0.084 0.093 0.820 0.365 0.92 0.767 - 1.103 
West 0.015 0.126 0.014 0.907 1.015 0.793 - 1.299 
ESRD duration -0.042 0.013 9.976 0.002 0.959 0.934 - 0.984 
Primary 
disease 
causing 
ESRD e 
Hypertension 0.284 0.107 7.115 0.008 1.329 1.078 - 1.638 
Glomerulonephritis 0.065 0.268 0.059 0.808 1.067 0.631 -1.805 
Cystic Kidney 0.253 0.518 0.239 0.625 1.288 0.467 - 3.557 
Other  0.002 0.168 0.000 0.991 1.002 0.722 - 1.391 
Charlson Comorbidity Index (CCI) 
score 
-0.137 0.039 12.555 0.000 0.872 0.808 - 0.941 
Presence of 
chronic 
disease  
Diabetes mellitus 0.145 0.130 1.243 0.265 1.156 0.896 - 1.491 
Hypertension 0.063 0.074 0.737 0.391 1.065 0.922 - 1.231 
Dyslipidemia 0.017 0.096 0.033 0.856 1.018 0.843 - 1.228 
Cancer 0.369 0.180 4.208 0.040 1.447 1.017 - 2.059 
Chronic lung disease 0.013 0.104 0.016 0.899 1.013 0.827 - 1.241 
Cardiovascular 
disease 
-0.047 0.097 0.239 0.625 0.954 0.788 - 1.154 
 
Model parameters: Likelihood Ratio = 170.27; d.f.=22; p<0.0001; Score = 166.13; d.f.=22; p<0.0001; Wald = 158.76; d.f.=22; p< 0.0001. 
a Reference: Cohort 4 
b Reference : Male 
c Reference: Black 
d Reference : Midwest 
e Reference : Diabetes mellitus 
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Antihypertensives 
Table 3.9 shows the results of the logistic regression model comparing the proportion of 
patients with MPR≥ 80% in patients receiving antihypertensive drugs among cohorts, 
while controlling for covariates.  The overall statistics for the model testing the null 
hypothesis that all parameter estimates are equal to zero indicated that the null hypothesis 
was rejected (p<0.001).  In addition, the Hosmer-Lemeshow test indicated that the 
model was of good fit (χ2=4.89; d.f.=8; p=0.7694).   
This model indicated that patients in cohort 1 were 41.1 percent less likely to be adherent 
(OR= 0.589; 95% CI= 0.522 – 0.665) but patients in cohort 3 were 68.1 percent more 
likely to be adherent to antihypertensive drugs (OR= 1.681; 95% CI= 1.428 – 1.978) 
compared to patients in cohort 4 after controlling for covariates.  There was no 
significant differences between patients with MPR≥ 80% in cohort 2 and cohort 4 
(OR=1.055; 95% CI=0.937 – 1.188).  
Significant predictors of adherence to antihypertensive drugs were age, gender, race, 
ESRD duration, and CCI score.  Each year increase in age was associated with a 1.1 
percent increase in the odds of being adherent to antihypertensive drugs (OR=1.011; 95% 
CI= 1.007 – 1.015).  Female gender was associated with a 12.0 percent increase in the 
odds of adherence to antihypertensive drugs compared with male gender (OR = 1.120; 
95% CI: 1.030 - 1.218).  Being white were 21.1 percent more likely to be adherent to 
antihypertensive drugs compared with being black (OR=1.211; 95% CI=1.097 - 1.335).  
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Each unit increase in the year of ESRD duration was associated with a 2.2 percent 
decrease in the odds of being adherent to antihypertensive drugs (OR=0.978; 95% 
CI=0.967 - 0.989).  Each unit increase in CCI score was associated with a 7.2 percent 
decrease in the odds of adherence to antihypertensive drugs (OR=0.928; 95% CI = 0.885 
-0.972).  
H0 (3g): Rejected. 
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Table 3.9   Logistic Regression Model Comparing the Proportion of Patients with 
MPR ≥ 80% in Patients Receiving Antihypertensive Drugs while Controlling for 
Covariates (N=9863) 
Variable 
Parameter 
Estimate 
Standard 
Error 
Wald 
Chi-
Square 
p-value Odds 
Ratio 
95% 
Confidence 
Interval 
Intercept -0.277 0.153 3.292 0.070     
Cohort a 
1 -0.529 0.062 73.514 <.0001 0.589 0.522 - 0.665 
2 0.054 0.060 0.785 0.376 1.055 0.937 - 1.188 
3 0.519 0.083 39.111 <.0001 1.681 1.428 - 1.978 
Age 0.011 0.002 33.301 <.0001 1.011 1.007 - 1.015 
Gender b Female 0.113 0.043 7.018 0.008 1.120 1.030 - 1.218 
Race c 
White 0.191 0.050 14.545 0.000 1.211 1.097 - 1.335 
Other 0.015 0.122 0.015 0.902 1.015 0.799 - 1.290 
Region of 
residence d 
Northeast  -0.079 0.062 1.655 0.198 0.924 0.819 - 1.042 
South -0.088 0.058 2.317 0.128 0.916 0.817 - 1.026 
West 0.023 0.080 0.081 0.776 1.023 0.875 - 1.196 
ESRD duration -0.022 0.006 15.081 0.000 0.978 0.967 - 0.989 
Primary 
disease 
causing 
ESRD e 
Hypertension 0.033 0.059 0.320 0.572 1.034 0.921 - 1.160 
Glomerulonephritis 0.011 0.083 0.016 0.898 1.011 0.859 - 1.189 
Cystic Kidney -0.176 0.137 1.649 0.199 0.839 0.642 - 1.097 
Other  -0.045 0.077 0.341 0.559 0.956 0.823 - 1.111 
Charlson Comorbidity Index (CCI) 
score 
-0.075 0.024 9.817 0.002 0.928 0.885 - 0.972 
Presence of 
chronic 
disease  
Diabetes mellitus -0.015 0.066 0.051 0.821 0.985 0.865 - 1.122 
Hypertension 0.086 0.045 3.590 0.058 1.089 0.997 - 1.190 
Dyslipidemia 0.032 0.063 0.264 0.608 1.033 0.913 - 1.169 
Cancer 0.162 0.103 2.494 0.114 1.176 0.962 - 1.439 
Chronic lung disease 0.003 0.061 0.002 0.966 1.003 0.890 - 1.130 
Cardiovascular 
disease 
0.086 0.058 2.217 0.137 1.090 0.973 - 1.220 
Model parameters: Likelihood Ratio = 423.50; d.f.=22; p<0.0001; Score = 1416.46; d.f.=22; p<0.0001; Wald = 400.49; d.f.=22; p<0.0001 
a Reference: Cohort 4 
b Reference : Male 
c Reference: Black 
d Reference : Midwest 
e Reference : Diabetes mellitus 
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Lipid-lowering drugs 
Table 3.10 shows the results of the logistic regression model comparing the proportion of 
patients with MPR≥ 80% in patients receiving lipid-lowering drugs among cohorts, while 
controlling for covariates.  The overall statistics for the model testing the null hypothesis 
that all parameter estimates are equal to zero indicated that the null hypothesis was 
rejected (p<0.001).  In addition, the Hosmer-Lemeshow test indicated that the model 
was of good fit (χ2=4.75; d.f.=8; p=0.7836).   
This model indicated that patients in cohort 1 and cohort 2 were 49.0 percent and 20.2 
percent less likely to be adherent to lipid-lowering drugs compared to those in cohort 4, 
respectively (OR=0.510; 95% CI= 0.416 – 0.625; OR=0.798; 95% CI= 0.669 – 0.951).  
However, patients in cohort 3 were 70.9 percent more likely to be adherent to lipid-
lowering drugs compared to those in cohort 4 after controlling for covariates (OR= 1.709; 
95% CI= 1.372 – 2.130).  
Significant predictors of adherence to lipid-lowering drugs were age, race, primary 
disease causing ESRD (hypertension or glomerulonephritis), and the presence of CVD.  
Each year increase in age was associated with a 2.3 percent increase in the odds of being 
adherent to lipid-lowering drugs (OR=1.023; 95% CI= 1.017 – 1.030).  Being white and 
other were 55.3 percent and 51.2 percent more likely to be adherent to lipid-lowering 
drugs compared with being black (OR=1.553; 95% CI=1.334 – 1.808; OR=1.512; 95% 
CI= 1.053 – 2.172).  Hypertension and glomerulonephritis as the primary disease 
causing ESRD were 20.4 percent and 31.4 percent more likely to be adherent to lipid-
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lowering drugs compared with diabetes mellitus (OR=1.204; 95% CI= 1.018 – 1.426; 
OR= 1.314; 95% CI=1.015 – 1.700).  The presence of CVD was associated with a 16.7 
percent decrease in the odds of being adherent to lipid-lowering drugs (OR=0.833; 95% 
CI= 0.705 – 0.985).      
H0 (3h): Rejected. 
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Table 3.10  Logistic Regression Model Comparing the Proportion of Patients with 
MPR ≥ 80% in Patients Receiving Lipid-lowering Drugs while Controlling for 
Covariates (N=4607) 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
Wald 
Chi-
Square 
p-value Odds 
Ratio 
95% 
Confidence 
Interval 
Intercept -1.639 0.259 40.125 <.0001     
Cohort a 
1 -0.673 0.104 42.291 <.0001 0.510 0.416 - 0.625 
2 -0.226 0.090 6.349 0.012 0.798 0.669 - 0.951 
3 0.536 0.112 22.822 <.0001 1.709 1.372 - 2.130 
Age 0.023 0.003 52.617 <.0001 1.023 1.017 - 1.030 
Gender b Female 0.014 0.062 0.052 0.820 1.014 0.898 - 1.146 
Race c 
White 0.440 0.078 32.128 <.0001 1.553 1.334 - 1.808 
Other 0.414 0.185 5.016 0.025 1.512 1.053 - 2.172 
Region of 
residence d 
Northeast  0.056 0.088 0.407 0.524 1.058 0.890 - 1.256 
South -0.149 0.085 3.090 0.079 0.862 0.730 - 1.017 
West 0.121 0.114 1.127 0.288 1.128 0.903 - 1.410 
ESRD duration 0.009 0.010 0.847 0.358 1.009 0.990 - 1.028 
Primary 
disease 
causing 
ESRD e 
Hypertension 0.186 0.086 4.682 0.031 1.204 1.018 - 1.426 
Glomerulonephritis 0.273 0.132 4.302 0.038 1.314 1.015 - 1.700 
Cystic Kidney -0.212 0.216 0.964 0.326 0.809 0.529 - 1.236 
Other  0.116 0.113 1.053 0.305 1.123 0.900 - 1.402 
Charlson Comorbidity Index (CCI) 
score 
-0.012 0.035 0.124 0.725 0.988 0.923 - 1.057 
Presence of 
chronic 
disease  
Diabetes mellitus 0.017 0.096 0.030 0.862 1.017 0.843 - 1.226 
Hypertension 0.127 0.066 3.699 0.054 1.135 0.998 - 1.291 
Dyslipidemia -0.088 0.077 1.306 0.253 0.916 0.787 - 1.065 
Cancer 0.012 0.146 0.007 0.935 1.012 0.761 - 1.346 
Chronic lung disease -0.077 0.088 0.761 0.383 0.926 0.780 - 1.100 
Cardiovascular 
disease 
-0.182 0.086 4.553 0.033 0.833 0.705 - 0.985 
Model parameters: Likelihood Ratio = 301.49; d.f.=22; p<0.0001; Score = 291.76; d.f.=22; p<0.0001; Wald = 273.98; d.f.=22; p< 
0.0001. 
a Reference: Cohort 4 
b Reference : Male 
c Reference: Black 
d Reference : Midwest 
e Reference : Diabetes mellitus 
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Phosphate binders 
Table 3.11 shows the results of the logistic regression model comparing the proportion of 
patients with MPR≥ 80% in patients receiving phosphate binders among cohorts, while 
controlling for covariates.  The overall statistics for the model testing the null hypothesis 
that all parameter estimates are equal to zero indicated that the null hypothesis was 
rejected (p<0.001).  In addition, the Hosmer-Lemeshow test indicated that the model 
was of good fit (χ2=10.35; d.f.=8; p=0.2413).   
This model indicated that patients in cohort 1 and cohort 2 were 61.1 percent and 35.3 
percent less likely to be adherent to phosphate binders compared to those in cohort 4, 
respectively (OR=0.389; 95% CI= 0.320 – 0.474; OR=0.647; 95% CI= 0.549 – 0.761).  
However, patients in cohort 3 were 67.6 percent more likely to be adherent to phosphate 
binders compared to those in cohort 4 after controlling for covariates (OR= 1.676; 95% 
CI= 1.399 – 2.008).  
Significant predictors of adherence to phosphate binders were age, gender, race, and 
region of residence (south).  Each year increase in age was associated with a 1.3 percent 
increase in the odds of being adherent to phosphate binders (OR=1.013; 95% CI= 1.008 – 
1.018).  Female gender was associated with a 12.7 percent decrease in the odds of being 
adherent to phosphate binders compared with male gender (OR = 0.873; 95% CI: 0.779 – 
0.979).  Being white and other were 98.4 percent and two times more likely to be 
adherent to phosphate binders compared to being black (OR=1.984; 95% CI=1.701 - 
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2.314; OR=3.008; 95% CI= 2.236 – 4.046).  Patients who resided in the south region 
were 23.8 percent less likely to adhere to phosphate binders compared to those in the 
Midwest region (OR = 0.762; 95% CI: 0.653 – 0.889).        
H0 (3i): Rejected. 
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Table 3.11  Logistic Regression Model Comparing the Proportion of Patients with 
MPR ≥ 80% in Patients Receiving Phosphate Binders while Controlling for 
Covariates (N=7753) 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
Wald 
Chi-
Square 
p-value Odds 
Ratio 
95% 
Confidence 
Interval 
Intercept -2.249 0.220 104.856 <.0001     
Cohort a 
1 -0.944 0.100 88.538 <.0001 0.389 0.320 - 0.474 
2 -0.436 0.083 27.484 <.0001 0.647 0.549 - 0.761 
3 0.517 0.092 31.326 <.0001 1.676 1.399 - 2.008 
Age 0.013 0.003 23.012 <.0001 1.013 1.008 - 1.018 
Gender b Female -0.135 0.058 5.375 0.020 0.873 0.779 - 0.979 
Race c 
White 0.685 0.079 76.170 <.0001 1.984 1.701 - 2.314 
Other 1.101 0.151 52.989 <.0001 3.008 2.236 - 4.046 
Region of 
residence d 
Northeast  0.015 0.080 0.032 0.857 1.015 0.867 - 1.188 
South -0.272 0.079 11.888 0.001 0.762 0.653 - 0.889 
West 0.101 0.101 1.002 0.317 1.106 0.908 - 1.348 
ESRD duration -0.009 0.008 1.336 0.248 0.991 0.975 - 1.007 
Primary 
disease 
causing 
ESRD e 
Hypertension 0.033 0.082 0.162 0.688 1.033 0.881 - 1.213 
Glomerulonephritis 0.013 0.111 0.013 0.910 1.013 0.815 - 1.259 
Cystic Kidney 0.035 0.178 0.038 0.845 1.035 0.731 - 1.467 
Other  -0.051 0.101 0.251 0.616 0.951 0.780 - 1.159 
Charlson Comorbidity Index (CCI) 
score 
-0.021 0.033 0.407 0.524 0.979 0.918 - 1.044 
Presence of 
chronic 
disease  
Diabetes mellitus 0.054 0.091 0.347 0.556 1.055 0.883 - 1.261 
Hypertension 0.041 0.062 0.437 0.509 1.042 0.922 - 1.177 
Dyslipidemia -0.098 0.087 1.269 0.260 0.907 0.764 - 1.075 
Cancer 0.094 0.136 0.479 0.489 1.098 0.842 - 1.433 
Chronic lung disease 0.126 0.082 2.356 0.125 1.135 0.966 - 1.333 
Cardiovascular 
disease 
-0.108 0.078 1.900 0.168 0.898 0.770 - 1.047 
 
Model parameters: Likelihood Ratio = 502.69; d.f.=22; p<0.0001; Score = 497.12; d.f.=22; p<0.0001; Wald = 455.11; d.f.=22; p< 
0.0001. 
a Reference: Cohort 4 
b Reference : Male 
c Reference: Black 
d Reference : Midwest 
e Reference : Diabetes mellitus 
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Cinacalcet 
Table 3.12 shows the results of the logistic regression model comparing the proportion of 
patients with MPR≥ 80% in patients receiving cinacalcet among cohorts, while 
controlling for covariates.  The overall statistics for the model testing the null hypothesis 
that all parameter estimates are equal to zero indicated that the null hypothesis was 
rejected (p<0.001).  In addition, the Hosmer-Lemeshow test indicated that the model 
was of good fit (χ2=8.92; d.f.=8; p=0.3493).   
This model indicated that patients in cohort 1 and cohort 2 were 73.1 percent and 61.5 
percent less likely to be adherent to cinacalcet compared with patients in cohort 4, 
respectively (OR=0.269; 95% CI= 0.186 – 0.390; OR=0.385; 95% CI= 0.301 – 0.491).  
However, patients in cohort 3 were 44.6 percent more likely to be adherent to cinacalcet 
compared to those in cohort 4 after controlling for covariates (OR= 1.446; 95% CI= 
1.127 – 1.854).  
Significant predictors of adherence to cinacalcet were age, race, and the presence of 
dyslipidemia.  Each year increase in age was associated with a 1.4 percent increase in 
the odds of adherence to cinacalcet (OR=1.014; 95% CI= 1.006 – 1.022).  Being white 
were 50.9 percent more likely to be adherent to cinacalcet compared with being black 
(OR=1.509; 95% CI=1.228 - 1.854).  The presence of dyslipidemia was associated with 
a 35.9 percent increase in the odds of adherence to cinacalcet (OR=1.359; 95% CI=1.033 
- 1.788).       H0 (3j): Rejected.  
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Table 3.12  Logistic Regression Model Comparing the Proportion of Patients with 
MPR ≥ 80% in Patients Receiving Cinacalcet while Controlling for Covariates 
(N=2436) 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
Wald 
Chi-
Square 
p-value Odds 
Ratio 
95% 
Confidence 
Interval 
Intercept -1.309 0.319 16.841 <.0001     
Cohort a 
1 -1.313 0.190 47.981 <.0001 0.269 0.186 - 0.390 
2 -0.955 0.125 58.694 <.0001 0.385 0.301 - 0.491 
3 0.369 0.127 8.443 0.004 1.446 1.127 - 1.854 
Age 0.014 0.004 11.752 0.001 1.014 1.006 - 1.022 
Gender b Female -0.017 0.092 0.036 0.851 0.983 0.821 - 1.177 
Race c 
White 0.411 0.105 15.280 <.0001 1.509 1.228 - 1.854 
Other 0.145 0.276 0.275 0.600 1.156 0.673 - 1.985 
Region of 
residence d 
Northeast  0.101 0.138 0.542 0.462 1.107 0.845 - 1.450 
South -0.095 0.133 0.510 0.475 0.909 0.700 - 1.180 
West 0.273 0.179 2.333 0.127 1.314 0.926 - 1.865 
ESRD duration -0.006 0.011 0.315 0.575 0.994 0.974 - 1.015 
Primary 
disease 
causing 
ESRD e 
Hypertension -0.191 0.136 1.980 0.159 0.826 0.634 - 1.078 
Glomerulonephritis 0.200 0.166 1.448 0.229 1.221 0.882 - 1.690 
Cystic Kidney -0.066 0.246 0.072 0.788 0.936 0.577 - 1.517 
Other  -0.047 0.164 0.084 0.772 0.954 0.692 - 1.314 
Charlson Comorbidity Index (CCI) 
score 
-0.003 0.056 0.003 0.960 0.997 0.893 - 1.113 
Presence of 
chronic 
disease  
Diabetes mellitus -0.297 0.152 3.817 0.051 0.743 0.552 - 1.001 
Hypertension 0.147 0.099 2.187 0.139 1.158 0.953 - 1.407 
Dyslipidemia 0.307 0.140 4.811 0.028 1.359 1.033 - 1.788 
Cancer 0.273 0.221 1.518 0.218 1.314 0.851 - 2.027 
Chronic lung disease 0.101 0.136 0.548 0.459 1.106 0.847 - 1.444 
Cardiovascular 
disease 
-0.116 0.126 0.858 0.354 0.890 0.696 - 1.138 
 
Model parameters: Likelihood Ratio = 267.88; d.f.=22; p<0.0001; Score = 259.36; d.f.=22; p<0.0001; Wald = 236.04; d.f.=22; p< 
0.0001. 
a Reference: Cohort 4 
    b Reference : Male 
    c Reference: Black 
    d Reference : Midwest 
    e Reference : Diabetes mellitus 
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3.3.2.3 Mean MPR Before and After Coverage Gap 
To determine whether medication adherence differs before and after the coverage gap is 
exceeded among patients receiving drug therapy in the primary cohort (cohort 2) who 
reached coverage gap but not catastrophic coverage. 
For this analysis, patients in cohort 2 who had at least two prescriptions and at least one 
prescription before the coverage gap was exceeded (each therapeutic classes separately 
analyzed).  
H0 (3k-o):  Medication adherence with antihyperglycemics [H0(3k)], antihypertensives 
[H0(3l)], lipid-lowering drugs [H0(3m)], phosphate binders [H0(3n)], or cinacalcet [H0(3o)])  
will not differ significantly before and after the gap is exceeded. 
Table 3.13 shows the mean MPR by five therapeutic classes of outpatient prescription 
drugs before and after reaching coverage gap among cohort 2.  Paired t- tests revealed 
that the mean MPR differed significantly before and after reaching the coverage gap 
across all five therapeutic classes of outpatient prescription medications.   
Among patients who received antihyperglycemic drugs (n=1578), the mean MPR 
significantly declined after reaching the coverage gap (Mean= 57.88%; SD=34.28) 
compared to the mean before reaching the coverage gap (Mean=72.41%; SD=26.62) 
(t=18.53; d.f.=1577; p <0.0001). 
H0 (3k): Rejected. 
170 
Among patients who received antihypertensive drugs (n=3815), mean MPR 
significantly declined after reaching the coverage gap (Mean= 75.37%; SD=28.45) 
compared to the mean before reaching the coverage gap (Mean=84.87%; SD=19.60) 
(t=21.07; d.f.=1577; p <0.0001). 
H0 (3l): Rejected. 
 
Among patients who received lipid-lowering drugs (n=2501), mean MPR significantly 
declined after reaching the coverage gap (Mean= 67.31%; SD=33.11) compared to the 
mean before reaching the coverage gap (Mean=81.13%; SD=22.43) (t=20.35; d.f.=1577; 
p <0.0001). 
H0 (3m): Rejected. 
 
Among patients who received phosphate binders (n=3101), mean MPR significantly 
declined after reaching the coverage gap (Mean= 48.94%; SD=32.99) compared to the 
mean before reaching the coverage gap (Mean=65.74%; SD=24.68) (t=27.94; d.f.=1577; 
p <0.0001). 
H0 (3n): Rejected. 
 
Among patients who received cinacalcet (n=779), mean MPR significantly declined after 
reaching the coverage gap (Mean= 47.81%; SD=34.36) compared to the mean before 
reaching the coverage gap (Mean=68.97%; SD=25.92) (t=16.03; d.f.=1577; p <0.0001). 
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H0 (3o): Rejected. 
 
Table 3.13  Mean MPR by Five Therapeutic Classes of Outpatient Prescription 
Drugs Before and After Reaching Part D Coverage Gap among Cohort 2 
 
  Before After 
Test 
statistics 
p-
value 
    Mean SD Mean SD 
Antihyperglycemic drugs 
(n=1578)             
Study period (days) 176 77 158 73     
MPR (Mean, SD)  72.41 26.62 57.88 34.28 18.53 <.0001 
Antihypertensive drugs 
(n=3815)             
Study period (days) 200 74 159 75     
MPR (Mean, SD)  84.87 19.60 75.37 28.45 21.07 <.0001 
Lipid-lowering drugs (n=2501)             
Study period (days) 179 76 159 75     
MPR (Mean, SD)  81.13 22.43 67.31 33.11 20.35 <.0001 
Phosphate binders (n=3101)             
Study period (days) 179 76 148 72     
MPR (Mean, SD)  65.74 24.68 48.94 32.99 27.94 <.0001 
Cinacalcet (n=779)             
Study period (days) 142 78 166 74     
MPR (Mean, SD)  68.97 25.92 47.81 34.36 16.03 <.0001 
 
Note: Degrees of freedom equal 1 for all paired t-tests  
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3.3.2.4 Proportion of Patients with MPR ≥ 80% Before and After Coverage Gap 
H0 (3p-t): The proportion of patients who were adherent (MPR ≥ 80%) to 
antihyperglycemics [H0(3p)], antihypertensives [H0(3q)], lipid-lowering drugs [H0(3r)], 
phosphate binders [H0(3s)], or cinacalcet [H0(3t)]) will not differ significantly before and 
after reaching the gap. 
Table 3.14 shows the McNemar test comparisons of MPR≥80% before and after reaching 
the Part D coverage gap by five therapeutic classes of outpatient prescription drugs.  
McNemar tests revealed that proportion of patients with MPR ≥ 80% differed 
significantly before and after reaching the Part D coverage gap across all five therapeutic 
classes of outpatient prescription medications.   
Among patients on antihyperglycemic drugs (n=1578), the proportion of patients with 
MPR ≥ 80% for antihyperglycemic drugs was 34.66 percent after reaching the part D 
coverage gap, significantly lower than the proportion (48.16 %) before the coverage gap 
(χ2=95.57; d.f.=3; p<.0001).   
Among patients on drugs for hypertension (n=3518), 55.96 percent patients were 
adherent (MPR≥ 80%) to antihypertensive drugs after reaching the Part D coverage gap, 
significantly lower than that of 68.49 percent before the coverage gap (χ2=173.62; d.f.=3; 
p<.0001).   
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Among patients on lipid-lowering drugs (n=2501), 48.37 percent patients were adherent 
(MPR≥ 80%) to lipid-lowering after reaching the Part D coverage gap, significantly 
lower than that of 65.72 percent before the coverage gap (χ2=179.01; d.f.=3; p<.0001).   
Among patients on phosphate binders (n=3101), 22.38 percent patients were adherent 
(MPR≥ 80%) to lipid-lowering after reaching the Part D coverage gap, significantly 
lower than that of 33.57 percent before the coverage gap (χ2=126.61; d.f.=3; p<.0001).   
Among patients who received cinacalcet (n=779), 24.13 percent patients were adherent 
(MPR≥ 80%) to cinacalcet after reaching the Part D coverage gap, significantly lower 
than that of 42.23 percent before the coverage gap (χ2=67.85; d.f.=3; p<.0001).   
 
Table 3.14  Proportion of Patients with MPR ≥ 80% by Five Therapeutic Classes 
of Outpatient Prescription Drugs Before and After Reaching Part D Coverage Gap  
 
  Before After 
χ2 
p-
value   N % N % 
Antidiabetic drugs (n=1578)             
MPR ≥ 80%  760 48.16 547 34.66 95.57 <.0001 
Antihypertensive drugs (n=3815)             
MPR  ≥ 80%  2613 68.49 2135 55.96 173.62 <.0001 
Lipid-lowering drugs (n=2501)             
MPR ≥ 80%  1348 65.72 992 48.37 179.01 <.0001 
Phosphate binders (n=3101)             
MPR  ≥ 80%  1041 33.57 694 22.38 126.61 <.0001 
Cinacalcet (n=779)             
MPR  ≥ 80%  329 42.23 188 24.13 67.85 <.0001 
Note: Degrees of freedom equal 1 for all McNemar tests 
174 
Based on the results from descriptive statistics, MPR<80% was used as the dependent 
variable for generalized estimating regression models to assess the risk of drug 
nonadherence as patients reached the coverage gap.  
 Antihyperglycemics 
Table 3.15 shows the results of a generalized estimating regression model comparing the 
proportion of patients with MPR< 80% in patients receiving antihyperglycemic drugs 
before and after reaching the Part D coverage gap among cohort 2, while controlling for 
covariates.  This model indicated that patients were 71.7 percent more likely to be 
nonadherent to antihyperglycemic drugs after reaching the coverage gap while 
controlling for covariates. (Adjusted OR=1.717; 95% CI= 1.483 – 1.989).  Significant 
predictors of nonadherence to antihyperglycemic drugs were race, region of residence, 
primary disease causing ESRD, and CCI score.  Being white was associated with a 28.9 
percent decrease in the odds of being nonadherent compared with being black (OR= exp 
(-0.3405) = 0.711; 95% CI=0.591 – 0.857).  Patients who resided in the south regions 
were 21.0 percent more likely to be nonadherent to antihyperglycemic drugs compared to 
those in Midwest (OR= exp (0.190) = 1.210; 95% CI: 1.005 – 1.456).  Cystic kidney as 
the primary disease causing ESRD was associated with a 64.2 percent decrease in the 
odds of being nonadherent to antihyperglycemic drugs compared with diabetes mellitus 
(OR= exp (-1.028) =0.358; 95% CI= 0.155 – 0.824).  Each unit increase in CCI score 
was associated with a 13.0 percent decrease in the odds of being nonadherent to 
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antihyperglycemic drugs (OR= exp (0.123) =1.130; 95% CI = 1.045-1.224). [Odds ratios 
for predictors are not shown] H0 (3p): Rejected. 
 
Table 3.15  Generalized Estimating Equation Model Comparing the Proportion of 
Patients with MPR < 80% for Antihyperglycemics Before and After Reaching Part 
D Coverage Gap while Controlling for Covariates (N=1578) 
 
Variable 
Parameter 
Estimate 
Standard 
Error 95% Confidence 
Limits 
Pr > |Z| 
Intercept -0.294 0.316 -0.913 0.325 0.352 
After a   0.541 0.075 0.394 0.688 <.0001 
Adjusted odds ratio (after vs before) 1.717 0.129 1.483 1.989   
Age 0.007 0.004 -0.001 0.014 0.094 
Gender b Female -0.013 0.073 -0.157 0.131 0.860 
Race c 
White -0.341 0.095 -0.527 -0.154 0.000 
Other -0.374 0.207 -0.780 0.032 0.071 
Region of 
residence d 
Northeast  -0.064 0.099 -0.258 0.130 0.516 
South 0.190 0.095 0.005 0.376 0.044 
West 0.114 0.129 -0.138 0.367 0.375 
ESRD duration 0.018 0.015 -0.012 0.047 0.240 
Primary disease 
causing ESRD e 
Hypertension -0.197 0.107 -0.407 0.014 0.067 
Glomerulonephritis 0.526 0.309 -0.079 1.132 0.088 
Cystic Kidney -1.028 0.426 -1.862 -0.194 0.016 
Other  -0.128 0.191 -0.502 0.246 0.503 
Charlson Comorbidity Index (CCI) score 0.123 0.041 0.044 0.202 0.002 
Presence of 
chronic disease  
Diabetes mellitus -0.223 0.140 -0.498 0.052 0.112 
Hypertension -0.019 0.078 -0.173 0.134 0.804 
Dyslipidemia 0.179 0.099 -0.016 0.373 0.072 
Cancer -0.313 0.163 -0.633 0.006 0.055 
Chronic lung disease -0.042 0.109 -0.256 0.171 0.697 
Cardiovascular disease -0.132 0.104 -0.335 0.070 0.201 
 
Model distribution= binomial; link=logit 
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Antihypertensives 
Table 3.16 shows the results of a generalized estimating regression model comparing the 
proportion of patients with MPR< 80% in patients receiving antihypertensive drugs 
before and after reaching the Part D coverage gap among cohort 2, while controlling for 
covariates.  
This model indicated that patients were 69.0 percent more likely to be nonadherent to 
antihypertensive drugs after reaching coverage gap after controlling for covariates. 
(Adjusted OR=1.690; 95% CI= 1.541 – 1.853).  Significant predictors of nonadherence 
to antihypertensive drugs were age, region of residence, primary disease causing ESRD, 
and CCI score.  Each year increase in age was associated with a 0.6 percent increase in 
the odds of being nonadherent to antihypertensive drugs (OR=0.994; 95% CI= 0.989 – 
0.999).  Patients who resided in the western region were 22.3 percent more likely to be 
nonadherent to antihypertensive drugs compared to those in the Midwest (OR = 1.223; 
95% CI: 1.030 – 1.452).  ‘Other’ as the primary disease category causing ESRD was 
associated with a 64.2 percent decrease in the odds of nonadherence to antihypertensive 
drugs compared with diabetes mellitus (OR=1.287; 95% CI= 1.086 – 1.526).  Each unit 
increase in CCI score was associated with a 6.4 percent increase in the odds of being 
nonadherent to antihypertensive drugs (OR=1.064; 95% CI = 1.007-1.125).   
H0 (3q): Rejected. 
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Table 3.16  Generalized Estimating Equation Model Comparing the Proportion of 
Patients with MPR < 80% for Antihypertensives Before and After Reaching Part D 
Coverage Gap while Controlling for Covariates (N=3815) 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
95% Confidence 
Limits 
Pr > |Z| 
Intercept -0.389 0.210 -0.800 0.023 0.064 
After a   0.525 0.047 0.433 0.617 <.0001 
Adjusted odds ratio (after vs before) 1.690 0.080 1.541 1.853   
Age -0.006 0.003 -0.011 -0.001 0.021 
Gender b Female -0.075 0.050 -0.173 0.022 0.131 
Race c 
White -0.099 0.065 -0.226 0.029 0.131 
Other -0.281 0.164 -0.602 0.041 0.087 
Region of 
residence d 
Northeast  0.094 0.067 -0.036 0.225 0.157 
South -0.024 0.066 -0.153 0.105 0.712 
West 0.201 0.088 0.030 0.373 0.021 
ESRD duration 0.010 0.007 -0.005 0.024 0.178 
Primary disease 
causing ESRD e 
Hypertension 0.022 0.070 -0.115 0.158 0.754 
Glomerulonephritis -0.061 0.099 -0.254 0.132 0.536 
Cystic Kidney 0.173 0.158 -0.137 0.482 0.274 
Other  0.252 0.087 0.082 0.423 0.004 
Charlson Comorbidity Index (CCI) 
score 
0.062 0.028 0.007 0.118 0.027 
Presence of 
chronic disease  
Diabetes mellitus 0.018 0.077 -0.133 0.169 0.814 
Hypertension -0.088 0.053 -0.191 0.016 0.097 
Dyslipidemia 0.094 0.072 -0.047 0.235 0.191 
Cancer -0.007 0.114 -0.230 0.216 0.948 
Chronic lung disease -0.129 0.070 -0.265 0.008 0.065 
Cardiovascular disease -0.107 0.069 -0.243 0.028 0.121 
 
Model distribution= binomial; link=logit. 
a Reference : Before part D coverage gap 
b Reference : Male 
c Reference: Black 
d Reference : Midwest 
e Reference : Diabetes mellitus 
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Lipid-lowering drugs 
Table 3.17 shows the results of a generalized estimating regression model comparing the 
proportion of patients with MPR< 80% in patients receiving lipid-lowering drugs before 
and after reaching the Part D coverage gap among cohort 2, while controlling for 
covariates.  
This model indicated that patients were 2 times more likely to be nonadherent to lipid-
lowering drugs after reaching the coverage gap after controlling for covariates. (Adjusted 
OR=2.006; 95% CI= 1.541 – 1.853).  Significant predictors of nonadherence to lipid 
lowering drugs were age, race, and primary disease causing ESRD.  Each year increase 
in age was associated with a 1.3 percent decrease in the odds of being nonadherent to 
antihypertensive drugs (OR=0.987; 95% CI= 0.980 – 0.994).  Being white was 
associated with an 18.0 percent decrease in the odds of being nonadherent compared with 
being black (OR= 0.820; 95% CI=0.694 – 0.969).  Being other was associated with a 
40.3 percent decrease in the odds of being nonadherent compared with being black (OR= 
0.597; 95% CI=0.405 – 0.880).  Hypertension as the primary disease category causing 
ESRD was associated with an 18.3 percent decrease in the odds of nonadhernce to 
antihypertensive drugs compared with diabetes mellitus (OR=0.817; 95% CI= 0.686 – 
0.972).   
H0 (3r): Rejected. 
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Table 3.17  Generalized Estimating Equation Model Comparing the Proportion of 
Patients with MPR < 80% For Lipid-lowering Drugs Before and After Reaching 
Part D Coverage Gap while Controlling for Covariates (N=2501) 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
95% Confidence 
Limits 
Pr > |Z| 
Intercept 0.502 0.287 -0.059 1.064 0.080 
After a   0.696 0.067 0.565 0.827 <.0001 
Adjusted odds ratio (after vs before) 2.006 0.134 1.760 2.287   
Age -0.013 0.003 -0.020 -0.006 0.000 
Gender b Female 0.075 0.063 -0.049 0.199 0.235 
Race c 
White -0.198 0.085 -0.365 -0.032 0.020 
Other -0.516 0.198 -0.904 -0.128 0.009 
Region of 
residence d 
Northeast  -0.116 0.087 -0.287 0.054 0.181 
South 0.086 0.084 -0.079 0.250 0.307 
West -0.214 0.111 -0.431 0.003 0.053 
ESRD duration 0.001 0.010 -0.020 0.021 0.947 
Primary 
disease causing 
ESRD e 
Hypertension -0.203 0.089 -0.376 -0.029 0.022 
Glomerulonephritis -0.203 0.127 -0.452 0.046 0.110 
Cystic Kidney -0.221 0.202 -0.618 0.175 0.274 
Other  0.078 0.112 -0.141 0.297 0.487 
Charlson Comorbidity Index (CCI) score 0.014 0.036 -0.056 0.083 0.703 
Presence of 
chronic disease  
Diabetes mellitus -0.165 0.097 -0.355 0.026 0.091 
Hypertension 0.063 0.067 -0.069 0.194 0.353 
Dyslipidemia 0.145 0.078 -0.008 0.297 0.064 
Cancer -0.045 0.146 -0.331 0.240 0.756 
Chronic lung disease -0.118 0.091 -0.297 0.061 0.196 
Cardiovascular disease 0.101 0.089 -0.074 0.275 0.257 
       Model distribution= binomial; link=logit. 
     a Reference : Before part D coverage gap 
    b Reference : Male 
     c Reference: Black 
     d Reference : Midwest 
     e Reference : Diabetes mellitus 
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Phosphate binders 
Table 3.18 shows the results of a generalized estimating regression model comparing the 
proportion of patients with MPR< 80% in patients receiving phosphate binders before 
and after reaching the Part D coverage gap among cohort 2, while controlling for 
covariates.  
This model indicated that patients were 1.74 times more likely to be nonadherent to 
phosphate binders after reaching coverage gap after controlling for covariates. (Adjusted 
OR=1.735; 95% CI= 1.547 – 1.945).  A significant predictor of nonadherence to 
phosphate binders was race.  Being white were 23 percent times less likely to be 
nonadherent compared with being black (OR= 0.769; 95% CI=0.661 – 0.893).  
H0 (3s): Rejected. 
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Table 3.18  Generalized Estimating Equation Model Comparing the Proportion of 
Patients with MPR < 80% for Phosphate Binders Before and After Reaching Part D 
Coverage Gap while Controlling for Covariates (N=3101) 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
95% Confidence 
Limits 
Pr > |Z| 
Intercept 1.042 0.243 0.566 1.518 <.0001 
After a   0.551 0.058 0.436 0.665 <.0001 
Adjusted odds ratio (after vs before) 1.735 0.101 1.547 1.945   
Age -0.002 0.003 -0.008 0.004 0.546 
Gender b Female 0.071 0.058 -0.042 0.184 0.215 
Race c 
White -0.263 0.077 -0.414 -0.113 0.001 
Other -0.048 0.185 -0.411 0.316 0.797 
Region of 
residence d 
Northeast  0.061 0.077 -0.089 0.211 0.426 
South 0.140 0.075 -0.007 0.287 0.061 
West 0.108 0.100 -0.088 0.304 0.279 
ESRD duration -0.012 0.009 -0.029 0.005 0.175 
Primary 
disease 
causing ESRD 
e 
Hypertension -0.055 0.080 -0.212 0.102 0.490 
Glomerulonephritis 0.000 0.108 -0.212 0.212 0.998 
Cystic Kidney 0.047 0.197 -0.339 0.432 0.812 
Other  -0.016 0.099 -0.210 0.177 0.870 
Charlson Comorbidity Index (CCI) 
score 
-0.017 0.031 -0.078 0.044 0.578 
Presence of 
chronic 
disease  
Diabetes mellitus -0.100 0.089 -0.275 0.074 0.258 
Hypertension -0.060 0.062 -0.181 0.062 0.338 
Dyslipidemia -0.056 0.081 -0.215 0.102 0.486 
Cancer -0.032 0.132 -0.291 0.226 0.806 
Chronic lung disease 0.029 0.082 -0.131 0.189 0.720 
Cardiovascular disease 0.104 0.077 -0.046 0.255 0.174 
 
Model distribution= binomial; link=logit. 
a Reference : Before part D coverage gap 
b Reference : Male 
c Reference: Black 
d Reference : Midwest 
e Reference : Diabetes mellitus 
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Cinacalcet 
Table 3.19 shows the results of a generalized estimating regression model comparing the 
proportion of patients with MPR< 80% in patients receiving cinacalcet before and after 
reaching the Part D coverage gap among cohort 2, while controlling for covariates.  
This model indicated that patients were two times more likely to be nonadherent to 
cinacalcet after reaching the coverage gap after controlling for covariates. (Adjusted 
OR=2.079; 95% CI= 1.664 – 2.598).  Significant predictors of nonadherence to 
cinacalcet were age and race.  Each year increase in age was associated with a 0.7 
percent increase in the odds of being nonadherent to cinacalcet (OR=0.993; 95% CI= 
0.799 – 0.994).  Being white was associated with a 25 percent decrease in the odds of 
being nonadherent compared with being black (OR= 0.750; 95% CI=0.584 – 0.963). 
H0 (3t): Rejected. 
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Table 3.19  Generalized Estimating Equation Model Comparing the Proportion of 
Patients with MPR < 80% for Cinacalcet Before and After Reaching Part D 
Coverage Gap while Controlling for Covariates (N=779) 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
95% Confidence 
Limits 
Pr > |Z| 
Intercept 1.694 0.437 0.837 2.551 0.000 
After a   0.732 0.114 0.509 0.955 <.0001 
Adjusted odds ratio (after vs before) 2.079 0.236 1.664 2.598   
Age -0.016 0.005 -0.026 -0.006 0.002 
Gender b Female -0.007 0.111 -0.225 0.210 0.949 
Race c 
White -0.288 0.128 -0.538 -0.038 0.024 
Other -0.031 0.379 -0.773 0.711 0.934 
Region of 
residence d 
Northeast  -0.142 0.151 -0.438 0.154 0.347 
South 0.022 0.150 -0.272 0.316 0.883 
West -0.244 0.213 -0.661 0.173 0.251 
ESRD duration -0.016 0.015 -0.045 0.013 0.284 
Primary 
disease 
causing ESRDe 
Hypertension 0.237 0.152 -0.060 0.535 0.118 
Glomerulonephritis -0.153 0.170 -0.487 0.180 0.368 
Cystic Kidney 0.019 0.238 -0.447 0.484 0.938 
Other  0.175 0.186 -0.189 0.539 0.347 
Charlson Comorbidity Index (CCI) 
score 
0.046 0.065 -0.082 0.174 0.481 
Presence of 
chronic 
disease  
Diabetes mellitus -0.186 0.170 -0.520 0.148 0.275 
Hypertension 0.094 0.116 -0.132 0.321 0.414 
Dyslipidemia 0.126 0.171 -0.209 0.460 0.461 
Cancer -0.487 0.268 -1.011 0.038 0.069 
Chronic lung disease -0.076 0.162 -0.393 0.240 0.636 
Cardiovascular disease -0.046 0.151 -0.342 0.250 0.760 
 
Model distribution= binomial; link=logit. 
a Reference : Before part D coverage gap 
b Reference : Male 
c Reference: Black 
d Reference : Midwest 
e Reference : Diabetes mellitus 
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3.3.2.5 Mean Persistence 
H0 (3u-y): Medication persistence with antihyperglycemics [H0(3u)], antihypertensives 
[H0(3v)], lipid-lowering drugs [H0(3w)], phosphate binders [H0(3x)], or cinacalcet [H0(3y)]) 
will not differ significantly when categorized by Part D coverage.   
Table 3.20 shows mean persistence until the first 30-day treatment gap in taking 
medication for five therapeutic classes of outpatient prescription medications.  One-way 
ANOVAs revealed that mean persistence differed significantly across all five therapeutic 
classes of outpatient prescription medications among cohorts.  Mean persistence until 
the first 60-day treatment gap was also conducted as sensitivity analysis.  Appendix C1 
provides mean persistence until the first 60-day treatment gap for five therapeutic classes 
of outpatient prescription medications.  Results using a 60-day gap trended in the same 
direction as the 30-day gap.  
Antihyperglycemics 
Regarding antihyperglycemic drug therapies, the mean persistence for patients in cohort 3 
was 209 days (SD=135), higher than the means of 166 days (SD=131) for patients in 
cohort 2 and that of 168 days for patients in cohort 4 (SD=135).  The mean persistence 
was lowest for patients in cohort 1 (Mean=139 days; SD=126) compared to the other 3 
cohorts.  A one-way ANOVA indicated that mean persistence for antihyperglycemic 
drugs differed significantly among the cohorts (F=30.50; d.f.=3; p<.0001).  A Kruskal-
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Wallis test also showed a statistically significant difference among the cohorts (χ2=84.59; 
d.f.=3; p<.0001).  H0 (3u): Rejected. 
 
Antihypertensives 
Regarding antihypertensive drug therapies, the mean persistence for patients in cohort 3 
was 291 days (SD=113), longer than that of 271 days for patients in cohort 2 (SD=121) 
and that of 252 days for patients in cohort 4 (SD=132).  The mean persistence was 
lowest for patients in cohort 1 (Mean=211 days; SD=136) compared to the other 3 
cohorts.  A one-way ANOVA indicated that mean persistence for antihypertensive drugs 
differed significantly among the cohorts (F=165.01; d.f.=3; p<.0001).  A Kruskal-Wallis 
test also showed a statistically significant difference among the cohorts (χ2=484.68; 
d.f.=3; p<.0001).  
H0 (3v): Rejected. 
 
Lipid-lowering drugs 
Regarding lipid-lowering drug therapies, the mean persistence for patients in cohort 3 
was 262 days (SD=119), longer than that of 222 days for those in cohort 2 (SD=126) and 
that of 212 days for those in cohort 4 (SD=132).  The mean persistence was lowest for 
patients in cohort 1 (Mean=179 days; SD=128) compared to the other 3 cohorts.  A one-
way ANOVA indicated that that mean persistence for lipid-lowering drugs differed 
significantly among the cohorts (F=61.44; d.f.=3; p<.0001).  A Kruskal-Wallis test also 
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showed a statistically significant difference among the cohorts (χ2=188.40; d.f.=3; 
p<.0001).   
H0 (3w): Rejected. 
 
Phosphate binders 
Regarding phosphate binder therapies, the mean persistence for patients in cohort 3 was 
195 days (SD=132), longer than that of 146 days for those in cohort 2 (SD=117) and that 
of 134 days for those in cohort 4 (SD=123).  The mean persistence was lowest for 
patients in cohort 1 (Mean=103 days; SD=102) compared to the other 3 cohorts.  A one-
way ANOVA indicated that mean persistence for phosphate binders differed significantly 
among the cohorts (F=142.73; d.f.=3; p<.0001).  A Kruskal-Wallis test also showed a 
statistically significant difference among the cohorts (χ2=419.14; d.f.=3; p<.0001).  
H0 (3x): Rejected. 
 
Cinacalcet 
Regarding cinacalcet therapies, the mean persistence for patients in cohort 3 was 200 
days (SD=128), longer than that of 132 days for those in cohort 2 (SD=103) and that of 
161 days for those in cohort 4 (SD=124).  The mean persistence was lowest for patients 
in cohort 1 compared to the other 3 cohorts (Mean=100 days; SD=89).  A one-way 
ANOVA indicated that mean persistence for cinacalcet differed significantly among the 
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cohorts (F=62.56; d.f.=3; p<.0001).  A Kruskal-Wallis test also showed a statistically 
significant difference among the cohorts (χ2=151.55; d.f.=3; p<.0001).  
H0 (3y): Rejected. 
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Table 3.20  Medication Persistence (Mean Days Until First 30-day Treatment Gap) by Five Therapeutic Classes of 
Outpatient Prescription Drugs among Cohorts (N=11732) 
 
  Cohort 1 
(n=3678) 
Cohort 2 
(n=4349) 
Cohort 3 
(n=1310) 
Cohort 4 
(n=2395) F-value p-value 
  Mean SD Mean SD Mean SD Mean SD     
Antihyperglycemic drugs 
(n=3819) 851   1630   523   815       
persistence (Mean, SD) 139 126 166 131 209 135 168 135 30.50 <.0001 
Antihypertensive drugs 
(n=9863) 2975   3976   1189   2133       
persistence (Mean, SD) 211 136 271 121 291 113 252 132 165.01 <.0001 
Lipid-lowering drugs (n=4607) 922   2119   746   820       
persistence (Mean, SD) 179 128 222 126 262 119 212 132 61.44 <.0001 
Phosphate binders (n=7753) 1729   3185   1151   1688       
persistence (Mean, SD) 103 102 146 117 195 132 134 123 142.73 <.0001 
Cinacalcet (n=2436) 261   854   606   718       
persistence (Mean, SD) 100 89 132 103 200 128 161 124 62.56 <.0001 
Note: Degrees of freedom equal 3 for all one-way ANOVAs
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3.3.2.6 Proportion of Patients with Therapy Discontinuation  
H0 (3z-zd): The proportion of patients who are persistent (until a 30-day treatment gap) to 
antihyperglycemics [H0(3z)], antihypertensives [H0(3za)], lipid-lowering drugs [H0(3zb)], 
phosphate binders [H0(3zc)], or cinacalcet [H0(3zd)]) will not differ significantly when 
categorized by Part D coverage.   
Table 3.21 shows the chi-square comparison of the proportion of patients with a 30-day 
treatment gap (discontinuation) by five therapeutic classes of outpatient prescription 
drugs among the cohorts.   
For patients on antihyperglycemic drugs, about eighty percent of patients in cohort 1 
discontinued therapy, higher than the proportions in cohort 2 (77.24%) and cohort 4 
(72.52%), respectively.  A lower proportion of patients in cohort 3 (62.72%) 
discontinued therapy than any other cohorts.  A chi-square analysis showed a significant 
difference among the cohorts (χ2=54.46; d.f.=3; p<.0001).  
For patients on antihypertensive drugs, about sixty percent of patients in cohort 1 
discontinued therapy, higher than the proportions in cohort 2 (43.49%) and cohort 4 
(46.77%).  A lower proportion of patients in cohort 3 (34.02%) discontinued therapy 
than any other cohorts.  A chi-square analysis showed a significant difference among the 
cohorts (χ2=293.54; d.f.=3; p<.0001).  
For patients on lipid-lowing drugs, about seventy percent of patients in cohort 1 
discontinued therapy, higher than the proportions in cohort 2 (61.68%) and cohort 4 
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(57.44%).  A lower proportion of patients in cohort 3 (46.11%) discontinued therapy 
than any other cohorts.  A chi-square analysis showed a significant difference among the 
cohorts (χ2=96.30; d.f.=3; p<.0001).  
For patients on phosphate binders, about ninety percent of patients in cohort 1 
discontinued therapy, higher than the proportions in cohort 2 (84.46%) and cohort 4 
(83.06%).  A lower proportion of patients in cohort 3 (68.11%) discontinued therapy 
than any other cohorts.  A chi-square analysis showed a significant difference among the 
cohorts (χ2=237.24; d.f.=3; p<.0001).  
For patients on cinacalcet, about eight-five percent of patients in cohort 1 discontinued 
therapy, higher than the proportions in cohort 2 (82.67%) and cohort 4 (69.92%).  A 
lower proportion of patients in cohort 3 (55.78%) discontinued therapy than any other 
cohorts.  A chi-square analysis showed a significant difference among the cohorts 
(χ2=149.60; d.f.=3; p<.0001). 
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Table 3.21  Proportion of Patients with a 30-day Treatment Gap (Discontinuation) by Five Therapeutic Classes of 
Outpatient Prescription Drugs among Cohorts  (N=11732) 
 
  Cohort 1 
(n=3678) 
Cohort 2 
(n=4349) 
Cohort 3 
(n=1310) 
Cohort 4 
(n=2395) 
χ2  p-value 
  N % N % N % N %     
Antidiabet drugs (n=3819) 851   1630   523   815       
Discontinuation (N, %) 674 79.2 1259 77.24 328 62.72 591 72.52 54.46 <.0001 
Antihypertensive drugs (n=9863) 2975   3976   1189   2133       
Discontinuation (N, %) 1673 60.35 1680 43.49 397 34.02 964 46.77 293.54 <.0001 
Lipid-lowering drugs (n=4607) 922   2119   746   820       
Discontinuation (N, %) 637 69.09 1307 61.68 344 46.11 471 57.44 96.30 <.0001 
Phosphate binders (n=7753) 1729   3185   1151   1688       
Discontinuation (N, %) 1549 89.59 2690 84.46 784 68.11 1402 83.06 237.24 <.0001 
Cinacalcet (n=2436) 261   854   606   718       
Discontinuation (N, %) 220 84.29 706 82.67 338 55.78 502 69.92 149.60 <.0001 
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Antihyperglycemics 
Figure 3.2 shows Kaplan-Meier curves comparing the percentage of patients who remain 
persistent on antihyperglycemic drugs among the cohorts.  The Log-Rank test (χ2= 
75.17; d.f.=3; p<0.0001) showed a significant difference among cohorts.  As shown in 
the figure, a higher percentage of patients in cohort 3 remained persistent to 
antihyperglycemic drugs compared with the other 3 cohorts.  
 
Figure 3.2  Kaplan-Meier survival curves comparing percentage of patients who 
remain on antihyperglycemic drugs among cohorts
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Table 3.22 shows the results of the Cox proportional hazards regression model comparing 
persistence for antihyperglycemic drugs among the cohorts, while controlling for 
covariates.  The overall statistics for the model testing the null hypothesis that all 
parameter estimates are equal to zero indicated that the null hypothesis was rejected 
(p<0.0001).  This model indicated that patients in cohort 1 and cohort 2 were 38.3 
percent (hazard ratio (HR) = 1.383; 95% CI= 1.232 – 1.552) and 17.8 percent more likely 
to discontinue antihyperglycemic drug therapies (HR= 1.178; 95% CI= 1.061 – 1.309) 
compared to those in cohort 4, respectively.  However, patients in cohort 3 had a 21.7 
percent decrease in the risk for discontinuation (HR= 0.783; 95% CI= 0.681 – 0.902) 
compared to patients in cohort 4, after controlling for covariates.  
Significant predictors for discontinuation of antihyperglycemic drugs were age, race, 
primary disease causing ESRD, ESRD duration, CCI score and presence of cancer.  
Each year increase in age was associated with a 0.5 percent decrease in the risk of 
discontinuation (HR=0.995; 95% CI= 0.991 – 0.998).  Being white were 17.4 percent 
less likely to discontinue antihyperglycemic drugs compared to being black (HR=0.826; 
95% CI=0.756 - 0.901).  Each unit increase in the year of ESRD duration was associated 
with a 3.1 percent increase in the risk of discontinuation (HR=1.031; 95% CI=1.018-
1.044).  Hypertension as the primary disease causing ESRD was associated with a 3.1 
percent decrease in the risk of discontinuation compared to diabetes mellitus (HR=0.818; 
95% CI= 0.726 – 0.923).  Each unit increase in CCI score was associated with an 11.0 
percent increase in the risk of discontinuation (HR=1.110; 95% CI = 1.067-1.154).  The 
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presence of cancer was associated with a 22.9 percent decrease in the risk of 
discontinuation (HR=0.771; 95% CI= 0.634 – 0.939).       
H0 (3z): Rejected. 
Table 3.22  Cox Proportional Hazards Regression Model Comparing Therapy 
Discontinuation for Antihyperglycemic Drugs with a 30-day Treatment Gap among 
Cohorts while Controlling for Covariates (N=3819) 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
p-value 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits 
Cohort a 
1 0.324 0.059 30.146 <.0001 1.383 1.232 - 1.552 
2 0.164 0.053 9.433 0.002 1.178 1.061 - 1.309 
3 -0.244 0.072 11.583 0.001 0.783 0.681 - 0.902 
Age -0.005 0.002 7.650 0.006 0.995 0.991 - 0.998 
Gender b Female 0.061 0.038 2.543 0.111 1.063 0.986 - 1.145 
Race c 
White -0.192 0.045 18.256 <.0001 0.826 0.756 - 0.901 
Other -0.155 0.106 2.138 0.144 0.856 0.695 - 1.054 
Region of 
residence d 
Northeast  -0.030 0.056 0.298 0.585 0.970 0.870 - 1.082 
South 0.015 0.051 0.086 0.769 1.015 0.918 - 1.122 
West -0.060 0.071 0.734 0.392 0.941 0.820 - 1.081 
ESRD duration 0.030 0.007 21.048 <.0001 1.031 1.018 - 1.044 
Primary 
disease 
causing 
ESRD e 
Hypertension -0.200 0.061 10.650 0.001 0.818 0.726 - 0.923 
Glomerulonephritis -0.184 0.149 1.521 0.217 0.832 0.621 - 1.115 
Cystic Kidney -0.205 0.304 0.454 0.501 0.815 0.449 - 1.479 
Other  -0.123 0.095 1.650 0.199 0.885 0.734 - 1.067 
Charlson Comorbidity Index (CCI) 
score 
0.104 0.020 27.301 <.0001 1.110 1.067 - 1.154 
Presence of 
chronic 
disease  
Diabetes mellitus -0.141 0.073 3.703 0.054 0.869 0.753 - 1.003 
Hypertension 0.010 0.041 0.062 0.803 1.010 0.933 - 1.094 
Dyslipidemia 0.091 0.052 3.030 0.082 1.095 0.989 - 1.213 
Cancer -0.260 0.100 6.723 0.010 0.771 0.634 - 0.939 
Chronic lung disease 0.018 0.055 0.104 0.747 1.018 0.914 - 1.134 
Cardiovascular 
disease 
-0.001 0.053 0.000 0.990 0.999 0.900 - 1.109 
 
Model parameters: Likelihood Ratio = 221.94; d.f.=22; p<0.0001; Score = 223.65; d.f.=22; p<0.0001; Wald = 222.40; d.f.=22; p< 0.0001. 
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Antihypertensives 
Figure 3.3 shows Kaplan-Meier curves comparing the percentage of patients who remain 
persistent on antihypertensive drugs among cohorts.  The Log-Rank test (χ2= 406.37; 
d.f.=3; p<0.0001) showed a significant difference among cohorts.  As shown in the 
figure, a higher percentage of patients in cohort 3 remained persistent to antihypertensive 
drugs compared with the other 3 cohorts.  
 
Figure 3.3  Kaplan-Meier survival curves comparing percentage of patients who 
remain on antihypertensive drugs among cohorts 
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Table 3.23 shows the results of the Cox proportional hazards regression model comparing 
persistence for antihypertensive drugs among the cohorts, while controlling for 
covariates.  The overall statistics for the model testing the null hypothesis that all 
parameter estimates are equal to zero indicated that the null hypothesis was rejected 
(p<0.0001).  This model indicated that patients in cohort 1 were 69.2 percent more 
likely to discontinue (HR= 1.692; 95% CI= 1.558 – 1.838) but those in cohort 3 were 
26.7 percent less likely to discontinue antihypertensive drug therapies (HR= 0.733; 95% 
CI= 0.649 – 0.827) compared to those in cohort 4, respectively.  There was no 
significant difference between cohort 2 and cohort 4 (HR= 1.012; 95% CI= 0.930 – 
1.102), after controlling for covariates.  
Significant predictors for discontinuation of antihypertensive drug therapy were age, 
gender, race, region of residence, ESRD duration, CCI score and presence of cancer.  
Each year increase in age was associated with a 0.8 percent decrease in the risk of 
discontinuation (HR=0.992; 95% CI= 0.990 – 0.995).  Female gender was associated 
with an 11.6 percent decrease in the risk of discontinuation compared with male gender 
(HR = 0.884; 95% CI: 0.833 - 0.937).  Being white were 19.6 percent less likely to 
discontinue antihypertensive drugs compared with being black (HR=0.804; 95% 
CI=0.752 - 0.859).  Patients who lived in the northeast and south regions were 9.3 
percent and 11.6 percent more likely to discontinue compared with those in Midwest, 
respectively (HR = 1.093; 95% CI= 1.003 – 1.191; HR=1.116; 95% CI= 1.030 – 1.210).  
Each unit increase in the year of ESRD duration was associated with a 1.8 percent 
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increase in the risk of discontinuation (HR=1.018; 95% CI=1.011-1.026).  Each unit 
increase in CCI score was associated with a 6.8 percent increase in the risk of 
discontinuation (HR=1.068; 95% CI = 1.034-1.102).  The presence of cancer was 
associated with a 19.4 percent decrease in the risk of discontinuation (HR=0.806; 95% 
CI= 0.699 – 0.930).       
H0 (3za): Rejected. 
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Table 3.23  Cox Proportional Hazards Regression Model Comparing Therapy 
Discontinuation for Antihypertensive Drugs with a 30-day Treatment Gap among 
Cohorts while Controlling for Covariates (N=9863) 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
p-value 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits 
Cohort a 
1 0.526 0.042 155.349 <.0001 1.692 1.558 - 1.838 
2 0.012 0.043 0.082 0.774 1.012 0.930 - 1.102 
3 -0.311 0.062 25.375 <.0001 0.733 0.649 - 0.827 
Age -0.008 0.001 33.820 <.0001 0.992 0.990 - 0.995 
Gender b Female -0.124 0.030 16.873 <.0001 0.884 0.833 - 0.937 
Race c 
White -0.219 0.034 41.472 <.0001 0.804 0.752 - 0.859 
Other -0.216 0.086 6.240 0.013 0.806 0.680 - 0.955 
Region of 
residence d 
Northeast  0.089 0.044 4.114 0.043 1.093 1.003 - 1.191 
South 0.110 0.041 7.139 0.008 1.116 1.030 - 1.210 
West 0.110 0.056 3.800 0.051 1.116 0.999 - 1.247 
ESRD duration 0.018 0.004 23.784 <.0001 1.018 1.011 - 1.026 
Primary 
disease 
causing 
ESRD e 
Hypertension -0.070 0.041 2.888 0.089 0.932 0.860 - 1.011 
Glomerulonephritis -0.049 0.058 0.723 0.395 0.952 0.850 - 1.066 
Cystic Kidney 0.106 0.094 1.279 0.258 1.112 0.925 - 1.337 
Other  0.007 0.054 0.016 0.900 1.007 0.906 - 1.119 
Charlson Comorbidity Index (CCI) 
score 
0.065 0.016 16.006 <.0001 1.068 1.034 - 1.102 
Presence of 
chronic 
disease  
Diabetes mellitus -0.045 0.046 0.966 0.326 0.956 0.873 - 1.046 
Hypertension -0.040 0.031 1.612 0.204 0.961 0.903 - 1.022 
Dyslipidemia 0.055 0.043 1.620 0.203 1.057 0.971 - 1.151 
Cancer -0.216 0.073 8.735 0.003 0.806 0.699 - 0.930 
Chronic lung disease -0.052 0.042 1.473 0.225 0.950 0.874 - 1.032 
Cardiovascular 
disease 
0.019 0.040 0.215 0.643 1.019 0.942 - 1.102 
 
Model parameters: Likelihood Ratio = 610.85; d.f.=22; p<0.0001; Score = 639.35; d.f.=22; p<0.0001; Wald = 625.35; d.f.=22; p< 
0.0001.     
a Reference: Cohort 4 
        b Reference : Male 
        c Reference: Black 
        d Reference : Midwest 
        e Reference : Diabetes mellitus 
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Lipid-lowering drugs 
Figure 3.4 shows Kaplan-Meier curves comparing the percentage of patients who remain 
persistent on lipid lowering drugs among cohorts.  The Log-Rank test (χ2= 142.42; 
d.f.=3; p<0.0001) showed a significant difference among cohorts.  As shown in the 
figure, a higher percentage of patients in cohort 3 who remained persistent to lipid-
lowering drugs compared with the other 3 cohorts.  
 
Figure 3.4  Kaplan-Meier survival curves comparing percentage of patients who 
remain on lipid-lowering drugs among cohorts 
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Table 3.24 shows the results of the Cox proportional hazards regression model comparing 
persistence for lipid-lowering drugs among cohorts, while controlling for covariates.  
The overall statistics for the model testing the null hypothesis that all parameter estimates 
are equal to zero indicated that the null hypothesis was rejected (p<0.0001).  This model 
indicated that patients in cohort 1 and cohort 2 were 70.7 percent (HR= 1.707; 95% CI= 
1.506 – 1.935) and 25.4 percent more likely to discontinue lipid-lowering drug therapies 
(HR= 1.254; 95% CI= 1.120 – 1.404) compared to those in cohort 4, respectively.  
However, patients in cohort 3 had a 21.9 percent decrease in the risk for discontinuation 
(HR= 0.781; 95% CI= 0.676 – 0.902) compared to patients in cohort 4 after controlling 
for covariates.  
Significant predictors for discontinuation of lipid-lowering drug therapies were age, race, 
region of residence, and presence of hypertension.  Each year increase in age was 
associated with a 1.2 percent decrease in the risk of discontinuation (HR=0.988; 95% CI= 
0.984 – 0.992).  Being white were 25.5 percent less likely to discontinue lipid-lowering 
drugs compared to being black (HR=0.745; 95% CI=0.680 - 0.817).  Patients who lived 
in the south regions were 11.6 percent more likely to discontinue compared to those in 
the Midwest (HR = 1.116; 95% CI= 1.005 – 1.239).  The presence of hypertension and 
CVD were associated with an 8.2 percent decrease (HR=0.918; 95% CI= 0.847 – 0.995) 
and a 12.5 percent increase in the risk of discontinuation (HR=1.125; 95% CI= 1.014 – 
1.249), respectively.       
H0 (3zb): Rejected. 
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Table 3.24  Cox Proportional Hazards Regression Model Comparing Therapy 
Discontinuation for Lipid-lowering Drugs with a 30-day Treatment Gap among 
Cohorts while Controlling for Covariates (N=4607) 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
p-value 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits 
Cohort a 
1 0.535 0.064 70.041 <.0001 1.707 1.506 - 1.935 
2 0.227 0.058 15.477 <.0001 1.254 1.120 - 1.404 
3 -0.247 0.074 11.291 0.001 0.781 0.676 - 0.902 
Age -0.012 0.002 37.718 <.0001 0.988 0.984 - 0.992 
Gender b Female -0.014 0.039 0.136 0.712 0.986 0.913 - 1.064 
Race c 
White -0.294 0.047 39.744 <.0001 0.745 0.680 - 0.817 
Other -0.205 0.114 3.249 0.072 0.815 0.652 - 1.018 
Region of 
residence d 
Northeast  0.005 0.056 0.010 0.922 1.005 0.901 - 1.122 
South 0.109 0.053 4.206 0.040 1.116 1.005 - 1.239 
West 0.058 0.072 0.659 0.417 1.060 0.921 - 1.220 
ESRD duration -0.001 0.006 0.012 0.914 0.999 0.988 - 1.011 
Primary 
disease 
causing 
ESRD e 
Hypertension -0.042 0.054 0.592 0.442 0.959 0.863 - 1.067 
Glomerulonephritis -0.086 0.083 1.070 0.301 0.917 0.779 - 1.080 
Cystic Kidney 0.184 0.129 2.018 0.156 1.202 0.933 - 1.549 
Other  -0.024 0.072 0.114 0.736 0.976 0.848 - 1.124 
Charlson Comorbidity Index (CCI) 
score 
0.022 0.021 1.063 0.302 1.022 0.980 - 1.066 
Presence of 
chronic 
disease  
Diabetes mellitus 0.008 0.060 0.020 0.888 1.009 0.896 - 1.135 
Hypertension -0.086 0.041 4.371 0.037 0.918 0.847 - 0.995 
Dyslipidemia 0.026 0.048 0.290 0.590 1.026 0.934 - 1.128 
Cancer -0.062 0.092 0.451 0.502 0.940 0.786 - 1.125 
Chronic lung disease 0.009 0.055 0.025 0.875 1.009 0.906 - 1.123 
Cardiovascular 
disease 
0.118 0.053 4.930 0.026 1.125 1.014 - 1.249 
 
Model parameters: Likelihood Ratio = 279.46; d.f.=22; p<0.0001; Score = 283.11; d.f.=22; p<0.0001; Wald = 278.71; d.f.=22; p< 
0.0001.   
a Reference: Cohort 4 
       b Reference : Male 
       c Reference: Black 
       d Reference : Midwest 
       e Reference : Diabetes mellitus 
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Phosphate binders 
Figure 3.5 shows Kaplan-Meier curves comparing the percentage of patients who remain 
persistent on phosphate binders among cohorts.  The Log-Rank test (χ2= 380.57; d.f.=3; 
p<0.0001) showed a significant difference among cohorts.  As shown in the figure 3.5, a 
higher percentage of patients in cohort 3 remained persistent to phosphate binders 
compared with the other 3 cohorts.  
 
Figure 3.5  Kaplan-Meier survival curves comparing percentage of patients who 
remain on phosphate binders among cohorts 
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Table 3.25 shows the results of the Cox proportional hazards regression model comparing 
persistence for phosphate binders among cohorts, while controlling for covariates.  The 
overall statistics for the model testing the null hypothesis that all parameter estimates are 
equal to zero indicated that the null hypothesis was rejected (p<0.0001).  This model 
indicated that patients in cohort 1 and cohort 2 were 54.9 percent (HR= 1.549; 95% CI= 
1.434 – 1.673) and 12.5 percent more likely to discontinue phosphate binder therapies 
(HR= 1.125; 95% CI= 1.047 – 1.208) compared to those in cohort 4, respectively.  
However, patients in cohort 3 had a 29.1 percent decrease in the risk for discontinuation 
(HR= 0.709; 95% CI= 0.646 – 0.778) compared to those in cohort 4 after controlling for 
covariates.  
Significant predictors for discontinuation of phosphate binder therapies were age, gender, 
race, region of residence, ESRD duration, primary disease causing ESRD, and the 
presence of CVD.  Each year increase in age was associated with a 0.6 percent decrease 
in the risk of discontinuation (HR=0.994; 95% CI= 0.992 – 0.996).  Female gender was 
associated with a 6.4 percent increase in the risk of discontinuation compared to male 
gender (HR = 1.064; 95% CI: 1.012 - 1.119).  Being white, and patients of ‘Other’ races 
were 23.8 percent and 31.9 percent less likely to discontinue phosphate binders compared 
with being black (HR=0.762; 95% CI=0.719 - 0.809; HR=0.681; 95% CI=0.590 - 0.785).  
Patients who lived in the South were 12.1 percent more likely to discontinue compared to 
those in the Midwest (HR = 1.121; 95% CI= 1.047 – 1.202).  Each year increase in 
ESRD duration was associated with a 0.7 percent increase in the risk of discontinuation 
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(HR=1.007; 95% CI = 1.000 - 1.014).  The presence of CVD was associated with a 7.9 
percent increase in the risk of discontinuation (HR=1.079; 95% CI= 1.009 – 1.154).   
H0 (3zc): Rejected.  
Table 3.25  Cox Proportional Hazards Regression Model Comparing Therapy 
Discontinuation for Phosphate Binders with a 30-day Treatment Gap among 
Cohorts while Controlling for Covariates (N=7753) 
Variable 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
p-value 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits 
Cohort a 
1 0.437 0.039 123.803 <.0001 1.549 1.434 - 1.673 
2 0.118 0.036 10.394 0.001 1.125 1.047 - 1.208 
3 -0.345 0.047 52.818 <.0001 0.709 0.646 - 0.778 
Age -0.006 0.001 26.234 <.0001 0.994 0.992 - 0.996 
Gender b Female 0.062 0.026 5.949 0.015 1.064 1.012 - 1.119 
Race c 
White -0.271 0.030 81.358 <.0001 0.762 0.719 - 0.809 
Other -0.384 0.073 27.895 <.0001 0.681 0.590 - 0.785 
Region of 
residence d 
Northeast  -0.025 0.037 0.452 0.501 0.975 0.907 - 1.049 
South 0.115 0.035 10.590 0.001 1.121 1.047 - 1.202 
West 0.047 0.049 0.926 0.336 1.048 0.953 - 1.153 
ESRD duration 0.007 0.003 4.274 0.039 1.007 1.000 - 1.014 
Primary 
disease 
causing 
ESRD e 
Hypertension -0.069 0.036 3.749 0.053 0.933 0.870 - 1.001 
Glomerulonephritis -0.102 0.049 4.239 0.040 0.903 0.820 - 0.995 
Cystic Kidney -0.131 0.082 2.588 0.108 0.877 0.747 - 1.029 
Other  -0.071 0.045 2.523 0.112 0.931 0.853 - 1.017 
Charlson Comorbidity Index (CCI) 
score 
0.005 0.014 0.112 0.738 1.005 0.977 - 1.033 
Presence of 
chronic 
disease  
Diabetes mellitus -0.048 0.040 1.477 0.224 0.953 0.881 - 1.030 
Hypertension 0.000 0.027 0.000 0.993 1.000 0.948 - 1.055 
Dyslipidemia -0.004 0.038 0.011 0.915 0.996 0.924 - 1.073 
Cancer -0.007 0.060 0.015 0.903 0.993 0.882 - 1.117 
Chronic lung disease 0.029 0.037 0.647 0.421 1.030 0.959 - 1.106 
Cardiovascular 
disease 
0.076 0.034 4.949 0.026 1.079 1.009 - 1.154 
Model parameters: Likelihood Ratio = 562.47; d.f.=22; p<0.0001; Score = 567.70; d.f.=22; p<0.0001; Wald = 556.32; d.f.=22; 
p< 0.0001.     a  Reference: Cohort 4; b Reference: Male; c Reference: Black; d Reference: Midwest; e Reference: Diabetes 
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Cinacalcet 
Figure 3.6 shows Kaplan-Meier curves comparing the percentage of patients who remain 
persistent on cinacalcet among cohorts.  The Log-Rank test (χ2= 199.74; d.f.=3; 
p<0.0001) showed a significant difference among cohorts.  As shown in the figure, a 
higher percentage of patients in cohort 3 remained persistent to cinacalcet compared with 
the other 3 cohorts.  
 
Figure 3.6  Kaplan-Meier survival curves comparing percentage of patients who 
remain on cinacalcet among cohorts 
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Table 3.26 shows the results of the Cox proportional hazards regression model comparing 
persistence for cinacalcet among cohorts, while controlling for covariates.  The overall 
statistics for the model testing the null hypothesis that all parameter estimates are equal to 
zero indicated that the null hypothesis was rejected (p<0.0001).  This model indicated 
that patients in cohort 1 and cohort 2 were about 100 percent (HR= 2.067; 95% CI= 
1.751 – 2.439) and 60.8 percent more likely to discontinue cinacalcet therapies (HR= 
1.608; 95% CI= 1.418 – 1.823) compared to those in cohort 4, respectively.  However, 
patients in cohort 3 had a 22.7 percent decrease in the risk for discontinuation (HR= 
0.773; 95% CI= 0.666 – 0.899) compared to those in cohort 4 after controlling for 
covariates.  
Significant predictors for discontinuation of cinacalcet therapies were age, gender, race, 
and presence of diabetes mellitus.  Each year increase in age was associated with a 0.7 
percent decrease in the risk of discontinuation (HR=0.993; 95% CI= 0.989 – 0.997).  
Being white were 17.6 percent less likely to discontinue compared to being black 
(HR=0.824; 95% CI=0.740 - 0.918).  The presence of diabetes mellitus was associated 
with a 18.6 percent increase in the risk of discontinuation (HR=1.186; 95% CI= 1.017 – 
1.384).       
H0 (3zd): Rejected. 
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Table 3.26  Cox Proportional Hazards Regression Model Comparing Therapy 
Discontinuation for Cinacalcet with a 30-day Treatment Gap among Cohorts while 
Controlling for Covariates (N=2436) 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
p-value 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits 
Cohort a 
1 0.726 0.085 73.733 <.0001 2.067 1.751 - 2.439 
2 0.475 0.064 55.053 <.0001 1.608 1.418 - 1.823 
3 -0.257 0.077 11.250 0.001 0.773 0.666 - 0.899 
Age -0.007 0.002 10.516 0.001 0.993 0.989 - 0.997 
Gender b Female 0.030 0.049 0.372 0.542 1.030 0.936 - 1.134 
Race c 
White -0.194 0.055 12.408 0.000 0.824 0.740 - 0.918 
Other 0.032 0.144 0.051 0.822 1.033 0.779 - 1.370 
Region of 
residence d 
Northeast  -0.094 0.075 1.590 0.207 0.910 0.786 - 1.054 
South 0.041 0.072 0.329 0.566 1.042 0.905 - 1.199 
West -0.058 0.099 0.347 0.556 0.943 0.778 - 1.145 
ESRD duration 0.006 0.006 1.053 0.305 1.006 0.995 - 1.017 
Primary 
disease 
causing 
ESRD e 
Hypertension 0.091 0.070 1.676 0.196 1.095 0.954 - 1.257 
Glomerulonephritis -0.135 0.092 2.183 0.140 0.873 0.730 - 1.045 
Cystic Kidney 0.029 0.135 0.045 0.831 1.029 0.790 - 1.340 
Other  -0.030 0.089 0.110 0.741 0.971 0.815 - 1.157 
Charlson Comorbidity Index 
(CCI) score 
-0.022 0.029 0.563 0.453 0.979 0.925 - 1.035 
Presence 
of chronic 
disease  
Diabetes mellitus 0.171 0.078 4.740 0.030 1.186 1.017 - 1.384 
Hypertension -0.028 0.053 0.276 0.599 0.973 0.877 - 1.079 
Dyslipidemia -0.101 0.078 1.662 0.197 0.904 0.776 - 1.054 
Cancer -0.125 0.121 1.069 0.301 0.882 0.696 - 1.119 
Chronic lung disease 0.104 0.074 1.974 0.160 1.109 0.960 - 1.282 
Cardiovascular 
disease 
0.068 0.066 1.078 0.299 1.070 0.941 - 1.217 
 
Model parameters: Likelihood Ratio = 250.71; d.f.=22; p<0.0001; Score = 251.72; d.f.=22; p<0.0001; Wald = 243.90; d.f.=22; 
p< 0.0001. 
a Reference: Cohort 4 
 b Reference : Male 
 c Reference: Black 
 d Reference : Midwest 
 e Reference : Diabetes mellitus 
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3.4 Phase III: Medical Services and Costs 
3.4.1 Objective 4: Cardiovascular Disease Morbidity 
To determine whether cardiovascular morbidity rates differ when categorized by Part D 
coverage. 
3.4.1.1 Incidence of Cardiovascular Disease 
Patients who did not have any CVD events in 2006 were included to compare incidence 
of CVD among cohorts in 2007.  The incidence of CVD was measured using both 
descriptive analysis and multivariate regression.  The descriptive analysis estimated the 
number of patients who were newly diagnosed with CVD, with statistical significance 
determined using chi-square test.  A logistic regression model was constructed to 
determine if the incidence of CVD is associated with the Part D coverage gap while 
controlling for age, gender, race, region of residence, primary disease causing ESRD, 
ESRD duration, CCI score, presence of chronic disease including diabetes mellitus, 
hypertension, dyslipidemia, cancer and chronic lung disease.   
 
H0 (4): Incidence of cardiovascular disease will not differ significantly when categorized 
by Part D coverage 
Of 5254 patients who had no CVD diagnosis during 2006, a total of 2151 (41%) patients 
newly developed CVD during 2007.  Table 3.27 shows chi-square test comparison of 
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incidence of CVD among the cohorts.  This test revealed that the incidence of CVD 
differed significantly among cohorts (χ2=60.29; d.f.=3; p<.0001).  Patients in cohort 2 
(46.89%) and cohort 3 (45.42%) were more likely to develop CVD than those in cohort 1 
(38.44%) and cohort 4 (33.78%), respectively.  
 
Table 3.27  The Proportion of Patients who Newly Developed Cardiovascular 
Disease in 2007 among Cohorts (N= 5254)   
 
Cohort 1 
(n=1761) 
Cohort 2 
(n=1787) 
Cohort 3  
(n=513) 
Cohort 4 
(n=1193) χ2 p-value 
N % N % N % N % 
677 38.44 838 46.89 233 45.42 403 33.78 60.29 <.0001 
Note: Degree of freedom equal 3 for chi-square test. 
Table 3.28 shows the results of the logistic regression model comparing incidence of 
CVD among cohorts, while controlling for covariates.  The overall statistics for the 
model testing the null hypothesis that all parameter estimates are equal to zero indicated 
that the null hypothesis was rejected (p<0.0001).  In addition, the Hosmer-Lemeshow 
test indicated that the model was of decent fit (χ2=15.83; d.f.=8; p=.05).  
The incidence of CVD was significantly different among cohorts after controlling for 
covariates.  Patients in cohort 2 and cohort 3 were 42.0 percent and 37.6 percent more 
likely to develop CVD compared to those in cohort 4, respectively (OR=1.420; 95% CI= 
1.203 – 1.675; OR=1.376; 95% CI=1.100-1.720)  However, there was no significant 
210 
difference in the incidence of CVD between patients in cohort 1and cohort 4 (OR=1.085; 
95% CI=0.921 – 1.277).  
Significant predictors of CVD in the model were age, race, primary disease causing 
ESRD, and the presence of chronic lung disease.  Each year increase in age was 
associated with a 1.6 percent higher likelihood to develop CVD (OR=1.016; 95% CI= 
1.011 – 1.021).  Being white was associated with a 15.8 percent higher likelihood to 
develop CVD compared with being black (OR=1.158; 95% CI=1.011 - 1.326).  
Hypertension, glomerulonephritis, cystic kidney, and ‘other’ as the primary disease 
causing ESRD were associated with a 17.7 percent (OR=0.823; 95% CI= 0.704 – 0.961), 
a 33.9 percent (OR=0.661; 95% CI= 0.536 – 0.814), a 37.3 percent (OR=0.627; 95% CI= 
0.443 – 0.887) and a 33.7 percent (OR=0.663; 95% CI= 0.546 – 0.804) lower likelihood 
to develop CVD when compared with the patients with a diabetes mellitus listed as the 
major disease causing ESRD.  The presence of chronic lung disease was associated with 
a 61.7 percent higher likelihood to develop CVD (OR=1.617; 95% CI= 1.299 – 2.013).      
H0 (4): Rejected. 
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Table 3.28  Logistic Regression Model Comparing the Proportion of Patients who 
Newly Developed Cardiovascular Disease in 2007 among Cohorts while Controlling 
for Covariates (N= 5254)  
 
Variable 
Parameter 
Estimate 
Standard 
Error 
Wald 
Chi-
Square 
p-value Odds 
Ratio 
95% 
Confidence 
Interval 
Intercept -1.6518 0.205 65.260 <.0001     
Cohort a 
1 0.0813 0.083 0.950 0.330 1.085 0.921 - 1.277 
2 0.3503 0.084 17.265 <.0001 1.420 1.203 - 1.675 
3 0.3190 0.114 7.838 0.005 1.376 1.100 - 1.720 
Age 0.0157 0.002 40.197 <.0001 1.016 1.011 - 1.021 
Gender b Female -0.0694 0.059 1.397 0.237 0.933 0.832 - 1.047 
Race c 
White 0.1466 0.069 4.489 0.034 1.158 1.011 - 1.326 
Other 0.0767 0.165 0.216 0.642 1.08 0.781 - 1.492 
Region of 
residence d 
Northeast  -0.0028 0.088 0.001 0.975 0.997 0.839 - 1.185 
South 0.0529 0.082 0.422 0.516 1.054 0.899 - 1.237 
West -0.1871 0.106 3.103 0.078 0.829 0.674 - 1.021 
ESRD duration -0.0016 0.007 0.047 0.829 0.998 0.984 - 1.013 
Primary 
disease 
causing 
ESRD e 
Hypertension -0.1950 0.079 6.036 0.014 0.823 0.704 - 0.961 
Glomerulonephritis -0.4145 0.106 15.204 <.0001 0.661 0.536 - 0.814 
Cystic Kidney -0.4667 0.177 6.958 0.008 0.627 0.443 - 0.887 
Other  -0.4112 0.099 17.359 <.0001 0.663 0.546 - 0.804 
Charlson Comorbidity Index 
(CCI) score 
0.0140 0.050 0.079 0.778 1.014 0.920 - 1.118 
Presence of 
chronic 
disease  
Diabetes mellitus 0.1587 0.104 2.342 0.126 1.172 0.956 - 1.436 
Hypertension 0.1037 0.068 2.348 0.126 1.109 0.971 - 1.267 
Dislipidemia 0.0525 0.105 0.248 0.619 1.054 0.857 - 1.296 
Cancer -0.0429 0.172 0.062 0.804 0.958 0.683 - 1.343 
Chronic lung 
disease 
0.4806 0.112 18.459 <.0001 1.617 1.299 - 2.013 
 
Model parameters: Likelihood Ratio = 223.38; d.f.=21; p<0.0001; Score = 217.76; d.f.=21; p<0.0001; Wald = 208.71; d.f.=21; p< 
0.0001. 
a Reference: Cohort 4 
    b Reference : Male 
    c Reference: Black 
    d Reference : Midwest 
    e Reference : Diabetes mellitus 
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3.4.2 Objective 5: Cardiovascular-related and All-cause Medical Service Utilization 
and Costs 
To determine whether all-cause and cardiovascular-related medical service utilization and 
costs differ when categorized by Part D coverage.   
3.4.2.1 Proportion of Patients with All-cause Medical Service Visits 
H 0 (5a-c): The proportion of patients who used all-cause medical services including 
inpatient [H0(5a)], outpatient [H0(5b)], and other visits [H0(5c)] will not differ significantly 
when categorized by Part D coverage.  
Medical service utilization was measured by the percentage of patients who have medical 
services (i.e., inpatient, outpatient or other visits) for the 1-year follow-up period, with 
statistical significance determined using chi-square.   
Table 3.29 shows the chi-square comparison of patients who utilized all-cause medical 
services including inpatient, outpatient, and other visits (i.e., home health agency, skilled 
nursing facility, or hospice).  The chi-square tests of medical service utilization revealed 
that the proportion of patients with all-cause medical service visits including inpatient, 
outpatient and other visits differed significantly among cohorts.  
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The proportions of patients with ≥ 1 claims for all-cause inpatient visits were 65.39 
percent in cohort 2 and 63.21 percent in cohort 3, higher than the proportions in cohort 1 
(59.49%) and cohort 4 (58.37%) (χ2=45.15; d.f.=3; p<.0001).  
H0 (5a): Rejected. 
 
The proportion of patients with ≥ 1 claims for all-cause outpatient visits were 93.40 
percent in cohort 2 and 92.37 percent in cohort 3, slightly higher than the proportions in 
cohort 1 (89.97%) and cohort 4 (90.73%) (χ2=34.97; d.f.=3; p<.0001).    
H0 (5b): Rejected. 
 
The proportion of patients with ≥ 1 claims for all-cause other visits were 37.80 percent in 
cohort 2 and 35.97 percent in cohort 3, higher than the proportions in cohort 1 (31.89%) 
and cohort 4 (65.20%) (χ2=34.97; d.f.=3; p<.0001).    
H0 (5c): Rejected. 
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Table 3.29  Proportion of Patients with Any Medical Service Utilization during 2007 among Cohorts (N=11732) 
 
Medical services 
Cohort 1  
(n=3678) 
Cohort 2  
(n=4349) 
Cohort 3  
(n=1310) 
Cohort 4  
(n=2395)  
  
 
No. of patients with at 
least 1 visit, N (%) 
N % N % N % N % χ2  p-value 
Inpatient 2188 59.49 2844 65.39 828 63.21 1398 58.37 45.15 <.0001 
Outpatient 3309 89.97 4062 93.40 1210 92.37 2173 90.73 34.97 <.0001 
Other 1173 31.89 1651 37.96 469 35.80 697 29.10 65.20 <.0001 
Note: Degrees of freedom equal 3 for all chi-square tests 
Other included home health agency, skilled nursing facility, and hospice. 
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3.4.2.2 Mean Numbers of All-cause Medical Service Utilization 
H0 (5d-f): The mean number of medical service visits (i.e., inpatient [H0(5d)], outpatient 
[H0(5e)], and other visits [H0(5f)]) will not differ significantly when categorized by Part D 
coverage. 
Descriptive analysis estimated the unadjusted mean number of medical service visits 
among cohorts, with statistical significance determined by using one-way ANOVAs and 
Kruskal-Wallis tests.  In addition, Poisson regressions or zero-inflated Poisson 
regressions were used to estimate the adjusted mean number of medical service visits and 
differences among costs after controlling for age, gender, race, region of residence, 
primary disease causing ESRD, ESRD duration, CCI score, and presence of chronic 
diseases (including diabetes mellitus, hypertension, dyslipidemia, cancer, chronic lung 
disease or CVD).    
Table 3.30 shows the unadjusted mean numbers of all-cause medical service visits 
including inpatient, outpatient, other visits, and dialysis.  One-way ANOVAs revealed 
that the unadjusted mean number of all-cause medical service visits (i.e., inpatient, 
outpatient, and other visits) differed significantly among the cohorts.  
The unadjusted mean numbers of all-cause inpatient visits for patients in cohort 2 
(Mean=1.76; SD=2.18) and cohort 3 (Mean= 1.64; SD=1.99) were higher than means for 
patients in cohort 1 (Mean= 1.50; SD=1.97) and cohort 4 (Mean=1.56; SD=2.11), 
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respectively.  A one-way ANOVA indicated a significant difference among the cohorts 
(F=10.64; d.f.=3; p<.0001).  A Kruskal-Wallis test showed a significant difference 
among the cohorts (χ2=42.00; d.f.=3; p<.0001).    
The unadjusted mean numbers of all-cause outpatient visits for patients in cohort 2 
(Mean=8.31; SD=9.85) and cohort 3 (Mean=8.34; SD=8.84) were higher than the means 
for patients in cohort 1 (Mean=6.87; SD=8.27) and cohort 4 (Mean=6.43; SD=7.15), 
respectively.  A one-way ANOVA indicated a significant difference among the cohorts 
(F=34.58; d.f.=3;  p<.0001).  A Kruskal-Wallis test also showed a significant 
difference among the cohorts (χ2=128.40; d.f.=3; p<.0001).    
The unadjusted mean numbers of all-cause other visits for patients in cohort 2 
(Mean=1.29; SD=2.56) and cohort 3 (Mean=1.17; SD=2.34) were also higher than the 
means for those in cohort 1 (Mean=1.09; SD=2.33) and cohort 4 (Mean=0.94; SD=2.26), 
respectively.  A one-way ANOVA indicated a significant difference among the cohorts 
(F=11.84; d.f.=3; p<.0001).  A Kruskal-Wallis test showed a significant difference 
among the cohorts (χ2=65.27; d.f.=3; p<.0001).  
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Table 3.30  Mean Numbers of All-cause Medical Service Visits during 2007 among Cohorts (N=11732) 
 
Medical services 
Cohort 1  
(n=3678) 
Cohort 2  
(n=4349) 
Cohort 3  
(n=1310) 
Cohort 4  
(n=2395)  
  
 
No. of visits, 
 Mean (SD) 
Mean SD Mean SD Mean SD Mean SD F-value  p-value  
Inpatient 1.50 1.97 1.76 2.18 1.64 1.99 1.56 2.11 10.64 <.0001 
Outpatient 6.87 8.27 8.31 9.85 8.34 8.84 6.43 7.15 34.58 <.0001 
Other 1.09 2.33 1.29 2.56 1.17 2.34 0.94 2.26 11.84 <.0001 
Note: Degrees of freedom equal 3 for all one-way ANOVAs 
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Table 3.31 shows the results of the zero-inflated Poisson regression model comparing 
adjusted mean numbers of all-cause inpatient visits (a) and differences (b), while 
controlling for covariates.  
This model indicated that the adjusted mean number of inpatient visits for patients in 
cohort 2 was 1.732 (CI= 1.682 – 1.783), 0.16 higher than the mean of 1.572 for those in 
cohort 4 (p <0.001).  Appendix D1 shows the results of the zero-inflated Poission 
regression model of each predictor variable included in the model.   
H0 (5d): Rejected. 
 
Table 3.31  Zero-inflated Poisson Regression Adjusted All-cause Inpatient Visits 
(A) and Differences (B) during 2007 among Cohorts while Controlling for 
Covariates (N=11732) 
 
(a) Zero-inflated Poisson regression adjusted all-cause inpatient visits      
Cohort Mean 
Standard 
Error z 
95% Confidence 
Interval     
1 1.551 0.026 58.580 1.499 1.603     
2 1.732 0.026 67.340 1.682 1.783     
3 1.575 0.044 35.800 1.489 1.661     
4 1.572 0.035 45.040 1.504 1.640     
                
(b) Differences in zero-inflated Poisson regression adjusted all-cause inpatient visits compared with 
cohort 4 
Contrast Mean 
Standard 
Error z 
95% Confidence 
Interval p-value 
  
1 -0.021 0.044 -0.480 -0.107 0.065 0.629   
2 0.160 0.045 3.590 0.073 0.247 0.000   
3 0.003 0.057 0.050 -0.109 0.115 0.960   
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Table 3.32 shows the results of the zero-inflated Poisson regression model comparing 
adjusted mean numbers of all-cause outpatient visits (a) and differences (b), while 
controlling for covariates.  This model indicated that the adjusted mean number of 
outpatient visits for patients in cohort 1, cohort 2, and cohort 3 were 7.091 (95% CI= 
6.982 – 7.200), 8.011 (95% CI= 7.908 – 8.114), and 7.821 (95% CI = 7.632 – 8.009), 
0.257, 1.174, 0.987 higher than the mean of 6.834 for those in cohort 4, respectively (p 
<0.005).  Appendix D2 shows the results of the zero-inflated Poission regression model 
of each predictor variable included in the model.   
H0 (5e): Rejected. 
Table 3.32  Zero-inflated Poisson Regression Adjusted All-cause Outpatient Visits 
(A) and Differences (B) during 2007 among Cohorts while Controlling for 
Covariates (N=11732) 
(a) Zero-inflated Poisson regression adjusted all-cause outpatient visits      
Cohort Mean 
Standard 
Error 
z 
95% 
Confidence 
Interval   
  
1 7.091 0.055 127.880 6.982 7.200     
2 8.011 0.053 152.260 7.908 8.114     
3 7.821 0.096 81.420 7.632 8.009     
4 6.834 0.069 98.900 6.698 6.969     
                
(b) Differences in zero-inflated Poisson regression adjusted all-cause outpatient visits compared 
with cohort 4 
Contrast Mean 
Standard 
Error 
z 
95% 
Confidence 
Interval p-value 
  
1 0.257 0.088 2.910 0.084 0.430 0.004   
2 1.177 0.089 13.210 1.003 1.352 < 0.001   
3 0.987 0.120 8.230 0.752 1.222 < 0.001   
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Table 3.33 shows the results of the zero-inflated Poisson regression model comparing 
adjusted mean numbers of all-cause other medical service visits (a) and differences (b), 
while controlling for covariates.  This model indicated that the adjusted mean numbers 
of other visits for patients in cohort 1 and cohort 2 were 1.161 (95% CI= 1.101 – 1.222) 
and 1.204 (95% CI= 1.151 – 1.257), 0.119, 0.162 higher than the mean of 1.042 for 
patients in cohort 4, respectively (p <0.05).  Appendix D3 shows the results of the zero-
inflated Poission regression model of each predictor variable included in the model.   
H0 (5f): Rejected. 
 
Table 3.33  Zero-inflated Poisson Regression Adjusted All-cause Other Medical 
Service Utilization (A) and Differences (B) during 2007 among Cohorts while 
Controlling for Covariates (N=11732) 
 
(a) Zero-inflated Poisson regression adjusted all-cause other medical service utilization   
Cohort Mean 
Standard 
Error 
z 
95% 
Confidence 
Interval   
  
1 1.161 0.031 37.590 1.101 1.222     
2 1.204 0.027 44.420 1.151 1.257     
3 1.065 0.046 23.360 0.976 1.154     
4 1.042 0.037 27.850 0.968 1.115     
                
(b) Differences in zero-inflated Poisson regression adjusted all-cause other medical service 
utilization compared with cohort 4 
Contrast Mean 
Standard 
Error 
z 
95% 
Confidence 
Interval p-value 
  
1 0.119 0.048 2.480 0.025 0.214 0.013   
2 0.162 0.047 3.430 0.070 0.255 0.001   
3 0.023 0.060 0.390 -0.094 0.140 0.696   
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3.4.2.3 Proportion of Patients with Cardiovascular-related Medical Services 
H0 (5g-i): The proportion of patients who used medical services related to cardiovascular 
disease including inpatient [H0(5g)], outpatient [H0(5h)], and other visits [H0(5i)], will not 
differ significantly when categorized by Part D coverage. 
Table 3.34 shows the chi-square comparison of patients who utilized cardiovascular-
related medical services including inpatient, outpatient, and other visits (i.e., home health 
agency, skilled nursing facility, and hospice).  Chi-square tests of medical service 
utilization revealed that the proportion of patients with cardiovascular-related medical 
service visits including inpatient, outpatient and other visits differed significantly among 
the cohorts. 
The proportion of patients with ≥ 1 claims for cardiovascular-related hospitalization 
were 41.16 percent in cohort 2 and 39.47 percent in cohort 3, higher than those in cohort 
1 (34.91%) and cohort 4 (34.82%).  A chi-square test showed that the proportion of 
patients with ≥ 1 claims for cardiovascular-related hospitalization differed significantly 
among the cohorts (χ2=44.51; d.f.=3; p<.0001).    
H0 (5g): Rejected. 
 
The proportion of patients with ≥ 1 claims for cardiovascular-related outpatient visits 
were 38.79 percent in cohort 2 and 35.88 percent in cohort 3, higher than those in cohort 
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1 (31.21%) and cohort 4 (31.65%).  A chi-square test showed that the proportion of 
patients with ≥ 1 claims for cardiovascular-related outpatient visits differed 
significantly among the cohorts (χ2=62.53; d.f.=3; p<.0001).    
H0 (5h): Rejected. 
 
The proportion of patients with ≥ 1 claims for cardiovascular-related other visits (i.e., 
home health agency, skilled nursing facility, or hospice) was 15.01 percent in cohort 2, 
higher than the proportions in cohort 1 (11.83%), cohort 3 (12.82%), and cohort 4 
(10.56%).  A chi-square test showed that the proportion of patients with ≥ 1 claims for 
cardiovascular-related other visits differed significantly among the cohorts (χ2=32.79; 
d.f.=3; p<.0001).    
H0 (5i): Rejected. 
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Table 3.34  Proportion of Patients with Cardiovascular-related Medical Service Utilization during 2007 among 
Cohorts (N=11732) 
 
Medical services 
Cohort 1 
(n=3678) 
Cohort 2  
(n=4349) 
Cohort 3  
(n=1310) 
Cohort 4 
(n=2395)   
No. of patients with 
at least 1 visit, n (%) 
N % N % N % N % 
 Test 
statistics 
 p-
value 
Inpatient 1284 34.91 1790 41.16 517 39.47 834 34.82 44.51 <.0001 
Outpatient 1148 31.21 1687 38.79 470 35.88 758 31.65 62.53 <.0001 
Other 435 11.83 653 15.01 168 12.82 253 10.56 32.79 <.0001 
Degrees of freedom equal 3 for all chi-square tests
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3.4.2.4 Mean Numbers of Cardiovascular-related Medical Service Utilization 
H0 (5j-l): The mean number of medical service visits (i.e., inpatient [H0(5j)], outpatient 
[H0(5k)], and other visits [H0(5l)]) will not differ significantly when categorized by Part D 
coverage. 
 
Descriptive analysis estimated the unadjusted mean numbers of cardiovascular-related 
medical service visits among cohorts, with statistical significance determined by using 
the Kruskal-Wallis test.  Poisson regressions or Zero-inflated Poisson regressions were 
used to estimate the adjusted mean number of medical service visits and differences 
among cohorts after controlling for age, gender, race, region of residence, primary 
disease causing ESRD, ESRD duration, CCI score, and presence of chronic diseases 
(including diabetes mellitus, hypertension, dyslipidemia, cancer, chronic lung disease and 
CVD.)    
Table 3.35 shows the unadjusted mean number of cardiovascular-related medical service 
visits including inpatient, outpatient, and other visits.  One-way ANOVAs revealed that 
the unadjusted mean numbers of cardiovascular-related medical service differed 
significantly among the cohorts.  
The unadjusted mean number of cardiovascular-related inpatient visits for patients in 
cohort 2 (Mean=0.77; SD=2.17) was higher than the means for those in cohort 1 (Mean= 
0.63; SD=1.14) and cohort 4 (Mean=0.65; SD=1.22), respectively.  A one-way ANOVA 
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indicated a significant difference among the cohorts (F=10.82; d.f.=3; p<.0001).  A 
kruskal-wallis test also showed a statistically significant difference among the cohorts 
(χ2=46.14; d.f.=3; p<.0001).    
 
The unadjusted mean numbers of cardiovascular-related outpatient visits for patients 
in cohort 2 (Mean=0.85; SD=2.16) and cohort 3 (Mean=0.79; SD=1.67) were higher than 
the means for patients in cohort 1 (Mean=0.65; SD=1.82) and cohort 4 (Mean=0.63; 
SD=1.37), respectively.  A one-way ANOVA indicated a significant difference among 
the cohorts (F=10.82; d.f.=3; p<.0001).  A Kruskal-Wallis test also showed a 
statistically significant difference among the cohorts (χ2=65.72; d.f.=3; p<.0001).    
 
The unadjusted mean number of cardiovascular-related other visits for patients in 
cohort 2 (Mean=0.35; SD=1.17) was higher than the means for patients in cohort 1 
(Mean=0.26; SD=0.98) and cohort 4 (Mean=0.22; SD= 0.88), respectively.  A one-way 
ANOVA indicated a significant difference among the cohorts (F=10.25; d.f.=3; p<.0001).  
A Kruskal-Wallis test also showed a statistically significant difference among the cohorts 
(χ2=34.90; d.f.=3; p<.0001).    
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Table 3.35  Mean Numbers of Cardiovascular-related Medical Service Visits during 2007 among Cohorts (N=11732) 
 
Medical services 
Cohort 1  
(n=3678) 
Cohort 2  
(n=4349) 
Cohort 3  
(n=1310) 
Cohort 4  
(n=2395)   
No. of visits, 
mean (SD) 
Mean SD Mean SD Mean SD Mean SD 
 Test 
statistics 
 p-value 
Inpatient 0.63 1.14 0.77 1.27 0.71 1.18 0.65 1.22 10.82 <.0001 
Outpatient 0.65 1.82 0.85 2.16 0.79 1.67 0.63 1.37 10.82 <.0001 
Other 0.26 0.98 0.35 1.17 0.27 0.90 0.22 0.88 10.25 <.0001 
Note: Degrees of freedom equal 3 for all one-way ANOVAs 
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Table 3.36 shows the results of the zero-inflated Poisson regression model comparing 
adjusted mean numbers of cardiovascular-related inpatient visits (a) and differences (b), 
while controlling for covariates.  This model indicated that the adjusted mean number of 
inpatient visits for patients in cohort 2 was 0.743 (95% CI= 0.711 – 0.775), 0.06 higher 
than the mean of 0.682 for patients in cohort 4 (p <0.05).  Appendix D4 shows the 
results of the zero-inflated Poission regression model of each predictor variable included 
in the model.   
H0 (5j):  Rejected. 
 
Table 3.36  Zero-inflated Poisson Regression Adjusted Cardiovascular-related 
Inpatient Visits (A) and Differences (B) during 2007 among Cohorts while 
Controlling for Covariates (N=11732) 
 
(a) Zero-inflated Poisson regression adjusted cardiovascular-related inpatient visits   
Cohort Mean 
Standard 
Error 
z 
95% 
Confidence 
Interval     
1 0.652 0.017 38.620 0.619 0.685     
2 0.743 0.016 45.630 0.711 0.775     
3 0.663 0.027 24.480 0.610 0.716     
4 0.682 0.023 30.330 0.638 0.727     
                
(b) Differences in zero-inflated Poisson regression adjusted cardiovascular-related inpatient visits 
compared with cohort 4 
Contrast Mean 
Standard 
Error 
z 
95% 
Confidence 
Interval p-value 
  
1 -0.030 0.028 -1.070 -0.085 0.025 0.284   
2 0.060 0.028 2.110 0.004 0.116 0.035   
3 -0.019 0.036 -0.540 -0.089 0.051 0.589   
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Table 3.37 shows the results of the zero-inflated Poisson regression model comparing 
adjusted mean numbers of cardiovascular-related outpatient visits (a) and differences (b), 
while controlling for covariates.  This model indicated that the adjusted mean number of 
outpatient visits for patients in cohort 2 was 0.795 (95% CI= 0.759 – 0.830), 0.087 higher 
than the mean of 0.708 for patients in cohort 4 (p <0.001).  Appendix D5 shows the 
results of the zero-inflated Poission regression model of each predictor variable included 
in the model.   
H0 (5k): Rejected. 
 
Table 3.37  Zero-inflated Poisson Regression Adjusted Cardiovascular-related 
Outpatient Visits (A) and Differences (B) during 2007 among Cohorts while 
Controlling for Covariates (N=11732) 
 
(a) Zero-inflated Poisson regression adjusted cardiovascular-related outpatient visits   
Cohort Mean 
Standard 
Error 
z 
95% 
Confidence 
Interval     
1 0.679 0.019 35.810 0.642 0.716     
2 0.795 0.018 43.920 0.759 0.830     
3 0.726 0.031 23.110 0.665 0.788     
4 0.708 0.025 28.150 0.659 0.757     
                
(b) Differences in zero-inflated Poisson regression adjusted cardiovascular-related outpatient 
visits compared with cohort 4 
Contrast Mean 
Standard 
Error 
z 
95% 
Confidence 
Interval p-value 
  
1 -0.029 0.031 -0.930 -0.090 0.032 0.353   
2 0.087 0.032 2.740 0.025 0.149 0.006   
3 0.019 0.041 0.460 -0.061 0.098 0.649   
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Table 3.38 shows the results of the zero-inflated Poisson regression model comparing 
adjusted mean numbers of cardiovascular-related other medical service visits (a) and 
differences (b), while controlling for covariates.  This model indicated that there were 
no significant differences in adjusted mean number of cardiovascular-related other visits 
among the cohorts.  Appendix D6 shows the results of the zero-inflated Poission 
regression model of each predictor variable included in the model.   
H0 (5l): Not rejected. 
 
Table 3.38  Zero-Inflated Poisson Regression Adjusted Cardiovascular-related 
Other Medical Service Utilization (A) and Differences (B) during 2007 among 
Cohorts while Controlling for Covariates (N=11732) 
 
(a) Zero-inflated Poisson regression adjusted cardiovascular-related other medical service 
utilization 
Cohort Mean 
Standard 
Error z 
95% Confidence 
Interval   
  
1 0.283 0.014 19.760 0.255 0.311     
2 0.315 0.013 24.160 0.290 0.341     
3 0.234 0.019 12.140 0.196 0.272     
4 0.271 0.019 14.580 0.235 0.308     
                
(b) Differences in zero-inflated Poisson regression adjusted cardiovascular-related other medical 
service utilization compared with cohort 4 
Contrast Mean 
Standard 
Error z 
95% Confidence 
Interval p-value 
  
1 0.012 0.023 0.520 -0.034 0.058 0.604   
2 0.044 0.023 1.910 -0.001 0.090 0.056   
3 -0.037 0.027 -1.360 -0.090 0.016 0.172   
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3.4.2.5 All-cause Medical Care Costs 
H0 (5m-t): All-cause medical care costs including inpatient [H0(5m)], outpatient [H0(5n)], 
other visits [H0(5o)], physician/supplier [H0(5p)], dialysis [H0(5q)], total medical costs 
[H0(5r)], pharmacy costs [H0(5s)], and total health care costs [H0(5t)] will not differ 
significantly when categorized by Part D coverage. 
Descriptive analyses of unadjusted medical care costs among cohorts are presented, with 
statistical significance between cohorts determined by using one-way ANOVA and the 
Kruskal-Wallis tests.  The regression model was based on a two-part model or 
generalized linear model to estimate the adjusted medical care costs and costs differences 
among cohorts after controlling for age, gender, race, region of residence, primary 
disease causing ESRD, ESRD duration, CCI score, presence of chronic disease including 
diabetes mellitus, hypertension, dyslipidemia, cancer, chronic lung disease and CVD.  
Health care costs were estimated from a Medicare perspective using both medical and 
pharmacy claims data during 2007.    
 
Table 3.39 shows the unadjusted mean costs for all-cause medical care services including 
inpatient, outpatient, other visits, physician/supplier, dialysis, total medical service, 
pharmacy and total health care.  One-way ANOVAs and Kruskal-Wallis tests revealed 
that unadjusted all-cause medical care costs differed significantly among cohorts.  
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The unadjusted mean cost for all-cause inpatient services for patients in cohort 2 was 
$17,447 (SD=26,163), higher than means for patients in cohort 3 (Mean= $16,405; 
SD=24,324) and cohort 4 (Mean=$16,038; SD=26,330), respectively.  Patients in cohort 
1 had relatively the lowest unadjusted mean cost for all-cause inpatient services among 
the cohorts (Mean= $15,631; SD=25,130).  A one-way ANOVA indicated a statistically 
significant difference among the cohorts (F=3.64; d.f.=3; p <.05).  A Kruskal-Wallis test 
also showed a statistically significant difference among the cohorts (χ2=33.23; d.f.=3; 
p<.0001).   
 
The unadjusted mean cost for all-cause outpatient services for patients in cohort 2 
(Mean=$3,831; SD=5,294) and cohort 3 (Mean=$3,933; SD=5,486) were higher than the 
means for patients in cohort 1 (Mean=$3,307; SD=4,641) and cohort 4 (Mean=$3,362; 
SD=4,938), respectively.  A one-way ANOVA indicated a statistically significant 
difference among the cohorts (F=10.80; d.f.=3; p<.0001).  A Kruskal-Wallis test also 
showed a statistically significant difference among the cohorts (χ2=57.89; d.f.=3; 
p<.0001).   
 
The unadjusted mean cost for all-cause physician/supplier services for patients in 
cohort 4 was $3,255 (SD=6203), higher than the means for patients in cohort 1 
(Mean=$2,897; SD= 5,708) and cohort 3 (Mean=$2,844; SD=6,702).  Patients in cohort 
2 had relatively the lowest unadjusted mean cost for all-cause physician/supplier services 
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among the cohorts (Mean= $2,607; SD=6,019).  A one-way ANOVA indicated a 
statistically significant difference among the cohorts (F=6.00; d.f.=3; p=0.0004).  A 
Kruskal-Wallis test also showed a statistically significant difference among the cohorts 
(χ2=37.95; d.f.=3; p<.0001).   
 
The unadjusted mean cost for all-cause other services for patients in cohort 2 was 
$4,172 (SD=8623), higher than the means for patients in cohort 1 (Mean=$3,634; SD= 
8,470) and cohort 3 (Mean=$3,634; SD=7,570).  Patients in cohort 4 had relatively the 
lowest unadjusted mean cost for all-cause other services among the cohorts (Mean= 
$2,704; SD=6,766).  A one-way ANOVA indicated a statistically significant difference 
among the cohorts (F=16.86; d.f.=3; p<.0001).  A Kruskal-Wallis test also showed a 
statistically significant difference among the cohorts (χ2=71.47; d.f.=3; p<.0001).   
 
The unadjusted mean cost for dialysis for patients in cohort 3 was $28,725 (SD=7307), 
higher than the means for patients in cohort 2 (Mean=$27,652; SD= 6,943) and cohort 4 
(Mean=$27,758; SD=7,775).  Patients in cohort 1 had relatively the lowest unadjusted 
mean cost (Mean= $26,982; SD=7,582) for dialysis compared to the means for the other 
3 cohorts.  A one-way ANOVA indicated a statistically significant difference among the 
cohorts (F=19.27; d.f.=3; p<.0001).  A Kruskal-Wallis test also showed a statistically 
significant difference among the cohorts (χ2=92.72; d.f.=3; p<.0001).   
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Total medical service costs included costs from medical services including inpatient, 
outpatient, physician/supplier, other, and dialysis costs.  The unadjusted mean cost for 
total medical services for patients in cohort 2 and cohort 3 were $55,708 (SD=32,897) 
and $55,541 (SD=30,959), higher than the means for patients in cohort 1 
(Mean=$52,451; SD= 32,060) and cohort 4 (Mean=$53,117; SD=31,951).  A one-way 
ANOVA indicated a statistically significant difference among the cohorts (F=8.43; 
d.f.=3; p<.0001).  A Kruskal-Wallis test also showed a statistically significant difference 
among the cohorts (χ2=52.18; d.f.=3; p<.0001).  
 
The unadjusted mean costs for pharmacy for patients in cohort 3 and cohort 4 were 
$6506 (SD=6,719) and $5120 (SD=4,866), higher than the mean of $ 2577 (SD=2,513) 
for patients cohort 2.  Patients in cohort 1 had the lowest unadjusted mean cost for 
pharmacy among the cohorts (Mean=$1,397; SD=1,535).  A one-way ANOVA 
indicated a statistically significant difference among the cohorts (F=946.74; d.f.=3; 
p<.0001).  A Kruskal-Wallis test also showed a statistically significant difference 
among the cohorts (χ2=4418.93; d.f.=3; p<.0001).  These pharmacy costs were defined 
as payment made by Medicare, different from total drug (Medicare payment + out-of-
pocket costs) and out-of-pocket drug costs in Table 3.5 (Ho(2p)) . 
 
Total all-cause health care costs included costs from medical services and pharmacy 
claims for any reason.  The unadjusted mean cost for total health care services for 
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patients in cohort 3 was $62,047 (SD=31,747), $3,762 and $3,810 higher than the means 
of $58,285 (SD=32,904) and $58,237 (SD=32,492) for patients in cohort 2 and cohort 4, 
respectively.  Patients in cohort 1 had relatively the lowest unadjusted mean cost for 
total health care services among cohorts (Mean=$53,847; SD=32,182).  A one-way 
ANOVA indicated a statistically significant difference among the cohorts (F=25.20; 
d.f.=3; p<.0001).  A Kruskal-Wallis test also showed a statistically significant difference 
among the cohorts (χ2=184.12; d.f.=3; p<.0001). 
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Table 3.39  All-cause Medical Service Costs during 2007 among Cohorts (N=11732) 
 
Medical services 
Cohort 1 
(n=3678) 
Cohort 2 
(n=4349) 
Cohort 3 
(n=1310) 
Cohort 4 
(n=2395) 
F-value p-value 
Mean SD Mean SD Mean SD Mean SD 
Inpatient $15,631 25,130 $17,447 26,163 $16,405 24,324 $16,038 26,330 3.64 0.0123 
Outpatient $3,307 4,641 $3,831 5,294 $3,933 5,486 $3,362 4,938 10.80 <.0001 
Physician/supplier $2,897 5,708 $2,607 6,019 $2,844 6,702 $3,255 6,203 6.00 0.0004 
Other $3,634 8,470 $4,172 8,623 $3,634 7,570 $2,704 6,766 16.86 <.0001 
Dialysis $26,982 7,582 $27,652 6,943 $28,725 7,307 $27,758 7,775 19.27 <.0001 
Total medical service $52,451 32,060 $55,708 32,897 $55,541 30,959 $53,117 31,951 8.43 <.0001 
Pharmacy $1,397 1,535 $2,577 2,513 $6,506 6,719 $5,120 4,866 946.74 <.0001 
Total health care cost $53,847 32,182 $58,285 32,904 $62,047 31,747 $58,237 32,492 25.20 <.0001 
 Note: Degrees of freedom equal 3 for all one-way ANOVAs 
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Table 3.40 shows the results of the two-part model comparing adjusted mean costs for 
all-cause inpatient services (a) and differences (b) among cohorts, while controlling for 
covariates.  This model indicated that the adjusted mean cost for inpatient services was 
$17,560 for patients in cohort 2, $1,949 higher than the mean for those in cohort 4 
(Mean=$15,611) (p<0.01).  However, the adjusted mean cost for all-cause inpatient 
services did not differ significantly for patients in cohort 1 (Mean=$15,948) and cohort 3 
(Mean=$15,973) compared to the mean for those in cohort 4 (p>0.05).   Appendix E1 
shows the results of the two-part model of each predictor variable included in the models.   
H0 (5m): Rejected. 
 
Table 3.40  A Two-part Model Adjusted All-cause Inpatient Costs (A) and 
Differences (B) during 2007 among Cohorts while Controlling for Covariates 
(N=11732) 
 
(a) A two-part model adjusted all-cause inpatient costs     
Cohort Mean 
Standard 
Error 
z 
95% Confidence 
Interval     
1 $15,948 418 38.12 $15,129 $16,768     
2 $17,560 403 43.62 $16,744 $18,375     
3 $15,973 626 25.51 $14,701 $17,245     
4 $15,611 513 30.44 $14,639 $16,583     
 
(b) Differences in a two-part model adjusted all-cause inpatient costs compared with 
cohort 4 
Contrast Mean 
Standard 
Error 
z 
95% Confidence 
Interval 
p-value   
1 vs 4 $337 654 0.52 -$944 $1,619 0.606   
2 vs 4 $1,949 644 3.03 $687 $3,211 0.002   
3 vs 4 $362 806 0.45 -$1,218 $1,943 0.653   
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Table 3.41 shows the results of the two-part model comparing adjusted mean costs for 
all-cause outpatient services (a) and differences (b) among cohorts, while controlling for 
covariates.  This model indicated that the adjusted mean cost for outpatient services 
were $3,829 for patients in cohort 2 and $3,859 for patients in cohort 3, $473 and $503 
higher than the mean of $3,356 for patients in cohort 4, respectively (p<0.01).  The 
adjusted mean costs for all-cause outpatient services did not differ significantly between 
patients in cohort 1 (Mean=$3,346) and cohort 4 (Mean=$3,356).  Appendix E2 shows 
the results of the two-part model of each predictor variable included in the models.   
H0 (5n): Rejected. 
Table 3.41  A Two-part Model Adjusted All-cause Outpatient Costs (A) and 
Differences (B) during 2007 among Cohorts while Controlling for Covariates 
(N=11732) 
 
(a) A two-part model adjusted all-cause outpatient costs     
Cohort Mean 
Standard 
Error 
z 
95% 
Confidence 
Interval     
1 $3,346 76 44.08 $3,197 $3,495     
2 $3,829 83 46.41 $3,667 $3,991     
3 $3,859 141 27.3 $3,582 $4,136     
4 $3,356 105 31.88 $3,149 $3,562     
                
(b) Differences in a two-part model adjusted all-cause outpatient costs compared 
with cohort 4 
Contrast Mean 
Standard 
Error 
z 
95% 
Confidence 
Interval 
p-value 
  
1 vs 4 -$10 131 -0.07 -$265 $246 0.942   
2 vs 4 $473 141 3.35 $197 $750 0.001   
3 vs 4 $503 183 2.75 $144 $862 0.006   
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Table 3.42 shows the results of the two-part model comparing adjusted mean costs for 
all-cause physician/supplier services (a) and differences (b) among cohorts, while 
controlling for covariates.  This model indicated that the adjusted mean costs for 
physician/supplier services among the 4 cohorts were not significantly different (p>0.05).  
Appendix E3 shows the results of the two-part model of each predictor variable included 
in the models.   
H0 (5o): Not rejected. 
 
Table 3.42  A Two-part Model Adjusted All-cause Physician/Supplier Costs (A) 
and Differences (B) during 2007 among Cohorts while Controlling for Covariates 
(N=11732) 
 
(a) A two-part model adjusted all-cause physician/supplier costs     
Cohort Mean 
Standard 
Error 
z 
95% Confidence 
Interval 
    
1 $2,852 90 31.61 $2,675 $3,029     
2 $2,783 98 28.3 $2,590 $2,975     
3 $3,019 194 15.6 $2,640 $3,399     
4 $2,884 123 23.44 $2,642 $3,125     
                
(b) Differences in a two-part model adjusted all-cause physician/supplier costs compared with 
cohort 4 
Contrast Mean 
Standard 
Error 
z 
95% Confidence 
Interval 
p-value   
1 vs 4 -$32 152 -0.21 -$330 $266 0.835   
2 vs 4 -$101 165 -0.61 -$424 $222 0.541   
3 vs 4 $136 232 0.59 -$319 $591 0.558   
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Table 3.43 shows the results of the two-part model comparing adjusted mean costs for 
all-cause other services (a) and differences (b) among cohorts, while controlling for 
covariates.  This model indicated that the adjusted mean costs for all-cause other 
services were $3,890 and $3,801 for patients in cohort 1 and cohort 2, $724 and $635 
higher than the mean of $3,166 for those in cohort 4, respectively (p<0.01).  The 
adjusted mean costs for all-cause other services did not differ significantly between 
patients in cohort 3 (Mean=$3,270) and cohort 4 (Mean=$3,166) (p>0.05).   Appendix 
E4 shows the results of the two-part model of each predictor variable included in the 
model.   
H0 (5p): Rejected. 
Table 3.43  A Two-part Model Adjusted All-cause Other Costs (A) and Differences 
(B) during 2007 among Cohorts while Controlling for Covariates (N=11732) 
 
(a) A two-part model adjusted all-cause other costs       
Cohort Mean 
Standard 
Error 
z 
95% Confidence 
Interval 
    
1 $3,890 144 26.97 $3,607 $4,173     
2 $3,801 121 31.5 $3,564 $4,037     
3 $3,270 191 17.14 $2,896 $3,644     
4 $3,166 163 19.47 $2,847 $3,485     
                
(b) Differences in a two-part model adjusted all-cause other costs compared with cohort 4 
Contrast Mean 
Standard 
Error 
z 
95% Confidence 
Interval 
p-value   
1 vs 4 $724 214 3.39 $305 $1,142 0.001   
2 vs 4 $635 203 3.12 $236 $1,033 0.002   
3 vs 4 $104 259 0.40 -$404 $611 0.689   
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Table 3.44 shows the results of the generalized linear model comparing adjusted mean 
costs for dialysis (a) and differences (b) among cohorts, while controlling for covariates.  
This model indicated that the adjusted mean costs for dialysis were $27,917 for patients 
in cohort 2 and $29,030 for patients in cohort 3, $644 and $1,757 higher than the mean of 
$27,274 for those in cohort 4, respectively (p<0.005).  The adjusted mean cost for 
dialysis for patients in cohort 1 was $384 lower than the mean for those in cohort 4, but 
the difference was not statistically significant (p>0.05).  Appendix E5 shows the results 
of the two-part model of each predictor variable included in the models.   
H0 (5q): Rejected. 
 
Table 3.44  A Generalized Linear Model Adjusted Dialysis Costs (A) and 
Differences (B) during 2007 among Cohorts while Controlling for Covariates 
(N=11732) 
 
(a) A generalized linear model adjusted dialysis costs       
Cohort Mean 
Standard 
Error 
z 
95% Confidence 
Interval 
    
1 $26,890 120 224.62 $26,655 $27,125     
2 $27,917 105 265.44 $27,711 $28,123     
3 $29,030 206 141.12 $28,627 $29,433     
4 $27,274 160 170.51 $26,960 $27,587     
                
(b) Differences in a generalized linear model adjusted dialysis costs compared with cohort 4 
Contrast Mean 
Standard 
Error 
z 
95% Confidence 
Interval 
p-value   
1 vs 4 -$384 200 -1.91 -$776 $9 0.056   
2 vs 4 $644 197 3.27 $258 $1,029 0.001   
3 vs 4 $1,757 268 6.56 $1,232 $2,282 <0.001   
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Table 3.45 shows the results of the generalized linear model comparing adjusted mean 
costs for all-cause medical services (a) and differences (b) among cohorts, while 
controlling for covariates.  This model indicated that the adjusted mean costs for all-
cause medical service were $55,819 for patients in cohort 2 and $55,187 for patients in 
cohort 3, $3,369 and $2,736 higher than the mean of $52,451 for those in cohort 4, 
respectively (p<0.001).  The adjusted mean costs for all-cause medical service did not 
differ significantly between patients in cohort 1 (Mean=$52,879) and cohort 4 
(Mean=$52,451).  Appendix E6 shows the results of the generalized linear model of 
each predictor variable included in the model.  H0 (5r): Rejected. 
Table 3.45  A Generalized Linear Model Adjusted All-cause Medical Service Costs 
(A) and Differences (B) during 2007 among Cohorts while Controlling for 
Covariates (N=11732) 
 
(a) A generalized linear model  adjusted all-cause medical service costs   
Cohort Mean 
Standard 
Error 
z 
95% Confidence 
Interval 
    
1 $52,879 498 106.08 $51,902 $53,856     
2 $55,819 494 112.89 $54,850 $56,789     
3 $55,187 826 66.81 $53,568 $56,806     
4 $52,451 662 79.27 $51,154 $53,748     
                
(b) Differences in a generalized linear model adjusted all-cause medical service costs 
compared with cohort 4 
Contrast Mean 
Standard 
Error 
z 
95% Confidence 
Interval 
p-value   
1 vs 4 $428 849 0.50 -$1,236 $2,091 0.614   
2 vs 4 $3,369 833 4.04 $1,735 $5,002 <0.001   
3 vs 4 $2,736 1111 2.46 $558 $4,914 0.014   
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Table 3.46 shows the results of the generalized linear model comparing adjusted mean 
costs for pharmacy (a) and differences (b) among cohorts, while controlling for 
covariates.  This model indicated that the adjusted mean cost for all-cause pharmacy 
was $6,325 for patients in cohort 3, $1,299 higher than the mean of $5,026 for those in 
cohort 4 (p<0.001).  However, the adjusted mean costs for all-cause pharmacy were 
$1,408 and $2,607 for patients in cohort 1 and cohort 2, $3618 and $2419 lower than the 
mean for patients in cohort 4.  Appendix E7 shows the results of the generalized liner 
model of each predictor variable included in the model.   
H0 (5s): Rejected. 
 
Table 3.46  A Generalized Linear Model Adjusted All-cause Pharmacy Costs (A) 
and Differences (B) during 2007 among Cohorts while Controlling for Covariates 
(N=11732) 
(a) A generalized linear model adjusted all-cause pharmacy costs     
Cohort Mean 
Standard 
Error 
z 
95% Confidence 
Interval 
    
1 $1,408 24 57.97 $1,360 $1,455     
2 $2,607 38 68.70 $2,532 $2,681     
3 $6,325 158 39.91 $6,015 $6,636     
4 $5,026 101 49.64 $4,827 $5,224     
                
(b) Differences in a generalized linear model adjusted all-cause pharmacy costs compared with 
cohort 4 
Contrast Mean 
Standard 
Error 
z 
95% Confidence 
Interval 
p-value   
1 vs 4 -$3,618 103 -35.24 -$3,819 -$3,417 < 0.001   
2 vs 4 -$2,419 111 -21.77 -$2,637 -$2,201 <0.001   
3 vs 4 $1,299 189 6.87 $929 $1,670 < 0.001   
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Table 3.47 shows the results of the generalized linear model comparing adjusted mean 
costs for all-cause health care services (a) and differences (b) among cohorts, while 
controlling for covariates.  This model indicated that the adjusted mean costs for all-
cause health care services was $61,663 for patients in cohort 3, $4,211 higher than the 
mean of $57,453 for patients in cohort 4 (p<0.001).  The adjusted mean cost for all-
cause health care services for patients in cohort 1 was $54,265, $3,188 lower than the 
mean for patients in cohort 4.  The adjusted mean costs for all-cause health care services 
for patients in cohort 2 and cohort 4 did not differ significantly (p>0.05).  Appendix E8 
shows the results of the two-part model of each predictor variable included in the model.   
H0 (5t): Rejected. 
Table 3.47  A Generalized Linear Model Adjusted All-cause Health Care (Medical 
Service + Pharmacy) Costs (A) and Differences (B) during 2007 among Cohorts 
while Controlling for Covariates (N=11732) 
 
Cohort Mean 
Standard 
Error 
z 
95% Confidence 
Interval 
    
1 $54,265 508 106.76 $53,269 $55,261     
2 $58,451 502 116.45 $57,468 $59,435     
3 $61,663 849 72.67 $60,000 $63,327     
4 $57,453 637 90.12 $56,203 $58,702     
                
(b) Differences in a generalized linear model adjusted all-cause health care costs 
compared with cohort 4 
Contrast Mean 
Standard 
Error 
z 
95% Confidence 
Interval 
p-value   
1 vs 4 -$3,188 820 -3.89 -$4,794 -$1,581 < 0.001   
2 vs 4 $999 834 1.2 -$636 $2,634 0.231   
3 vs 4 $4,211 1067 3.95 $2,119 $6,303 < 0.001   
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3.4.2.6 Cardiovascular-related Medical Care Costs 
H0 (5u-y): Cardiovascular disease-related medical care costs including inpatient [H0(5u)], outpatient 
[H0(5v)], and other visits [H0(5w)], and physician/supplier [H0(5x)], and total costs [H0(5y)], will not 
differ significantly when categorized by Part D coverage. 
Descriptive analysis estimated unadjusted mean costs for cardiovascular-related medical 
care services among cohorts, with statistical significance determined by using one-way 
ANOVAs and the Kruskal-Wallis tests.  The regression model was based on two-part 
model or generalized linear model to estimate the adjusted mean costs for cardiovascular-
related medical care services and cost differences among cohorts after controlling for age, 
gender, race, region of residence, primary disease causing ESRD, ESRD duration, CCI 
score, presence of chronic disease including diabetes mellitus, hypertension, 
dyslipidemia, cancer, chronic lung disease and CVD.    
Table 3.48 shows the unadjusted mean costs for cardiovascular-related medical care 
services including inpatient, outpatient, other visits, physician/supplier and total medical 
services.  One-way ANOVAs and Kruskal-Wallis tests revealed that unadjusted mean 
costs for cardiovascular-related medical care services differed significantly among the 
cohorts.  
 
The unadjusted mean cost for cardiovascular-related inpatient services for patients 
in cohort 2 was $7,422 (SD=14,608), higher than the means for those in cohort 3 (Mean= 
$6,957; SD=13,966) and cohort 4 (Mean=$6,824; SD=15,391), respectively.  Patients in 
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cohort 1 had relatively the lowest unadjusted mean cost for cardiovascular-related 
inpatient services among cohorts (Mean= $6,403; SD=14,398).  A one-way ANOVA 
indicated a statistically significant difference among the cohorts (F=3.27; d.f.=3; 
p=0.0203).  A Kruskal-Wallis test showed a statistically significant difference among 
the cohorts (χ2=57.69; d.f.=3; p<.0001).    
 
The unadjusted mean cost for cardiovascular-related outpatient services for patients in 
cohort 2 (Mean=$586; SD=1,881) was higher than the means for patients in cohort 1 
(Mean=$464; SD=1,740), cohort 3 (Mean = $518; SD= 2033) and cohort 4 (Mean=$486; 
SD=1,606), respectively.  A one-way ANOVA indicated a statistically significant 
difference among the cohorts (F=3.41; d.f.=3; p=0.0167).  A Kruskal-Wallis test also 
showed a statistically significant difference among the cohorts (χ2=57.69; d.f.=3; 
p<.0001).  
 
The unadjusted mean cost for cardiovascular-related physician/supplier services for 
patients in cohort 2 was $636 (SD=2,419), higher than patients in cohort 1 (Mean=$497; 
SD= 2,005), cohort 3 (Mean=$569; SD=1,614), and cohort 4 (Mean=$500; SD=3,121).  
A one-way ANOVA indicated a statistically significant difference among the cohorts 
(F=2.82; d.f.=3; p=0.0375).  A kruskal-wallis test also showed a statistically significant 
difference among the cohorts (χ2=125.59; d.f.=3; p<.0001).    
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The unadjusted mean cost for cardiovascular-related other services for patients in 
cohort 2 was $1,200 (SD=4,196), higher than the means for patients in cohort 1 
(Mean=$905; SD= 3,676) and cohort 3 (Mean=$846; SD=3,281).  Patients in cohort 4 
had the lowest unadjusted mean cost for cardiovascular-related other services among the 
cohorts (Mean= $664; SD=3031).  A one-way ANOVA indicated a statistically 
significant difference among the cohorts (F=11.77; d.f.=3; p<0.0001).  A Kruskal-
Wallis test also showed a statistically significant difference among the cohorts (χ2=35.93; 
d.f.=3; p<.0001).    
 
Cardiovascular-related total medical service costs included costs from cardiovascular-
related medical services including inpatient, outpatient, physician/supplier, and other 
costs.  The unadjusted mean cost for cardiovascular-related total medical services for 
patients in cohort 2 (Mean=$9,843; SD=16,961) was higher than the means for patients in 
cohort 3 (Mean=$8,890; SD= 15,886) and cohort 4 (Mean=$8,474; SD=17,309).  
Patients in cohort 1 had relatively the lowest unadjusted mean cost for cardiovascular-
related medical service among the cohorts (Mean= $8,269; SD=16,453).  A one-way 
ANOVA indicated a statistically significant difference among the cohorts (F=6.79; 
d.f.=3; p=0.0001).  A Kruskal-Wallis test also showed a statistically significant 
difference among the cohorts (χ2=107.41; d.f.=3; p=0.0001). 
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Table 3.48  Cardiovascular-Related Medical Service Costs during 2007 among Cohorts (N=11732) 
Medical services 
Cohort 1 
(n=3678) 
Cohort 2 
(n=4349) 
Cohort 3 
(n=1310) 
Cohort 4 
(n=2395) F-value p-value 
Mean SD Mean SD Mean SD Mean SD 
Inpatient $6,403 14,398 $7,422 14,608 $6,957 13,966 $6,824 15,391 3.27 0.0203 
Outpatient $464 1,740 $586 1,881 $518 2,033 $486 1,606 3.41 0.0167 
Physician/supplier $497 2,005 $636 2,419 $569 1,614 $500 3,121 2.82 0.0375 
Other $905 3,676 $1,200 4,196 $846 3,281 $664 3,031 11.77 <0.0001 
Total medical service $8,269 16,453 $9,843 16,961 $8,890 15,886 $8,474 17,309 6.79 0.0001 
Note: Degrees of freedom equal 3 for all one-way ANOVAs 
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H0 (5u-y): Cardiovascular-related medical care costs including inpatient [H0(5u)], outpatient 
[H0(5v)], other visits [H0(5w)], physician/supplier [H0(5x)], and total medical costs [H0(5y)], 
will not differ significantly when categorized by Part D coverage. 
Table 3.49 shows the results of the two-part model comparing adjusted mean costs for 
cardiovascular-related inpatient services (a) and differences (b) among cohorts, while 
controlling for covariates.  This model indicated that the adjusted mean costs for 
cardiovascular-related inpatient services were not significantly different among the 4 
cohorts (p>0.05).  Appendix E9 shows the results of the two-part model of each 
predictor variable included in the model.  H0 (5u): Not rejected. 
Table 3.49  A Two-part Model Adjusted Cardiovascular-related Inpatient Costs 
(A) and Differences (B) during 2007 among Cohorts while Controlling for 
Covariates (N=11732) 
 
(a) A two-part model adjusted cardiovascular-related inpatient costs   
Cohort Mean 
Standard 
Error 
z 
95% 
Confidence 
Interval 
    
1 $6,584 235 28.02 $6,123 $7,045     
2 $7,292 213 34.23 $6,874 $7,709     
3 $6,553 348 18.83 $5,871 $7,235     
4 $6,980 313 22.3 $6,367 $7,594     
                
(b) Differences in a two-part model adjusted cardiovascular-related inpatient costs 
compared with cohort 4 
Contrast Mean 
Standard 
Error 
z 
95% 
Confidence 
Interval 
p-value   
1 vs 4 -$396 388 -1.02 -$1,156 $364 0.307   
2 vs 4 $312 399 0.78 -$470 $1,093 0.435   
3 vs 4 -$428 482 -0.89 -$1,372 $517 0.375   
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Table 3.50 shows the results of the two-part model comparing adjusted mean costs for 
cardiovascular-related outpatient services (a) and differences (b) among cohorts, while 
controlling for covariates.  This model indicated that the adjusted mean costs for 
cardiovascular-related outpatient services among the 4 cohorts were not significantly 
different (p>0.05).  Appendix F10 shows the results of the two-part model of each 
predictor variable included in the model. 
H0 (5v): Not rejected. 
 
Table 3.50  A Two-part Model Adjusted Cardiovascular-related Outpatient Costs 
(A) and Differences (B) during 2007 among Cohorts while Controlling for 
Covariates (N=11732) 
 
(a) A two-part model adjusted cardiovascular-related outpatient costs   
Cohort Mean 
Standard 
Error 
z 
95% 
Confidence 
Interval 
    
1 $475 28 16.85 $420 $530     
2 $562 26 21.38 $510 $613     
3 $499 51 9.81 $399 $599     
4 $519 37 14.20 $448 $591     
                
(b) Differences in a two-part model adjusted cardiovascular-related outpatient costs 
compared with cohort 4 
Contrast Mean 
Standard 
Error 
z 
95% 
Confidence 
Interval 
p-value   
1 vs 4 -$45 46 -0.96 -$135 $46 0.336   
2 vs 4 $42 45 0.94 -$46 $131 0.348   
3 vs 4 -$20 62 -0.33 -$143 $102 0.743   
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Table 3.51 shows the results of the two-part model comparing adjusted mean costs for 
cardiovascular-related physician/supplier services (a) and differences (b) among cohorts, 
while controlling for covariates.  This model indicated that adjusted mean costs for 
cardiovascular-related physician/supplier services among the 4 cohorts were not 
significantly different (p>0.05).  Appendix E11 shows the results of the two-part model 
of each predictor variable included in the model.  
H0 (5w): Not rejected. 
 
Table 3.51  A Two-part Model Adjusted Cardiovascular-related 
Physician/Supplier Costs (A) and Differences (B) during 2007 among Cohorts while 
Controlling for Covariates (N=11732) 
 
(a) A two-part model adjusted cardiovascular-related physician/supplier costs 
Cohort Mean 
Standard 
Error 
z 
95% 
Confidence 
Interval 
    
1 $518 29 17.85 $461 $575     
2 $592 29 20.12 $535 $650     
3 $533 38 14.15 $459 $607     
4 $566 61 9.32 $447 $685     
                
(b) Differences in a two-part model adjusted cardiovascular-related physician/supplier 
costs compared with cohort 4 
Contrast Mean 
Standard 
Error 
z 
95% 
Confidence 
Interval 
p-value   
1 vs 4 -$48 63 -0.76 -$172 $76 0.448   
2 vs 4 $26 67 0.39 -$106 $158 0.696   
3 vs 4 -$33 70 -0.47 -$171 $105 0.641   
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Table 3.52 shows the results of the two-part model comparing adjusted mean costs for 
cardiovascular-related other services (a) and differences (b) among cohorts, while 
controlling for covariates.  This model indicated that the adjusted mean cost for 
cardiovascular-related other services for patients in cohort 2 was $1,056, $201 higher 
than the mean for patients in cohort 4 (Mean=$854) (p<0.05).  The adjusted mean costs 
for cardiovascular-related other services did not differ significantly for patients in cohort 
1 (Mean=$985) and cohort 3 (Mean=$729) compared to those in cohort 4, respectively 
(p>0.05).  Appendix E12 shows the results of two-part model of each predictor variable 
included in the models. H0 (5x): Rejected. 
 
Table 3.52  A Two-part Model Adjusted Cardiovascular-related Other Costs (A) 
and Differences (B) during 2007 among Cohorts while Controlling for Covariates 
(N=11732) 
 
(a) A two-part model adjusted cardiovascular-related other costs     
Cohort Mean 
Standard 
Error 
z 
95% Confidence 
Interval 
    
1 $985 65 15.06 $857 $1,114     
2 $1,056 54 19.55 $950 $1,162     
3 $729 80 9.14 $572 $885     
4 $854 80 10.67 $697 $1,011     
                
(b) Differences in a two-part model adjusted cardiovascular-related physician/supplier costs 
compared with cohort 4 
Contrast Mean 
Standard 
Error 
z 
95% Confidence 
Interval 
p-value   
1 vs 4 $131 100 1.31 -$65 $327 0.190   
2 vs 4 $201 99 2.03 $7 $396 0.042   
3 vs 4 -$126 117 -1.07 -$354 $103 0.283   
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Table 3.53 shows the results of the two-part model comparing adjusted mean costs for 
cardiovascular-related total medical services (a) and differences (b) among cohorts, while 
controlling for covariates.  This model indicated that the adjusted mean costs for 
cardiovascular-related total medical services were $9,530 and $8,275 for patients in 
cohort 2 and cohort 3, $502 higher and $753 lower than the mean for patients in cohort 4 
(Mean=$9,028), but the differences were not statistically significant (p>0.05).  
Appendix E13 shows the results of the two-part model of each predictor variable 
included in the model.  
H0 (5y): Not rejected. 
Table 3.53  A Two-part Model Adjusted Cardiovascular-related Total Medical 
Service Costs (A) and Differences (B) during 2007 among Cohorts while Controlling 
for Covariates (N=11732) 
 
(a) A two-part model adjusted cardiovascular-related other costs     
Cohort Mean 
Standard 
Error 
z 
95% Confidence 
Interval 
    
1 $8,501 261 32.51 $7,988 $9,013     
2 $9,530 256 37.19 $9,028 $10,032     
3 $8,275 407 20.31 $7,476 $9,073     
4 $9,028 386 23.37 $8,271 $9,785     
                
(b) Differences in a two-part model adjusted cardiovascular-related other costs compared with 
cohort 4 
Contrast Mean 
Standard 
Error 
z 
95% Confidence 
Interval 
p-value   
1 vs 4 -$527 468 -1.13 -$1,444 $390 0.260   
2 vs 4 $502 470 1.07 -$419 $1,423 0.286   
3 vs 4 -$753 566 -1.33 -$1,863 $357 0.183   
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3.5 Phase IV: Mortality Rates 
Phase IV of the study examined all-cause and cardiovascular-related mortality rates.  
3.5.1 Objective 6: All-cause and Cardiovascular-related Mortality 
To determine whether all-cause mortality rates differ when categorized by Part D 
coverage.   
The associations between Part D coverage and a 3-year mortality rates were assessed 
using descriptive and survival analyses.  The descriptive analysis estimated the numbers 
of patients who died from any or CVD-related reasons, with statistical significance 
determined using chi-square test.  Survival curves were calculated using the Kaplan-
Meier method.  Cox proportional hazards regression models were constructed to 
determine if mortality rates are associated with the Part D coverage gap while controlling 
for age, gender, race, region of residence, primary disease causing ESRD, ESRD 
duration, CCI score, and presence of chronic diseases ( including diabetes mellitus, 
hypertension, dyslipidemia, cancer, chronic lung disease and CVD).  Sensitivity 
analyses were also performed to control for laboratory data including GFR, BMI, serum 
creatinine, serum hematocrit, hemoglobin value (g/dl), serum albumin (g/dl), BUN, 
ethnicity (Hispanic vs. Non-Hispanic), and the receipt of a transplant in addition to 
covariates included in base case analyses above. Note: These laboratory data were 
obtained from the CMS End-Stage Renal Disease Medical Evidence Report (CMS-2728), 
which is used to register patients at the onset of ESRD.  
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3.5.1.1 All-cause Mortality Rates  
H0 (6a): All-cause mortality rates will not differ when categorized by Part D coverage. 
Of the 11732 patients included in this study, 9814 (83.65%) deaths were observed during 
a 3-year follow-up period.  Table 3.54 shows the chi-square test comparison of mortality 
status among the cohorts.  This test revealed that all-cause mortality differed 
significantly among the cohorts (χ2=651.90; d.f.=3; p<.0001).  Greater proportions of 
patients in cohort 1 (85.07%), cohort 2 (89.68%) and cohort 3 (90.23%) died compared to 
those in cohort 4 (66.93%).  
 
Table 3.54  All-cause Mortality between January 2008 and December 2010 among 
Cohorts (N=11732) 
 
Cohort 1 
(n=3678) 
Cohort 2 
(n=4349) 
Cohort 3 
(n=1310) 
Cohort 4 
(n=2395) 
Test 
statistics 
p-value 
N % N % N % N % 
3129 85.07 3900 89.68 1182 90.23 1603 66.93 651.9 <.0001 
Note: Degree of freedom equal 1 for all chi-square tests 
 
Figure 3.7 shows Kaplan-Meier curves comparing the percentage of patients who 
survived during the 3-year follow-up period among cohorts.  The Log-Rank test (χ2= 
492.72; d.f.=3; p<0.0001) showed a significant difference among cohorts.  As shown in 
the figure, patients in cohort 4 had a higher survival rate compared with the other 3 
cohorts.  
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Figure 3.7  Kaplan-Meier survival curves comparing survival rates among cohorts 
 
 
Table 3.55 shows the results of the Cox proportional hazards regression model comparing 
the mortality rates among cohorts, while controlling for covariates.  The overall 
statistics for the model testing the null hypothesis that all parameter estimates are equal to 
zero indicated that the null hypothesis was rejected (p<0.0001).  This model indicated 
that patients in cohort 1, cohort 2, and cohort 3 had a 30.4 percent (HR= 1.304; 95% CI= 
1.225 – 1.388), a 35.5 percent (HR= 1.355; 95% CI= 1.273 – 1.441), and a 37.1 percent 
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increased risk of death (HR= 1.371; 95% CI= 1.268 – 1.482) compared to those in cohort 
4, respectively.   
Significant predictors for death were age, gender, race, ESRD duration, primary disease 
causing ESRD, CCI score, presence of CVD and newly developed CVD in 2007.  Each 
year increase in age was associated with a 2.3 percent increase in the risk of death 
(HR=1.023; 95% CI= 1.021 – 1.025).  Female gender was associated with an 8 percent 
decrease in the risk of death compared with male gender (HR = 0.920; 95% CI: 0.883 - 
0.958).  Being white and other were a 33.2 percent and a 16.6 percent increased risk of 
death compared with being black (HR=1.332; 95% CI=1.267 - 1.401; HR=1.166; 95% 
CI=1.033 - 1.316).  Each year increase in ESRD duration was associated with a 0.9 
percent increase in the risk of death (HR=1.009; 95% CI = 1.004 - 1.015).  
Hypertension, glomerulonephritis, cystic kidney, other as primary disease causing ESRD 
were associated with a 5.9 percent, a 10 percent, a 19.9 percent, and a 12.3 percent 
decreased risk of death compared to diabetes mellitus (HR=0.941; 95% CI= 0.889 – 
0.995; HR=0.900; 95% CI=0.831-0.974; HR=0.801; 95% CI=0.702 – 0.913; HR=0.877; 
95% CI=0.817-0.942).  Each unit increase in CCI score was associated with an 8.3 
percent increase in the risk of death (HR=1.083; 95% CI = 1.059-1.106).  The presence 
of diabetes mellitus, hypertension, dyslipidemia, and cancer were associated with a 7.1 
percent, a 5.5 percent, a 6.5 percent, and a 13.4 percent decreased risk of death 
(HR=0.929; 95% CI= 0.873 – 0.989; HR=0.945; 95% CI= 0.905 – 0.986; HR= 0.935; 
95% CI=0.881- 0.992; HR=0.866; 95% CI=0.788-0.952).  In contrast, the presence of 
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CVD and newly diagnosis of CVD were associated with a 25.3 percent and 33.5 percent 
increased risk of death (HR=1.253; 95% CI=1.179-1.332; HR=1.335; 95% CI=1.254-
1.420).    
Table 3.55  Cox Proportional Hazards Regression Model Comparing a 3-year All-
cause Mortality Rates among Cohorts while Controlling for Covariates (N=11732)  
Variable 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
p-
value 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits 
cohort a 
1 0.266 0.032 69.414 <.0001 1.304 1.225 - 1.388 
2 0.303 0.032 92.511 <.0001 1.355 1.273 - 1.441 
3 0.315 0.040 62.567 <.0001 1.371 1.268 - 1.482 
Age 0.022 0.001 516.355 <.0001 1.023 1.021 - 1.025 
Gender b Female -0.084 0.021 16.258 <.0001 0.920 0.883 - 0.958 
Race c 
White 0.287 0.026 124.571 <.0001 1.332 1.267 - 1.401 
Other 0.154 0.062 6.213 0.013 1.166 1.033 - 1.316 
Region of 
residence d 
Northeast  -0.013 0.029 0.216 0.642 0.987 0.932 - 1.044 
South -0.005 0.028 0.037 0.847 0.995 0.942 - 1.050 
West -0.024 0.037 0.424 0.515 0.976 0.907 - 1.050 
ESRD duration 0.009 0.003 11.285 0.001 1.009 1.004 -1.015 
Primary 
disease 
causing 
ESRD e 
Hypertension -0.061 0.029 4.520 0.034 0.941 0.889 - 0.995 
Glomerulonephritis -0.106 0.041 6.735 0.010 0.900 0.831 - 0.974 
Cystic Kidney -0.222 0.067 11.063 0.001 0.801 0.702 - 0.913 
Other  -0.131 0.036 12.970 0.000 0.877 0.817 - 0.942 
Charlson Comorbidity Index 
(CCI) score 
0.079 0.011 51.348 <.0001 1.083 1.059 - 1.106 
Presence of 
chronic 
disease  
Diabetes mellitus -0.074 0.032 5.359 0.021 0.929 0.873 - 0.989 
Hypertension -0.057 0.022 6.752 0.009 0.945 0.905 - 0.986 
Dyslipidemia -0.068 0.030 4.970 0.026 0.935 0.881 - 0.992 
Cancer -0.144 0.048 8.871 0.003 0.866 0.788 - 0.952 
Chronic lung 
disease 
-0.001 0.029 0.001 0.972 0.999 0.944 - 1.057 
Cardiovascular 
disease 
0.226 0.031 52.546 <.0001 1.253 1.179 - 1.332 
Newly diagnosis of cardiovascular 
disease 2007 
0.289 0.032 82.938 <.0001 1.335 1.254 - 1.420 
Model parameters: Likelihood Ratio = 1820.96; d.f.=23; p<0.0001; Score = 1681.55; d.f.=23; p<0.0001; Wald = 1644.18; 
d.f.=23; p< 0.0001. 
a  Reference: Cohort 4; b Reference: Male; c Reference: Black; d Reference: Midwest; e Reference: Diabetes mellitus    
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Table 3.56 shows the sensitivity analysis results of the Cox proportional hazards 
regression model comparing the mortality rates among cohorts, while controlling for 
GFR, BMI, serum creatinine, serum hematocrit, hemoglobin value (g/dl), serum albumin 
(g/dl), BUN, ethnicity (Hispanic vs. Non-Hispanic), and the receipt of transplant in 
addition to covariates included in Table 3.55.  A total of 5989 patients were used for this 
sensitivity analysis due to missing values.  The overall statistics for the model testing 
the null hypothesis that all parameter estimates are equal to zero indicated that the null 
hypothesis was rejected (p<0.0001).  This model indicated that patients in cohort 1, 
cohort 2, cohort 3 were associated with a 24.6 percent (HR= 1.246; 95% CI= 1.141 – 
1.362), a 31.6 percent (HR= 1.355; 95% CI= 1.205 – 1.437), and a 34.5 percent increased 
risk of death (HR= 1.371; 95% CI= 1.206 – 1.500) compared to those in cohort 4, 
respectively.   
Significant predictors for death were age, gender, race, CCI score, presence of 
cardiovascular disease, newly developed CVD in 2007, serum albumin and ethnicity 
(Hispanic vs non-Hispanic).  Compared with Table 3.55, serum albumin and ethnicity 
became significant predictors while primary disease causing ESRD and presence of 
chronic diseases were not significant in this sensitivity analysis.  Each year increase in 
age was associated with a 1.5 percent increase in the risk of death (HR=1.015; 95% CI= 
1.012 – 1.018).  Female gender was associated with a 14.7 percent decrease in the risk 
of death compared with male gender (HR = 0.853; 95% CI: 0.839 - 0.952).  Being white 
was associated with a 40.8 percent increase in the risk of death compared with being 
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black (HR=1.408; 95% CI=1.303 - 1.521).  Each year increase in ESRD duration was 
associated with a 1.1 percent increase in the risk of death (HR=1.011; 95% CI = 1.000 - 
1.021).  Each unit increase in CCI score was associated with an 8.4 percent increase in 
the risk of death (HR=1.084; 95% CI = 1.052 - 1.170).  The presence of CVD and 
having a new diagnosis of CVD were associated with a 23.5 percent and a 42.2 percent 
increased risk of death (HR=1.235; 95% CI=1.134-1.344; HR=1.422; 95% CI=1.306-
1.549).  Each unit increase in serum albumin was associated with a 4.7 percent decrease 
in the risk of death (HR=0.953; 95% CI= 0.911 – 0.998).  Lastly, being Hispanic was 
associated with a 23.3 percent decrease in the risk of death compared to non-Hispanic 
patients (HR=0.767; 95% CI = 0.686 – 0.858). 
H0 (6a): Rejected. 
Table 3.56  Cox Proportional Hazards Regression Model Comparing a 3-year All-
cause Mortality Rates among Cohorts while Controlling for Covariates (N=5989) :  
Sensitivity Analysis 
 
Variable 
Paramete
r 
Estimate 
Standard 
Error 
Chi-
Square 
p-value 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits 
cohort a 
1 0.220 0.045 23.657 <.0001 1.246 1.141 - 1.362 
2 0.275 0.045 37.141 <.0001 1.316 1.205 - 1.437 
3 0.296 0.056 28.278 <.0001 1.345 1.206 - 1.500 
Age 0.023 0.001 237.594 <.0001 1.023 1.020 - 1.026 
Gender b Female -0.113 0.032 12.189 0.001 0.894 0.839 - 0.952 
Race c 
White 0.342 0.039 75.146 <.0001 1.408 1.303 - 1.521 
Other 0.266 0.084 10.126 0.002 1.304 1.107 - 1.536 
Region of 
residence d 
Northeast  0.041 0.041 1.003 0.317 1.042 0.962 - 1.128 
South 0.030 0.040 0.576 0.448 1.031 0.953 - 1.115 
West 0.031 0.054 0.319 0.572 1.031 0.927 - 1.146 
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Table 3.56 (continued) 
ESRD duration 0.011 0.005 4.172 0.041 1.011 1.000 - 1.021 
Primary 
disease 
causing ESRD 
e 
Hypertension -0.028 0.041 0.475 0.491 0.972 0.897 - 1.054 
Glomerulonephrit
is 
-0.109 0.056 3.754 0.053 0.897 0.803 - 1.001 
Cystic Kidney -0.140 0.096 2.123 0.145 0.869 0.720 - 1.050 
Other  -0.101 0.051 3.851 0.050 0.904 0.817 - 1.000 
Charlson Comorbidity Index 
(CCI) score 
0.081 0.015 27.475 <.0001 1.084 1.052 - 1.170 
Presence of 
chronic 
disease  
Diabetes mellitus -0.015 0.045 0.111 0.739 0.985 0.902 - 1.076 
Hypertension -0.043 0.031 1.922 0.166 0.958 0.902 - 1.018 
Dyslipidemia -0.066 0.042 2.457 0.117 0.936 0.861 - 1.017 
Cancer -0.172 0.068 6.347 0.012 0.842 0.737 - 0.963 
Chronic lung 
disease 
-0.035 0.041 0.743 0.389 0.965 0.891 - 1.046 
Cardiovascular 
disease 
0.211 0.043 23.631 <.0001 1.235 1.134 - 1.344 
Newly diagnosis of cardiovascular 
disease 2007 
0.352 0.043 65.669 <.0001 1.422 1.306 - 1.549 
GFR   0.004 0.006 0.399 0.527 1.004 0.992 - 1.016 
BMI   0.000 0.002 0.025 0.875 1.000 0.995 - 1.004 
Serum creatinine  -0.001 0.008 0.005 0.943 0.999 0.983 - 1.016 
Serum hematocrit 0.004 0.010 0.162 0.687 1.004 0.985 - 1.023 
Hemoglobin  -0.006 0.030 0.037 0.848 0.994 0.938 - 1.054 
Serum albumin  -0.048 0.023 4.245 0.039 0.953 0.911 - 0.998 
Blood urea nitrogen (BUN) 0.000 0.001 0.127 0.721 1.000 0.999 - 1.001 
Kidney transplant -0.201 0.179 1.260 0.262 0.818 0.575 - 1.162 
Hispanic -0.265 0.057 21.616 <.0001 0.767 0.686 - 0.858 
 
Model parameters: Likelihood Ratio = 1820.96; d.f.=23; p<0.0001; Score = 1681.55; d.f.=23; p<0.0001; Wald = 1644.18; d.f.=23; 
p< 0.0001. Number of observations used : 5989. 
a Reference: Cohort 4 
b Reference : Male 
c Reference: Black 
d Reference : Midwest 
e Reference : Diabetes mellitus 
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3.5.1.2 Cardiovascular-related Mortality Rates 
H0 (6b): Cardiovascular-related mortality rates will not differ when categorized by Part D 
coverage. 
Of the 11732 patients in this study, 4149 (35.4%) cardiovascular-related deaths were 
observed during a 3-year follow-up period.  Table 3.57 shows a chi-square test 
comparison of cardiovascular-related mortality status among the cohorts.  This test 
revealed that cardiovascular-related mortality differed significantly among cohorts 
(χ2=56.63; d.f.=3; p<.0001).  Greater proportions of patients in cohort 1 (35.18%), 
cohort 2 (38.49%) and cohort 3 (36.41%) had CVD-related deaths compared to those in 
cohort 4 (29.39%).  
 
Table 3.57  Cardiovascular-related Mortality Rates between January 2008 and 
December 2010 among Cohorts (N=11732) 
Cohort 1 
(n=3678) 
Cohort 2 
(n=4349) 
Cohort 3 
(n=1310) 
Cohort 4 
(n=2395) 
Test 
statistics 
p-value 
N % N % N % N % 
1294 35.18 1674 38.49 477 36.41 704 29.39 56.63 <.0001 
Note: Degree of freedom equal 1 for all chi-square tests 
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Figure 3.8 shows Kaplan-Meier curves comparing the percentage of patients who survive 
during a 3-year follow-up period among cohorts.  The Log-Rank test (χ2= 163.96; 
d.f.=3; p<0.0001) showed a significant difference among cohorts.  As shown in the 
figure, patients in cohort 4 had a higher survival rates compared with other cohorts.  
 
Figure 3.8  Kaplan-Meier survival curves comparing cardiovascular-related 
survival rates among cohorts 
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Table 3.58 shows the results of the Cox proportional hazards regression model comparing 
cardiovascular-related mortality rates among cohorts, while controlling for covariates.  
The overall statistics for the model testing the null hypothesis that all parameter estimates 
are equal to zero indicated that the null hypothesis was rejected (p<0.0001).  This model 
indicated that patients in cohort 1, cohort 2, cohort 3 had a 26.5 percent (HR= 1.265; 95% 
CI= 1.151 – 1.392), a 37.8 percent (HR= 1.378; 95% CI= 1.255 – 1.514), and a 30.4 
percent increased risk of cardiovascular-related death (HR= 1.304; 95% CI= 1.156 – 
1.472) compared to those in cohort 4, respectively.   
Significant predictors for death were age, gender, race, region of residence, ESRD 
duration, primary disease causing ESRD, CCI score, presence of CVD and newly 
developed CVD in 2007.  Each year increase in age was associated with a 1.5 percent 
increase in the risk of cardiovascular-related death (HR=1.015; 95% CI= 1.012 – 1.018).  
Female gender was associated with a 14.7 percent decrease in the risk of cardiovascular-
related death compared to male gender (HR = 0.853; 95% CI: 0.801 - 0.908).  Being 
white was associated with a 31.1 percent increase in the risk of cardiovascular-related 
death compared to black (HR=1.311; 95% CI=1.215 - 1.415).  Patient who lived in the 
Northeast and South were 17.6 percent and 16.2 percent more likely to die from 
cardiovascular-related reasons compared with those in Midwest, respectively (HR = 
1.176; 95% CI= 1.075 – 1.287; HR=1.162; 95% CI= 1.067 – 1.267).  Hypertension, 
glomerulonephritis, cystic kidney, and ‘other’ as the primary disease causing ESRD were 
associated with an 11.5 percent, a 14.8 percent, a 33.8 percent, and a 21.5 percent 
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decreased risk of cardiovascular-related death compared with diabetes mellitus 
(HR=0.885; 95% CI= 0.812 – 0.965; HR=0.852; 95% CI=0.753-0.964; HR=0.662; 95% 
CI=0.532 – 0.823; HR=0.785; 95% CI=0.702-0.879).  Each unit increase in CCI score 
was associated with a 6.9 percent increase in the risk of cardiovascular-related death 
(HR=1.069; 95% CI = 1.034 - 1.106).  The presence of CVD and having a new 
diagnosis of CVD were associated with a 37.5 percent and a 45.5 percent increased risk 
of cardiovascular-related death (HR=1.375; 95% CI=1.250-1.513; HR=1.455; 95% 
CI=1.321 - 1.602).   
 
Table 3.58  Cox Proportional Hazards Regression Model Comparing 3-year 
Cardiovascular-Related Mortality Rates among Cohorts while Controlling for 
Covariates (N=11732) 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
p-value 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits 
cohort a 
1 0.235 0.049 23.509 <.0001 1.265 1.151 - 1.392 
2 0.321 0.048 44.967 <.0001 1.378 1.255 - 1.514 
3 0.266 0.062 18.552 <.0001 1.304 1.156 - 1.472 
Age 0.015 0.001 106.319 <.0001 1.015 1.012 - 1.018 
Gender b Female -0.159 0.032 24.638 <.0001 0.853 0.801 - 0.908 
Race c 
White 0.271 0.039 48.365 <.0001 1.311 1.215 -1.415 
Other 0.175 0.092 3.608 0.058 1.192 0.994 - 1.428 
Region of 
residence d 
Northeast  0.163 0.046 12.596 0.000 1.176 1.075 - 1.287 
South 0.150 0.044 11.804 0.001 1.162 1.067 - 1.267 
West 0.090 0.059 2.351 0.125 1.094 0.975 - 1.228 
ESRD duration 0.002 0.004 0.230 0.632 1.002 0.994 - 1.011 
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Table 3.58 (continued) 
Primary 
disease 
causing 
ESRD e 
Hypertension -0.122 0.044 7.702 0.006 0.885 0.812 - 0.965 
Glomerulonephritis -0.160 0.063 6.447 0.011 0.852 0.753 - 0.964 
Cystic Kidney -0.413 0.111 13.823 0.000 0.662 0.532 - 0.823 
Other  -0.242 0.057 17.769 <.0001 0.785 0.702 - 0.879 
Charlson Comorbidity Index (CCI) 
score 
0.067 0.017 15.162 <.0001 1.069 1.034 - 1.106 
Presence of 
chronic 
disease  
Diabetes mellitus -0.037 0.049 0.561 0.454 0.964 0.875 -1.061 
Hypertension -0.059 0.034 3.109 0.078 0.942 0.882 - 1.007 
Dyslipidemia -0.060 0.046 1.671 0.196 0.942 0.860 - 1.031 
Cancer -0.200 0.076 6.880 0.009 0.818 0.705 - 0.951 
Chronic lung 
disease 
-0.030 0.044 0.444 0.505 0.971 0.890 - 1.059 
Cardiovascular 
disease 
0.318 0.049 42.692 <.0001 1.375 1.250 - 1.513 
Newly diagnosis of cardiovascular 
disease 2007 
0.375 0.049 58.064 <.0001 1.455 1.321 - 1.602 
 
Model parameters: Likelihood Ratio = 1057.18; d.f.=32; p<0.0001; Score = 975.07; d.f.=32; p<0.0001; Wald = 949.12; d.f.=32; 
p< 0.0001. 
Number of observations used : 5989 patients 
a Reference: Cohort 4 
b Reference : Male 
c Reference: Black 
d Reference : Midwest 
e Reference : Diabetes mellitus 
 
 
Table 3.59 shows the sensitivity analysis results of the Cox proportional hazards 
regression model comparing cardiovascular-related mortality rates among cohorts, while 
controlling for GFR, BMI, serum creatinine, serum hematocrit, hemoglobin value (g/dl), 
serum albumin (g/dl), BUN, ethnicity (Hispanic vs Non-Hispanic), and the receipt of 
transplant in addition to covariates included in Table 3.58.  A total of 5989 patients were 
used for this sensitivity analysis due to missing values.  The overall statistics for the 
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model testing the null hypothesis that all parameter estimates are equal to zero indicated 
that the null hypothesis was rejected (p<0.0001).  This model indicated that patients in 
cohort 1, cohort 2, cohort 3 had a 20.9 percent (HR= 1.209; 95% CI= 1.056 – 1.385), a 
34.9 percent (HR= 1.349; 95% CI= 1.180 – 1.542), and a 22.2 percent increased risk of 
cardiovascular-related death (HR= 1.222; 95% CI= 1.031 – 1.449) compared to those in 
cohort 4, respectively.   
Significant predictors for death were age, gender, race, region of residence, primary 
disease causing ESRD, CCI score, presence of cancer and CVD, newly developed CVD 
in 2007, serum albumin and ethnicity (Hispanic vs non-Hispanic).   
 
Compared with Table 3.58, serum albumin and ethnicity became significant predictors in 
addition to significant predictors in the previous model (Table 3.57).  Each year increase 
in age was associated with a 1.5 percent increase in the risk of cardiovascular-related 
death (HR=1.015; 95% CI= 1.010 – 1.019).  Female gender was associated with a 20.4 
percent decrease in the risk of cardiovascular-related death compared with male gender 
(HR = 0.796; 95% CI: 0.721 - 0.879).  Being white was associated with a 36.4 percent 
increase in the risk of cardiovascular-related death compared with being black 
(HR=1.364; 95% CI=1.212 - 1.534).  Patients who lived in the Northeast and South 
were 22.4 percent and 17.4 percent more likely to die from cardiovascular-related reasons 
compared with those in Midwest, respectively (HR = 1.224; 95% CI= 1.080 – 1.388; 
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HR=1.174; 95% CI= 1.038 – 1.329).  Glomerulonephritis, cystic kidney, and ‘other’ as 
the primary disease causing ESRD were associated with a 20.8 percent, a 30.6 percent, 
and a 25.3 percent decreased risk of cardiovascular-related death compared with patients 
who had diabetes mellitus as the primary disease causing ESRD (HR=0.792; 95% CI= 
0.667 – 0.942; HR=0.694; 95% CI=0.507 - 0.948; HR=0.747; 95% CI=0.636 – 0.878).  
Each unit increase in CCI score was associated with a 7.7 percent increase in the risk of 
cardiovascular-related death (HR=1.077; 95% CI = 1.028 - 1.128).  The presence of 
cancer was associated with a 20.6 percent decrease in the risk of cardiovascular-related 
death (HR=0.794; 95% CI = 0.643 – 0.980).  The presence of CVD and having a new 
diagnosis of CVD were associated with a 44.0 percent and a 58.8 percent increased risk 
of cardiovascular-related death (HR=1.440; 95% CI=1.259 - 1.647; HR=1.588; 95% 
CI=1.388 - 1.816).  Each unit increase in serum albumin was associated with a 7.9 
percent decrease in the risk of death (HR=0.921; 95% CI= 0.858 – 0.988).  Lastly, being 
Hispanic was associated with a 29 percent decrease in the risk of death compared to non-
Hispanic patients (HR=0.710; 95% CI = 0.598 – 0.843). 
H0 (6b): Rejected. 
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Table 3.59  Cox Proportional Hazards Regression Model Comparing 3-year 
Cardiovascular-related Mortality Rates among Cohorts while Controlling for 
Covariates (N=5989) : Sensitivity Analysis 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
p-value 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits 
cohort a 
1 0.190 0.069 7.553 0.006 1.209 1.056 - 1.385 
2 0.299 0.068 19.201 <.0001 1.349 1.180 - 1.542 
3 0.201 0.087 5.335 0.021 1.222 1.031 - 1.449 
Age 0.014 0.002 40.883 <.0001 1.015 1.010 - 1.019 
Gender b Female -0.228 0.051 20.407 <.0001 0.796 0.721 - 0.879 
Race c 
White 0.310 0.060 26.698 <.0001 1.364 1.212 - 1.534 
Other 0.211 0.127 2.751 0.097 1.235 0.962 - 1.583 
Region of 
residenced 
Northeast  0.202 0.064 9.957 0.002 1.224 1.080 - 1.388 
South 0.161 0.063 6.475 0.011 1.174 1.038 - 1.329 
West 0.083 0.086 0.915 0.339 1.086 0.917 - 1.286 
ESRD duration 0.000 0.008 0.001 0.983 1.000 0.984 - 1.016 
Primary 
disease 
causing ESRD 
e 
Hypertension -0.124 0.063 3.833 0.050 0.884 0.781 - 1.000 
Glomeruloneph
ritis 
-0.233 0.088 6.950 0.008 0.792 0.667 - 0.942 
Cystic Kidney -0.366 0.159 5.272 0.022 0.694 0.507 - 0.948 
Other  -0.291 0.082 12.553 0.000 0.747 0.636 - 0.878 
Charlson Comorbidity Index 
(CCI) score 
0.074 0.024 9.615 0.002 1.077 1.028 - 1.128 
Presence of 
chronic 
disease  
Diabetes 
mellitus 
-0.050 0.070 0.512 0.474 0.951 0.829 - 1.091 
Hypertension -0.011 0.047 0.051 0.821 0.989 0.902 - 1.086 
Dyslipidemia -0.060 0.065 0.869 0.351 0.941 0.829 - 1.069 
Cancer -0.231 0.107 4.612 0.032 0.794 0.643 - 0.980 
Chronic lung 
disease 
-0.096 0.063 2.324 0.127 0.908 0.802 - 1.028 
Cardiovascular 
disease 
0.365 0.068 28.382 <.0001 1.440 1.259 - 1.647 
Newly diagnosis of 
cardiovascular disease 2007 
0.462 0.069 45.488 <.0001 1.588 1.388 - 1.816 
GFR   -0.016 0.010 2.711 0.100 0.984 0.965 - 1.003 
BMI   -0.004 0.003 1.273 0.259 0.996 0.989 - 1.003 
Serum creatinine  -0.024 0.013 3.222 0.073 0.976 0.951 - 1.002 
Serum hematocrit -0.005 0.015 0.100 0.752 0.995 0.966 - 1.025 
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Table 3.59 (continued) 
Hemoglobin 0.015 0.046 0.099 0.753 1.015 0.927 - 1.11 
Serum albumin  -0.083 0.036 5.311 0.021 0.921 0.858 - 0.988 
Blood urea nitrogen (BUN) 0.000 0.001 0.011 0.916 1.000 0.999 - 1.002 
Kidney transplant -0.621 0.320 3.776 0.052 0.537 0.287 - 1.005 
Hispanic -0.343 0.088 15.276 <.0001 0.710 0.598 - 0.843 
 
Model parameters: Likelihood Ratio = 426.78; d.f.=32; p<0.0001; Score = 393.36; d.f.=32; p<0.0001; Wald = 381.97; d.f.=32; 
p< 0.0001. Number of observations used : 5989. 
a Reference: Cohort 4 
b Reference : Male 
c Reference: Black 
d Reference : Midwest 
e Reference : Diabetes mellitus 
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Table 3.60 shows a summary of hypothesis testing results for the present study 
Table 3.60  Summary of Hypotheses Testing 
Study 
phase/Obje
ctive/Hypot
hesis  
Objective/Hypothesis  Result 
PHASE I DEMOGRAPHIC AND CLINICAL CHARACTERISTICS  
Objective 1 To compare patient characteristics for Medicare beneficiaries 
with dialysis, categorized into four cohorts based on their Part D 
coverage. 
 
H0 (1a) Mean age will not differ significantly when categorized by Part D 
coverage. 
Rejected 
H0 (1b) The proportion of patients in each gender category will not differ 
significantly when categorized by Part D coverage. 
Rejected 
H0 (1c) The proportion of patients in each race category will not differ 
significantly when categorized by Part D coverage. 
Rejected 
H0 (1d) The proportion of patients in each region category will not differ 
significantly when categorized by Part D coverage. 
Rejected 
H0 (1e) The proportion of patients in primary disease causing ESRD will not 
differ significantly when categorized by Part D coverage. 
Rejected 
H0 (1f) Mean ESRD duration will not differ significantly when categorized 
by Part D coverage. 
Rejected 
H0 (1g) Mean comorbidity score will not differ significantly when 
categorized by Part D coverage. 
Rejected 
H0 (1h) The proportion of patients in the presence of cardiovascular disease 
will not differ significantly when categorized by Part D coverage. 
Rejected 
H0 (1i) The proportion of patients in the presence of diabetes will not differ 
significantly when categorized by Part D coverage. 
Rejected 
H0 (1j) The proportion of patients in the presence of hypertension will not 
differ significantly when categorized by Part D coverage. 
Rejected 
H0 (1k) The proportion of patients in the presence of chronic diseases 
dyslipidemia will not differ significantly when categorized by Part D 
coverage. 
Rejected 
H0 (1l) The proportion of patients in the presence of cancer will not differ 
significantly when categorized by Part D coverage. 
Rejected 
H0 (1m) The proportion of patients in the presence of chronic lung disease 
will not differ significantly when categorized by Part D coverage. 
Rejected 
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Table 3.60 (continued) 
PHASE II MEDICATION ADHERENCE AND COSTS  
Objective 2 
 
To determine whether the proportion and number of oral 
prescription medications and pharmacy costs differ when 
categorized by Part D coverage.   
 
H0 (2a) The proportion of patients using will not differ significantly when 
categorized by Part D coverage. 
Rejected 
H0 (2b) The proportion of patients using antihypertensives will not differ 
significantly when categorized by Part D coverage. 
Rejected 
H0 (2c) The proportion of patients using lipid-lowering drugs will not differ 
significantly when categorized by Part D coverage. 
Rejected 
H0 (2d) The proportion of patients using phosphate binders will not differ 
significantly when categorized by Part D coverage. 
Rejected 
H0 (2e) The proportion of patients using cinacalcet will not differ 
significantly when categorized by Part D coverage. 
Rejected 
H0 (2f) The mean number of antihyperglycemics will not differ significantly 
when categorized by Part D coverage. 
Rejected 
H0 (2g) The mean number of antihypertensives will not differ significantly 
when categorized by Part D coverage. 
Rejected 
H0 (2h) The mean number of lipid-lowering drugs will not differ 
significantly when categorized by Part D coverage. 
Rejected 
H0 (2i) The mean number of phosphate binders will not differ significantly 
when categorized by Part D coverage. 
Rejected 
H0 (2j) The mean number of cinacalcet will not differ significantly when 
categorized by Part D coverage. 
Rejected 
H0 (2k) Pharmacy costs for antihyperglycemics will not differ significantly 
when categorized by Part D coverage. 
Rejected 
H0 (2l) Pharmacy costs for antihypertensives will not differ significantly 
when categorized by Part D coverage. 
Rejected 
H0 (2m) Pharmacy costs for lipid-lowering drugs will not differ significantly 
when categorized by Part D coverage. 
Rejected 
H0 (2n) Pharmacy costs for phosphate binders will not differ significantly 
when categorized by Part D coverage. 
Rejected 
H0 (2o) Pharmacy costs for cinacalcet will not differ significantly when 
categorized by Part D coverage. 
Rejected 
H0 (2p) Pharmacy costs for all prescription medications will not differ 
significantly when categorized by Part D coverage. 
Rejected 
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Table 3.60 (continued) 
Objective 3 
 
To determine whether medication adherence and persistence among 
patients receiving drug therapy for diabetes, hypertension, 
hyperlipidemia, hyperphosphatemia or secondary parathyroid differ 
when categorized by Part D coverage. 
 
H0 (3a) Medication adherence for antihyperglycemics will not differ 
significantly when categorized by Part D coverage.   
Rejected 
H0 (3b) Medication adherence for antihypertensives will not differ 
significantly when categorized by Part D coverage.   
Rejected 
H0 (3c) Medication adherence for lipid-lowering drugs will not differ 
significantly when categorized by Part D coverage.   
Rejected 
H0 (3d) Medication adherence for phosphate binders will not differ 
significantly when categorized by Part D coverage.   
Rejected 
H0 (3e) Medication adherence for cinacalcet will not differ significantly 
when categorized by Part D coverage.   
Rejected 
H0 (3f) The proportion of patients who are adherent (MPR ≥ 80%) to 
antihyperglycemics will not differ significantly when categorized by 
Part D coverage. 
Rejected 
H0 (3g) The proportion of patients who are adherent (MPR ≥ 80%) to 
antihypertensives will not differ significantly when categorized by 
Part D coverage. 
Rejected 
H0 (3h) The proportion of patients who are adherent (MPR ≥ 80%) to lipid-
lowering drugs will not differ significantly when categorized by Part 
D coverage. 
Rejected 
H0 (3i) The proportion of patients who are adherent (MPR ≥ 80%) to 
phosphate binders will not differ significantly when categorized by 
Part D coverage. 
Rejected 
H0 (3j) The proportion of patients who are adherent (MPR ≥ 80%) to  
cinacalcet will not differ significantly when categorized by Part D 
coverage. 
Rejected 
 To determine whether medication adherence differs before and after 
the coverage gap is exceed among patients receiving drug therapy in 
our primary cohort (cohort 2) who reach coverage gap but not 
catastrophic coverage. 
 
H0 (3k) Medication adherence with antihyperglycemics will not differ 
significantly before and after reaching the gap. 
Rejected 
H0 (3l) Medication adherence with antihypertensives will not differ 
significantly before and after reaching the gap. 
Rejected 
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Table 3.60 (continued) 
H0 (3m) Medication adherence with lipid-lowering drugs will not differ 
significantly before and after reaching the gap. 
Rejected 
H0 (3n) Medication adherence with phosphate binders will not differ 
significantly before and after reaching the gap. 
Rejected 
H0 (3o) Medication adherence with cinacalcet will not differ significantly 
before and after reaching the gap. 
Rejected 
H0 (3p) The proportion of patients who are adherent (MPR ≥ 80%) to 
antihyperglycemics will not differ significantly before and after 
reaching the gap. 
Rejected 
H0 (3q) The proportion of patients who are adherent (MPR ≥ 80%) to 
antihypertensives will not differ significantly before and after 
reaching the gap. 
Rejected 
H0 (3r) The proportion of patients who are adherent (MPR ≥ 80%) to lipid-
lowering drugs will not differ significantly before and after reaching 
the gap. 
Rejected 
H0 (3s) The proportion of patients who are adherent (MPR ≥ 80%) to 
phosphate binders will not differ significantly before and after 
reaching the gap. 
Rejected 
H0 (3t) The proportion of patients who are adherent (MPR ≥ 80%) to 
cinacalcet will not differ significantly before and after reaching the 
gap. 
Rejected 
H0 (3u) Medication persistence with antihyperglycemics will not differ 
significantly when categorized by Part D coverage.   
Rejected 
H0 (3u) Medication persistence with antihypertensives will not differ 
significantly when categorized by Part D coverage.   
Rejected 
H0 (3u) Medication persistence with lipid-lowering drugs will not differ 
significantly when categorized by Part D coverage.   
Rejected 
H0 (3u) Medication persistence with phosphate binders will not differ 
significantly when categorized by Part D coverage.   
Rejected 
H0 (3u) Medication persistence with cinacalcet will not differ significantly 
when categorized by Part D coverage.   
Rejected 
H0 (3z) The proportion of patients who are persistent (until 30days gap) to 
antihyperglycemics will not differ significantly when categorized by 
Part D coverage.   
Rejected 
 
274 
Table 3.60 (continued) 
H0 (3za) The proportion of patients who are persistent (until 30days gap) to 
antihypertensives will not differ significantly when categorized by 
Part D coverage.   
Rejected 
H0 (3zb) The proportion of patients who are persistent (until 30days gap) to 
lipid-lowering drugs will not differ significantly when categorized 
by Part D coverage.   
Rejected 
H0 (3zc) The proportion of patients who are persistent (until 30days gap) to 
phosphate binders will not differ significantly when categorized by 
Part D coverage.   
Rejected 
H0 (3zd) The proportion of patients who are persistent (until 30days gap) to 
cinacalcet will not differ significantly when categorized by Part D 
coverage.   
Rejected 
PHASE III MEDICAL SERVICES AND COSTS  
Objective 4 
 
To determine whether cardiovascular morbidity rates differ when 
categorized by Part D coverage. 
 
H0 (4) Incidence of cardiovascular disease will not differ significantly 
when categorized by Part D coverage 
Rejected 
Objective 5 
 
To determine whether all-cause and cardiovascular-related medical 
service utilization (i.e., inpatient, outpatient and other visits) and 
costs differ when categorized by Part D coverage. 
 
H0 (5a) The proportion of patients used all-cause inpatient services will not 
differ significantly when categorized by Part D coverage.  
Rejected 
H0 (5b) The proportion of patients used all-cause outpatient services will not 
differ significantly when categorized by Part D coverage. 
Rejected 
H0 (5c) The proportion of patients used all-cause other services will not 
differ significantly when categorized by Part D coverage. 
Rejected 
H0 (5d) Mean number of all-cause inpatient visits will not differ significantly 
when categorized by Part D coverage. 
Rejected 
H0 (5e) Mean number of all-cause outpatient visits will not differ 
significantly when categorized by Part D coverage. 
Rejected 
H0 (5f) Mean number of all-cause other visits will not differ significantly 
when categorized by Part D coverage. 
Rejected 
H0 (5g) The proportion of patients used cardiovascular-related inpatient 
services will not differ significantly when categorized by Part D 
coverage. 
Rejected 
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Table 3.60 (continued) 
H0 (5h) The proportion of patients used cardiovascular-related inpatient 
services will not differ significantly when categorized by Part D 
coverage. 
Rejected 
H0 (5i) The proportion of patients used cardiovascular-related outpatient 
services will not differ significantly when categorized by Part D 
coverage. 
Not 
rejected 
H0 (5g) The proportion of patients used cardiovascular-related other services 
will not differ significantly when categorized by Part D coverage. 
Rejected 
H0 (5j) Mean numbers of cardiovascular-related inpatient visits will not 
differ significantly when categorized by Part D coverage. 
Rejected 
H0 (5k) Mean numbers of cardiovascular-related outpatient visits will not 
differ significantly when categorized by Part D coverage. 
Rejected 
H0 (5l) Mean numbers of cardiovascular-related other visits will not differ 
significantly when categorized by Part D coverage. 
Rejected 
H0 (5m) All-cause inpatient service costs will not differ significantly when 
categorized by Part D coverage. 
Rejected 
H0 (5n) All-cause medical inpatient costs will not differ significantly when 
categorized by Part D coverage. 
Rejected 
H0 (5o) All-cause physician/supplier costs will not differ significantly when 
categorized by Part D coverage. 
Not 
rejected 
H0 (5p) All-cause other service costs will not differ significantly when 
categorized by Part D coverage. 
Rejected 
H0 (5q) All-cause dialysis costs will not differ significantly when 
categorized by Part D coverage. 
Rejected 
H0 (5r) All-cause total medical care costs will not differ significantly when 
categorized by Part D coverage. 
Rejected 
H0 (5s) All-cause total pharmacy costs will not differ significantly when 
categorized by Part D coverage. 
Rejected 
H0 (5t) All-cause total health care costs will not differ significantly when 
categorized by Part D coverage. 
Rejected 
H0 (5u) Cardiovascular-related inpatient service costs will not differ 
significantly when categorized by Part D coverage. 
Not 
rejected 
H0 (5v) Cardiovascular-related outpatient service costs will not differ 
significantly when categorized by Part D coverage. 
Not 
rejected 
H0 (5w) Cardiovascular-related physician/supplier costs will not differ 
significantly when categorized by Part D coverage. 
Not 
rejected 
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Table 3.60 (continued) 
H0 (5x) Cardiovascular-related other service costs will not differ 
significantly when categorized by Part D coverage. 
Rejected 
H0 (5y) Cardiovascular-related total medical service costs will not differ 
significantly when categorized by Part D coverage. 
Not 
rejected 
PHASE IV MORTALITY RATES  
Objective 6 
 
To determine whether cardiovascular-related and all-cause mortality 
rates differ when categorized by Part D coverage. 
 
H0 (6a) All-cause mortality rates will not differ when categorized by Part D 
coverage. 
Rejected 
H0 (6b) Cardiovascular-related mortality rates will not differ when 
categorized by Part D coverage. 
Rejected 
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Chapter 4: Discussion and Conclusions 
4.1 Chapter Overview 
This chapter provides a detailed discussion of the results of the study.  The chapter 
begins with a brief review of objectives and corresponding study results.  Possible 
explanations for the study findings are proposed.  This is followed by a discussion of the 
study strengths and limitations.  The chapter concludes with a summary of the major 
findings and recommendations for future research.  
Study purpose 
The purpose of this study was to evaluate the impact of Medicare Part D coverage on 
health outcomes in dialysis patients.  Health outcomes included medication adherence 
and costs, medical service utilization and costs, CVD morbidity, all-cause and CVD-
related mortality among Medicare beneficiaries with dialysis, categorized into four 
cohorts based on their Part D coverage. 
Six objectives were address in this study.  The results of the study are discussed 
according to the study objectives in line with the four study phases, i.e.:  
 Phase I: Demographic and Clinical Characteristics (Objective 1) 
 Phase II: Medication Adherence and Costs (Objectives 2-3) 
 Phase III: Medical Services and Costs (Objectives 4-5) 
 Phase IV: Mortality Rates (Objective 6) 
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4.2 Phase I and Phase II 
4.2.1 Objective 1: Demographic and Clinical Characteristics 
The proportion of dialysis patients whose out-of-pocket spending reached the coverage 
gap threshold of $799 and the catastrophic coverage phase threshold of $3850 were 
calculated.  A total of 11732 patients were identified as meeting inclusion criteria: 3678 
patients (31.3%) had out-of-pocket costs <$799; 4349 patients (37.1%) had out-of-pocket 
costs between $799 and $3850; 1310 patients (11.2%) had out-of-pocket costs > $3850; 
and the remaining 2395 patients (20.4%) had out-of-pocket costs < $799 with a low 
income subsidy (LIS).  Overall, in present study, 61 percent of Part D non-LIS enrollees 
(cohort 1, cohort 2 and cohort 3) reached the coverage gap.  Of these patients who 
reached the coverage gap, 23 percent reached the catastrophic coverage level (cohort 3).  
According to the 2012 USRDS annual report, in 2010, 41 percent of hemodialysis 
patients reached the coverage gap, and 23 percent of patients reached catastrophic 
coverage. (US Renal Data System 2012)  Possible explanations for the differences in the 
proportion of patients who reached the coverage gap (61 versus 41 percent) could be 
differences in study populations.  In the present study, we used the inclusion criteria of 
patients who were continuously enrolled in Parts A, B and D plans in 2007 and alive at 
the end of 2007.  In addition, the coverage cost sharing structure in 2007 was different 
from 2010, where patients fell into the coverage gap with out-of-pocket drug spending 
from $940 to $4550.  For the entire study cohort, the mean age was 69.4 years 
(SD=12.7), 56.2 percent were male, and 66.2 percent were white.  The primary disease 
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causing ESRD was diabetes (43.1%), followed by hypertension (30.8%), and 
glomerulonephritis (10.4%).  The mean ESRD duration was 5.3 years (SD=4.1).  The 
mean CCI was 2.1 (1.8) and 44.8 percent had a cardiovascular diagnosis during 2006.  
 
4.2.2 Objective 2: Medication Utilization and Costs 
Overall, antihypertensive drugs were the most commonly used (87.6%), followed by 
phosphate binders (75.5%), lipid-lowering drugs (44.3%), antihyperglycemic drugs 
(36.6%), and cinacalcet (25.7%).  Regarding mean total and out-of-pocket drug costs 
per person per year, cinacalcet was the most costly drug ($2653 and $592), followed by 
phosphate binders ($1520 and $377), antihypertensive drugs ($696 and $247), 
antihyperglycemic drugs ($572 and $207), and lipid-lowering drugs ($504 and $183).  
Similar results were observed within cohorts.  Among the 4 cohorts, patients who 
received LIS assistance (cohort 4) experienced much lower mean out-of-pocket costs 
(n=2395; $192 for out-of-pocket cost; $5312 for total drug cost; ratio of out-of-pocket 
cost to total cost= 3.6%) than patients not receiving the subsidy (cohorts 1, 2 and 3).  
Patients in cohort 3 experienced the highest mean out-of-pocket costs (n=1310; $4153 for 
out-of-pocket cost; $10659 for total drug cost; ratio of out-of-pocket costs to total costs= 
39.0%) but those in cohort 2 had the highest ratio of out-of-pocket costs to total costs 
(n=4349; $4153 for out-of-pocket cost; $10659 for total drug cost; ratio of out-of-pocket 
costs to total costs= 41.8%).  Patients in cohort 1 experienced the lowest mean out-of-
pocket cost and the ratio of out-of-pocket costs to total costs among those not receiving 
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the LIS assistance (n=3678; $423 for out-of-pocket cost; $1820 for total drug cost; ratio 
of out-of-pocket cost to total cost= 23.2%)     
4.2.3 Objective 3: Medication Adherence and Persistence  
The effects of Part D coverage on medication adherence and persistence were examined.  
Poor medication adherence (MPR ≥ 80%) was common, and in the four cohorts ranged 
from: 29 to 53 percent for antihyperglycemic drugs; 47 to 73 percent for antihypertensive 
drug; 43 to 71 percent for lipid-lowering drugs; 13 to 40 percent for phosphate binders; 
and 17 to 55 percent for cinacalcet.  These results were consistent with previous 
adherence studies in dialysis patients, which found that adherence to phosphate binder 
was 38 percent (Chiu, Teitelbaum et al. 2009), adherence to cinacalcet was 29 percent 
(Gincherman, Moloney et al. 2010), and adherence to antihypertensives was 58 percent. 
(Curtin, Svarstad et al. 1999)   
High medication discontinuation (using a 30-day treatment gap) was also observed, 
ranging from 63 to 79 percent for antihyperglycemic drugs; 34 to 60 percent for 
antihypertensive drugs; 46 to 69 percent for lipid-lowering drugs; 68 to 89 percent for 
phosphate binders; and 56 to 84 percent for cinacalcet.  These results were consistent 
with the previous study, which reported that the monthly refill rate for cinacalcet fell 
significantly over five quarterly periods from 53 percent in the first quarter to 37 percent 
in the 5th quarter. (Gincherman, Moloney et al. 2010)     
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In general, adherence and persistence to dialysis-specific medications (i.e., phosphate 
binders and cinacalcet) were worse than those to non dialysis-specific medications (i.e., 
antihyperglycemics, antihypertensives, and lipid-lowering drugs).  A possible 
explanation for these differences could be differences in drug costs by therapeutic 
classes.  Based on the findings from pharmacy costs, total and out-of-pocket costs for 
phosphate binders and cinacalcet were significantly higher than drug costs for diabetes 
mellitus, hypertension, and dyslipidemia.   
There were consistently significant differences in medication adherence and 
discontinuation among the 4 cohorts across all five therapeutic classes of outpatient 
prescription drugs.  Patients in cohort 2 had significantly lower adherence and 
persistence levels compared to those in cohort 4.  Interestingly, after adjustment for the 
covariates measured in our study, patients in cohort 1 had the lowest while those in 
cohort 3 had the highest adherence and persistence among the 4 cohorts.  This may be 
explained by the operational definitions used to categorize patients into 4 cohorts.  
Patients may fall into the initial coverage phase (cohort 1), evidenced by out-of-pocket 
spending < $799, because they may not be adherent or persistent with filling 
prescriptions.  In addition patients may fall into the catastrophic coverage phase (cohort 
3), evidenced by out-of-pocket spending ≥ $3850, because they were adherent and 
persistent with filling prescriptions.    
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Further analysis of patients’ adherence before and after reaching the coverage gap (cohort 
2) provides information regarding the association between the coverage gap and 
adherence.  After adjustment for the covariates, patients were significantly more likely 
to be nonadherent to prescription drugs; as indicated by a 72 percent, 70 percent, 101 
percent, 74 percent, and 108 percent increased risk for nonadherence to 
antihyperglycemics, antihypertensives, lipid-lowering drugs, phosphate binders, and 
cinacalcet after reaching coverage gap.  Our findings were consistent with previous 
studies.  Several studies on the Part D coverage gap used the number of prescriptions 
filled as the outcome variable (Pedan, Lu et al. 2009; Zhang, Donohue et al. 2009; US 
Renal Data System 2011), while few studies compared the adherence or discontinuation 
before and after reaching the coverage gap. (Gu, Zeng et al. 2010; Polinski, Shrank et al. 
2011)  Gu et al. found that compared with Part D beneficiaries with full coverage of 
both generic and brand name drugs, beneficiaries with no coverage were 62 percent less 
likely to be adherent to diabetic medication after reaching the coverage gap. (Gu, Zeng et 
al. 2010)  Polinski et al. also found that gap-exposed patients were twice as likely to 
discontinue their medications for cardiovascular conditions, diabetes, depression, 
dementia, or rheumatoid arthritis. (Polinski, Shrank et al. 2011)  
 
  
283 
4.3 Phase III: Medical Services and Costs 
4.3.1 Objective 4: Cardiovascular Disease Morbidity 
The effects of Part D coverage on incident CVD were examined.  No previous study had 
evaluated the effects of Part D or cost sharing on incident CVD in dialysis patients, even 
though CVD is the leading cause of mortality in dialysis patients.  This study found that 
patients with out-of-pocket spending ≥ $799 (cohort 2 and cohort 3) had a 42 percent and 
a 38 percent increased risk of CVD compared to those in cohort 4, but there was no 
significant difference between patients in cohort 1 and cohort 4, after controlling for 
covariates.     
4.3.2 Objective 5: All-cause and Cardiovascular-related Medical Service Utilization 
and Costs 
The effects of Part D coverage on all-cause and cardiovascular-related medical service 
utilization and costs were examined.  This study found that patients in cohort 2 had 
increased all-cause inpatient and outpatient visits compared to those in cohort 4 (1.73 
versus 1.58 for inpatient visits and 7.98 versus 6.95 for outpatient visits) after controlling 
for covariates.  There were no significant differences between those in cohort 1 or 
cohort 3 and cohort 4 except for patients in cohort 3 had higher inpatient visits than those 
in cohort 4.  Similar results were observed for cardiovascular-related medical service 
utilization, where patients in cohort 2 had increased medical service utilization compared 
to those in cohort 4 (0.75 versus 0.69 for inpatient visits and 0.75 versus 0.71 for 
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outpatient visits).  There were no significant differences in cardiovascular-related 
medical service utilization between patients in cohort 1 or cohort 3 and cohort 4.  
Accordingly, patients in cohort 2 had $1949 higher inpatient and $473 higher outpatient 
costs, which contributed to $3368 higher medical service costs compared to those in 
cohort 4, after controlling for covariates (p<0.0001).  Patients in cohort 3 also had 
$2736 higher medical service costs compared to those in cohort 4, after controlling for 
covariates.  The adjusted mean pharmacy costs for patients in cohort 1 and cohort 2 
were $3618 and $ 2419 lower but the mean was $1299 higher for patients in cohort 3 
compared to those in cohort 4, respectively.  Taken together, the lower pharmacy costs 
and the higher medical service costs led to an overall $2644 increase in total health care 
costs for patients in cohort 2 ($60304) compared to those in cohort 4 ($57660), after 
controlling for covariates (p<0.0001).  Patients in cohort 1 and cohort 3 had $3188 
lower and $4211 higher all-cause health care costs compared to those in cohort 4, after 
controlling for covariates (p<0.0001).  These results were consistent with a previous 
study, which found that patients whose drug benefits were capped at $1000 had higher 
relative rates of visits to the emergency department and nonelective hospitalizations. 
(Hsu, Price et al. 2006)   
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4.4 Phase IV: Mortality Rates 
4.4.1 Objective 6: All-cause and Cardiovascular-related Mortality 
The effects of Part D coverage on all-cause and cardiovascular-related mortality were 
examined.  Results indicated that patients in cohort 1, cohort 2, and cohort 3 had a 30.4 
percent, a 35.5 percent and a 37.1 percent increased risk of all-cause death compared to 
those in cohort 4 for a 3-year follow-up period, respectively (p<0.0001).  Similar results 
were observed for cardiovascular-related deaths, where patients in cohort 1, cohort 2, and 
cohort 3 had a 26.5 percent, a 37.8 percent, and a 30.4 percent increased risk of 
cardiovascular-related deaths, compared to those in cohort 4 for a 3-year follow-up 
period, respectively (p<0.0001).  These relationships remained significant after 
controlling for additional potential confounders including GFR, BMI, serum creatinine, 
serum hematocrit, hemoglobin value (g/dl), serum albumin (g/dl), BUN, ethnicity 
(Hispanic vs. Non-Hispanic), and the receipt of transplant and were robust to sensitivity 
analyses.  After controlling for 22 covariates, patients in cohort 2 had a 31.6 percent, 
increased risk of all-cause death and a 34.0 percent increased risk of cardiovascular 
death, compared to those in cohort 4 (p<0.0001).  Despite controlling for additional 
important variables, the time periods observed to obtain laboratory values might have 
been different among patients because the evidence file contained data collected at ESRD 
onset.  The mean ESRD duration ranged from 4.8 – 6.0 years among the 4 cohorts 
(p<0.0001).  Several previous studies suggested that mild-to-moderate elevations in 
serum creatinine levels (Mann, Gerstein et al. 2001; Drey, Roderick et al. 2003), a 
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reduced GFR (Muntner, He et al. 2002; Go, Chertow et al. 2004), or high and low 
HgbA1c levels (Kalantar-Zadeh, Kopple et al. 2007; Shurraw, Majumdar et al. 2010) 
were independently associated with an increased risk of death in dialysis patients and the 
presence of malnutrition/inflammations including cholesterol levels, serum albumin, and 
BMI were also important predictors. (Liu, Coresh et al. 2004; Kalantar-Zadeh, Kopple et 
al. 2007; Baigent, Landray et al. 2011)  Thus, it is important to control for these factors 
using sensitivity analyses despite some limited time period issues.  Interestingly, 
sensitivity analyses found that increased serum albumin was associated with a decreased 
risk of all-cause and cardiovascular-related deaths, after controlling for all other 
covariates.  A study of Japanese patients receiving hemodialysis reported that high 
cholesterol levels were associated with lower mortality in persons with low albumin 
levels but were associated with higher mortality in a subgroup with high serum albumin 
levels. (Iseki, Yamazato et al. 2002)   
Results indicated that CVD accounted for 41 to 44 percent of all deaths.  This result was 
consistent with a previous study, which reported that CVD is the leading cause of 
mortality in ESRD, accounting for about 45 percent of all deaths. (Wright and Hutchison 
2009) 
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4.5 Comparison of Main Study Findings for Cohort 2 vs Cohort 4 
Previous studies that evaluated the effect of drug cost sharing on health outcomes 
compared patients with a cap on drug benefits versus unlimited drug benefits. (Federman, 
Adams et al. 2001; Tamblyn, Laprise et al. 2001; Hsu, Price et al. 2006)  For 
comparison with previous studies, this section summarized main study findings for 
patients in cohort 2 compared with those in cohort 4.  
Overall, an important finding was that the Part D coverage gap was consistently 
associated with negative economic and clinical outcomes.  Among dialysis patients who 
fell into the coverage gap phase in 2007, defined as out-of-pocket costs ≥ $799, the 
coverage gap was associated with decreased drug adherence, increased incident CVD, 
increased inpatient and outpatient visits, increased medical service costs, and increased 
mortality rates.  Patients in cohort 2 were 70 to 108 percent more likely to be  
nonadherent to outpatient prescription drugs including antihyperglycemics, 
antihypertensives, lipid-lowering drugs, phosphate binders, and cinacalcet after reaching 
the coverage gap, while controlling for covariates (p<0.0001).  After adjustment for the 
covariates measured in this study, patients in cohort 2 had higher mean total medical 
costs due to increased rates of hospitalizations and outpatient visits compared to those in 
cohort 4.   When comparing cohort 2 to cohort 4, despite having lower pharmacy costs, 
the increase in higher medical service costs resulted in significantly higher mean total 
health care costs, after controlling for covariates (p<0.0001).  The higher costs of 
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hospitalizations and outpatient visits did not offset much of the savings in pharmacy costs 
as the cost sharing burden was shifted from Medicare to patients.  In addition, patients 
in cohort 2 had a 42% increased risk of CVD during a 1-year follow-up.  These patients 
also had a 35.5 percent and a 37.8 percent increased risk of all-cause and cardiovascular-
related deaths for a 3-year follow-up period compared to those in cohort 4, respectively.  
These relationships remained significant after controlling for additional potential 
confounders and were robust to sensitivity analyses.  Our findings were consistent with 
previous retrospective and prospective studies that compared cost sharing in prescription 
drug coverage plans. (Tamblyn, Laprise et al. 2001; Hsu, Price et al. 2006)  Tamblyn et 
al. conducted a retrospective time-series analysis of data before and after the introduction 
of a prescription coinsurance and deductible cost-sharing policy in Quebec. (Tamblyn, 
Laprise et al. 2001)  Researchers found that increased cost-sharing for prescription 
drugs in elderly persons in Canada was followed by a 9 percent reduction in the use of 
essential drugs and a 7 percent higher rate of serious adverse events and a 14 percent 
increase in ED visits associated with these reductions. (Tamblyn, Laprise et al. 2001)    
A prospective study compared health outcomes for beneficiaries whose annual drug 
benefits were capped at $1000 and those who had unlimited drug benefits. (Hsu, Price et 
al. 2006)  The results indicated that individuals whose benefits were capped had a 13 
percent increase in hospitalizations, a 9 percent increase in ER visits, and a 22 percent 
increase in deaths.   
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4.6 Study Strengths and Limitations 
Study aims were to investigate the associations between Medicare Part D coverage and 
health outcomes including: mortality, incident CVD, medical service utilization and 
costs, and medication adherence and persistence in dialysis patients.  To the best of our 
knowledge, this is the first study to examine the associations between the Medicare Part 
D coverage cost sharing structure and health outcomes in dialysis patients.  This 
provided valuable information on association between Medicare Part D coverage and 
mortality, as well as on incident CVD; neither of which has been examined previously 
among dialysis patients.  This is important because it was reported that morbidity and 
mortality of dialysis patients remains high due to high cardiovascular morbidity and 
mortality although survival rates have improved steadily in the US ESRD population 
since the late 1980s. (Foley and Collins 2007)  All-cause mortality is clinically 
meaningful and provides a measure of net benefits versus harms.  In addition, there is 
now increasing interest in the cardiovascular status of patients due to high CVD-related 
morbidity and mortality. (Go, Chertow et al. 2004)  
Using national USRDS data, the study provides national estimates on medication 
adherence, health care utilization, health care costs, CVD morbidity and mortality for 
dialysis patients who were enrolled in Medicare’s Part D program in 2007.  The USRDS 
database includes almost 95 percent of ESRD patients in the U.S.  The generalizability 
is a clear advantage over studies that were based on specific or regional health plans.  
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Furthermore, availability of data on laboratory values including GFR, BMI, serum 
creatinine, serum hematocrit, hemoglobin value (g/dl), serum albumin (g/dl), and BUN 
allowed for sensitivity analyses.   
Relatively few studies have evaluated the impact of Part D coverage in the Medicare 
population.  This is one of few studies that focused on the impact of Part D coverage on 
direct health outcomes.  Although several studies reported that the lack of drug coverage 
has been associated with poor outcomes (Soumerai, Ross-Degnan et al. 1991; Federman, 
Adams et al. 2001; Tamblyn, Laprise et al. 2001; Hsu, Price et al. 2006), this is the only 
study that compared patients based on the Part D coverage phases including initial, 
coverage gap, and catastrophic coverage phases.  In addition, this study directly 
investigated the associations between the coverage gap and patient outcomes compared to 
previous studies that mainly focused on drug utilization and adherence during the 
coverage gap. (Schmittdiel, Ettner et al. 2009; Zhang, Donohue et al. 2009; Fung, 
Mangione et al. 2010; Polinski, Shrank et al. 2011)  Therefore, findings from this study 
provide valuable information to existing literature on the Medicare Part D.  
This study also has several limitations that deserve mention.  Although patients were 
categorized into 4 cohorts based on the Part D coverage, it is possible that patients’ 
coverage within cohorts might have been different.  Prescription drug plans (PDPs) have 
the latitude to structure their plans differently from standard Part D plans; nonstandard 
plans are available when their coverage is at least actuarially equivalent to the standard 
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plan. (US Renal Data System 2012)  Many PDPs have developed plans with no 
deductibles or with drug copayments instead of the 25 percent co-insurance, and some 
include drug coverage during the coverage gap.  According to the 2012 USRDS annual 
report, in 2010, 60 percent and 15 percent hemodialysis patients had no deductible and 
some type of gap coverage. (US Renal Data System 2012)  The structure of standard 
Part D plans used for this study may be different from some patients’ nonstandard plans.  
However, actual out-of-pocket drug spending was used to categorize patients into 4 
cohorts that apply to all Part D beneficiaries as thresholds for coverage gap and 
catastrophic coverage phases regardless the presence of deductibles.  
According to 2013 Medicare Part D Plan Facts, in 2012, during the coverage gap, only7 
percent of Part D plans had some brand coverage while a 26 percent of Part D plans had 
some generic coverage. (Medicare 2013)  Fung et al. observed that generic gap coverage 
did not contribute to patients’ annual out-of-pocket spending compared to those without 
gap coverage because there were no available generics within some therapeutic classes 
and the optimal drug regimen might not have a generic equivalent for some patients. 
(Fung, Mangione et al. 2010)  In the present study, most out-of-pocket drug spending 
was observed for phosphate binders and cinacalcet where generics or equivalent generics 
are not available.  Thus, we assumed that generic gap coverage would have a limited 
impact on patients’ out-of-pocket spending in dialysis patients; and only few patients 
might have brand coverage during coverage gap.  
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Second, because this was an observational retrospective study, we could not conclude 
that there was a causal relationship between the Part D coverage gap and poor adherence, 
poor clinical outcomes, high medical service costs, and high mortality, only associations.  
This relationship warrants further consideration.   
Third, although many important demographic and clinical factors were controlled for in 
this study, there may be residual confounding, such as kidney functioning, inflammatory 
factors (Shlipak, Fried et al. 2003; Go, Chertow et al. 2004), hemoglobin A1c levels 
(Kalantar-Zadeh, Kopple et al. 2007; Shurraw, Majumdar et al. 2010; Williams, Lacson 
et al. 2010), blood pressure readings (Zager, Nikolic et al. 1998; Foley, Herzog et al. 
2002) and cholesterol levels, which all affect patient’ health outcomes.  However, 
sensitivity analyses for all-cause and cardiovascular-related mortality that adjusted for 
additional laboratory values yielded similar findings.  
Fourth, as a general limitation with the use of a claims database, MPR was used as a 
proxy measure of adherence, which could not ascertain that the patients used the 
medications as prescribed, but merely that they had picked up their medication fills or 
refills.  In addition, there is the possibility that MPR calculations might have under- or 
over-estimated adherence.  Patients were classified as using polytherapy (i.e., dual, 
triple, or quad therapy) only during the period when the medications overlapped but 
received monotherapy for the remaining part of the study period.  This might have 
underestimated adherence measures.  Patients classified as using monotherapy may have 
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received two different drugs in the same class of medication (e.g., 2 beta-blockers), 
which might have overestimated adherence measures.   
Fifth, patients may have filled prescriptions outside the Part D benefit.  To what extent 
dialysis patients fill prescriptions outside of their Part D plans is unknown, (Frankenfield, 
Howell et al. 2011) but inclusion/exclusion criteria in this study probably were 
conservative.  Patients were excluded if they were dual-eligible, received a retiree drug 
subsidy, or were on an employer-sponsored health benefit plans.  
Lastly, patients’ out-of-pocket drug spending in 2007 was used to categorize patients into 
the 4 cohorts.  Our findings were from the 2007 of Part D, and extrapolation to another 
year or generalization to dialysis patients not enrolled in Part D may not be appropriate.   
 
4.7 Study Implications and Future Research 
To control prescription drug costs, health plans and employers have increased 
prescription drug cost sharing amounts for patients.  For Medicare as well as other 
payers, determining ways to control and pay drug costs is an ongoing concern. (Hsu, 
Fung et al. 2008)  In comparison with commercial insurance, Part D benefits use 
complex and high levels of cost sharing due to budget constraints, including monthly 
premiums, a deductible, and a coverage gap.  A controversial and unique aspect of the 
Part D benefit design was the donut hole, a gap in coverage of out-of-pocket spending 
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between $799 and $3850, meaning that beneficiaries were responsible for all of their drug 
costs during this gap. (Zhang, Donohue et al. 2009)  To date, the lack of drug coverage 
has been associated with poor outcomes in non-Medicare populations (Tamblyn, Laprise 
et al. 2001; Hsu, Price et al. 2006).  In Medicare populations, the coverage gap has been 
associated with reduced drug adherence. (Raebel, Delate et al. 2008; Schmittdiel, Ettner 
et al. 2009; Zhang, Donohue et al. 2009; Fung, Mangione et al. 2010; Polinski, Shrank et 
al. 2011)  However, there is little information available regarding how and to what 
extent the Part D coverage impacts health outcomes in dialysis patients, although a 
majority of dialysis patients are enrolled in Part D.  We have shown that 60 percent of 
dialysis patients reached the coverage gap after enrollment.  Dialysis patients appear to 
be more vulnerable than the general Medicare population, especially regarding their 
experiences under Medicare Part D.  The findings for this study suggest that the 
coverage gap may adversely affect health outcomes through its effects on drug 
utilization.  Considering the substantial impact that drug policy can have on patient’s 
health, there is a need for more studies on the outcomes associated with the coverage gap 
and, possibly, to modify cost sharing policies for drugs used by dialysis patients.  
 
4.8 Conclusions and Future Research  
In conclusion, reaching the Part D coverage gap was associated with decreased 
medication adherence and unfavorable clinical and economic outcomes in dialysis 
patients.  The coverage gap was associated with increased out-of-pocket spending, 
295 
decreased drug adherence, decreased pharmacy costs, increased medical service 
utilization and costs, increased total health care costs, increased incident CVD, increased 
all-cause and CVD-related mortality among dialysis patients with Part A, B and D 
benefits.   
Several areas deserve attention in future research.  Since the associations between Part 
D coverage and medication adherence for patients in cohort 2 was measured in this study, 
future studies can focus on medication adherence for patients in cohort 3 who went 
through the coverage gap and reached the catastrophic coverage phase.  Further study is 
warranted to delineate patients’ medication taking behaviors by the Part D coverage 
phases (i.e., initial coverage, coverage gap, and catastrophic coverage gap phases).  In 
addition, we only examined the 1- year follow-up period for medication adherence, 
medical service utilization and costs, and incident CVD.  Because the Part D coverage 
resets on January 1 each year, it is not feasible to measure medication adherence longer 
than 1-year for patients with Part D benefits.  However, repeated exposure to Part D 
coverage for multiple years may confirm our findings.  Additional research is needed to 
shed light on how repeated exposure to the Part D coverage gap impacts health outcomes 
in dialysis patients.  
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Appendices 
Appendix A   List of Acronyms 
 
BUN – Blood Urea Nitrogen 
CCI - Charlson Comorbidity Index  
CKD-MBD – Chronic Kidney Disease –Mineral and Bone Disorder 
CMS – Centers for Medicare & Medicaid 
DOPPS - Dialysis Outcomes and Practice Patterns Study 
HDL – High Density Lipoprotein 
HIE – Health Insurance Experiment 
IRB – Institutional Review Board 
KDIGO – Kidney Disease Improving Global Outcomes 
KDOQI - Kidney Disease Outcomes Quality Initiative 
LDL - Low Density Lipoprotein 
LIS – Low Income Subsidy 
MPR – Medication Possession Ratio 
MAPDs- Medicare Advantage prescription drug plans 
MCBS – Medicare Current beneficiary Survey 
MSP – Medicare as Secondary Payer 
NIDDK – National Institute of Diabetes and Digestive and Kidney Diseases 
NKF - National Kidney Foundation 
PDPs – stand-alone prescription drug plans 
PMMIS – Program Management and Medical Information System 
PTH – Parathyroid hormone 
REBUS – Renal Beneficiary and Utilization System 
SAFs – Standard Analytical Files 
USRDS – United States Renal Data System  
UNOS – United Network for Organ Sharing 
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Appendix B   ICD-9 Codes for Cardiovascular Disease 
Cardiovascular disease ICD-9-CM CPT 
Atrial fibrillation (AF) 427.3  
Acute myocardial 
infarction (AMI) 
410, 410.x0, and 410.x1  
Congestive heart failure 
(CHF) 
398.91, 425.x, 428.xx, 
402.x1, 404.x1, and 404.x3 
 
Cerebrovascular 
accident/transient ischemic 
attack (CVA/TIA) 
430–437  
Peripheral arterial disease 
(PAD) 
440–444, 447, and 557 
(ICD-9-CM diagnosis 
codes); 84.0, 84.1, 84.91, 
39.25, 39.26, and 39.29 
(ICD-9-CM procedure 
codes) 
24900, 24920, 25900, 25905, 25920, 
25927, 27295, 27590, 27591, 27592, 
27598, 27880, 27881, 27882, 27888, 
27889, 28800, 28805, 34900, 35131, 
35132, 35141, 35142, 35151, 35152, 
34051, 34151, 34201, 34203, 34800–
34834, 35081–35103, 35331, 35341, 
35351, 35355, 35361, 35363, 35371, 
35372, 35381, 35450, 35452, 35454, 
35456, 35459, 35470, 35471, 35472, 
35473, 35474, 35480, 35481, 35482, 
35483, 35485, 35490, 35491, 35492, 
35493, 35495, 35521, 35531, 35533, 
35541, 35546, 35548, 35549, 35551, 
35556, 35558, 35563, 35565, 35566, 
35571, 35583, 35585, 35587, 35621, 
35623, 35646, 35647, 35651, 35654, 
35656, 35661, 35663, 35665, 35666, 
and 35671 
Coronary artery bypass 
graft surgery (CABG) 
36.1x (ICD-9-CM 
procedure codes) 
33510–33523 and 33533–33536 
Use of an implantable 
cardioverter defibrillator 
(ICD) 
37.94 (ICD-9-CM 
procedure code) 
 
Use of cardiac 
resynchronization therapy 
with defibrillator (CRT-D) 
00.51 (ICD-9-CM 
procedure code) 
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Appendix C1  Medication Persistence (Mean Days Until First a 60-day Treatment Gap) by Five Therapeutic 
Classes of Outpatient Prescription Drugs among Cohorts (N=11732) 
 
Medication persistence (60 days) 
Cohort 1 
(n=3678) 
Cohort 2 
(n=4349) 
Cohort 3 
(n=1310) 
Cohort 4 
(n=2395) 
F-
value 
p-
value 
Mean SD Mean SD Mean SD Mean SD     
Antidiabetic drugs (n=3819)                     
persistence (Mean, SD) 191.40 130.67 220.16 128.51 259.06 121.28 223.20 132.96 30.09 <.0001 
Antihypertensive drugs (n=9863) 2975   3976   1189   2133       
persistence (Mean, SD) 254.12 124.61 304.54 99.16 320.34 87.16 290.65 111.29 155.44 <.0001 
Lipid-lowering drugs (n=4607) 922   2119   746   820       
persistence (Mean, SD) 222.70 123.68 258.71 114.69 297.45 98.35 254.31 120.14 58.33 <.0001 
Phosphate binders (n=7753) 1729   3185   1151   1688       
persistence (Mean, SD) 158.70 119.40 204.74 120.97 258.02 118.52 203.09 131.30 152.57 <.0001 
Cinacalcet (n=2436) 261   854   606   718       
persistence (Mean, SD) 136.62 105.98 171.47 111.07 244.68 119.36 202.88 125.91 70.48 <.0001 
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Appendix C2  Number of Patients with a 60-day Treatment Gap (Discontinuation) by Five Therapeutic Classes 
of Outpatient Prescription Drugs among Cohorts (N=11732) 
 
Medication persistence (60 days) 
Cohort 1  
(n=3678) 
Cohort 2  
(n=4349) 
Cohort 3  
(n=1310) 
Cohort 4  
(n=2395) Test 
statistics 
p-
value 
N % N % N % N % 
Antidiabetic drugs (n=3819) 851   1630   523   815       
Discontinuation (N, %) 583 68.51 1089 66.81 259 49.52 481 59.02 17.37 0.0006 
Antihypertensive drugs (n=9863) 2975   3976   1189   2133       
Discontinuation (N, %) 1346 48.56 1264 32.72 272 23.31 728 35.32 286.15 <.0001 
Lipid-lowering drugs (n=4607) 922   2119   746   820       
Discontinuation (N, %) 524 56.83 1066 50.31 246 32.98 372 45.37 103.08 <.0001 
Phosphate binders (n=7753) 1729   3185   1151   1688       
Discontinuation (N, %) 1401 81.03 2365 74.25 590 51.26 1149 68.07 325.76 <.0001 
Cinacalcet (n=2436) 261   854   606   718       
Discontinuation (N, %) 198 75.86 643 75.29 257 42.41 413 57.52 190.07 <.0001 
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Appendix C3  Cox Proportional Hazards Regression Model Comparing 
Therapy Discontinuation for Antihyperglycemic Drugs with a 60-day Treatment 
Gap among Cohorts while Controlling for Covariates (N=3819) 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
p-value 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits 
Cohort a 
1 0.379 0.065 34.380 <.0001 1.461 1.287 - 1.658 
2 0.234 0.059 15.822 <.0001 1.263 1.126 - 1.418 
3 -0.249 0.080 9.711 0.002 0.779 0.666 - 0.912 
Age -0.004 0.002 3.612 0.057 0.996 0.992 - 1.000 
Gender b Female 0.073 0.042 3.128 0.077 1.076 0.992 - 1.167 
Race c 
White -0.222 0.048 21.357 <.0001 0.801 0.728 - 0.880 
Other -0.256 0.118 4.681 0.031 0.774 0.614 - 0.976 
Region of 
residence d 
Northeast  0.012 0.060 0.039 0.844 1.012 0.899 - 1.139 
South 0.038 0.056 0.470 0.493 1.039 0.932 - 1.159 
West -0.079 0.078 1.020 0.313 0.924 0.793 - 1.077 
ESRD duration 0.021 0.007 8.787 0.003 1.022 1.007 - 1.036 
Primary 
disease 
causing ESRD 
e 
Hypertension -0.080 0.066 1.504 0.220 0.923 0.811 - 1.049 
Glomerulonephritis 0.059 0.156 0.141 0.707 1.060 0.781 - 1.439 
Cystic Kidney -0.253 0.356 0.506 0.477 0.776 0.386 - 1.560 
Other  -0.059 0.102 0.333 0.564 0.943 0.771 - 1.152 
Charlson Comorbidity Index (CCI) 
score 
0.102 0.022 22.011 <.0001 1.107 1.061 - 1.155 
Presence of 
chronic 
disease  
Diabetes mellitus -0.146 0.079 3.404 0.065 0.864 0.740 - 1.009 
Hypertension -0.023 0.044 0.273 0.602 0.977 0.896 - 1.065 
Dyslipidemia 0.061 0.057 1.153 0.283 1.063 0.951 - 1.188 
Cancer -0.280 0.111 6.410 0.011 0.756 0.609 - 0.939 
Chronic lung disease -0.046 0.060 0.582 0.446 0.955 0.849 - 1.075 
Cardiovascular 
disease 
0.028 0.058 0.239 0.625 1.029 0.919 - 1.152 
Model parameters: Likelihood Ratio = 187.32; d.f.=22; p<0.0001; Score = 187.27; d.f.=22; p<0.0001; Wald = 185.66; d.f.=22; p< 
0.0001. 
a Reference: Cohort 4 
b Reference : Male 
c Reference: Black 
d Reference : Midwest 
e Reference : Diabetes mellitus 
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Appendix C4  Cox Proportional Hazards Regression Model Comparing 
Therapy Discontinuation for Antihypertensive Drugs with a 60-day Treatment 
Gap among Cohorts while Controlling for Covariates (N=9863) 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
p-value 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits 
Cohort a 
1 0.599 0.048 155.944 <.0001 1.821 1.658 - 2.001 
2 0.045 0.050 0.821 0.365 1.046 0.949 - 1.154 
3 -0.364 0.073 24.598 <.0001 0.695 0.602 - 0.802 
Age -0.010 0.001 45.244 <.0001 0.990 0.987 - 0.993 
Gender b Female -0.112 0.034 10.631 0.001 0.894 0.836 - 0.956 
Race c 
White -0.184 0.039 22.596 <.0001 0.832 0.771 - 0.898 
Other -0.224 0.101 4.944 0.026 0.799 0.656 - 0.974 
Region of 
residence d 
Northeast  0.057 0.050 1.309 0.253 1.059 0.960 - 1.168 
South 0.083 0.047 3.163 0.075 1.086 0.992 - 1.190 
West 0.010 0.066 0.021 0.885 1.010 0.888 - 1.148 
ESRD duration 0.022 0.004 25.973 <.0001 1.022 1.013 - 1.030 
Primary 
disease 
causing ESRD 
e 
Hypertension -0.083 0.047 3.080 0.079 0.920 0.839 - 1.010 
Glomerulonephritis -0.065 0.066 0.963 0.326 0.937 0.823 - 1.067 
Cystic Kidney 0.064 0.108 0.354 0.552 1.066 0.863 - 1.318 
Other  0.009 0.061 0.023 0.880 1.009 0.895 - 1.138 
Charlson Comorbidity Index (CCI) 
score 
0.061 0.019 10.900 0.001 1.063 1.025 - 1.103 
Presence of 
chronic 
disease  
Diabetes mellitus 0.001 0.053 0.001 0.978 1.001 0.903 - 1.110 
Hypertension -0.097 0.036 7.267 0.007 0.907 0.845 - 0.974 
Dyslipidemia 0.061 0.050 1.484 0.223 1.062 0.964 - 1.171 
Cancer -0.206 0.084 6.000 0.014 0.814 0.690 - 0.960 
Chronic lung disease -0.003 0.048 0.005 0.945 0.997 0.907 - 1.096 
Cardiovascular 
disease 
0.031 0.046 0.461 0.497 1.032 0.943 - 1.128 
Model parameters: Likelihood Ratio = 579.49; d.f.=22; p<0.0001; Score = 606.39; d.f.=22; p<0.0001; Wald = 589.80; d.f.=22; p< 
0.0001. 
a Reference: Cohort 4 
b Reference : Male 
c Reference: Black 
d Reference : Midwest 
e Reference : Diabetes mellitus 
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Appendix C5  Cox Proportional Hazards Regression Model Comparing 
Therapy Discontinuation for Lipid-lowering Drugs with a 60-day Treatment 
Gap among Cohorts while Controlling for Covariates (N=4607) 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
p-value 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits 
Cohort a 
1 0.607 0.072 72.091 <.0001 1.835 1.595 - 2.111 
2 0.323 0.065 24.925 <.0001 1.381 1.216 - 1.567 
3 -0.297 0.085 12.217 0.001 0.743 0.629 - 0.878 
Age -0.015 0.002 48.243 <.0001 0.985 0.981 - 0.989 
Gender b Female 0.010 0.044 0.052 0.821 1.010 0.927 - 1.100 
Race c 
White -0.287 0.052 30.747 <.0001 0.751 0.678 - 0.831 
Other -0.147 0.127 1.346 0.246 0.863 0.673 - 1.107 
Region of 
residence d 
Northeast  0.012 0.062 0.039 0.843 1.012 0.896 - 1.144 
South 0.132 0.059 4.979 0.026 1.142 1.016 - 1.282 
West -0.054 0.082 0.436 0.509 0.947 0.806 - 1.113 
ESRD duration -0.007 0.007 1.127 0.288 0.993 0.980 - 1.006 
Primary disease 
causing ESRD e 
Hypertension -0.024 0.060 0.164 0.686 0.976 0.868 - 1.098 
Glomerulonephritis -0.029 0.093 0.100 0.752 0.971 0.809 - 1.165 
Cystic Kidney 0.226 0.145 2.427 0.119 1.254 0.943 - 1.667 
Other  0.038 0.080 0.230 0.631 1.039 0.889 - 1.215 
Charlson Comorbidity Index (CCI) 
score 
0.019 0.024 0.649 0.421 1.020 0.973 - 1.069 
Presence of 
chronic disease  
Diabetes mellitus 0.031 0.067 0.213 0.645 1.032 0.904 - 1.177 
Hypertension -0.083 0.046 3.285 0.070 0.921 0.842 - 1.007 
Dyslipidemia 0.037 0.053 0.495 0.482 1.038 0.935 - 1.152 
Cancer -0.138 0.104 1.746 0.186 0.871 0.710 - 1.069 
Chronic lung 
disease 
0.031 0.061 0.250 0.617 1.031 0.915 - 1.162 
Cardiovascular 
disease 
0.170 0.060 8.077 0.005 1.185 1.054 - 1.332 
Model parameters: Likelihood Ratio = 294.35; d.f.=22; p<0.0001; Score = 292.26; d.f.=22; p<0.0001; Wald = 286.55; d.f.=22; p< 
0.0001. 
a Reference: Cohort 4 
b Reference : Male 
c Reference: Black 
d Reference : Midwest 
e Reference : Diabetes mellitus 
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Appendix C6  Cox Proportional Hazards Regression Model Comparing 
Therapy Discontinuation for Phosphate Binders with a 60-day Treatment Gap 
among Cohorts while Controlling for Covariates (N=7753) 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
p-value 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits 
Cohort a 
1 0.605 0.042 203.673 <.0001 1.832 1.686 - 1.990 
2 0.290 0.040 52.918 <.0001 1.337 1.236 -1.446 
3 -0.357 0.053 44.457 <.0001 0.700 0.630 - 0.777 
Age -0.007 0.001 30.903 <.0001 0.993 0.991 - 0.996 
Gender b Female 0.062 0.028 5.045 0.025 1.064 1.008 - 1.123 
Race c 
White -0.303 0.032 87.938 <.0001 0.738 0.693 - 0.787 
Other -0.441 0.080 30.157 <.0001 0.643 0.549 - 0.753 
Region of 
residence d 
Northeast  -0.081 0.040 4.122 0.042 0.922 0.852 - 0.997 
South 0.071 0.038 3.544 0.060 1.074 0.997 - 1.157 
West -0.011 0.053 0.042 0.837 0.989 0.892 - 1.097 
ESRD duration 0.004 0.004 1.439 0.230 1.004 0.997 - 1.011 
Primary 
disease 
causing ESRD 
e 
Hypertension -0.020 0.038 0.276 0.599 0.980 0.909 - 1.057 
Glomerulonephritis -0.014 0.053 0.066 0.797 0.986 0.888 - 1.095 
Cystic Kidney -0.010 0.088 0.013 0.908 0.990 0.833 - 1.176 
Other  0.013 0.048 0.073 0.788 1.013 0.922 - 1.114 
Charlson Comorbidity Index (CCI) 
score 
0.018 0.015 1.430 0.232 1.018 0.988 - 1.049 
Presence of 
chronic 
disease  
Diabetes mellitus 0.003 0.043 0.006 0.939 1.003 0.923 - 1.091 
Hypertension -0.021 0.030 0.524 0.469 0.979 0.924 - 1.037 
Dyslipidemia 0.009 0.041 0.051 0.821 1.009 0.931 - 1.094 
Cancer -0.024 0.065 0.131 0.718 0.977 0.859 - 1.110 
Chronic lung disease 0.042 0.039 1.114 0.291 1.042 0.965 - 1.126 
Cardiovascular 
disease 
0.081 0.037 4.890 0.027 1.085 1.009 - 1.166 
Model parameters: Likelihood Ratio = 663.76; d.f.=22; p<0.0001; Score = 663.62; d.f.=22; p<0.0001; Wald = 644.35; d.f.=22; p< 
0.0001. 
a Reference: Cohort 4 
 b Reference : Male 
 c Reference: Black 
 d Reference : Midwest 
 e Reference : Diabetes mellitus 
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Appendix C7  Cox Proportional Hazards Regression Model Comparing 
Therapy Discontinuation for Cinacalcet with a 60-day Treatment Gap among 
Cohorts while Controlling for Covariates (N=2436) 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
p-value 
Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits 
Cohort a 
1 0.835 0.091 84.677 <.0001 2.305 1.929 - 2.754 
2 0.603 0.069 76.266 <.0001 1.827 1.596 - 2.092 
3 -0.317 0.086 13.528 0.000 0.729 0.615 - 0.863 
Age -0.007 0.002 9.344 0.002 0.993 0.989 - 0.997 
Gender b Female 0.062 0.053 1.367 0.242 1.064 0.959 - 1.180 
Race c 
White -0.182 0.059 9.503 0.002 0.834 0.743 - 0.936 
Other 0.042 0.156 0.072 0.789 1.043 0.767 - 1.417 
Region of 
residence d 
Northeast  -0.077 0.081 0.900 0.343 0.926 0.789 - 1.086 
South 0.110 0.078 2.018 0.155 1.117 0.959 - 1.300 
West -0.122 0.109 1.254 0.263 0.885 0.714 - 1.096 
ESRD duration 0.002 0.006 0.059 0.808 1.001 0.990 - 1.014 
Primary 
disease 
causing ESRD 
e 
Hypertension 0.095 0.075 1.589 0.208 1.100 0.949 - 1.275 
Glomerulonephritis -0.204 0.100 4.158 0.041 0.815 0.670 - 0.992 
Cystic Kidney 0.191 0.140 1.881 0.170 1.211 0.921 - 1.592 
Other  -0.028 0.096 0.082 0.774 0.973 0.805 - 1.175 
Charlson Comorbidity Index (CCI) 
score 
-0.015 0.031 0.223 0.637 0.985 0.927 - 1.047 
Presence of 
chronic 
disease  
Diabetes mellitus 0.119 0.085 1.928 0.165 1.126 0.952 - 1.331 
Hypertension -0.045 0.057 0.607 0.436 0.956 0.855 - 1.070 
Dyslipidemia -0.021 0.084 0.062 0.803 0.979 0.830 - 1.155 
Cancer -0.112 0.132 0.723 0.395 0.894 0.689 - 1.158 
Chronic lung disease 0.004 0.081 0.002 0.962 1.004 0.856 - 1.177 
Cardiovascular 
disease 
0.098 0.070 1.964 0.161 1.103 0.961 - 1.266 
Model parameters: Likelihood Ratio = 300.10; d.f.=22; p<0.0001; Score = 299.50; d.f.=22; p<0.0001; Wald = 285.20; d.f.=22; p< 
0.0001. 
a Reference: Cohort 4 
  b Reference : Male 
  c Reference: Black 
  d Reference : Midwest 
  e Reference : Diabetes mellitus 
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Appendix D1  Zero-Inflated Poission Regression Model Comparing Total 
Inpatient Visits during 2007 among Cohorts 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
z p-value 
95% Confidence 
Interval 
Intercept 1.101 0.066 16.570 0.000 0.971 1.231 
Cohort a 
1 -0.042 0.025 -1.670 0.095 -0.091 0.007 
2 0.028 0.024 1.170 0.242 -0.019 0.076 
3 -0.037 0.032 -1.140 0.256 -0.100 0.026 
Age -0.006 0.001 -7.460 0.000 -0.007 -0.004 
Gender b Female -0.021 0.017 -1.210 0.227 -0.054 0.013 
Race c 
White -0.038 0.020 -1.890 0.058 -0.077 0.001 
Other -0.138 0.052 -2.650 0.008 -0.241 -0.036 
Region of 
residence d 
Northeast  0.051 0.024 2.150 0.032 0.004 0.098 
South -0.022 0.023 -0.980 0.327 -0.067 0.022 
West 0.003 0.033 0.080 0.937 -0.061 0.067 
ESRD duration -0.004 0.002 -1.650 0.099 -0.009 0.001 
Primary 
disease 
causing 
ESRD e 
Hypertension 0.031 0.024 1.320 0.185 -0.015 0.078 
Glomerulonephritis 0.045 0.034 1.310 0.190 -0.022 0.112 
Cystic Kidney 0.081 0.057 1.420 0.156 -0.031 0.193 
Other  0.015 0.030 0.490 0.626 -0.045 0.075 
Charlson Comorbidity Index 
(CCI) score 0.090 0.008 11.220 0.000 0.074 0.105 
Presence of 
chronic 
disease  
Diabetes mellitus -0.012 0.026 -0.480 0.630 -0.063 0.038 
Hypertension -0.002 0.018 -0.130 0.898 -0.037 0.032 
Dyslipidemia 0.058 0.023 2.520 0.012 0.013 0.103 
Cancer -0.196 0.037 -5.250 0.000 -0.269 -0.122 
Chronic lung 
disease 0.066 0.021 3.170 0.002 0.025 0.107 
Cardiovascular 
disease -0.126 0.023 -5.410 0.000 -0.172 -0.080 
Inflate             
Intercept -0.225 0.197 -1.140 0.254 -0.610 0.161 
Cohort a 
1 -0.096 0.072 -1.330 0.182 -0.238 0.045 
2 -0.248 0.073 -3.390 0.001 -0.391 -0.105 
3 -0.133 0.099 -1.350 0.177 -0.327 0.060 
Age -0.006 0.002 -2.630 0.009 -0.010 -0.001 
Gender b Female 0.147 0.053 2.790 0.005 0.044 0.250 
Race c 
White 0.004 0.061 0.060 0.950 -0.115 0.123 
Other -0.169 0.162 -1.040 0.297 -0.485 0.148 
Region of Northeast  -0.122 0.076 -1.600 0.110 -0.272 0.027 
306 
residence d South -0.021 0.071 -0.300 0.762 -0.160 0.117 
West -0.021 0.098 -0.210 0.831 -0.213 0.171 
ESRD duration -0.009 0.007 -1.230 0.220 -0.022 0.005 
Primary 
disease 
causing 
ESRD e 
Hypertension 0.078 0.072 1.080 0.279 -0.063 0.220 
Glomerulonephritis 0.084 0.100 0.850 0.397 -0.111 0.279 
Cystic Kidney 0.280 0.154 1.820 0.068 -0.021 0.582 
Other  0.107 0.091 1.180 0.238 -0.071 0.286 
Charlson Comorbidity Index 
(CCI) score -0.131 0.031 -4.170 0.000 -0.192 -0.069 
Presence of 
chronic 
disease  
Diabetes mellitus 0.055 0.082 0.660 0.507 -0.107 0.216 
Hypertension -0.116 0.057 -2.040 0.041 -0.226 -0.005 
Dyslipidemia -0.035 0.079 -0.440 0.661 -0.190 0.121 
Cancer 0.005 0.133 0.040 0.970 -0.256 0.266 
Chronic lung 
disease -0.215 0.078 -2.770 0.006 -0.367 -0.063 
Cardiovascular 
disease 0.411 0.071 5.780 0.000 0.272 0.551 
 
Model parameters: Inflation model=logit; Log Likelihood = -20905.28; LR chi2 725.45; p<0.0001. 
a Reference: Cohort 4 
   b Reference : Male 
   c Reference: Black 
   d Reference : Midwest 
   e Reference : Diabetes mellitus 
   
Vuong test of zip vs. standard Poisson:            z =    22.20  Pr>z = 0.0000 
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Appendix D2  Zero-Inflated Poission Regression Model Comparing Total 
Outpatient Visits during 2007 among Cohorts 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
z p-value 
95% Confidence 
Interval 
Intercept 2.183 0.027 80.100 0.000 2.130 2.237 
Cohort a 
1 0.048 0.011 4.540 0.000 0.028 0.069 
2 0.147 0.010 14.200 0.000 0.127 0.168 
3 0.136 0.013 10.390 0.000 0.110 0.162 
Age -0.005 0.000 -15.080 0.000 -0.005 -0.004 
Gender b Female -0.014 0.007 -2.060 0.039 -0.028 -0.001 
Race c 
White 0.121 0.009 14.090 0.000 0.104 0.138 
Other -0.018 0.021 -0.840 0.399 -0.060 0.024 
Region of 
residence d 
Northeast  -0.127 0.009 -13.670 0.000 -0.145 -0.109 
South -0.308 0.009 -34.030 0.000 -0.326 -0.290 
West -0.177 0.012 -14.330 0.000 -0.202 -0.153 
ESRD duration -0.001 0.001 -1.430 0.153 -0.003 0.000 
Primary 
disease 
causing 
ESRD e 
Hypertension -0.018 0.010 -1.820 0.069 -0.037 0.001 
Glomerulonephritis 0.047 0.013 3.460 0.001 0.020 0.073 
Cystic Kidney 0.112 0.021 5.240 0.000 0.070 0.153 
Other  0.117 0.012 9.950 0.000 0.094 0.140 
Charlson Comorbidity Index 
(CCI) score 0.053 0.003 15.570 0.000 0.046 0.060 
Presence of 
chronic 
disease  
Diabetes mellitus 0.052 0.010 4.960 0.000 0.031 0.072 
Hypertension 0.201 0.007 28.130 0.000 0.187 0.215 
Dyslipidemia 0.111 0.009 11.820 0.000 0.092 0.129 
Cancer 0.129 0.015 8.900 0.000 0.101 0.158 
Chronic lung 
disease -0.002 0.009 -0.270 0.786 -0.020 0.016 
Cardiovascular 
disease -0.091 0.009 -9.910 0.000 -0.109 -0.073 
Inflate             
Intercept -1.769 0.272 -6.510 0.000 -2.301 -1.236 
Cohort a 
1 0.154 0.098 1.580 0.115 -0.037 0.346 
2 -0.181 0.104 -1.750 0.081 -0.385 0.022 
3 0.017 0.135 0.130 0.897 -0.248 0.283 
Age -0.006 0.003 -2.200 0.028 -0.012 -0.001 
Gender b Female 0.233 0.072 3.220 0.001 0.091 0.375 
Race c 
White 0.078 0.083 0.940 0.349 -0.085 0.241 
Other 0.259 0.184 1.410 0.159 -0.102 0.621 
Region of Northeast  0.607 0.111 5.450 0.000 0.388 0.825 
308 
residence d South 0.426 0.108 3.950 0.000 0.214 0.637 
West 0.446 0.136 3.270 0.001 0.179 0.712 
ESRD duration -0.007 0.009 -0.800 0.424 -0.024 0.010 
Primary 
disease 
causing 
ESRD e 
Hypertension -0.176 0.098 -1.800 0.072 -0.369 0.016 
Glomerulonephritis -0.501 0.138 -3.630 0.000 -0.771 -0.231 
Cystic Kidney -0.677 0.244 -2.770 0.006 -1.155 -0.198 
Other  -0.210 0.121 -1.730 0.083 -0.447 0.028 
Charlson Comorbidity Index 
(CCI) score -0.139 0.051 -2.740 0.006 -0.238 -0.040 
Presence of 
chronic 
disease  
Diabetes mellitus -0.383 0.120 -3.180 0.001 -0.618 -0.147 
Hypertension -0.560 0.086 -6.500 0.000 -0.729 -0.391 
Dyslipidemia -0.432 0.136 -3.170 0.002 -0.699 -0.165 
Cancer -0.478 0.222 -2.150 0.031 -0.914 -0.043 
Chronic lung 
disease -0.244 0.123 -1.980 0.048 -0.486 -0.002 
Cardiovascular 
disease 0.157 0.102 1.540 0.124 -0.043 0.357 
 
Model parameters: Inflation model=logit; Log Likelihood = -54619.76; LR chi2 7073.80; p<0.0001. 
a Reference: Cohort 4 
    b Reference : Male 
    c Reference: Black 
    d Reference : Midwest 
    e Reference : Diabetes mellitus 
    
Vuong test of zip vs. standard Poisson:            z =    22.21  Pr>z = 0.0000 
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Appendix D3  Zero-Inflated Poission Regression Model Comparing Total 
Other Medical Service Utilization during 2007 among Cohorts  
 
Variable 
Parameter 
Estimate 
Standard 
Error 
z p-value 
95% Confidence 
Interval 
Intercept 0.575 0.084 6.810 0.000 0.410 0.741 
Cohort a 
1 0.096 0.029 3.300 0.001 0.039 0.154 
2 0.057 0.028 2.010 0.044 0.001 0.113 
3 -0.004 0.037 -0.110 0.913 -0.077 0.069 
Age 0.004 0.001 4.670 0.000 0.003 0.006 
Gender b Female -0.102 0.019 -5.380 0.000 -0.139 -0.065 
Race c 
White 0.060 0.023 2.650 0.008 0.015 0.104 
Other -0.097 0.072 -1.350 0.177 -0.239 0.044 
Region of 
residence d 
Northeast  -0.039 0.028 -1.420 0.156 -0.093 0.015 
South 0.166 0.025 6.640 0.000 0.117 0.215 
West -0.084 0.039 -2.150 0.031 -0.161 -0.008 
ESRD duration 0.003 0.003 0.990 0.322 -0.003 0.008 
Primary 
disease 
causing 
ESRD e 
Hypertension -0.066 0.026 -2.490 0.013 -0.117 -0.014 
Glomerulonephritis -0.147 0.044 -3.350 0.001 -0.233 -0.061 
Cystic Kidney 0.011 0.064 0.160 0.870 -0.115 0.136 
Other  -0.074 0.036 -2.080 0.037 -0.144 -0.004 
Charlson Comorbidity Index 
(CCI) score 0.059 0.009 6.620 0.000 0.041 0.076 
Presence of 
chronic 
disease  
Diabetes mellitus 0.022 0.030 0.710 0.476 -0.038 0.081 
Hypertension 0.136 0.020 6.940 0.000 0.097 0.174 
Dyslipidemia 0.011 0.025 0.440 0.658 -0.038 0.061 
Cancer -0.198 0.043 -4.620 0.000 -0.281 -0.114 
Chronic lung 
disease -0.011 0.024 -0.480 0.635 -0.058 0.036 
Cardiovascular 
disease -0.096 0.027 -3.610 0.000 -0.148 -0.044 
Inflate             
Intercept 3.074 0.181 16.970 0.000 2.718 3.429 
Cohort a 
1 -0.021 0.064 -0.330 0.741 -0.147 0.105 
2 -0.156 0.064 -2.450 0.014 -0.280 -0.031 
3 -0.046 0.083 -0.550 0.581 -0.208 0.117 
Age -0.029 0.002 -13.960 0.000 -0.033 -0.025 
Gender b Female 0.228 0.043 5.280 0.000 0.143 0.312 
Race c 
White 0.048 0.052 0.920 0.357 -0.054 0.150 
Other 0.474 0.140 3.390 0.001 0.200 0.748 
Region of Northeast  -0.168 0.062 -2.700 0.007 -0.290 -0.046 
310 
residence d South -0.257 0.058 -4.410 0.000 -0.371 -0.143 
West -0.008 0.082 -0.100 0.920 -0.169 0.152 
ESRD duration -0.014 0.006 -2.350 0.019 -0.025 -0.002 
Primary 
disease 
causing 
ESRD e 
Hypertension 0.186 0.060 3.100 0.002 0.069 0.304 
Glomerulonephritis 0.196 0.088 2.230 0.026 0.023 0.369 
Cystic Kidney 0.064 0.138 0.460 0.644 -0.207 0.335 
Other  0.123 0.077 1.610 0.108 -0.027 0.274 
Charlson Comorbidity Index 
(CCI) score -0.215 0.023 -9.180 0.000 -0.261 -0.169 
Presence of 
chronic 
disease  
Diabetes mellitus -0.035 0.067 -0.530 0.599 -0.166 0.096 
Hypertension -0.281 0.045 -6.270 0.000 -0.369 -0.193 
Dyslipidemia -0.078 0.062 -1.260 0.208 -0.199 0.043 
Cancer 0.455 0.102 4.480 0.000 0.256 0.654 
Chronic lung 
disease 0.140 0.060 2.340 0.019 0.023 0.256 
Cardiovascular 
disease 0.227 0.058 3.920 0.000 0.114 0.341 
 
Model parameters: Inflation model=logit; Log Likelihood  = -16515.78; LR chi2 525.79; p<0.0001. 
a Reference: Cohort 4 
b Reference : Male 
c Reference: Black 
d Reference : Midwest 
e Reference : Diabetes mellitus 
 
Vuong test of zip vs. standard Poisson:            z =    31.24  Pr>z = 0.0000 
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Appendix D4  Zero-Inflated Poission Regression Model Comparing 
Cardiovascular-related Inpatient Visits during 2007 among Cohorts  
 
Variable 
Parameter 
Estimate 
Standard 
Error 
z p-value 
95% Confidence 
Interval 
Intercept 0.579 0.126 4.610 0.000 0.333 0.826 
Cohort a 
1 -0.030 0.046 -0.660 0.508 -0.119 0.059 
2 0.033 0.044 0.750 0.455 -0.053 0.118 
3 -0.067 0.058 -1.150 0.249 -0.182 0.047 
Age -0.005 0.001 -3.460 0.001 -0.008 -0.002 
Gender b Female -0.042 0.031 -1.360 0.173 -0.103 0.019 
Race c 
White -0.057 0.036 -1.590 0.112 -0.128 0.013 
Other -0.183 0.098 -1.880 0.061 -0.375 0.008 
Region of 
residence d 
Northeast  0.054 0.043 1.250 0.210 -0.030 0.138 
South -0.062 0.042 -1.500 0.134 -0.144 0.019 
West -0.028 0.060 -0.470 0.638 -0.145 0.089 
ESRD duration -0.006 0.005 -1.170 0.243 -0.015 0.004 
Primary 
disease 
causing 
ESRD e 
Hypertension 0.053 0.042 1.260 0.209 -0.030 0.136 
Glomerulonephritis 0.090 0.062 1.440 0.150 -0.032 0.213 
Cystic Kidney 0.069 0.108 0.640 0.523 -0.143 0.281 
Other  -0.031 0.058 -0.540 0.591 -0.144 0.082 
Charlson Comorbidity Index 
(CCI) score 0.088 0.014 6.170 0.000 0.060 0.115 
Presence of 
chronic 
disease  
Diabetes mellitus -0.066 0.047 -1.410 0.160 -0.157 0.026 
Hypertension -0.030 0.032 -0.940 0.347 -0.092 0.032 
Dyslipidemia 0.114 0.040 2.870 0.004 0.036 0.192 
Cancer -0.146 0.065 -2.230 0.025 -0.274 -0.018 
Chronic lung 
disease 0.092 0.036 2.560 0.011 0.021 0.162 
Cardiovascular 
disease -0.265 0.047 -5.620 0.000 -0.357 -0.173 
Inflate             
Intercept 0.833 0.247 3.380 0.001 0.350 1.317 
Cohort a 
1 0.035 0.091 0.390 0.700 -0.143 0.213 
2 -0.127 0.090 -1.410 0.159 -0.305 0.050 
3 -0.094 0.124 -0.760 0.449 -0.338 0.149 
Age -0.013 0.003 -4.550 0.000 -0.018 -0.007 
Gender b Female -0.051 0.065 -0.790 0.432 -0.179 0.076 
Race c 
White -0.094 0.074 -1.260 0.208 -0.239 0.052 
Other -0.164 0.203 -0.810 0.418 -0.562 0.234 
Region of Northeast  -0.173 0.091 -1.890 0.058 -0.352 0.006 
312 
residence d South -0.178 0.087 -2.050 0.040 -0.348 -0.008 
West -0.141 0.123 -1.140 0.253 -0.383 0.101 
ESRD duration 0.000 0.009 -0.030 0.976 -0.017 0.017 
Primary 
disease 
causing 
ESRD e 
Hypertension 0.123 0.089 1.380 0.168 -0.052 0.297 
Glomerulonephritis 0.378 0.120 3.170 0.002 0.144 0.613 
Cystic Kidney 0.430 0.196 2.190 0.028 0.046 0.814 
Other  0.262 0.115 2.280 0.022 0.037 0.486 
Charlson Comorbidity Index 
(CCI) score -0.095 0.034 -2.760 0.006 -0.162 -0.028 
Presence of 
chronic 
disease  
Diabetes mellitus 0.078 0.098 0.800 0.424 -0.114 0.271 
Hypertension -0.044 0.068 -0.650 0.519 -0.178 0.090 
Dyslipidemia 0.076 0.089 0.850 0.394 -0.099 0.251 
Cancer 0.309 0.143 2.160 0.031 0.028 0.589 
Chronic lung 
disease -0.294 0.087 -3.370 0.001 -0.464 -0.123 
Cardiovascular 
disease 0.670 0.089 7.500 0.000 0.495 0.846 
 
Model parameters: Inflation model=logit; Log Likelihood  = -13046.50; LR chi2 
300.23; p<0.0001. 
a Reference: Cohort 4 
    b Reference : Male 
    c Reference: Black 
    d Reference : Midwest 
    e Reference : Diabetes mellitus 
    
Vuong test of zip vs. standard Poisson:            z =    15.47  Pr>z = 0.0000 
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Appendix D5  Zero-Inflated Poission Regression Model Comparing 
Cardiovascular-related Outpatient Visits during 2007 among Cohorts 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
z p-value 
95% Confidence 
Interval 
Intercept 0.377 0.118 3.200 0.001 0.146 0.608 
Cohort a 
1 0.043 0.044 0.990 0.322 -0.042 0.128 
2 0.091 0.042 2.180 0.029 0.009 0.173 
3 0.070 0.053 1.330 0.185 -0.034 0.174 
Age 0.001 0.001 0.470 0.640 -0.002 0.003 
Gender b Female 0.101 0.028 3.590 0.000 0.046 0.157 
Race c 
White 0.015 0.035 0.410 0.681 -0.055 0.084 
Other -0.086 0.092 -0.930 0.354 -0.267 0.096 
Region of 
residence d 
Northeast  -0.012 0.036 -0.350 0.726 -0.082 0.057 
South -0.234 0.036 -6.500 0.000 -0.304 -0.163 
West -0.012 0.051 -0.240 0.811 -0.112 0.088 
ESRD duration -0.010 0.004 -2.190 0.029 -0.019 -0.001 
Primary 
disease 
causing 
ESRD e 
Hypertension -0.004 0.038 -0.090 0.926 -0.078 0.071 
Glomerulonephritis -0.117 0.061 -1.930 0.054 -0.236 0.002 
Cystic Kidney -0.167 0.102 -1.630 0.103 -0.367 0.033 
Other  -0.161 0.053 -3.040 0.002 -0.265 -0.057 
Charlson Comorbidity Index (CCI) 
score 0.042 0.013 3.220 0.001 0.016 0.067 
Presence of 
chronic 
disease  
Diabetes mellitus 0.026 0.042 0.620 0.535 -0.056 0.109 
Hypertension 0.154 0.028 5.450 0.000 0.098 0.209 
Dyslipidemia 0.010 0.036 0.280 0.777 -0.060 0.080 
Cancer -0.140 0.058 -2.420 0.016 -0.254 -0.026 
Chronic lung disease 0.155 0.034 4.600 0.000 0.089 0.220 
Cardiovascular 
disease -0.343 0.044 -7.830 0.000 -0.429 -0.257 
Inflate             
Intercept 0.549 0.214 2.570 0.010 0.131 0.968 
Cohort a 
1 0.168 0.080 2.100 0.036 0.011 0.324 
2 -0.051 0.079 -0.650 0.519 -0.206 0.104 
3 0.089 0.101 0.880 0.377 -0.109 0.288 
Age -0.005 0.002 -2.240 0.025 -0.010 -0.001 
Gender b Female -0.090 0.053 -1.680 0.093 -0.195 0.015 
Race c 
White -0.158 0.065 -2.440 0.015 -0.285 -0.031 
Other 0.021 0.159 0.130 0.894 -0.291 0.333 
Region of Northeast  0.247 0.072 3.450 0.001 0.107 0.387 
314 
residence d South 0.029 0.071 0.410 0.683 -0.111 0.169 
West 0.424 0.094 4.530 0.000 0.240 0.607 
ESRD duration 0.002 0.008 0.300 0.762 -0.013 0.017 
Primary 
disease 
causing 
ESRD e 
Hypertension 0.078 0.072 1.080 0.282 -0.064 0.220 
Glomerulonephritis 0.151 0.108 1.400 0.161 -0.060 0.362 
Cystic Kidney -0.163 0.189 -0.860 0.388 -0.533 0.207 
Other  0.124 0.097 1.280 0.200 -0.066 0.313 
Charlson Comorbidity Index (CCI) 
score -0.136 0.029 -4.740 0.000 -0.193 -0.080 
Presence of 
chronic 
disease  
Diabetes mellitus 0.099 0.082 1.210 0.226 -0.061 0.259 
Hypertension -0.057 0.055 -1.040 0.300 -0.164 0.051 
Dyslipidemia -0.085 0.074 -1.140 0.255 -0.231 0.061 
Cancer 0.182 0.121 1.510 0.132 -0.055 0.418 
Chronic lung disease 0.064 0.070 0.910 0.364 -0.074 0.202 
Cardiovascular 
disease 0.545 0.075 7.290 0.000 0.399 0.692 
 
Model parameters: Inflation model=logit; Log Likelihood  = -14192.85; LR chi2 514.57; 
p<0.0001. 
a Reference: Cohort 4 
  b Reference : Male 
  c Reference: Black 
  d Reference : Midwest 
  e Reference : Diabetes mellitus 
  
Vuong test of zip vs. standard Poisson:            z =    12.65  Pr>z = 0.0000 
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Appendix D6  Zero-Inflated Poission Regression Model Comparing 
Cardiovascular-related Other Medical Care Utilization during 2007 among 
Cohorts 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
z p-value 
95% Confidence 
Interval 
Intercept -0.280 0.211 -1.330 0.185 -0.693 0.133 
Cohort a 
1 0.078 0.069 1.130 0.259 -0.058 0.214 
2 0.130 0.066 1.950 0.051 0.000 0.260 
3 -0.060 0.091 -0.660 0.511 -0.239 0.119 
Age 0.011 0.002 4.730 0.000 0.007 0.016 
Gender b Female -0.183 0.044 -4.180 0.000 -0.269 -0.097 
Race c 
White -0.039 0.052 -0.750 0.455 -0.141 0.063 
Other -0.645 0.266 -2.420 0.015 -1.167 -0.123 
Region of 
residence d 
Northeast  -0.175 0.060 -2.920 0.003 -0.292 -0.058 
South 0.043 0.053 0.800 0.425 -0.062 0.147 
West -0.341 0.099 -3.460 0.001 -0.534 -0.148 
ESRD duration 0.010 0.007 1.340 0.180 -0.004 0.024 
Primary 
disease 
causing 
ESRD e 
Hypertension 0.036 0.059 0.600 0.546 -0.080 0.152 
Glomerulonephritis -0.054 0.100 -0.540 0.590 -0.251 0.142 
Cystic Kidney -0.006 0.147 -0.040 0.966 -0.294 0.281 
Other  -0.055 0.088 -0.620 0.532 -0.229 0.118 
Charlson Comorbidity Index (CCI) 
score 0.083 0.020 4.050 0.000 0.043 0.123 
Presence of 
chronic 
disease  
Diabetes mellitus -0.085 0.073 -1.170 0.244 -0.227 0.058 
Hypertension -0.003 0.044 -0.080 0.938 -0.090 0.083 
Dyslipidemia 0.094 0.056 1.690 0.091 -0.015 0.203 
Cancer -0.391 0.101 -3.880 0.000 -0.589 -0.193 
Chronic lung disease -0.101 0.053 -1.910 0.056 -0.205 0.002 
Cardiovascular 
disease -0.137 0.069 -1.970 0.048 -0.273 -0.001 
Inflate             
Intercept 3.708 0.286 12.990 0.000 3.149 4.268 
Cohort a 
1 0.044 0.098 0.450 0.651 -0.148 0.237 
2 -0.028 0.095 -0.290 0.769 -0.214 0.158 
3 0.111 0.127 0.880 0.381 -0.137 0.360 
Age -0.027 0.003 -8.190 0.000 -0.033 -0.020 
Gender b Female 0.082 0.064 1.290 0.196 -0.042 0.207 
316 
Race c 
White -0.011 0.077 -0.140 0.888 -0.161 0.140 
Other 0.255 0.306 0.830 0.405 -0.345 0.855 
Region of 
residence d 
Northeast  -0.108 0.089 -1.220 0.224 -0.281 0.066 
South -0.096 0.082 -1.160 0.246 -0.257 0.066 
West -0.063 0.131 -0.480 0.630 -0.320 0.194 
ESRD duration 0.005 0.010 0.490 0.623 -0.014 0.023 
Primary 
disease 
causing 
ESRD e 
Hypertension 0.166 0.088 1.890 0.059 -0.006 0.338 
Glomerulonephritis 0.204 0.138 1.480 0.139 -0.066 0.474 
Cystic Kidney 0.040 0.213 0.190 0.852 -0.378 0.458 
Other  0.338 0.122 2.760 0.006 0.098 0.577 
Charlson Comorbidity Index (CCI) 
score -0.170 0.031 -5.510 0.000 -0.230 -0.109 
Presence of 
chronic 
disease  
Diabetes mellitus 0.007 0.099 0.070 0.946 -0.188 0.202 
Hypertension -0.227 0.065 -3.490 0.000 -0.355 -0.100 
Dyslipidemia -0.002 0.085 -0.030 0.978 -0.170 0.165 
Cancer 0.327 0.149 2.200 0.028 0.035 0.619 
Chronic lung disease -0.036 0.081 -0.450 0.652 -0.195 0.122 
Cardiovascular 
disease 0.686 0.091 7.520 0.000 0.508 0.865 
 
Model parameters: Inflation model=logit; Log Likelihood  = -6675.37; LR chi2 145.78; p<0.0001. 
a Reference: Cohort 4 
  b Reference : Male 
  c Reference: Black 
  d Reference : Midwest 
  e Reference : Diabetes mellitus 
  
Vuong test of zip vs. standard Poisson:            z =    17.47  Pr>z = 0.0000 
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Appendix E1  A Two-part Model Comparing All-cause Inpatient Costs during 
2007 among Cohorts 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
z 
p-
value 
95% 
Confidence 
Interval 
probit             
Intercept -0.137 0.088 -1.560 0.118 -0.309 0.035 
Cohort a 
1 0.029 0.035 0.830 0.405 -0.039 0.098 
2 0.135 0.034 3.980 0.000 0.068 0.201 
3 0.050 0.045 1.120 0.261 -0.037 0.138 
Age 0.001 0.001 0.640 0.523 -0.001 0.003 
Gender b Female -0.081 0.025 -3.270 0.001 -0.130 -0.033 
Race c 
White -0.023 0.029 -0.790 0.431 -0.079 0.034 
Other 0.014 0.073 0.190 0.852 -0.129 0.156 
Region of 
residence d 
Northeast  0.077 0.035 2.170 0.030 0.008 0.146 
South 0.002 0.032 0.070 0.945 -0.061 0.065 
West 0.003 0.046 0.070 0.948 -0.087 0.093 
ESRD duration 0.002 0.003 0.770 0.443 -0.004 0.008 
Primary 
 disease 
causing ESRD e 
Hypertension -0.030 0.033 -0.900 0.368 -0.096 0.035 
Glomerulonephritis -0.020 0.049 -0.420 0.678 -0.116 0.075 
Cystic Kidney -0.097 0.080 -1.220 0.222 -0.253 0.059 
Other  -0.052 0.043 -1.210 0.224 -0.137 0.032 
Charlson Comorbidity Index (CCI) 
score 0.099 0.015 6.610 0.000 0.070 0.128 
Presence of 
chronic disease  
Diabetes mellitus -0.027 0.038 -0.710 0.476 -0.102 0.048 
Hypertension 0.055 0.027 2.010 0.045 0.001 0.109 
Dyslipidemia 0.040 0.038 1.060 0.289 -0.034 0.114 
Cancer -0.081 0.060 -1.360 0.174 -0.199 0.036 
Chronic lung 
disease 0.135 0.036 3.760 0.000 0.065 0.206 
Cardiovascular 
disease 0.263 0.034 7.670 0.000 0.196 0.330 
glm 
Intercept 10.497 0.091 115.730 0.000 10.319 10.674 
Cohort a 
1 0.004 0.036 0.110 0.910 -0.066 0.074 
2 0.041 0.034 1.200 0.231 -0.026 0.109 
3 -0.007 0.044 -0.150 0.878 -0.092 0.079 
Age -0.008 0.001 -7.270 0.000 -0.010 -0.006 
Gender b Female 0.058 0.024 2.410 0.016 0.011 0.106 
Race c 
White -0.085 0.029 -2.880 0.004 -0.143 -0.027 
Other -0.166 0.070 -2.360 0.019 -0.304 -0.028 
Region of 
residence d 
Northeast  0.153 0.034 4.550 0.000 0.087 0.219 
South 0.007 0.032 0.230 0.820 -0.055 0.070 
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West 0.160 0.043 3.690 0.000 0.075 0.246 
ESRD duration -0.002 0.003 -0.510 0.613 -0.008 0.005 
Primary 
disease causing 
ESRD e 
Hypertension -0.028 0.034 -0.840 0.399 -0.094 0.038 
Glomerulonephritis 0.016 0.050 0.310 0.756 -0.083 0.115 
Cystic Kidney 0.102 0.078 1.310 0.191 -0.051 0.256 
Other  -0.002 0.043 -0.040 0.972 -0.085 0.082 
Charlson Comorbidity Index (CCI) 
score 0.066 0.012 5.400 0.000 0.042 0.090 
Presence of 
chronic disease  
Diabetes mellitus -0.003 0.037 -0.080 0.937 -0.075 0.069 
Hypertension -0.027 0.026 -1.030 0.301 -0.078 0.024 
Dyslipidemia 0.063 0.035 1.770 0.076 -0.007 0.132 
Cancer -0.163 0.057 -2.840 0.004 -0.275 -0.051 
Chronic lung 
disease 0.015 0.032 0.450 0.649 -0.049 0.078 
Cardiovascular 
disease 0.077 0.034 2.280 0.022 0.011 0.142 
 
Model parameters: Wald chi2 =741.58 ; df= 22; p<0.0001. 
a Reference: Cohort 4 
  b Reference : Male 
  c Reference: Black 
  d Reference : Midwest 
  e Reference : Diabetes mellitus 
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Appendix E2  A Two-part Model Comparing All-cause Outpatient Costs 
during 2007 among Cohorts 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
z p-value 
95% 
Confidence 
Interval 
probit             
Intercept 0.926 0.130 7.110 0.000 0.671 1.181 
Cohort a 
1 -0.068 0.048 -1.420 0.155 -0.163 0.026 
2 0.102 0.050 2.060 0.039 0.005 0.200 
3 0.007 0.068 0.110 0.913 -0.127 0.142 
Age 0.003 0.002 2.060 0.039 0.000 0.006 
Gender b Female -0.106 0.035 -3.000 0.003 -0.175 -0.037 
Race c 
White -0.023 0.043 -0.530 0.597 -0.108 0.062 
Other -0.095 0.096 -0.990 0.321 -0.284 0.093 
Region of 
residence d 
Northeast  -0.302 0.053 -5.710 0.000 -0.406 -0.198 
South -0.212 0.051 -4.180 0.000 -0.311 -0.113 
West -0.229 0.066 -3.490 0.000 -0.358 -0.101 
ESRD duration 0.005 0.004 1.120 0.265 -0.004 0.013 
Primary 
disease causing 
ESRD e 
Hypertension 0.093 0.051 1.840 0.065 -0.006 0.192 
Glomerulonephritis 0.238 0.067 3.560 0.000 0.107 0.369 
Cystic Kidney 0.351 0.126 2.790 0.005 0.104 0.597 
Other  0.118 0.061 1.940 0.053 -0.001 0.237 
Charlson Comorbidity Index (CCI) 
score 0.057 0.025 2.250 0.025 0.007 0.107 
Presence of 
chronic disease  
Diabetes mellitus 0.212 0.060 3.540 0.000 0.095 0.330 
Hypertension 0.274 0.042 6.560 0.000 0.192 0.355 
Dyslipidemia 0.198 0.063 3.150 0.002 0.075 0.322 
Cancer 0.217 0.099 2.190 0.029 0.023 0.411 
Chronic lung 
disease 0.123 0.058 2.100 0.035 0.008 0.237 
Cardiovascular 
disease 0.101 0.050 2.030 0.042 0.004 0.199 
glm 
Intercept 8.422 0.098 86.170 0.000 8.230 8.613 
Cohort a 
1 0.008 0.039 0.210 0.834 -0.069 0.085 
2 0.117 0.039 3.030 0.002 0.041 0.193 
3 0.139 0.049 2.800 0.005 0.042 0.235 
Age -0.003 0.001 -2.750 0.006 -0.005 -0.001 
Gender b Female 0.012 0.025 0.480 0.632 -0.037 0.061 
Race c 
White -0.101 0.032 -3.120 0.002 -0.164 -0.037 
Other -0.118 0.071 -1.670 0.096 -0.256 0.021 
Region of Northeast  -0.073 0.037 -1.970 0.048 -0.145 -0.001 
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residence d South -0.136 0.032 -4.220 0.000 -0.200 -0.073 
West -0.164 0.046 -3.610 0.000 -0.254 -0.075 
ESRD duration -0.003 0.003 -1.000 0.319 -0.010 0.003 
Primary 
disease causing 
ESRD e 
Hypertension -0.110 0.035 -3.170 0.001 -0.177 -0.042 
Glomerulonephritis -0.027 0.051 -0.530 0.593 -0.127 0.073 
Cystic Kidney -0.024 0.082 -0.290 0.773 -0.184 0.137 
Other  0.047 0.045 1.050 0.295 -0.041 0.135 
Charlson Comorbidity Index (CCI) 
score 0.047 0.014 3.290 0.001 0.019 0.075 
Presence of 
chronic disease  
Diabetes mellitus 0.041 0.040 1.010 0.312 -0.038 0.120 
Hypertension 0.097 0.027 3.640 0.000 0.045 0.149 
Dyslipidemia 0.061 0.036 1.690 0.092 -0.010 0.133 
Cancer 0.050 0.058 0.870 0.385 -0.063 0.163 
Chronic lung 
disease -0.032 0.036 -0.890 0.373 -0.103 0.039 
Cardiovascular 
disease 0.051 0.036 1.400 0.161 -0.020 0.122 
 
Model parameters: Wald chi2 =354.08 ; df= 22; p<0.0001. 
a Reference: Cohort 4 
 b Reference : Male 
 c Reference: Black 
 d Reference : Midwest 
 e Reference : Diabetes mellitus 
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Appendix E3  A Two-part Model Comparing All-cause Physician/Supplier 
Costs during 2007 among Cohorts 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
z 
p-
value 
95% 
Confidence 
Interval 
probit             
Intercept 1.542 0.115 13.430 0.000 1.317 1.767 
Cohort a 
1 0.016 0.045 0.360 0.719 -0.072 0.105 
2 -0.001 0.045 -0.010 0.991 -0.089 0.087 
3 0.012 0.059 0.200 0.843 -0.105 0.128 
Age -0.003 0.001 -2.420 0.016 -0.006 -0.001 
Gender b Female -0.026 0.031 -0.850 0.397 -0.087 0.034 
Race c 
White 0.036 0.038 0.960 0.338 -0.038 0.110 
Other 0.012 0.091 0.140 0.892 -0.165 0.190 
Region of 
residence d 
Northeast  -0.010 0.046 -0.210 0.837 -0.100 0.081 
South -0.105 0.044 -2.370 0.018 -0.191 -0.018 
West -0.127 0.058 -2.190 0.029 -0.241 -0.013 
ESRD duration -0.007 0.004 -1.770 0.077 -0.014 0.001 
Primary 
disease 
causing 
ESRD e 
Hypertension 0.032 0.046 0.680 0.497 -0.060 0.123 
Glomerulonephritis -0.010 0.063 -0.170 0.868 -0.133 0.112 
Cystic Kidney 0.051 0.103 0.500 0.618 -0.150 0.253 
Other  -0.027 0.053 -0.510 0.611 -0.131 0.077 
Charlson Comorbidity Index 
(CCI) score 0.059 0.019 3.160 0.002 0.022 0.095 
Presence of 
chronic 
disease  
Diabetes mellitus -0.134 0.051 -2.630 0.008 -0.234 -0.034 
Hypertension -0.034 0.032 -1.050 0.296 -0.098 0.030 
Dyslipidemia 0.050 0.045 1.110 0.267 -0.039 0.139 
Cancer -0.075 0.077 -0.980 0.326 -0.225 0.075 
Chronic lung 
disease -0.040 0.046 -0.870 0.384 -0.131 0.050 
Cardiovascular 
disease -0.123 0.041 -3.000 0.003 -0.204 -0.043 
glm 
Intercept 8.786 0.133 66.120 0.000 8.526 9.046 
Cohort a 
1 -0.015 0.054 -0.270 0.786 -0.120 0.090 
2 -0.035 0.055 -0.640 0.521 -0.144 0.073 
3 0.044 0.076 0.570 0.567 -0.106 0.193 
Age -0.007 0.002 -4.070 0.000 -0.010 -0.003 
Gender b Female -0.096 0.040 -2.420 0.015 -0.174 -0.018 
Race c 
White -0.094 0.046 -2.030 0.043 -0.184 -0.003 
Other -0.076 0.099 -0.770 0.440 -0.271 0.118 
Region of Northeast  0.127 0.056 2.250 0.024 0.017 0.238 
322 
residence d South 0.090 0.051 1.770 0.076 -0.010 0.189 
West 0.013 0.063 0.200 0.842 -0.111 0.136 
ESRD duration 0.002 0.005 0.400 0.692 -0.007 0.011 
Primary 
disease 
causing 
ESRD e 
Hypertension -0.028 0.056 -0.490 0.622 -0.138 0.083 
Glomerulonephritis 0.022 0.066 0.330 0.740 -0.108 0.152 
Cystic Kidney -0.043 0.082 -0.520 0.604 -0.204 0.119 
Other  0.142 0.066 2.140 0.032 0.012 0.272 
Charlson Comorbidity Index 
(CCI) score -0.062 0.027 -2.300 0.022 -0.114 -0.009 
Presence of 
chronic 
disease  
Diabetes mellitus 0.089 0.061 1.460 0.145 -0.031 0.208 
Hypertension 0.109 0.045 2.400 0.016 0.020 0.197 
Dyslipidemia -0.067 0.064 -1.060 0.291 -0.193 0.058 
Cancer 0.250 0.099 2.520 0.012 0.056 0.444 
Chronic lung 
disease -0.058 0.058 -0.990 0.321 -0.173 0.057 
Cardiovascular 
disease -0.375 0.053 -7.120 0.000 -0.478 -0.271 
 
Model parameters: Wald chi2 =41.15 ; df= 22; p<0.0001. 
a Reference: Cohort 4 
  b Reference : Male 
  c Reference: Black 
  d Reference : Midwest 
  e Reference : Diabetes mellitus 
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Appendix E4  A Generalized Linear Model Comparing Dialysis Costs during 
2007 among Cohorts 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
z p-value 
95% 
Confidence 
Interval 
Intercept 10.333 0.019 535.890 0.000 10.295 10.371 
Cohort a 
1 -0.014 0.007 -1.920 0.055 -0.029 0.000 
2 0.023 0.007 3.260 0.001 0.009 0.037 
3 0.062 0.009 6.600 0.000 0.044 0.081 
Age -0.002 0.000 -9.720 0.000 -0.003 -0.002 
Gender b Female 0.059 0.005 11.670 0.000 0.049 0.069 
Race c 
White -0.066 0.006 -11.180 0.000 -0.077 -0.054 
Other -0.092 0.016 -5.920 0.000 -0.123 -0.062 
Region of 
residence 
d 
Northeast  0.027 0.007 3.820 0.000 0.013 0.041 
South -0.023 0.007 -3.520 0.000 -0.036 -0.010 
West 0.012 0.009 1.270 0.206 -0.006 0.030 
ESRD duration 0.000 0.001 0.450 0.655 -0.001 0.002 
Primary 
disease 
causing 
ESRD e 
Hypertension 0.002 0.007 0.290 0.769 -0.011 0.015 
Glomerulonephritis 0.028 0.010 2.840 0.004 0.009 0.047 
Cystic Kidney -0.030 0.016 -1.910 0.057 -0.061 0.001 
Other  0.017 0.009 1.800 0.072 -0.001 0.035 
Charlson Comorbidity Index 
(CCI) score 0.009 0.003 2.960 0.003 0.003 0.014 
Presence 
of 
chronic 
disease  
Diabetes mellitus 0.013 0.008 1.640 0.101 -0.002 0.028 
Hypertension -0.001 0.005 -0.150 0.880 -0.011 0.010 
Dyslipidemia 0.002 0.007 0.300 0.762 -0.012 0.016 
Cancer 0.024 0.012 1.920 0.055 0.000 0.048 
Chronic lung 
disease 0.007 0.007 0.950 0.341 -0.007 0.021 
Cardiovascular 
disease 0.010 0.007 1.440 0.149 -0.004 0.023 
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Appendix E5  A Generalized Linear Model Comparing All-cause Other Costs 
during 2007 among Cohorts 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
z 
p-
value 
95% 
Confidence 
Interval 
probit             
Intercept -1.955 0.103 -18.970 0.000 -2.157 -1.753 
Cohort a 
1 0.029 0.039 0.760 0.448 -0.046 0.105 
2 0.103 0.038 2.720 0.007 0.029 0.177 
3 0.020 0.048 0.420 0.673 -0.073 0.114 
Age 0.018 0.001 15.510 0.000 0.015 0.020 
Gender b Female -0.149 0.025 -5.980 0.000 -0.198 -0.100 
Race c 
White -0.019 0.029 -0.670 0.505 -0.077 0.038 
Other -0.306 0.081 -3.780 0.000 -0.465 -0.148 
Region of 
residence d 
Northeast  0.092 0.037 2.470 0.013 0.019 0.165 
South 0.178 0.034 5.180 0.000 0.110 0.245 
West -0.008 0.047 -0.160 0.869 -0.100 0.084 
ESRD duration 0.008 0.003 2.550 0.011 0.002 0.015 
Primary 
disease 
causing 
ESRD e 
Hypertension -0.122 0.034 -3.600 0.000 -0.188 -0.055 
Glomerulonephritis -0.141 0.049 -2.890 0.004 -0.237 -0.045 
Cystic Kidney -0.045 0.081 -0.560 0.575 -0.203 0.113 
Other  -0.082 0.043 -1.910 0.056 -0.167 0.002 
Charlson Comorbidity Index 
(CCI) score 0.135 0.014 9.610 0.000 0.107 0.162 
Presence of 
chronic 
disease  
Diabetes mellitus 0.028 0.039 0.730 0.464 -0.047 0.104 
Hypertension 0.184 0.026 7.050 0.000 0.133 0.235 
Dyslipidemia 0.048 0.037 1.320 0.188 -0.024 0.121 
Cancer -0.297 0.062 -4.780 0.000 -0.418 -0.175 
Chronic lung 
disease -0.084 0.035 -2.410 0.016 -0.152 -0.016 
Cardiovascular 
disease -0.152 0.035 -4.400 0.000 -0.220 -0.084 
glm 
Intercept 8.374 0.146 57.400 0.000 8.088 8.660 
Cohort a 
1 0.177 0.052 3.420 0.001 0.076 0.279 
2 0.085 0.051 1.660 0.096 -0.015 0.185 
3 0.012 0.066 0.190 0.849 -0.116 0.141 
Age 0.010 0.002 5.550 0.000 0.006 0.013 
Gender b Female -0.116 0.032 -3.590 0.000 -0.179 -0.053 
Race c 
White 0.085 0.038 2.230 0.026 0.010 0.159 
Other -0.002 0.116 -0.020 0.987 -0.230 0.226 
325 
Region of 
residence d 
Northeast  0.033 0.046 0.730 0.468 -0.057 0.123 
South -0.005 0.039 -0.130 0.896 -0.082 0.072 
West -0.022 0.062 -0.350 0.726 -0.143 0.100 
ESRD duration 0.006 0.005 1.270 0.204 -0.003 0.016 
Primary 
disease 
causing 
ESRD e 
Hypertension -0.116 0.044 -2.640 0.008 -0.202 -0.030 
Glomerulonephritis -0.176 0.075 -2.340 0.019 -0.323 -0.029 
Cystic Kidney -0.098 0.100 -0.980 0.328 -0.294 0.098 
Other  -0.095 0.059 -1.610 0.108 -0.212 0.021 
Charlson Comorbidity Index 
(CCI) score 0.041 0.016 2.610 0.009 0.010 0.071 
Presence of 
chronic 
disease  
Diabetes mellitus 0.011 0.050 0.220 0.823 -0.087 0.110 
Hypertension 0.104 0.033 3.180 0.001 0.040 0.168 
Dyslipidemia 0.020 0.044 0.460 0.647 -0.067 0.107 
Cancer -0.163 0.071 -2.310 0.021 -0.301 -0.024 
Chronic lung 
disease -0.014 0.042 -0.350 0.728 -0.096 0.067 
Cardiovascular 
disease -0.056 0.046 -1.230 0.220 -0.146 0.034 
 
Model parameters: Wald chi2 = 1125.77 ; df =22 ; p<0.0001. 
a Reference: Cohort 4 
  b Reference : Male 
  c Reference: Black 
  d Reference : Midwest 
  e Reference : Diabetes mellitus 
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Appendix E6  A Generalized Linear Model Comparing All-cause Medical 
Service Costs during 2007 among Cohorts  
 
Variable 
Parameter 
Estimate 
Standard 
Error 
z p-value 
95% 
Confidence 
Interval 
Intercept 10.872 0.037 295.270 0.000 10.800 10.945 
Cohort a 
1 0.008 0.016 0.500 0.615 -0.024 0.040 
2 0.062 0.016 4.000 0.000 0.032 0.093 
3 0.051 0.021 2.470 0.013 0.011 0.091 
Age -0.002 0.000 -5.410 0.000 -0.003 -0.002 
Gender b Female 0.009 0.011 0.870 0.385 -0.011 0.030 
Race c 
White -0.070 0.013 -5.520 0.000 -0.095 -0.045 
Other -0.130 0.029 -4.520 0.000 -0.187 -0.074 
Region of 
residence d 
Northeast  0.080 0.016 5.000 0.000 0.049 0.112 
South -0.011 0.013 -0.800 0.422 -0.037 0.015 
West 0.036 0.020 1.800 0.071 -0.003 0.075 
ESRD duration 0.001 0.001 0.690 0.489 -0.002 0.004 
Primary 
disease 
causing 
ESRD e 
Hypertension -0.029 0.015 -1.980 0.048 -0.058 0.000 
Glomerulonephritis 0.005 0.021 0.250 0.805 -0.036 0.046 
Cystic Kidney -0.008 0.035 -0.230 0.814 -0.078 0.061 
Other  0.005 0.019 0.280 0.782 -0.032 0.043 
Charlson Comorbidity Index 
(CCI) score 0.057 0.006 9.440 0.000 0.045 0.069 
Presence 
of chronic 
disease  
Diabetes mellitus 0.006 0.016 0.400 0.688 -0.025 0.038 
Hypertension 0.035 0.011 3.210 0.001 0.014 0.056 
Dyslipidemia 0.036 0.016 2.300 0.021 0.005 0.067 
Cancer -0.068 0.026 -2.650 0.008 -0.119 -0.018 
Chronic lung 
disease 0.018 0.015 1.160 0.246 -0.012 0.047 
Cardiovascular 
disease 0.069 0.015 4.690 0.000 0.040 0.098 
Model parameters: Log likelihood= -139468; AIC = 23.78 ; BIC = -106811. 
a Reference: Cohort 4 
 b Reference : Male 
 c Reference: Black 
 d Reference : Midwest 
 e Reference : Diabetes mellitus 
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Appendix E7  A Generalized Linear Model Comparing All-cause Pharmacy 
Costs during 2007 among Cohorts 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
z p-value 
95% 
Confidence 
Interval 
Intercept 8.777 0.050 174.330 0.000 8.678 8.876 
Cohort a 
1 -1.053 0.024 -44.040 0.000 -1.100 -1.006 
2 -0.163 0.022 -7.520 0.000 -0.206 -0.121 
3 0.687 0.025 27.720 0.000 0.639 0.736 
Age -0.005 0.001 -7.350 0.000 -0.006 -0.003 
Gender b Female -0.070 0.014 -5.160 0.000 -0.096 -0.043 
Race c 
White 0.083 0.017 4.910 0.000 0.050 0.116 
Other 0.211 0.050 4.200 0.000 0.112 0.309 
Region of 
residence d 
Northeast  0.144 0.018 7.970 0.000 0.109 0.180 
South 0.013 0.016 0.820 0.414 -0.019 0.046 
West 0.088 0.025 3.590 0.000 0.040 0.137 
ESRD duration 0.002 0.002 1.040 0.300 -0.002 0.006 
Primary 
disease 
causing 
ESRD e 
Hypertension -0.057 0.018 -3.160 0.002 -0.092 -0.022 
Glomerulonephritis -0.005 0.026 -0.190 0.849 -0.055 0.045 
Cystic Kidney -0.030 0.040 -0.760 0.446 -0.108 0.048 
Other  0.028 0.026 1.060 0.287 -0.024 0.080 
Charlson Comorbidity Index 
(CCI) score -0.002 0.008 -0.210 0.837 -0.018 0.014 
Presence 
of chronic 
disease  
Diabetes mellitus 0.010 0.021 0.490 0.623 -0.031 0.052 
Hypertension -0.003 0.014 -0.170 0.861 -0.031 0.026 
Dyslipidemia 0.030 0.019 1.620 0.106 -0.006 0.067 
Cancer 0.186 0.038 4.900 0.000 0.112 0.261 
Chronic lung 
disease 0.025 0.019 1.320 0.186 -0.012 0.062 
Cardiovascular 
disease 0.020 0.020 0.980 0.328 -0.020 0.059 
Model parameters: Log likelihood= -18.49; AIC = 23.78 ; BIC = -104177. 
a Reference: Cohort 4 
b Reference : Male 
c Reference: Black 
d Reference : Midwest 
e Reference : Diabetes mellitus 
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Appendix E8  A Generalized Linear Model Comparing All-cause Health Care 
Costs during 2007 among Cohorts 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
z p-value 
95% Confidence 
Interval 
Intercept 10.992 0.036 308.370 0.000 10.923 11.062 
Cohort a 
1 -0.053 0.015 -3.600 0.000 -0.082 -0.024 
2 0.045 0.014 3.170 0.002 0.017 0.073 
3 0.132 0.018 7.500 0.000 0.098 0.167 
Age -0.003 0.000 -6.050 0.000 -0.004 -0.002 
Gender b Female 0.004 0.010 0.390 0.693 -0.016 0.023 
Race c 
White -0.061 0.012 -5.150 0.000 -0.084 -0.038 
Other -0.109 0.027 -3.980 0.000 -0.162 -0.055 
Region of 
residence d 
Northeast  0.081 0.015 5.460 0.000 0.052 0.110 
South -0.009 0.013 -0.740 0.458 -0.034 0.016 
West 0.038 0.018 2.120 0.034 0.003 0.074 
ESRD duration 0.001 0.001 0.850 0.396 -0.001 0.004 
Primary 
disease 
causing 
ESRD e 
Hypertension -0.031 0.013 -2.400 0.016 -0.057 -0.006 
Glomerulonephritis 0.007 0.019 0.360 0.718 -0.031 0.045 
Cystic Kidney -0.008 0.032 -0.240 0.807 -0.070 0.054 
Other  0.011 0.018 0.640 0.524 -0.023 0.046 
Charlson Comorbidity Index 
(CCI) score 0.053 0.006 9.560 0.000 0.042 0.064 
Presence of 
chronic 
disease  
Diabetes mellitus 0.005 0.016 0.310 0.753 -0.026 0.036 
Hypertension 0.033 0.010 3.140 0.002 0.012 0.053 
Dyslipidemia 0.037 0.015 2.430 0.015 0.007 0.066 
Cancer -0.042 0.023 -1.820 0.068 -0.087 0.003 
Chronic lung 
disease 0.018 0.014 1.300 0.195 -0.009 0.045 
Cardiovascular 
disease 0.064 0.013 4.740 0.000 0.037 0.090 
Model parameters: Log likelihood= -140398; AIC = 23.94 ; BIC = -107150. 
a Reference: Cohort 4 
 b Reference : Male 
 c Reference: Black 
 d Reference : Midwest 
 e Reference : Diabetes mellitus 
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Appendix E9  A Two-part Model Comparing Cardiovascular-related Inpatient 
Costs during 2007 among Cohorts 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
z 
p-
value 
95% 
Confidence 
Interval 
probit             
Intercept -1.015 0.091 -11.200 0.000 -1.192 -0.837 
Cohort a 
1 -0.028 0.037 -0.770 0.442 -0.100 0.044 
2 0.072 0.037 1.950 0.051 0.000 0.144 
3 0.011 0.048 0.240 0.812 -0.083 0.106 
Age 0.004 0.001 3.400 0.001 0.001 0.006 
Gender b Female -0.004 0.025 -0.150 0.883 -0.052 0.045 
Race c 
White 0.015 0.031 0.470 0.636 -0.046 0.075 
Other -0.019 0.075 -0.260 0.794 -0.166 0.127 
Region of 
residence d 
Northeast  0.101 0.035 2.890 0.004 0.032 0.169 
South 0.048 0.032 1.500 0.134 -0.015 0.111 
West 0.047 0.046 1.030 0.302 -0.042 0.136 
ESRD duration -0.003 0.003 -0.800 0.424 -0.009 0.004 
Primary disease 
causing ESRD e 
Hypertension -0.030 0.035 -0.850 0.393 -0.099 0.039 
Glomerulonephritis -0.127 0.048 -2.620 0.009 -0.222 -0.032 
Cystic Kidney -0.157 0.079 -1.990 0.046 -0.312 -0.003 
Other  -0.140 0.046 -3.060 0.002 -0.229 -0.050 
Charlson Comorbidity Index (CCI) 
score 0.089 0.014 6.250 0.000 0.061 0.117 
Presence of 
chronic disease  
Diabetes mellitus -0.071 0.040 -1.800 0.072 -0.149 0.006 
Hypertension 0.005 0.026 0.180 0.855 -0.046 0.056 
Dyslipidemia 0.023 0.038 0.620 0.538 -0.051 0.098 
Cancer -0.216 0.061 -3.560 0.000 -0.334 -0.097 
Chronic lung 
disease 0.179 0.036 4.910 0.000 0.107 0.250 
Cardiovascular 
disease 0.428 0.033 12.860 0.000 0.363 0.493 
glm 
Intercept 10.244 0.121 84.760 0.000 10.007 10.480 
Cohort a 
1 -0.032 0.046 -0.690 0.492 -0.122 0.059 
2 -0.022 0.044 -0.500 0.618 -0.109 0.065 
3 -0.074 0.057 -1.290 0.195 -0.186 0.038 
Age -0.007 0.001 -5.230 0.000 -0.010 -0.005 
Gender b Female 0.042 0.030 1.410 0.159 -0.016 0.101 
Race c 
White -0.068 0.038 -1.780 0.076 -0.143 0.007 
Other -0.238 0.091 -2.630 0.009 -0.415 -0.060 
Region of Northeast  0.131 0.042 3.120 0.002 0.049 0.213 
330 
residence d South -0.005 0.039 -0.130 0.895 -0.082 0.072 
West 0.176 0.053 3.310 0.001 0.072 0.281 
ESRD duration -0.006 0.004 -1.510 0.132 -0.014 0.002 
Primary disease 
causing ESRD e 
Hypertension -0.013 0.042 -0.310 0.754 -0.096 0.070 
Glomerulonephritis -0.024 0.062 -0.390 0.698 -0.145 0.097 
Cystic Kidney 0.090 0.094 0.950 0.342 -0.095 0.275 
Other  -0.027 0.063 -0.430 0.669 -0.150 0.096 
Charlson Comorbidity Index (CCI) 
score 0.050 0.014 3.440 0.001 0.021 0.078 
Presence of 
chronic disease  
Diabetes mellitus -0.038 0.046 -0.820 0.413 -0.128 0.052 
Hypertension -0.009 0.031 -0.300 0.766 -0.069 0.051 
Dyslipidemia 0.068 0.042 1.620 0.106 -0.014 0.151 
Cancer -0.102 0.071 -1.440 0.149 -0.241 0.037 
Chronic lung 
disease -0.028 0.038 -0.750 0.455 -0.102 0.046 
Cardiovascular 
disease 0.050 0.042 1.200 0.230 -0.032 0.132 
 
Model parameters: Wald chi2 = 939.94 ; df =22 ; p<0.0001. 
a Reference: Cohort 4 
 b Reference : Male 
 c Reference: Black 
 d Reference : Midwest 
 e Reference : Diabetes mellitus 
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Appendix E10  A Two-part Model Comparing Cardiovascular-related 
Outpatient Costs during 2007 among Cohorts 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
z p-value 
95% 
Confidence 
Interval 
probit             
Intercept -1.006 0.093 -10.810 0.000 -1.188 -0.824 
Cohort a 
1 -0.063 0.038 -1.690 0.092 -0.137 0.010 
2 0.074 0.036 2.040 0.042 0.003 0.145 
3 -0.008 0.047 -0.170 0.866 -0.101 0.085 
Age 0.003 0.001 2.770 0.006 0.001 0.005 
Gender b Female 0.084 0.026 3.270 0.001 0.034 0.135 
Race c 
White 0.083 0.031 2.710 0.007 0.023 0.144 
Other -0.041 0.075 -0.550 0.581 -0.188 0.105 
Region of 
residence d 
Northeast  -0.136 0.037 -3.730 0.000 -0.208 -0.065 
South -0.106 0.033 -3.180 0.001 -0.172 -0.041 
West -0.234 0.047 -4.940 0.000 -0.326 -0.141 
ESRD duration -0.005 0.003 -1.550 0.122 -0.011 0.001 
Primary disease 
causing ESRD e 
Hypertension -0.043 0.036 -1.190 0.236 -0.113 0.028 
Glomerulonephritis -0.131 0.049 -2.700 0.007 -0.226 -0.036 
Cystic Kidney 0.004 0.082 0.050 0.962 -0.157 0.165 
Other  -0.134 0.044 -3.030 0.002 -0.220 -0.047 
Charlson Comorbidity Index (CCI) 
score 0.086 0.014 6.180 0.000 0.059 0.113 
Presence of 
chronic disease  
Diabetes mellitus -0.043 0.038 -1.110 0.266 -0.118 0.032 
Hypertension 0.091 0.027 3.400 0.001 0.039 0.144 
Dyslipidemia 0.051 0.037 1.370 0.169 -0.022 0.123 
Cancer -0.150 0.060 -2.490 0.013 -0.269 -0.032 
Chronic lung 
disease 0.028 0.035 0.800 0.421 -0.041 0.097 
Cardiovascular 
disease 0.419 0.033 12.690 0.000 0.354 0.484 
glm 
Intercept 7.140 0.225 31.800 0.000 6.700 7.580 
Cohort a 
1 -0.027 0.083 -0.330 0.745 -0.189 0.135 
2 0.008 0.078 0.110 0.916 -0.145 0.161 
3 -0.032 0.113 -0.290 0.775 -0.254 0.189 
Age -0.001 0.002 -0.370 0.708 -0.006 0.004 
Gender b Female 0.166 0.057 2.900 0.004 0.054 0.277 
Race c 
White -0.059 0.072 -0.820 0.414 -0.199 0.082 
Other -0.171 0.158 -1.080 0.278 -0.480 0.138 
Region of Northeast  0.022 0.082 0.270 0.789 -0.139 0.183 
332 
residence d South 0.049 0.071 0.700 0.486 -0.090 0.188 
West -0.037 0.100 -0.370 0.708 -0.233 0.158 
ESRD duration -0.001 0.008 -0.160 0.871 -0.016 0.014 
Primary disease 
causing ESRD e 
Hypertension -0.096 0.078 -1.230 0.217 -0.248 0.056 
Glomerulonephritis -0.068 0.142 -0.480 0.634 -0.346 0.211 
Cystic Kidney 0.055 0.284 0.200 0.845 -0.501 0.612 
Other  -0.270 0.100 -2.710 0.007 -0.466 -0.075 
Charlson Comorbidity Index (CCI) 
score 0.023 0.031 0.760 0.447 -0.037 0.084 
Presence of 
chronic disease  
Diabetes mellitus 0.027 0.085 0.320 0.752 -0.140 0.193 
Hypertension -0.041 0.060 -0.690 0.491 -0.159 0.076 
Dyslipidemia -0.015 0.074 -0.200 0.842 -0.159 0.130 
Cancer 0.010 0.136 0.070 0.941 -0.256 0.276 
Chronic lung 
disease -0.001 0.082 -0.010 0.991 -0.162 0.160 
Cardiovascular 
disease 0.245 0.081 3.010 0.003 0.085 0.404 
 
Model parameters: Wald chi2 = 966.10 ; df =22 ; p<0.0001. 
a Reference: Cohort 4 
 b Reference : Male 
 c Reference: Black 
 d Reference : Midwest 
 e Reference : Diabetes mellitus 
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Appendix E11  A Two-part Model Comparing Cardiovascular-related 
Physician/Supplier Costs during 2007 among Cohorts 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
z p-value 
95% 
Confidence 
Interval 
probit             
Intercept -0.859 0.088 -9.800 0.000 -1.031 -0.687 
Cohort a 
1 0.038 0.035 1.070 0.287 -0.032 0.107 
2 0.161 0.036 4.440 0.000 0.090 0.231 
3 0.153 0.046 3.310 0.001 0.063 0.244 
Age 0.008 0.001 7.750 0.000 0.006 0.010 
Gender b Female 0.056 0.025 2.280 0.023 0.008 0.104 
Race c 
White 0.064 0.029 2.250 0.025 0.008 0.120 
Other -0.066 0.069 -0.950 0.344 -0.201 0.070 
Region of 
residence d 
Northeast  0.171 0.035 4.820 0.000 0.101 0.240 
South 0.043 0.033 1.300 0.194 -0.022 0.109 
West 0.070 0.046 1.520 0.129 -0.020 0.161 
ESRD duration -0.005 0.003 -1.720 0.085 -0.011 0.001 
Primary disease 
causing ESRD e 
Hypertension -0.033 0.034 -0.970 0.331 -0.101 0.034 
Glomerulonephritis -0.162 0.048 -3.380 0.001 -0.256 -0.068 
Cystic Kidney -0.157 0.073 -2.140 0.032 -0.300 -0.013 
Other  -0.177 0.042 -4.160 0.000 -0.260 -0.093 
Charlson Comorbidity Index (CCI) 
score 0.127 0.015 8.390 0.000 0.097 0.157 
Presence of 
chronic disease  
Diabetes mellitus -0.085 0.039 -2.180 0.029 -0.161 -0.009 
Hypertension -0.017 0.027 -0.610 0.539 -0.070 0.037 
Dyslipidemia 0.122 0.038 3.180 0.001 0.047 0.198 
Cancer -0.262 0.060 -4.370 0.000 -0.379 -0.144 
Chronic lung 
disease 0.073 0.038 1.930 0.053 -0.001 0.147 
Cardiovascular 
disease 0.354 0.033 10.610 0.000 0.288 0.419 
glm 
Intercept 6.145 0.229 26.880 0.000 5.697 6.593 
Cohort a 
1 -0.110 0.113 -0.970 0.332 -0.333 0.112 
2 -0.042 0.115 -0.370 0.711 -0.267 0.182 
3 -0.144 0.123 -1.170 0.240 -0.385 0.096 
Age 0.005 0.003 1.350 0.178 -0.002 0.011 
Gender b Female 0.219 0.059 3.690 0.000 0.103 0.336 
Race c 
White 0.031 0.069 0.450 0.653 -0.104 0.166 
Other 0.130 0.227 0.570 0.567 -0.315 0.575 
Region of Northeast  0.378 0.094 4.000 0.000 0.193 0.562 
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residence d South 0.125 0.062 2.000 0.045 0.003 0.247 
West 0.132 0.088 1.500 0.134 -0.041 0.305 
ESRD duration -0.023 0.007 -3.510 0.000 -0.036 -0.010 
Primary disease 
causing ESRD e 
Hypertension -0.131 0.074 -1.760 0.078 -0.276 0.015 
Glomerulonephritis -0.056 0.168 -0.340 0.737 -0.385 0.272 
Cystic Kidney 0.049 0.144 0.340 0.732 -0.233 0.332 
Other  -0.236 0.100 -2.360 0.018 -0.432 -0.040 
Charlson Comorbidity Index (CCI) 
score 0.083 0.034 2.430 0.015 0.016 0.150 
Presence of 
chronic disease  
Diabetes mellitus -0.090 0.093 -0.960 0.335 -0.273 0.093 
Hypertension 0.091 0.070 1.310 0.191 -0.046 0.228 
Dyslipidemia -0.003 0.077 -0.040 0.971 -0.154 0.148 
Cancer -0.459 0.106 -4.350 0.000 -0.666 -0.252 
Chronic lung 
disease 0.063 0.073 0.860 0.389 -0.081 0.207 
Cardiovascular 
disease 0.136 0.082 1.670 0.095 -0.024 0.296 
 
Model parameters: Wald chi2 = 1134.32 ; df =22 ; p<0.0001. 
a Reference: Cohort 4 
 b Reference : Male 
 c Reference: Black 
 d Reference : Midwest 
 e Reference : Diabetes mellitus 
 
 
  
335 
Appendix E12  A Two-part Model Comparing Cardiovascular-related Other 
Costs during 2007 among Cohorts 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
z 
p-
value 
95% 
Confidence 
Interval 
probit             
Intercept -2.741 0.123 -22.290 0.000 -2.982 -2.500 
Cohort a 
1 -0.002 0.049 -0.040 0.965 -0.098 0.094 
2 0.047 0.047 1.010 0.314 -0.044 0.138 
3 -0.072 0.062 -1.160 0.245 -0.194 0.050 
Age 0.017 0.001 11.150 0.000 0.014 0.019 
Gender b Female -0.083 0.032 -2.620 0.009 -0.145 -0.021 
Race c 
White -0.007 0.038 -0.170 0.862 -0.081 0.068 
Other -0.326 0.116 -2.820 0.005 -0.553 -0.100 
Region of 
residence d 
Northeast  0.007 0.046 0.160 0.871 -0.082 0.097 
South 0.055 0.044 1.260 0.207 -0.030 0.140 
West -0.050 0.062 -0.800 0.421 -0.171 0.071 
ESRD duration 0.001 0.004 0.150 0.878 -0.008 0.009 
Primary disease 
causing ESRD e 
Hypertension -0.084 0.044 -1.900 0.057 -0.170 0.002 
Glomerulonephritis -0.134 0.064 -2.100 0.036 -0.259 -0.009 
Cystic Kidney -0.040 0.105 -0.390 0.700 -0.245 0.165 
Other  -0.196 0.058 -3.380 0.001 -0.310 -0.083 
Charlson Comorbidity Index (CCI) 
score 0.113 0.016 7.180 0.000 0.082 0.144 
Presence of 
chronic disease  
Diabetes mellitus -0.032 0.046 -0.700 0.486 -0.122 0.058 
Hypertension 0.115 0.032 3.610 0.000 0.053 0.177 
Dyslipidemia 0.023 0.045 0.510 0.609 -0.064 0.110 
Cancer -0.278 0.072 -3.870 0.000 -0.420 -0.137 
Chronic lung 
disease -0.007 0.040 -0.180 0.859 -0.086 0.072 
Cardiovascular 
disease 0.365 0.043 8.580 0.000 0.282 0.448 
glm 
Intercept 7.855 0.242 32.420 0.000 7.380 8.330 
Cohort a 
1 0.146 0.086 1.700 0.090 -0.023 0.315 
2 0.143 0.088 1.620 0.105 -0.030 0.316 
3 -0.051 0.118 -0.430 0.669 -0.282 0.181 
Age 0.013 0.003 4.540 0.000 0.007 0.019 
Gender b Female -0.096 0.053 -1.810 0.070 -0.200 0.008 
Race c 
White 0.038 0.064 0.590 0.554 -0.087 0.163 
Other -0.165 0.230 -0.720 0.473 -0.616 0.286 
Region of Northeast  -0.093 0.076 -1.230 0.218 -0.241 0.055 
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residence d South -0.067 0.065 -1.020 0.308 -0.195 0.061 
West -0.143 0.103 -1.400 0.163 -0.345 0.058 
ESRD duration 0.013 0.007 1.790 0.074 -0.001 0.028 
Primary disease 
causing ESRD e 
Hypertension -0.079 0.084 -0.940 0.349 -0.243 0.086 
Glomerulonephritis -0.243 0.124 -1.960 0.050 -0.486 0.000 
Cystic Kidney -0.177 0.177 -1.000 0.316 -0.524 0.169 
Other  -0.082 0.111 -0.740 0.462 -0.299 0.136 
Charlson Comorbidity Index (CCI) 
score 0.050 0.026 1.890 0.059 -0.002 0.102 
Presence of 
chronic disease  
Diabetes mellitus -0.081 0.092 -0.880 0.378 -0.261 0.099 
Hypertension -0.012 0.055 -0.220 0.827 -0.121 0.096 
Dyslipidemia 0.098 0.074 1.330 0.184 -0.047 0.242 
Cancer -0.266 0.115 -2.310 0.021 -0.491 -0.041 
Chronic lung 
disease -0.122 0.063 -1.940 0.052 -0.246 0.001 
Cardiovascular 
disease 0.036 0.075 0.480 0.630 -0.111 0.182 
 
Model parameters: Wald chi2 = 694.00 ; df =22 ; p<0.0001. 
a Reference: Cohort 4 
 b Reference : Male 
 c Reference: Black 
 d Reference : Midwest 
 e Reference : Diabetes mellitus 
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Appendix E13  A Two-part Model Comparing Cardiovascular-related Other 
Costs during 2007 among Cohorts 
 
Variable 
Parameter 
Estimate 
Standard 
Error 
z p-value 
95% 
Confidence 
Interval 
probit             
Intercept -0.699 0.090 -7.770 0.000 -0.876 -0.523 
Cohort a 
1 0.016 0.037 0.430 0.665 -0.056 0.088 
2 0.171 0.037 4.580 0.000 0.098 0.244 
3 0.152 0.052 2.930 0.003 0.050 0.253 
Age 0.009 0.001 7.810 0.000 0.006 0.011 
Gender b Female 0.071 0.026 2.720 0.007 0.020 0.122 
Race c 
White 0.068 0.030 2.260 0.024 0.009 0.127 
Other -0.105 0.075 -1.400 0.163 -0.253 0.042 
Region of 
residence d 
Northeast  0.123 0.038 3.230 0.001 0.048 0.198 
South 0.066 0.035 1.920 0.054 -0.001 0.134 
West 0.015 0.049 0.320 0.753 -0.081 0.111 
ESRD duration -0.006 0.003 -1.740 0.081 -0.012 0.001 
Primary disease 
causing ESRD e 
Hypertension -0.045 0.037 -1.240 0.216 -0.117 0.026 
Glomerulonephritis -0.198 0.050 -3.980 0.000 -0.296 -0.101 
Cystic Kidney -0.111 0.077 -1.440 0.150 -0.262 0.040 
Other  -0.199 0.044 -4.530 0.000 -0.285 -0.113 
Charlson Comorbidity Index (CCI) 
score 0.129 0.017 7.790 0.000 0.096 0.161 
Presence of 
chronic disease  
Diabetes mellitus -0.058 0.043 -1.350 0.177 -0.141 0.026 
Hypertension 0.040 0.028 1.390 0.163 -0.016 0.095 
Dyslipidemia 0.090 0.042 2.150 0.031 0.008 0.173 
Cancer -0.290 0.065 -4.430 0.000 -0.418 -0.162 
Chronic lung 
disease 0.156 0.041 3.810 0.000 0.076 0.236 
Cardiovascular 
disease 0.498 0.035 14.080 0.000 0.428 0.567 
glm 
Intercept 9.326 0.132 70.850 0.000 9.068 9.584 
Cohort a 
1 -0.067 0.051 -1.300 0.193 -0.168 0.034 
2 -0.013 0.052 -0.250 0.803 -0.116 0.090 
3 -0.147 0.065 -2.270 0.023 -0.275 -0.020 
Age -0.002 0.002 -1.470 0.140 -0.005 0.001 
Gender b Female 0.021 0.034 0.610 0.543 -0.046 0.087 
Race c 
White -0.061 0.040 -1.520 0.128 -0.139 0.018 
Other -0.208 0.098 -2.130 0.033 -0.400 -0.016 
Region of Northeast  0.150 0.047 3.200 0.001 0.058 0.242 
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residence d South 0.014 0.041 0.350 0.726 -0.066 0.094 
West 0.149 0.062 2.420 0.015 0.028 0.270 
ESRD duration -0.005 0.004 -1.160 0.247 -0.014 0.004 
Primary disease 
causing ESRD e 
Hypertension -0.047 0.045 -1.040 0.297 -0.136 0.041 
Glomerulonephritis -0.079 0.069 -1.140 0.253 -0.214 0.056 
Cystic Kidney -0.036 0.110 -0.330 0.742 -0.251 0.179 
Other  -0.113 0.063 -1.770 0.076 -0.237 0.012 
Charlson Comorbidity Index (CCI) 
score 0.093 0.015 6.000 0.000 0.062 0.123 
Presence of 
chronic disease  
Diabetes mellitus -0.100 0.050 -2.000 0.046 -0.198 -0.002 
Hypertension 0.008 0.035 0.220 0.823 -0.061 0.077 
Dyslipidemia 0.043 0.043 0.980 0.327 -0.043 0.128 
Cancer -0.228 0.076 -3.000 0.003 -0.376 -0.079 
Chronic lung 
disease 0.030 0.040 0.750 0.454 -0.048 0.108 
Cardiovascular 
disease 0.266 0.046 5.840 0.000 0.177 0.356 
 
Model parameters: Wald chi2 = 1319.33 ; df =22 ; 
p<0.0001. 
a Reference: Cohort 4 
 b Reference : Male 
 c Reference: Black 
 d Reference : Midwest 
 e Reference : Diabetes mellitus 
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